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A b s t r a c t
Coumarin, a member o f the benzopyrone family o f compounds, is a natural substance that has 
shown anti-tumour activity in vivo, with this effect believed to  be due to its metabolites. However, no 
definitive mode o f action has been identified, and this thesis aimed at gaining further insight into the 
precise target o f coumarin molecules at a cellular level. A novel biosensing instrument, the Cytosensor 
Microphysiometer, which detects cellular metabolism, was used throughout, to aid this investigation.
The effect o f four coumarin compounds (coumarin, 6-hydroxycoumarin, 7-hydroxycoumarin 
and esculetin) on the growth, metabolism and metastatic potential o f a range o f tumour cell lines was 
investigated. The toxicity o f  these four compounds was examined using a variety of in vitro tests 
(medium-term growth assays, Lactate dehydrogenase (LDH) assay and a tetrazolium salt-based 
(MTT) assay). A superior method to the M TT assay for examining the effect of compounds on 
metabolism was achieved using the Cytosensor Microphysiometer. The effect of coumarins on the 
metastatic potential o f tumour cells (in terms o f  their protease secretion) was also explored.
The effect o f 7-hydroxycoumarin and esculetin on growth signalling pathways within tumour 
cells was probed. Using the A431 cell line (which over-expresses the EGF-Receptor) and EGF as a 
model growth factor signalling mechanism, the effect of the two coumarins on tyrosine 
phosphorylation events in cells was explored. Direct in vitro tyrosine kinase assays with purified EGF- 
receptor, and ELISA, Western Blotting and Cytosensor studies in intact cells, were used to achieve 
this. The involvement o f  coumarin compounds in protein kinase C signalling was also examined.
A “model” monocyte system was developed and used in a preliminary assessment of the 
immunomodulatory role o f coumarins. The activation o f two “monocytic” cell lines was assessed 
using the Cytosensor Microphysiometer. Subsequently, the effect o f coumarins on the release of 
reactive oxygen species, reactive nitrogen intermediates and proteases from activated immune cells, 
was accomplished using luminometric, colourimetric and substrate gel analyses, respectively.
Chapter 1
Introduction to the Coumarin Family o f Compounds
1 .1  I N T R O D U C T I O N
Coumarin, which derives its name from the plant Coumarouna odorata, is a naturally 
occurring component of many plants and essential oils. This introduction describes the chemistry, 
metabolism and pharmacology of coumarin and many of its derivatives. The uses o f various 
coumarins in both industrial and clinical settings are reviewed. Finally, the utilisation of coumarin 
in cancer therapy is discussed.
Coumarin is classified as a member o f the benzopyrone family o f compounds. The 
benzopyrones, all members o f which consist o f a fused benzene and pyrone ring (Figure 1.1), can 
be sub-classified on the basis o f the position o f the oxygen atom within the pyrone ring - the 
benzo-a-pyrones, to which the coumarins belong, and the benzo-y-pyrones, o f which the 
flavonoids are the principal members.
Figure 1.1: Chemical structures o f the benzopyrone sub-classes, w ith  the basic coumarin
s tructu re  (benzo-a-pyrone) [A ], and flavonoid (benzo-y-pyrone) structure 
[B].
Dietary exposure to benzopyrones is quite significant, as these compounds are found in 
fruit, vegetables, nuts, seeds, tea, coffee and wine, and it is estimated that the average western 
diet contains approximately lg/day o f mixed benzopyrones (Pierpoint, 1986). Compounds 
belonging to both sub-classifications have been studied intensively in research and clinical 
settings, and both groups have been shown to possess a wide variety o f useful pharmacological 
and physiological activities (Table 1.1). The lead for the discovery o f many such properties was 
taken from traditional medicines, and benzopyrone compounds are now known to be the active 
agents in many folk remedies.
P h a rm a c o lo g ic a l
A c tiv ity
a - lie n  zopyron  es y-B en  zopyron  es
Analgesic Soine ( 1964) Formica & Regel son (1995)
Anti-allergic Middleton & Drzewiccki (1982)
Anli-coagulant Link (1959); Feuer (1979)
Anti-inflammatory Fontaine el rt/.(l967); Lee et a!. (1981) Moroney el i?/.(1988)
Anti-microbial/anti-viral Soine (1964): Feuer (1979) Kaul etal. (1985)
Anti-oxidant Paya et al. (1992); C hange/ al. (1996) Das & Ray (1988): Paya et al. (1992)
Anti-pyretic Ritschel et al. (1984) Middleton ( 1984)
Sedatory Ritschel & Hardt (1983b)
Vasodilatory Soi ne (1964) Duarte et al. (1993)
Table 1.1: This table summarises the important pharmacological and physiological
activities of both coumarin and flavonoid molecules, and includes relevant 
references.
3
1.2. OCCURRENCE
By virtue o f its structural simplicity coumarin has been assigned as head o f the benzo-a- 
pyrones, although it is generally accepted that 7-hydroxycoumarin (umbelliferone) be regarded as 
the parent compound (see below). Since 1820, when coumarin was first isolated from the tonka 
bean by Vogel, over one thousand coumarin derivatives have been described. These have been 
mainly isolated from natural sources (higher plants and micro-organisms), although the organic 
synthesis o f many “unnatural” derivatives has also been accomplished. The derivatives range 
from simple coumarins with hydroxyl, alkoxyl and alkyl side chains, to more complex forms 
containing furanoyl, pyranoyl and benzoyl functions (Table 1.2) (Murray el al., 1982). All but 35 
o f these are oxygenated at C-7, and as a result 7-hydroxycoumarin is often regarded, both 
structurally, and as shall be seen later, biochemically, as the parent o f the more complex 
coumarins.
C la s s ific a tio n  F ea tu res  E xam p les
Simple coumarins Hydroxylated, alkoxylated or
alkylated on benzene ring
7-hydroxycoumarin
Furanocoumarins 5-membered furan ring attached
to benzene ring.
Linear or Angular
Pyranocoumarins 6-membered pyran ring attached
to benzene ring.
Linear or Angular
Seselin Xanthyletin
Pvrone-substituted
coumarins
Substitution on pyrone ring, 
often at 3-C or 4-C position
Warfarin
Table 1.2: The four main coumarin sub-types are outlined in this table. The main
structural features and examples of each are also given.
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Both Murray et al. (1982), and more recently, Keating and O’Kennedy (1997) have 
reviewed the botanical source of all naturally isolated coumarin compounds. Coumarins are 
usually found free, or in combination with sugars as glycosides, in many higher plants, especially 
those o f the Umbelliferae, Rosaceae and Rutacecie families. They are found distributed 
throughout the roots, leaves, stems and fruits, occurring at highest levels in the fruits, but the 
levels tend to vary with seasonal and environmental changes (Feuer, 1979). Generally a number 
o f different coumarins are found within one plant. Although known to be secondary plant 
metabolites (see section 1.3) the role of coumarins in plants is still obscure, although their 
distribution appears to correlate with an ability to  protect against disease or infection (Feuer, 
1979). It has also been suggested that their role may be as plant growth regulators (Riordan & 
Daly, 1954).
Some important coumarin members have been isolated from microbial sources e.g. 
novobiocin and coumermycin from Streptomyces, and aflatoxins from Aspergillus species, but 
again their role in these organisms is unclear.
1.3. B IO S Y N T H E S IS
The coumarins are secondary metabolites in plant metabolism and are synthesised via the 
shikimate-chorismate pathway. This pathway is a central biosynthetic route in plants and micro­
organisms, and shikimate and chorismate are key intermediates in the biosynthesis of the aromatic 
acids L-phenylalanine, L-tyrosine and L-tryptophan. This pathway follows the route shown in 
Figure 1.2, and the reader is referred to any plant biochemistry text for full details o f the 
pathway. Briefly, shikimate is converted to chorismate through sequential phosphorylation, 
condensation and elimination reactions (not shown in Figure 1.2), involving 3-enolpyruvyl- 
shikimate-5-phosphate as an intermediate. The conversion o f chorismate to prephenate is 
achieved enzymatically, after which aromatisation o f prephenate yields phenylpyruvate, which is 
transaminated to  become phenylalanine. Enzymatic elimination o f ammonia from phenylalanine 
produces trans-cinnamic acid, which is die precursor for the production o f all coumarin species 
(Murray et al., 1982; Keating & O ’Kennedy, 1997).
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Figure 1.2: Biosynthetic routes for the natural production of coumarin and 7-
hydroxycoumarin. Details of the pathways are included in the text.
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At this stage the biosynthetic pathway diverges (pathways 1 and 2 in Figure 1.2), giving 
rise to two distinct coumarin types -  those which are oxygenated at carbon-7 (most natural 
coumarins) and those that are not. In the latter case (pathway 1, Figure 1.2), ?ra«.v-cinnamic acid 
undergoes ontào-hydroxylation (1) to  yield /ram -2’-hydroxycinnamic acid, which becomes 
glucosylated (2) to  give trans-2 ’ -glucosyloxycinnam i c acid. This is finally converted to the cis- 
isomer in an U.V.-mediated reaction (3) to  yield cis-2’-glucosyioxycinnamic acid (or coumarinyl 
glucoside) which is the primary form in which coumarin exists in plants.
The simple 7-oxygenated coumarins follow a very similar biosynthetic scheme (pathway 
2, Figure 1.2), the only difference being an initial, additional step where tram -cinnamic acid is 
converted to /»-coumaric acid by a para-hydroxylation (A). p-Coumaric acid then becomes ortho- 
hydroxylated (B), glucosylated (C) and undergoes an U.V.-dependent /ra«s-c/s-isomerisation (D) 
to form umbelliferyl glucoside. As mentioned previously the coumarin derivatives exist naturally 
in plants primarily as glycosides, and free compounds are released through physical or chemical 
disruption to cells, an example being the release of odouriferous coumarin when grass is cut.
1.4. P H A R M A C O K IN E T IC S
Following administration the therapeutic action o f any drug requires satisfactory 
concentration o f the active compound into the area surrounding the target tissue. The movement 
o f  drug molecules from the site o f administration to the target site {absorption and distribution} 
leads to this concentration effect, but its length and intensity is offset by negative factors such as 
the chemical modification o f  the active compound into non-active forms {metabolism} and their 
subsequent removal {elimination} (Rang & Dale, 1987).
1.4 .1 . A b s o rp tio n  a n d  D is tr ib u tio n
The ability of a compound to be absorbed well in the gastro-intestinal tract following oral 
administration relies heavily on its physico-chemical characteristics. Ritschel etal. (1981) studied 
the biopharmaceutical properties o f coumarin and its principal metabolite 7-hydroxycoumarin, in 
order to gain some insight into their possible behaviour in the body. Coumarin and 7- 
hydroxycoumarin are both poorly soluble in water (0.22% and 0.031%, respectively). This 
characteristic is cause for concern with respect to their bioavailability in vivo, as 0.3% solubility 
in water is considered the critical value at which the dissolution o f a compound limits its rate of 
absorption (Ritschel et a l,  1981). However, both compounds have high partition coefficients
(21.5% for coumarin and 10.4% for 7-hydroxycoumarin), which is considered favourable for the 
rapid absorption of the compounds once they are in aqueous solution. This coupled with the fact 
that coumarin is non-polar, suggests that in theory coumarin should cross lipid bilayers easily by 
passive diffusion.
In reality absorption from the gastro-intestinal tract has been shown to be quite high, with 
most o f the dose absorbed within 1 hour o f administration (Ritschel et a l, 1977). However, 
coumarin undergoes an extreme first pass effect i.e. metabolism to 7-hydroxycoumarin and its 
glucuronide, on passage from the gut, via the liver, to the systemic circulation, and only 2-6 % is 
available systemically unchanged following absorption (Ritschel et a l, 1979). Ritschel and 
Hoffman (1981) managed to dramatically improve this low availability by using an oral 
sustained-release formulation, and succeeded in making 35% of coumarin available to the 
systemic circulation unchanged. The low bioavailability o f coumarin, in addition to its short half- 
life (see below) has brought into question its importance in vivo and it is now accepted that 
coumarin is actually a pro-drug, with 7-hydroxycoumarin being the compound of therapeutic 
relevance.
Once absorbed any active compound must be distributed via the plasma to its target site 
(Rang & Dale, 1987). Most drugs bind reversibly to plasma proteins, particularly albumins, and 
this can prove crucial in terms o f the availability o f drug at its target site. Ritschel et a l (1981) 
have shown that 35% o f coumarin and 47% of 7-hydroxycoumarin bind to plasma proteins. They 
decided that because these proportions were well below the accepted critical value o f 80% 
binding, that availability of the compounds at their target tissues should not prove problematic. 
They also showed that 27% o f coumarin and 21% o f 7-hydroxycoumarin is bound to 
erythrocytes, and suggested that this might provide the drugs with temporary protection from 
biotransformations during transport.
Distribution o f coumarin and its metabolites in the body is widespread as demonstrated 
by pharmacokinetic studies in humans (Ritschel et a l, 1977, 1979). An open two-compartment 
model was found to best fit the experimentally-derived data. Ritschel et a l  (1977) showed that 
coumarin has a short half-life in vivo, which is independent o f the route o f administration (1.02 
hrs p.o  vs 0.8 hrs i.v.). As mentioned previously, coumarin is rapidly metabolised to form 7- 
hydroxycoumarin, which quickly becomes conjugated as the glucuronide, such that the 
concentrations o f 7-hydroxycoumarin are always low and rarely exceed 2.2% of the levels o f 7- 
hydroxycoumarin-glucuronide (Ritschel et a l, 1977).
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The distribution o f 7-hydroxycoumarin-glucuronide has also been shown to fit an open 
two-compartment model and the glucuronide has been shown to have a very large volume of 
distribution (Vd). Tins indicates the possibility o f  the glucuronide partitioning into fat stores in the 
body during its distribution. It has been suggested that this may act as a “reservoir”, with 
cellular glucuronidases reconverting it to the active 7-hydroxycoumarin form, but to date this 
effect has not been observed in vivo. The large clearance value o f the glucuronide (greater than 
ten times the glomerular filtration rate o f 120ml/min) suggests that it is excreted by active renal 
tubular processes (Ritschel etal., 1977).
The pharmacokinetic profiles o f coumarin in various species have been obtained 
(Ritschel & Grummich, 1981; Waller & Chasseud, 1981; Hardt & Ritschel, 1983; Ritschel & 
Hardt, 1983a, 1983b). O f the species tested only baboons, gerbils and certain mouse strains 
(DBA/2J) have similar profiles to humans. Tests in animals, using radiolabelled coumarin, have 
demonstrated its distribution throughout the body to nearly all organs and tissues, and highlighted 
its accumulation in the liver and kidney. This information has proven useful in illustrating which 
species are appropriate animal models for studies on the toxicity and therapeutic relevance of 
coumarin.
1.4.2. M e ta b o lism
1.4.2.1. Introduction to  Coumarin M etabolism
Traditionally coumarin has been viewed by pharmacologists as an ideal model for 
studying the complex metabolism of a structurally simple organic molecule, and as such, its 
metabolic fate has been extensively researched (Kaighen & Williams, 1961; Shilling el al., 1969; 
Pelkonen et a l, 1985; Moran et al., 1987; Fentem & Fry, 1992; van Iersel etal. 1994).
Like many lipophilic compounds, coumarin is oxidatively metabolised in the liver by 
microsomal cytochrome P450 enzymes. Metabolism occurs principally via hydroxylation, can 
take place at all available carbon atoms (Figure 1.3) and is required for phase II conjugation 
reactions by UDP-glucuronosyl transferases and sulfotransferases. The most common routes of 
hydroxylation are at positions 7 and 3 to yield 7-hydroxycoumarin and 3-hydroxycoumarin 
respectively. Hydroxylation at carbon 3 results in further metabolism via ring-opening, yielding 
two further products, o-hydroxyphenyllactic acid and o-hydroxyphenylacetic acid. The 
metabolism is notable for its display o f large inter-species (Fentem & Fry, 1992) and inter­
individual variability (Rautio et a l, 1992; Iscan et al., 1994) which has proven significant with
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regard to its toxicity and therapeutic relevance. The metabolism of coumarin has been recently 
reviewed (Pelkonen et al. 1997), and a few salient points will be discussed below.
1.4.2.2. M etabolism  in man
Human metabolic studies usually involve oral dosage followed by urine collection with or 
without timed fractionation (Moran et al., 1987; Egan & O’Kennedy, 1992; Bogan et al., 1995), 
although more recent studies have concentrated on the in vitro study o f metabolism using human 
liver microsomes or precision cut liver slices (van Iersel et al., 1994; Steensma et a l, 1994). 
Analysis is by one o f a number o f techniques including spectrofluorimetry, HPLC and more 
recently, capillary electrophoresis (see section 1.6).
In humans, as in primates, the major metabolic route is via 7-hydroxylation, catalysed by 
the specific cytochrome P450 enzyme CYP2A6. Various studies have shown that the conversion 
o f coumarin to 7-hydroxycoumarin is affected by the dose administered: with a dosage range of
5-200mg p.o. about 60-70% on average is excreted into the urine as 7-hydroxycoumarin (Moran 
et al., 1987; Rautio et al., 1992), while a peroral dose of l-2g results in only 20-40% being 
recovered in the urine as the 7-hydroxy-metabolite (Sharifi et al., 1991).
Substantial interindividual differences in the metabolism of xenobiotics are common 
(Conney and Kappas, 1985), these differences often being a result o f genetic or environmental 
factors. Recently it has been shown that some individuals can metabolise a considerable 
proportion o f coumarin through pathways other than 7-hydroxylation. In particular, van Iersel et 
al. (1994), have shown using human liver microsomes in vitro, that the contribution of the 3- 
hydroxylation pathway can equal, or in some cases exceed, that o f 7-hydroxylation. The existence 
o f 3-, 5-, 6- and 4-hydroxylations has also been shown (Fentem & Fry, 1992; Steensma et al., 
1994). Early metabolic studies detected the presence o f esculetin (6,7-dihydroxycoumarin), as 
well as 7-hydroxycoumarin in the urine o f normal and pathological human urines (van Sumere et 
al., 1959). It would appear, therefore, that although 7-hydroxycoumarin is the main human 
metabolite, other hydroxylation pathways are important in humans, and as such the therapeutic 
relevance o f non-7-hydroxymetabolites should be examined rather than disregarded.
1.4.2.3 M etabolism  in other species
Species differences in the metabolism o f coumarin are quite significant and have been 
well-reported. Kaighen and Williams (1961) found that in the rat the major route of metabolic
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conversion is via 3-hydroxylation, with several end-products including o-HPAA and o-HPLA 
(see Figure 1.3). The major urinary metabolites in rabbit are o-HPAA and 3-hydroxycoumarin, 
with approximately 10% excreted as 7-hydro xycouman n, and trace amounts o f 4-, 5-, 6- and 8- 
hydroxycoumarin also formed (Kaighen & Williams, 1961). As is mentioned in the next section, 
the observed hepatotoxic nature of coumarin appears to be due to metabolites o f the 3-hydroxy­
pathway. Hence it has proven important to discover effective animal 7-hydroxylators of 
coumarin, in order to effectively mirror the toxicity effects (if any) o f coumarin in humans.
Pelkonen et al. (1997) in their recent review included a table outlining the metabolites of 
coumarin in 13 different species. From this it is obvious that baboons and certain mouse strains 
are effective 7-hydroxylators, but most other species included in the table appear to prefer other 
routes for metabolism. As mentioned, the activity of coumarin-7-hydroxylase in mouse is very 
strain-dependent, with DBA/2J mice proving the most effective (Wood & Conney, 1974). In 
addition to those listed by Pelkonen et al. (1997), two other species, gerbils and chickens, have 
been shown to possess high coumarin 7-hydroxylase activity (Dominguez et a l,  1990; Cacini & 
Ritschel, 1980), and as such are probably also appropriate animal models in any future testing 
involving coumarin.
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Figure 1.3; Metabolism of coumarin. All biotransformations are possible, although the 
metabolism is species-specific and the reader is referred to the text for 
details.
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1.5. TOXICOLOGY
In 1954 the U.S. Food and Drug Administration (FDA) classified coumarin as a toxic 
substance and banned its use, labelling as adulterated all foods containing coumarin (Casley- 
Smith & Casley-Smith, 1986). This move was not copied by their European counterparts until 20 
years later. The FDA action was taken based on results from routine toxicity tests, which showed 
that coumarin initiated toxic liver damage in rats. No pathological effects were observed in any 
other organs. Hazelton et al. (1956) subsequently obtained similar results in their studies on rats 
and dogs, and to date numerous investigators have reported on the toxicity of coumarins (Jenner 
et al., 1964; Bar & Griepentrog, 1967; Endell & Seidel, 1978; Evans et al., 1979). The 
information reported has often been contradictory, which has created confusion in this whole 
area. It is now believed that the evaluation of the toxicity of coumarin in man on the basis of data 
obtained in rats and rabbits is unjustified and inherently flawed (see below).
With respect to acute toxicity studies, coumarin has been shown to produce narcosis, loss 
of reflexes, coma and death, in rats, mice and guinea pigs, when administered in large doses. 
Hepatotoxicity was implicated by the presence o f hepatic enzymes in the serum, and on death, 
liver degeneration with necrosis was observed. Unusually, LD50 values were found to differ 
within species e.g. LD50 values in rat ranged from 290-680 mg/kg (Hazelton et al., 1956; Jenner 
et al., 1964), an anomaly explained by investigators to result from differences in carriers! LD50 
values in mice were also wide-ranging, but this trait appeared to be strain-dependent (Endell & 
Seidel, 1978; Seidel & Kreuser, 1979). It is important to note here that in all cases the LD50 
figures obtained were extremely large compared to the actual relative doses given to humans.
Chronic toxicity studies are often perceived to be more useful than acute trials in 
assessing toxicities of compounds and in many chronic studies coumarin has been shown to have 
no or little effect. In baboons given 22.5 mg/kg /day for two years, no evidence of hepatotoxicity 
was observed (Evans et al., 1979). Baboons fed 67.5mg/kg/day in the same study did show slight 
hepatotoxic signs (slightly enlarged hver). Rats fed coumarin at a dose of lOOmg/kg/day for two 
years and golden hamsters fed up to 500mg/kg/day for the same period showed no adverse effects 
from this treatment (Bar & Griepentrog, 1967; Ueno & Hirono, 1981).
The reason for conflicting evidence from these studies appears now to be clarified, due to 
the wealth of information gained from metabolic studies in various species. The toxicity of 
coumarin in certain species can be related to the species-dependent metabolism of the compound. 
Therefore, animals which hydroxylate coumarin via 7-hydroxylation (e.g. baboons, gerbils, DBA
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mice) are not affected in toxicity studies as adversely by coumarin, as are common 3- 
hydroxylators (e.g. rats, rabbits) [c.f. section 1.4]. As stated in a recent report from the National 
Toxicology Program “Organ-specific toxicity occurs in species and strains only, that metabolise 
coumarin qualitatively and quantitatively different from man” (Weinmann, 1997). This would 
suggest that some metabolite of the 3-hydroxylation pathway is causing the observed toxic 
effects, and as the principal metabolic pathway in humans is 7-hydroxylation, this toxicity may 
not be relevant in humans. Therefore, extrapolation of data from animal studies requires a 
cautious approach, and in reality, only data derived from appropriate animal models, or in vitro 
approaches, should be considered in an assessment of coumarins toxicity.
Clinically, studies carried out on humans have shown little evidence of liver dysfunction. 
An idiosyncratic-type hepatotoxicity was observed in a clinical trial of 2163 patients, but with 
only a 0.37% incidence (Cox et al., 1989). In addition, cessation of coumarin therapy returned 
the elevated liver enzymes to normal levels, in patients with this response.
Coumarin has been cited as a chemical carcinogen by NIOSH [National Institute for 
Occupational Safety and Health] (Egan et al., 1990), and has been reported as a probable 
carcinogen in rodent carcinogenicity bioassays (Jones & Easterley, 1991). However, as before 
caution needs to be taken in extrapolating this information to human situations as these tests were 
carried out in rodents. Various tests (Ames, micronucleus) have shown that coumarin and its 
metabolites are non-mutagenic (Egan et al., 1990). Although coumarin can cause chromosome 
and DNA breaks in plant cells (Grigg, 1977), it offers anti-mutagenic protection in E. coli cells 
exposed to U.V. radiation or 4-nitro-quinoline-l-oxide (Ohta et al., 1983). In cultured Chinese 
hamster ovary cells, neither coumarin nor 7-hydroxycoumarin induces sister chromatid exchange 
(Sasaki et al., 1987). Coumarin is non-teratogenic (Preuss-Uberschar et al., 1984) and non­
phototoxic (Prosser et al., 1990).
1.6. A N A L Y S IS
The previous two sections have highlighted the wealth of information that has been 
collected on the pharmacology and toxicology of coumarin and its derivatives. This work could 
not have been achieved, without parallel development in the area of analysis, to provide the most 
sensitive and selective methods for detecting coumarin derivatives. The significant dietary, 
clinical, and now industrial exposure of humans to coumarins (section 1.7), with questions still
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unanswered about their precise action in vivo, also prompted significant development of state-of- 
the-art procedures for the detection of these compounds.
Although numerous analyses of coumarins in plant extracts and foodstuffs have been 
achieved (Thompson & Hoffmann, 1988; Gamache et a l ,  1993; Nykolov et al., 1993), most 
analytical techniques have focussed on the determination of coumarin and its metabolites in 
various biological fluids (Tan et a l ,  1976; Egan & O’Kennedy, 1992; Bogan et a l ,  1995). The 
techniques have been applied to the qualitative and quantitative detection of coumarin and its 
derivatives in a variety of samples, including urine, plasma, serum, whole blood and tissue 
homogenates. Through these studies much insight has been gained into the pharmacokinetic 
character of the coumarin molecule, in both humans and other species (see section 1.4). This 
information has demonstrated the inter-species variability in coumarin metabolism, and is 
invaluable for choosing appropriate animal models in future clinical studies.
Currently the analytical methods available include both traditional and modem 
chromatographic, spectrophotometric and immunoanalytical approaches. Bogan et al. (1997) 
have reviewed this area comprehensively, but a few important procedures will be outlined below.
1 .6 .1 . C h ro m a to g ra p h ic  M eth o d s
To date High Performance Liquid Chromatography (HPLC) has proven the most popular 
and versatile analytical technique for the analysis of coumarin compounds. It has been employed 
in the analysis of coumarin flavourings and plant extracts, as well as in in vivo and in vitro 
metabolic studies. Separation has been achieved with a range of stationary (C-8 and C-18) and 
mobile phases, and with a variety of detection systems (UV, fluorescence, electrochemical and 
radiochemical). Two reviews have effectively summarised this area with thorough reference to 
separating conditions and detection limits (Shkarenda and Kuznetsov, 1993; Bogan et al., 1997).
As mentioned earlier, most analytical procedures have concentrated on the area of 
coumarin metabolism, and HPLC studies have yielded extensive information on the 
pharmacological fate of coumarin, in particular orally administered coumarin. Walters et al. 
described the first method for the separation and quantification of coumarin and its metabolites in 
1980, The procedure employed was quite successful with excellent separation of a range of 
coumarin derivatives (o-hydroxyphenylacetic acid, 8-hydroxycoumarin, 7-hydroxycoumarin, 6- 
hydroxycoumarin, 5-hydroxycoumarin, 4-hydroxycoumarin, 3-hydroxycoumarin, coumarin and 
o-coumaric acid). However the analysis time taken was long at 65 minutes in addition to sample
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pre-treatment, and in subsequent years groups have concentrated on diminishing sample 
preparation and analysis times. They have achieved this goal, albeit by concentrating on the 
principal metabolites of interest i.e. 7-hydroxycoumarin and its glucuronide. Various groups have 
developed sensitive and accurate methods for the detection of coumarin and these two metabolites 
in plasma and urine (Egan and O’Kennedy, 1992; Sharifi et al., 1993; Bogan and O’Kennedy, 
1996b). In addition to decreasing processing times, increases in detection limits have also been 
attained. Urinary excretion profiles in man following oral administration of coumarin have been 
obtained (Moran el a l,  1987). Inter-individual variabilities in the extent and rate of 7- 
hydroxycoumarin formation has also been shown using HPLC methods (Rautio et al., 1992).
HPLC has also been applied in following the in vitro metabolism of coumarin by hepatic 
microsomes and liver slices from a range of species (Fentem & Fry, 1992; Lake et a l,  1992; van 
Iersel et a l ,  1994). In vitro phase II glucuronidation reactions using uridine diphosphate 
glucuronyl transferase (UDPGT) have also been followed using HPLC separation (Killard et a l,
1996).
Capillary electrophoresis is the most recent addition to the array of techniques available 
to the analyst. Despite the advantage of rapid analysis times, it has as yet enjoyed only limited use 
in the coumarin analysis field. The area of concentration has again been the analysis of coumarin, 
7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide. The separation of 7-hydroxycoumarin 
from coumarin in urine or serum can be accomplished in less than a minute (Bogan et a l,  1995). 
Separation of 7-hydroxycoumarin from its glucuronide in urine without sample clean-up has also 
been achieved (Bogan et a l ,  1996c), and the in vitro metabolism of coumarin has been followed 
(Bogan et al., 1996a).
1.6 .2 . S p e c tro sco p ic  m e th o d s
The principal spectroscopic method of interest in the analysis of coumarin is 
spectrofluorimetry. The original method developed by Tan et al. (1976), which allowed the 
quantitative analysis of coumarin and 7-hydroxycoumarin mixtures in whole blood, was 
extremely sensitive and interference-free, but did suffer from long assay times due to the intensive 
sample preparation involved. Even so, several groups have modified this technique and used it in 
metabolic studies following both the in vivo and in vitro fate of coumarin in humans (Ritschel el 
al. 1977, 1981; Rautio et a l ,  1992; Egan and O'Kennedy, 1993a; Iscan et a l ,  1994) and other 
species (Ritschel and Hardt, 1983b; Kaipainen et a l, 1985).
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1.6.3. Immunoanalytical methods
The specific recognition of an antibody for its antigen is the basis for very selective and 
sensitive analytical methods, and has been exploited in many formats for the determination of 
coumarin and its derivatives. Immunoanalytical approaches have included ELlSA-based methods 
for the detection of coumarin and 7-hydroxycoumarin in urine (Egan & O’Kennedy, 1993b; 
Reinartz et a l ,  1996). Antibody biosensors have also been employed, with either electrochemistry 
(Dempsey et al., 1993), or surface plasmon resonance [BlAcore®] (Keating, 1998) facilitating 
label-free detection of coumarin compounds in various matrices.
1.7. U S E S
The coumarins are well-known in terms of their use in clinical settings. However, the 
versatility of this family of compounds is only appreciated, when one considers the major 
expansion of their usage in non-clinical settings. This expansion has re-addressed concerns over 
the toxicity of coumarins, and prompted calls for research to probe the precise mode of action of 
these compounds within the body. This will establish if  benefits from their widespread usage 
outweigh the toxicity concerns.
1.7 .1 . In d u s tr ia l U ses o f  C o u m a rin s
Coumarin, with its strong, pleasant fragrance, is one of the most extensively used 
synthetic aroma chemicals (Taylor, 1987). It is applied in a variety of industrial settings, the most 
important being the perfumery industry. It is widely used by perfumists to enhance the fragrance 
of many essential oils such as lavender, rosemary and citrus, in addition to a more limited use in 
other cosmetics such as lotions, talcum powders, etc. 6-methylcoumarin, with a more subtle 
odour, is also a popular choice.
Coumarin has enjoyed only limited use as a food additive, as a result of the 1954 FDA 
ban and the subsequent confusion over its toxicity, as discussed in section 1.5. A coumarin 
derivative, 3,4-dihydrocoumarin, has GRAS (generally regarded as safe) status, and with its 
sweet, caramel-like taste, is often used to fortify flavours such as vanilla, rum and caramel. 
Coumarin itself has been included as an odour enhancer in tobacco products and is commonly 
used as an odour-masker, with applications in the paints, plastics and synthetic rubber industries.
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Coumarin addition to electroplating baths has been shown to cause metals (especially 
nickel, zinc and cadmium) to deposit with increased brightness and decreased porosity, which has 
resulted in frequent application of coumarin in the electroplating industries (Meuly, 1987).
The final industrial application of coumarin and its derivatives finds root in the natural 
U.V. absorbance and resulting fluorescence displayed by many of these compounds. 7- 
hydroxycoumarin, 7-hydroxy-4-methylcoumarin and 7-amino-4-methylcoumarin have all been 
added to soaps and detergents to act as textile fluorescent brighteners. 7-hydroxycoumarin has 
also been used in sunscreen lotions and creams (Meuly, 1987).
L  7.2. A n a ly tic a l U ses o f  C o u m a rin s
The coumarin family o f compounds has also found widespread use in many analytical 
scenarios. In many cases this application arises from their inherent fluorescence properties, which 
offer increased sensitivity in detection, compared to absorbance/colourimetric measurements. 
This area has been extensively reviewed recently by Cooke et al. (1997), but the most important 
applications will be briefly outlined.
1.7.2.1. Use o f  coum arins in enzym e assays
The most prevalent use of coumarin-based compounds is their application in research and 
diagnostic enzymology, as moieties coupled to enzyme substrates. The initial use, developed in 
the 1950s and 1960s, utilised the 4-methylumbelliferone (4-MU) moiety coupled to various 
derivatives (glucuronide, glycoside, acetate) to assay for levels of enzyme activity (glucuronidase, 
glucosidase, esterase) in biological samples (Mead et al., 1955; Leaback, 1961). On enzymatic 
hydrolysis of the appropriate substrate, e.g. 4-MU-Glucuronide by p-glucuronidase, the 
liberation of 4-MU could be followed fluorimetrically {Xex = 364nm, X,em = 448nm}. The basic 
principle outlined here has also been applied to other coumarins, and has lead to a proliferation of 
sensitive peptide substrates with attached coumarin groups e.g. the peptide amides of 7-amino-4- 
methylcoumarin (AMC) and 7-amino-4-trifluoro-methylcoumarm (AFC). These commercially 
available substrates have been applied extensively in research and diagnostic enzymology as 
reviewed by Cooke et al. (1997).
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1.7.2.2. Use of coumarins as macromolecule labelling agents
The fluorescent labelling of various molecules has been achieved with coumarin 
derivatives, with 7-amino-4-methylcoumarin acetic acid (AMCA) a popular choice for protein 
labelling (Aubry et al., 1990).
Coumarin itself has been used to label oligonucleotides for use in in situ hybridisation 
experiments. These blue fluorescing probes have proved particularly useful in experiments 
requiring simultaneous multiple probing of sequences, and have been frequently used in 
conjunction with rhodamine- and fluorescein-labelled DNA [red and green fluorescing, 
respectively] (Wiegant et al., 1993).
1.7.2.3. Use o f  coumarins in chemical analyses
Coumarins have found widespread use in a variety of chemical/analytical scenarios. The 
pH sensitivity of their absorbance/fluorescence spectra means they can be exploited as pH 
indicators (Dement, 1995)
Coumarin compounds are also well-established as analytical reagents in the 
determination of metals. Both photometric and gravimetric determination of a variety of metals 
has been accomplished using a range of hydroxycoumarin derivatives [e.g. 6,7-
dihydroxycoumarin, 6,7-dihydroxy-4-methylcoumarin and 3-acetyl-4-hydroxy-coumarin] (Jain 
and Singh, 1967; Katyal and Singh, 1968).
Coumarin-based compounds have also been used as ion indicators, with ion complexation 
causing the absorbance and emission spectra to undergo extreme shifts allowing determination. 
Calcein Blue (4-methylumbelliferone-6-methyleneimino-diacetic acid), is commonly used as an 
indicator in metal ion titrations for the determination of Ba, Ca, Co, Cu, Fe(III), Ni and Sr 
(Wilkins, 1960; Huitnik et al., 1974). Similarly, 7-hydroxycoumarin, 4-methylcoumarin and 7- 
hydroxy-8-amino-methylcoumarin diacetic acid can be used for the detection of Ca and Cu 
(Huitnik and Diehl, 1974).
The fluorescent coumarin entity is the basis for four new fluorescent probes for calcium 
described by Iatridou and co-workers (1994). The detection of aluminium and alkali earth metals 
using a crown ether-linked coumarin has also been outlined (Bourson et al., 1992). A simple and
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sensitive method for the detection of nitrite ion using 4-hydroxycoumarin has been accomplished 
(Ohta et al., 1986).
Aside from their uses as metal and ion indicators, the coumarins are also valuable for the 
determination of other biologically and chemically important compounds. 4-Bromomethyl-7- 
hydroxycoumarin (BrMmC) reacts with carboxylic acids to produce ester derivatives of marked 
blue fluorescence (Dunges, 1977; Wolf and Korf, 1992). This reaction is useful for pre-column 
derivatisation of compounds prior to their separation by chromatography, leading to enhanced 
sensitivity in the detection of the separated compounds. An analogous reagent is BrMaC (4- 
Bromomethyl-7-acetoxycoumarin), and both have been used for the pre-column derivatisation of 
various biological samples including prostaglandins, bile acids and gibberellins in a variety of 
biological matrices (Crozier et al., 1982; Tsuchiya et a l ,  1982; Guldutuna et a l, 1993). BrMmC 
has also been used for the derivatisation of compounds containing imidic nitrogens of an acidic 
nature, and has been used for the pre- and post-column derivatisation of thiouracil and thiouridine 
(Iwamoto et al., 1984).
Coumarin derivatives have also been employed for the derivatisation of hydroxyl moieties 
in biological molecules, with coumarin-3-carbonylchloride and 7-[(chlorocarbonyl)methoxy]-4- 
methylcoumarin (CMMC), two such examples. CMMC has been used to derivatise various 
steroid compounds (Karlsson et a l, 1985), while coumarin-3-carbonylchloride was applied to the 
fluorescent detection of mycotoxins (Cohen and Boutin-Muma, 1992).
Coumarins have been used extensively to tune lasers to desired wavelengths and there are 
a number of coumarin dyes available for this purpose. The use of these dyes is based on their 
broad absorption and fluorescent spectra, which allow the possibility of producing tunable lasers 
at a relatively low cost. Coumarin 153 has been used by Spanner and Niessner (1993) to tune a 
laser between 520 and 600nm, for the non-invasive determination of blood components. 
Coumarin 440 has been used in conjunction with other dyes in the determination of polynuclear 
aromatic compounds using laser-excited synchronous fluorescence (Stevenson and Tuan, 1995). 
Nilsson and co-workers (1995) have used the coumarin 500 dye to set their laser at 488nm for 
use in the fluorescence imaging of capillary electrophoretic separation of DNA samples in “real 
time”.
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1.7.3. Clinical Uses ofCoumarins
The diverse pharmacological and physiological effects of the coumarin family of 
compounds have been referred to previously (see Table 1.1). In the clinical arena, it is the 
activation of the immune system by coumarin, which has led to its use in a variety of disease 
states, including High Protein Oedemas, chronic infections and immune system disorders. Other 
coumarin derivatives have proven important in anti-coagulation therapy, and more recently as 
potential HIV therapies.
1.7.3.1. H igh Protein Oedema (HPO)
The lymph system is responsible for drainage of interstitial fluid within our tissues. If 
excess fluid is present, as a result of injury or lymph vessel blockage, the transport capacity of 
the lymph system is compromised, and oedema (swelling of tissue) develops. There are numerous 
detrimental effects of oedemas to the patient - apart from the burden of pain and swelling, 
oedemas can cause severe damage to the involved tissue. Often there is extensive injury to blood 
vessels, with fibrin deposition and fibrosis common effects. The oedema interferes with the 
metabolism of the tissue cells and reduces oxygen transport, resulting in problematic wound 
healing (Casley-Smith and Casley-Smith, 1986).
In the case of high protein oedemas (HPO), there is an accumulation of protein in the 
tissue following trauma or inflammation, with resulting permeability of the capillaries causing 
water leakage in the tissue spaces. If HPOs continue for some weeks they cause chronic 
inflammation with many associated problems: increased numbers of small blood vessels and 
lymphatics with damaged vessel walls cause increased leakage, exacerbating the problem; excess 
fibroblasts and protein in the tissues provide an excellent incubation medium for microbial 
infections to fester; and excess macrophage infiltration, though initially advantageous, eventually 
cause problems as they become inactive and filled with lipid. Many disease states are associated 
with high protein oedemas, ranging from extremely severe and chronic (e.g. lymphoedema and 
elephantiasis) through more common and acute forms (e.g. bums, accidental and surgical 
traumas). All forms have been shown to benefit from benzopyrone treatment (Casley-Smith and 
Casley-Smith, 1997).
Coumarin and numerous other benzopyrones have been tested in high protein oedema, 
and all have been shown to successfully reduce the swelling. Casley-Smith and co-workers have 
carried out most of the laboratory work in this area, and they have demonstrated that the
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benzopyrones act by increasing normal proteolysis in the oedematous tissue. In a succession of 
experiments, they demonstrated that this proteolytic increase arises from an increase in both the 
numbers and activity of macrophages in the tissue (Piller and Casley-Smith, 1975; Piller 1977a, 
1977b, 1977c, 1978). Proteolysis by macrophages results in a rapid decrease in oedema, as the 
high molecular weight proteins responsible for water retention are broken down into fragments 
and removed by capillaries. Unlike diuretic therapy, which acts only symptomatically to eliminate 
oedema fluid, coumarin treatment acts to eliminate the source of the oedema (accumulated plasma 
proteins) thus providing permanent reduction of swelling. Casley-Smith and colleagues further 
substantiated the crucial role of the benzopyrone/macrophage interaction by demonstrating that 
selective killing of the macrophages using silica prevented the oedema reduction observed with 
coumarin (Casley-Smith et al., 1978).
There have been over 300 clinical trials investigating the effects of coumarin and 
benzopyrones in oedematous presentations (Casley-Smith and Casley-Smith, 1986). In addition to 
laboratory-based work, Casley-Smiths team has been very closely involved with many of these 
clinical investigations. Full details of these trials have been recently reviewed by John and Judith 
Casley-Smith (1997), with respect to lymphoedema treatment with either coumarin alone, or a 
combined coumarin/troxerutin treatment (commercially available as Venalot®). All trials have 
shown that coumarin either alone, or in combination with other benzopyrones, leads to both 
objective (circumference and volume), and subjective (tension, heaviness, fullness, pain) 
improvement, and has lead to the introduction of coumarin as a lymphoedema treatment in a 
number of western and developing countries. A further potential area of clinical application is 
that of thermal wounding treatment, and a colleague of Casley-Smiths, Neil Piller, has shown that 
coumarin can consistently reduce the duration and damage of thermal wounding (Piller 1997). To 
date however, no clinical trials have been completed in this area.
1.7.3.2. Chronic Infections
In addition to its stimulatory effect on macrophages, coumarin has been shown to 
activate other cells of the immune system. This has lead to its classification pharmacologically as 
a biological response modifier. Coumarin is known to enhance the response of peripheral blood 
lymphocytes to phytohemagglutinin, but not to pokeweed mitogen or concanavalin A in vitro 
(Marshall and Hollingsworth, 1987). It also increases the ratio of TH : Ts cells and stimulates 
natural killer cells in vitro (Thornes & Lynch, 1983; Thornes, 1997). More recently coumarin 
has been shown to potentiate the release of cytokines from monocytes in response to 
lipopolysaccharide stimulation (Stuhlmeier et al., 1991; Zlabinger et al., 1993).
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As a result of these effects coumarin has been used clinically to treat chronic infections 
such as brucellosis (Thornes, 1983). In chronic brucellosis Brucella abords infects macrophages, 
thus eluding the immune response. When immunostimulatory drugs such as coumarin are 
administered, the symptoms of chronic brucellosis (chronic tiredness, intermittent fever and night 
sweats, depression, anxiety) disappear. Coumarin was found by Thornes (1983) to be the most 
effective and least toxic immunostimulant. It was also effective at augmenting and maintaining 
IgA levels (normally suppressed in chronic brucellosis) and restoring delayed hypersensitivity 
reactions (Thornes, 1983). These results have encouraged the use of coumarin in other chronic 
infections such as mononucleosis, mycoplasmosis, toxoplasmosis and Q fever.
A combined coumarin/troxerutin preparation has been tested on patients with chronic 
tuberculosis, in an open trial in conjunction with normal therapies. The trial was established to 
determine if the benzopyrone preparation could decrease the intensity of fibrosis surrounding the 
tubercles in patients, thus allowing better antibiotic penetration into the lesions. In a nine-year 
follow-up it was found that scar formation was reduced in coumarin-treated patients (Seeliger, 
1988)
1.7.3.3. A nti-C oagulan t Therapy.
The recognition of the anti-coagulant activity of certain coumarin derivatives dates back 
to a report by Butt et al. (1941), which concerned studies on the toxic agent of spoiled sweet 
clover hay which causes serious hemorrhagic conditions in cattle. The responsible agent was 
identified as a coumarin derivative, dicoumarol (3,3'-methylenebis-4-hydroxycoumarin). 
Subsequent studies by Link and other groups (Chmielewska and Cieslak, 1958; Link, 1959) 
concluded that the minimum structural requirements for anti-coagulant activity were an intact 4- 
hydroxycoumarin with a substituent at position 3. In 1944 Ikawa and colleagues synthesised a 
very potent agent, warfarin (3-(a-acetonylbenzyl-4-hydroxy-coumarin), which quickly underwent 
trials and was recommended for human use.
In  vivo, the coumarin anti-coagulants act by blocking the synthesis of four blood factor 
proteins essential to the blood clotting process. The factors (Factor II, VII, IX and X) are 
necessary components of the prothrombin complex, and vitamin K is essential for their correct 
post-translational modification. It is known that warfarin and other coumarin anti-coagulants 
interfere with this vitamin K-dependent process, by inhibiting the formation of vitamin K from its 
precursor (Vitamin K epoxide). This interference causes abnormal processing of blood factors,
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leading to accumulation of abnormal prothrombin proteins called PIVKAs, with a resultant 
depressed clotting activity.
The coumarin anti-coagulants are thus employed therapeutically to depress blood 
clotting. They have been applied in the treatment of venous thromboembolism, acute myocardial 
infarction and threathened stroke. Warfarin (also known as coumadin) is particularly extensively 
used in the clinical treatment of all thromboembolic disorders.
I.7.3.4. A ID S  Therapies
Recently, studies have been published highlighting the potential for using coumarin 
derivatives in AIDS treatment regimes. A single dose of coumarin derivatives (warfarin, 4- 
hydroxycoumarin and 7-hydroxycoumarin) exhibited a specific inhibition of HIV replication in 
lymphocytes (Bourinbaiar et a l ,  1993a). The investigating group examined the effect of these 
three coumarins on the in vitro infectivity of the HIV virus, in MOLT-4 lymphocytes, and found 
that all decreased infectivity dose-dependently. In addition, the transmission of the virus via cell­
cell interactions was decreased by the presence of coumarins. This occurred at low drug dosages 
and was observable even five days post-infection. In further experiments, lymphocytes 
chronically infected with the HIV virus, were exposed to coumarins in vitro, and a marked 
decline in gag  p24 release and reverse transcriptase activity was observed, with a 50% reduction 
occuring at 10'9M and 10"6M, respectively (Bourinbaiar et al., 1993a, 1993b). The observed 
activities were almost identical for all three compounds tested, suggesting that a basic 
hydroxycoumarin structure was essential for the observed anti-viral effect.
Tummino et al. (1994) showed that warfarin inhibits the HIV retroviral protease in a 
competitive manner in the micromolar concentration range. Screening of further active 4- 
hydroxycoumarin derivatives is ongoing (Thaisrivongs et al., 1994; Zhao et al., 1997). Two 
advantages of warfarin derivatives over other promising HIV therapy candidates are their non­
toxic effects on cells and their well-documented pharmacology, both of which facilitate clinical 
trials.
1.8. C O U M A R IN S  I N  C A N C E R
1.8.1 . C u rre n t C a n cer  T h era p ies
Over the last twenty-five years scientists have waged “war on cancer”, with many 
victories -  they have advanced the public understanding of the disease, battled to discover early
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diagnostic markers and invented a weaponry of effective anti-cancer drugs. Despite these 
successes, cancer is still one of the most common and vicious causes of death globally -  this year, 
hundreds of thousands of otherwise healthy people will die from some form of cancer.
Anti-cancer drugs have traditionally been targeted to damage the aberrantly dividing cell 
by interrupting the cell division process (Carter et al., 1989). Reagents used include DNA 
intercalating agents (e.g. adriamycin), DNA cross-linking agents (e.g. cis-platin), topoisomerase 
inhibitors (e.g. campothecins), cytoskeleton-disrupting agents (e.g. vinblastin) and anti­
metabolites (e.g. mercaptopurine). These drugs though effective, are cytotoxic, and thus exhibit 
severe side-effects, particularly on normal proliferating tissues such as the hematopoietic system. 
Often combination therapies, whereby several cytotoxic agents are combined in the treatment 
regime, offer better results with fewer toxic side-effects, as they are carefully regulated to allow 
recovery of normal, but not malignant cells, from drug exposure (Carter et al., 1989).
Currently, chemotherapy, radiotherapy and surgery combined, offer the best outcomes 
for cancer patients, and treatment combinations have been successfully applied to particular 
cancer types, for example, Hodgkins lymphoma, testicular cancer and various leukemias. 
Otherwise success has been limited, and the majority of cancers remain refractory to treatment. 
As existing therapies are unable to extend the life expectancy of patients, the search for new, 
effective approaches, to supplement current ones has proved relentless.
The interest in coumarin and 7-hydroxycoumarin as anti-cancer agents, arose from 
reports (discussed below) that these agents had achieved objective responses in some patients 
with advanced malignancies. To date, the particular mode of action of these agents in cancer cells 
is obscure, although various possibilities have been hypothesised, and these are also outlined 
below.
1 .8 .2 . C o u m a rin  in  M a lig n a n t M e la n o m a
Early diagnosis of malignant melanoma facilitates surgical removal of the primary lesion 
and achieves a good prognosis. However, if  the lesion progresses, the risk of recurrence becomes 
serious and represents a major challenge to the oncologist, as no satisfactory treatment for 
recurrent malignant melanoma currently exists. In the past malignant melanoma has been shown 
to respond well to immune cell manipulation e.g. macrophage stimulation in vivo with B.C.G. has 
been used as an adjuvant therapy, and recently, immunotherapies such as IL-2 and interferon 
have been proposed as treatment strategies.
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Original work with coumarin derivatives in the treatment of melanoma focussed on the 
use of warfarin as a maintenance therapy. This compound was known to inhibit tumour spread, 
and to stimulate granulocytes, lymphocytes and macrophages (Thornes et a l, 1968). In 1980, 
Maat illustrated that the decrease in tumour metastases due to warfarin was macrophage- 
dependent. This data prompted Thornes to assess the potential application of coumarin, the 
parent compound of warfarin, as an adjuvant therapy in melanoma. His rationale was manifold -  
like warfarin, the in vivo actions of coumarin were also known to be macrophage-derived (Piller, 
1978); coumarin was non-toxic and conveniently administered; unlike warfarin, coumarin had no 
anti-coagulant activity, and previous administration by Riordan had resulted in subjective 
improvement in cancer patients (Thornes, 1997).
Coumarin was first compared to warfarin in a small-scale trial on patients with stage IB 
[lesions > 1.70mm thickness] and stage II melanomas after primary resection. Five patients were 
anti-coagulated with warfarin and six were given 25mg coumarin daily. During the first year, 
coumarin matched warfarin in its therapeutic effectiveness, with one patient in each group 
recurring (Thornes, 1993).
hi a small-scale study, Thornes added cimetidine (to reduce T-suppressor cells) to the 
coumarin regime, in melanoma patients with stable disease. Addition of cimetidine resulted in 5 
objective regressions in 10 patients, but was only of benefit to patients who had remained stable 
for greater than two years on coumarin therapy alone (Thomes, 1982). In a similar study by 
Marshall et al. (1989a), 3/22 responses were obtained for a combined coumarin/cimetidine 
regime. All responses were correlated with low tumour burdens (Marshall et al., 1989a).
In 1984, a placebo-controlled, randomised, double-blind trial (50mg coumarin alone, 
daily for 2 years) was established, with twenty-seven patients admitted. All patients were treated 
with standard surgical excision of the melanoma lesions prior to coumarin treatment. In 1987 the 
trial results were published, and showed 10 recurrences in the control (N=14), but only 2 in the 
treated group (N=13). Since the trial termination, two more patients in the treated group have 
recurred, at two and four years (Thomes, 1997).
Only one further trial in melanoma patients has yielded results: an open trial in Australia 
found a dosage of 300mg of coumarin daily to be of no benefit to treated patients (Thomes,
1997). Thomes has continuously stated the importance of optimal dosing in the establishment of 
trials, believing that high doses of coumarin may inhibit rather than stimulate the immune system.
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Such a hypothesis may explain these conflicting results, but it is evident that further dosing trials 
are required to determine the real benefit of coumarin in malignant melanoma therapy.
1.8 .3 . C o u m a rin  in R e n a l C e ll C a rc in o m a
The clinical course of renal cell carcinoma (RCC) has been well-documented, with long- 
lasting stable periods and rapid tumour growth its principal features. Surgery remains the 
standard patient care, however lesions usually recur, with the lungs, liver and bones the common 
sites of secondary occurrence. Prognostically, long intervals between nephrectomy and metastasis 
development, lung metastases only and no bone involvement are favourable factors (Stahl et al., 
1992). Currently there is no curative therapy for renal cell carcinoma, and in the past twenty 
years neither hormonal therapy, nor chemotherapy have improved survival rates for patients with 
metastatic lesions. Spontaneous tumour regressions have been reported at a rate of 1-7%, which 
has aroused interest in the potential use of immunotherapies as treatment modalities. In 
particular, IFN-a and 1L-2 have received most attention, and they have demonstrated objective 
responses of 11-17.5% [IFN-a only], 0-33% [IL-2 only] and 0-50% [lFN-a/IL-2 combined] in 
RCC patients (Stahl et a l, 1992). Combination of IFN-a with cytotoxic drugs such as 
vinblastine has also yielded good results [remission range 10-45%, and tumour stabilisation in 
30% of patients] (Stahl et al., 1992). However, further drugs, which alone, or in combination 
with other agents might exhibit higher response rates and longer response durations, are 
constantly being sought.
Interest in the coumarin family of compounds as such an alternative, stemmed from 
reports by Thornes, of the immunomodulatory activity of coumarin and its utility in malignant 
melanoma (Thornes, 1982). With the clear response of RCC to immunotherapy regimes, 
Marshall et al. (1987b) set about investigating the clinical activity of coumarin in renal cell 
carcinoma patients. They did so initially by applying a treatment regime courtesy of Thornes 
[coumarin at lOOmg/day oral dosage, with the addition of cimetidine 4 X 300mgs/day from day 
15] to RCC patients. This preliminary study yielded some interesting results, with 14 objective 
results among 45 patients with metastatic RCC, and almost no toxic side effects. Validation of 
this anti-tumour activity was further demonstrated by other investigators (Dexeus et al., 1990; 
Kokron et al., 1991).
Following this success, it became obvious that additional information regarding doses 
and toxicities was required, and Marshall and colleagues implemented a phase I trial to define the
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maximally tolerated dose, and dose-limiting toxicities of coumarin and cimetidine. 54 patients 
with a variety of advanced malignancies were admitted to this trial, with 3 patients each, given 
one coumarin dose in the range 400mg-7000mg. Coumarin was administered as a single, oral 
dose continuously during the trial, with cimetidine [4 doses of 300mg daily] added to the dosage 
regime on day 15. All coumarin doses were well-tolerated, with the most common side-effect of 
nausea attributable to the intense aroma of coumarin. Objective responses were observed in 7 
patients, all with renal cell carcinoma, these responses being observed across a range of coumarin 
doses [600-5000mgs] (Marshall et a l, 1991a).
Kokron et al. (1993) questioned the significance of cimetidine in the observed responses 
in a 1989-1993 study. They showed similar response rates [3/19 for coumarin, and 3/25 for 
coumarin/cimetidine combined], suggesting the dispensability of cimetidine. However, patients in 
the cimetidine group did have longer survival times (294 days vs 191 days) compared to 
coumarin-only recipients (Kokron et al., 1993).
Since completion of their 1991 phase I trial, Marshall and colleagues have proceeded to 
conduct a trial of coumarin alone [lg daily] in the treatment of RCC patients. A double-blind 
randomised trial was implemented with patients receiving daily oral doses of either coumarin [lg 
daily; 10 tablets] or placebo [10 tablets]. Patients were evaluated monthly for anti-tumour 
response. Dosage was continued until progression of the disease was evidenced, after which 
placebo patients were crossed-over to receive coumarin, while patients on coumarin were 
removed from the study and followed for survival data. Although complete results from this trial 
remain to be published, it is known that objective responses were seen in patients receiving 
coumarin, while no responses were observed in placebo patients (Ebbinghaus et al., 1997).
Only one trial has been completed which compares the efficacy of coumarin with existing 
therapies. Sagaster et al. (1995) compared the efficacy of a combined coumarin/cimetidine/IFN-a 
combination therapy to IFN-a monotherapy in RCC patients. The results showed no 
improvement in response rates or survival by combining coumarin with IFN-a.
Ebbinghaus et al. (1997) have critically evaluated the current status of coumarin trials in 
renal cell carcinoma, and highlighted future trial requirements. It is quite evident from their 
summary that a mass of work remains to be achieved, before any clear decision on the 
effectiveness of coumarin in renal cell carcinoma can be reached.
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1.8.4. Coumarin in Prostate Cancer
Prostate cancer is characterised by a very slow growth rate and a wide biological 
variability, especially with regard to hormonal sensitivity (Bosland, 1991). These two traits have 
curbed attempts at curative treatments for patients, as most effective chemotherapeutic drugs rely 
on fast growth kinetics in the tumour mass, and due to differential hormonal dependencies 
hormonal therapy (androgen deprivation) is not effective in all presented cases. At present, early 
detection, and removal of clinically significant tumours by surgery or radiation, has been the 
focus of clinical strategies: this can lead to "cure", as evidenced by undetectable prostate specific 
antigen (PSA) levels and organ confinement. However, patient survival is dependent on 
métastasés [principal sites are regional lymph nodes and bone], and advancement often occurs, 
with palliative care the only therapeutic option. Approximately 80% of patients with metastatic 
symptomatic prostate cancer respond to androgen deprivation [average life expectancy = 43 
months], the other 20% have hormone-independent disease and survive an average of 7-9 months 
(Mohler et al., 1997). Eventually, however, almost every prostate carcinoma that initially 
regressed on androgen deprivation will relapse into a hormonal-insensitive state and grow in the 
absence o f androgen. Evidently, better therapeutic approaches to control both métastasés and 
hormone-insensitive prostate carcinomas are required.
One suggested approach has been augmentation of normal immune cell functions, in an 
attempt to curb the spread of micrometastatic disease. As coumarin had previously appeared to 
exert immunomodulating effects in other cancers, a small-scale study to test the efficacy of 
coumarin in prostate cancer was set up (Marshall et al., 1990). 14 patients received a single oral 
dose of lOOmg coumarin daily continuously during the trial, with 300mg of cimetidine 4 times 
daily added to the regime from day 15 onwards. Both drugs were continued until disease 
progression was observed. No objective responses were observed, but a significant subjective 
improvement in bone pain was noted in patients, which prompted further studies.
A phase I trial involving 40 patients with metastatic, hormone-naïve or hormone- 
refractory prostatic cancer was conducted (Mohler et al., 1992). Participants were administered 
3g of coumarin daily, and evaluated for toxicity and anti-tumour responses. 3 partial responses 
occurred, all in patients with low tumour loads. One responder remained with 3 responsive bone 
métastasés and stable PSA levels for 7 years following the trial.
On the basis of these results a US FDA-supervised, multi-centre study has been 
undertaken, to examine the effect of coumarin in metastatic (stage M l) prostate cancer. The
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study will investigate the effect of lg coumarin daily on 80 patients with either hormone-naive or 
hormone-independent metastatic disease [Group A], Additionally, 80 further patients with 
positive signs of micrometastases following prostatectomy, will partake in a randomised trial, 
receiving either placebo or lg  coumarin daily [Group B], In the most up-to-date report, 24 
patients have enrolled in group A, and only 1 has not progressed after 54 months, hi Group B, 
with 40 patients participating to date, 8 and 9 patients in each group [coumarin and placebo, 
respectively] have progressed [PSA evaluations]. To date no patient on this trial has developed 
symptoms, local clinical progression or bone metastases (Mohler et ah, 1997). Final trial results 
will prove very important in assessing the value of coumarin as a future therapy for prostate 
cancer patients.
1 .8 .5 . M o d e  o f  A c tio n
The precise mode of action of coumarin in vivo, which accounts for the described clinical 
responses in patients with advanced malignancies, remains obscure. Direct anti-tumour 
properties, immunomodulatory properties and chemopreventive properties have all been cited as 
possible explanations. Due to the pleiotropic effects of coumarins and other polyphenols (c .f  
Table 1.1) in vivo, it is probable that all are valid proposals. However, in order to understand and 
exploit the multiple effects of any drug correctly, it is essential to locate its precise cellular or 
molecular target(s).
This thesis aimed at achieving this with respect to coumarin and its derivatives. This was 
implemented through further examination of direct and immunological effects of coumarin 
derivatives in human in vitro  models, in Chapters 5 and 6, respectively. Detailed accounts of the 
direct anti-tumour effects, and immunological effects, of coumarin are therefore included in these 
chapters, and only a brief discussion of these will follow below.
1.8.5.1. D irect A nti-tum our Effects
In recent years interest in studying the direct effects of coumarin has stemmed from 
clinical observations of its efficacy in cancer patients. Coumarin and its principal human 
metabolite, 7-hydroxycoumarin, have been shown to reversibly inhibit the in vitro growth of a 
range of cell lines, in a dose- and time-dependent manner (Moran el ah, 1993; Siegers & 
Bostelmann, 1993; Marshall et ah, 1994). Some cell lines e.g. renal, breast, prostate, 
glioblastoma and leukemic, have been shown to be more sensitive than others, to these effects.
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This direct effect is cytostatic in nature, with treated cells illustrating decreased synthesis of 
DNA, RNA and protein (Marshall el al., 1994). In all cases, 7-hydroxycoumarin has been 
reported to be more potent in its effects than coumarin at equal concentrations, which correlates 
well with the belief that coumarin is a pro-drug for the active agent 7-hydroxycoumarin.
The mechanisms underlying the growth-inhibitory effects remain unclear, although 
various hypotheses have been presented. One proposal is that coumarin may exert its effects by 
down-regulating autocrine loops in growing cells. Some indirect evidence for this lies in the fact 
that both coumarin and 7-hydroxycoumarin inhibit the growth of glioblastoma cell lines that are 
heavily dependent on a PDGF autocrine loop (Seliger, 1993). More direct evidence backing this 
theory, is clear from the observation that 7-hydroxycoumarin reversibly and selectively 
downregulates the expression of PDGF mRNA in glioblastomas (Seliger & Pettersson, 1994a).
Another suggestion is that coumarin modulates the progression of the cell cycle through 
accumulation of coumarin-treated cells in Go/Gi phase, as shown by Conley and Marshall (1987), 
using flow cytometry. It is thought that coumarin may exert this effect by affecting the expression 
of the ras gene, which is important for the Gi S transition. Zanker (1993) showed that 7- 
hydroxycoumarin could alter the level of Ha-ra.v expression in the RBA cell line. Following this 
Kahn el al. (1994) showed that coumarin could decrease ras expression, and simultaneously 
decrease the number of cells entering S phase, in steroid-inducible cells transformed with the ras 
gene.
One final theory is that coumarin acts by inducing cell differentiation, as evidenced by 
timed kinetic analysis of glioblastoma cells which had been exposed to 7-hydroxycoumarin. 7- 
hydroxycoumarin induced increases in I-CAM and GFAP expression, with a maximum reached 
after 10 days exposure to the drug (Seliger and Pettersson, 1994b).
1.8.5.2. Im m unom odulatory E ffects
The immunomodulatory effects of coumarin and its derivatives in vivo have been 
mentioned previously with regard to the clinical application of coumarin in oedemas and chronic 
infections (sections 1.7.3.1 and 1.7.3.2.). Briefly, coumarin activates macrophages and natural 
killer cells (Piller, 1978; Thornes, 1997). It also increases the ratio of TH : Ts cells in vitro 
(Thornes & Lynch, 1983). Coumarin has been shown to enhance the expression of DR and DQ 
antigens on peripheral blood monocytes both in vitro and in vivo, a situation which is consistent 
with an activated cell state (Marshall el al., 1989a, 1991b). Coumarin also increases the release
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of inflammatory cytokines from monocytes in response to lipopolysaccharide stimulation 
(Stuhlmeier et al., 1991). It is believed therefore, that coumarin augments the activation level in 
the cells of the immune system, particularly those of the monocyte/macrophage lineage, which 
may cause them to become tumouricidal in vivo.
1.8.5.3. Chem opreventive E ffects
Chemoprevention of cancer involves controlling the onset and progression of cancer, 
through administration of compounds which curb the effects of carcinogenic agent exposure. At 
present 30 classes of chemicals with cancer chemopreventive properties have been described, and 
include phenolic anti-oxidants, flavonoids, indoles, cinnamates and coumarins. In animal cells, it 
is believed that their anti-carcinogenic properties arise due to their ability to enzymatically induce 
the inactivation of reactive electrophilic carcinogen forms. This is achieved by promoting 
increased activities in phase II xenobiotic-metabolising enzymes e.g. UDP-glucuronidases, 
glutathione-S-tranferases (GST), quinone reductases.
Coumarin protects against hydrocarbon-mediated carcinogenesis (Feuer et a l, 1976; 
Wattenberg et al., 1979), and causes GST elevation in rodent tissues (Spamins et al., 1982). It 
also raises quinone reductase levels in a murine hepatoma cell line (DeLong et a l, 1986). 
However, the importance of these chemopreventive effects in human situations is debatable, when 
inter-species metabolism differences are considered.
1.9. C H A P T E R  S U M M A R Y
In this chapter the coumarin family of compounds were reviewed, as a prelude to the 
work described in this thesis. The occurrence, sub-classification and biosynthesis of coumarins 
were described. Particular focus was given to the metabolism and toxicology of the parent 
compound, coumarin, with the importance of coumarin metabolites addressed. Many of these 
metabolites, and other coumarin derivatives are very important, both clinically and industrially, 
and the uses of coumarins in these settings were summarised. Finally, a review of the use of 
coumarin itself, in cancer therapy, the focus of this thesis, was given.
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1.10. A IM S  O F  T H IS  T H E S IS
The aim of this thesis was the examination of the effects of coumarin compounds on human cells, 
with determination of the precise anti-tumour mode of action of coumarin, a primary goal. This 
aim was addressed specifically as follows.
1. Determination of the effect of coumarin and hydroxycoumarins on the growth,
metabolism and metastatic potential of human tumour cells. This investigation examined 
the properties of a number of hydroxycoumarins, with relevance to various anti-tumour 
mechanisms (anti-proliferative (cytostatic vs cytotoxic), anti-metastatic etc.).
2. Examination of the effect of two hydroxycoumarins, 7-hydroxycoumarin and esculetin on 
signalling pathways within human tumour cells. This aimed at identifying a precise 
cellular target/mechanism by which coumarin achieves its anti-proliferative effect.
3. Examination of the effect of coumarin compounds on monocyte function, using a model
monocyte system. Through this investigation, the immunomodulatory effect of 
coumarins, believed to be important as an anti-cancer mechanism, was addressed.
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Chapter 2 
Materials & Methods
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2 .1 .  M A T E R I A L S
2.1 .1 . S O U R C E  O F  C O U M A R IN  C O M P O U N D S .
Coumarin was kindly donated by Schaper and Brummer, Salzgitter, Germany. 7- 
hydroxycoumarin and esculetin were purchased from Sigma Chemical Co., Poole, Dorset, 
England. 6-hydroxycoumarin was synthesised by Dr. Oliver Egan, BEST Centre, Dublin City 
University, Dublin 9, Ireland, as outlined in section 2.2. with chemicals purchased from Aldrich 
Chemical Co. Ltd., The Old Brickyard, New Road, Gillingham, Dorset, England.
2 .1 .2 . R E A G E N T S  A N D  C H E M IC A L S
All chemicals used were analytical grade unless otherwise specified. All reagents, unless 
otherwise specified, were purchased from Sigma Chemical Co., Poole, Dorset, England. 
Calbiochem-Novabiochem, Boulevard Industrial Estate, Beeston, Nottingham, England supplied 
Tyrphostin A25, suramin and H-7.
Cell culture media and supplements were obtained from Sigma Chemical Co., and sera 
were purchased from Life Technologies, 3 Fountain Drive, Inchinnan Business Park, Paisley, 
Scotland. Cell lines were purchased from American Type Culture Collection, 10801 University 
Boulevard, Manassas, Virginia, U.S.A. (A431, 28SC), European Collection of Animal Cell 
Cultures, Porton Down, Salisbury, U.K. (MCF-7, PC-3, T-24, A-549, HL-60), or obtained from 
DCU stocks (SW480, SW620, NIH3T3).
Anti-phosphotyrosine antibodies were purchased from Sigma Chemical Co. (address 
above), and Boehringer Mannheim U.K., Bell Lane, Lewes, East Sussex, U.K. Alkaline 
phosphatase-labelled antibodies were purchased from Promega Corporation, 2800 Woods Hollow 
Road, Madison, WI 53711, U.S.A. Bromo-chloro-indolyl-phosphate and nitroblue tetrazolium, 
for Western blotting, were also supplied by Promega Corporation. Nitrocellulose was purchased 
from BDH Chemicals Ltd., Poole, Dorset, England.
Interferon-y, luminol and LDH Assay kit were supplied by Boehringer Mannheim, 
(address above). Greiss reagents were purchased from Molecular Probes Europe, PoortGebouw, 
Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands. Bichonic agent (BCA) reagent for protein
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determination, and the non-radioactive tyrosine kinase kit were purchased from Pierce Chemicals, 
3747 North Meridian Road, PO Box 117, Rockford, IL 61105, U.S.A.
2 .1 .3 . P 1 A S T IC  C O N S U M A B L E S
Sterile plastic disposables for cell culture (flasks, plates, pipettes etc.) were purchased 
from Coming-Costar Corporation, 45 Nagog Park, Acton, MA 01720, U.S.A. Eppendorf tubes 
and micropipette tips were purchased from Sarstedt Ltd., Sinnottstown Lane, Drinagh, Co 
Wexford, Ireland. 15- and 50-ml polypropylene centrifuge tubes were purchased from Greiner 
Labortechnik, Greiner GmBH, Maybachstrasse, PO Box 1162, D-7443 Frickenhausen, 
Germany.
96-well ELISA plates were purchased from NUNC, Postbox 280, Kamstrup DK, 
Roskilde, Denmark. White cliniplates for luminometric assays were supplied by Labsystems 
Affinity Sensors Ltd., Saxon Way, Bar Hill, Cambridge, U.K.
All consumables for the Cytosensor Microphysiometer were supplied by Molecular 
Devices Ltd., Unit 6, Raleigh Court, Rutherford Way, Crawley, West Sussex, England.
2 .1 .4 . E Q U IP M E N T
All pH measurements were performed on a Sentek pH Electrode (p56/BNC) from 
Sentek, Unit 6-7 Crittall Court, Crittall Drive, Braintree, Essex, England. I.R. analysis was 
performed on a Nicolet I.R. spectrometer supplied by the Nicolet Instrument Corporation, 5225-1 
Verona Rd., Madison, WI 53711, U.S.A. NMR analysis was performed on a 400MHz AC 
NMR Spectrometer from Brucker, Banner Lane, Coventry, England.
Cell culture was performed in a Holten 2448K laminar air-flow cabinet supplied by 
Holten Laminair A/S, Gydevang 17, DK 3450 Allerod, Denmark. Incubations were carried out in 
a Heraeus C 0 2 Incubator from Heraeus Instuments Inc., 111-A Corporate Blvd., South 
Plainfield, N.J. 07080, U.S.A. Cells were viewed using a Nikon Diaphot phase contrast 
microscope from Nikon Corporation, 2-3 Marunouchi 3-chome, Chiyoda-ku, Tokyo, Japan.
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Centrifugation was performed on the centrifuges from Heraeus Instruments Inc., 111-A 
Corporate Blvd., South Plainfield, N.J. 07080, U.S.A (appropriate models are specified in the 
methods sections). Ultracentrifugation was performed on a Beckman L8-70M Ultracentrifuge, 
supplied by Beckman Instruments, High Wycombe, Bucks HP 11 1JV, U.K.
The Cytosensor Microphysiometer was purchased from Molecular Devices Ltd., Unit 6, 
Raleigh Court, Rutherford Way, Crawley, West Sussex, England.
Absorbances from MTT, LDH, BCA, ELISA and Greiss assays were measured using a 
Titertek Multiscan plate reader produced by Flow Laboratories Ltd., Woodcock Hill, Harefield 
Rd., Richmansworth, Hertsfordshire, England. Luminometric measurements were performed on 
a Luminoskan RS luminometer from Labsystems Affinity Sensors, Saxon Way, Bar Hill, 
Cambridge, England. Spectrophotometric measurements were made on a UV-160A 
spectrophotometer from the Shimadzu Corporation, 1 Nishinokyo-Kuwabaracho, Nakagyo-ku, 
Kyoto, Japan.
Protein Electrophoresis was performed on apparatus supplied by the ATTO Corporation, 
2-3 Hongo 7-chome, Bunkyo-Kui, Tokyo, Japan. Western blotting was accomplished using a 
Transblot Electrophoretic Transfer Cell (170-3910), from Bio-Rad Laboratories, 3300 Regatta 
Boulevard, Richmond, CA 94804, U.S.A. Gel Analysis and photography was performed on a 
Ultraviolet Products Gel Documentation System Image Store 7500 version 7.01, supplied by 
Medical Supply Company, Damastown, Dublin 15, Ireland. Densitometrie analysis was achieved 
with a Biorad GS670 densitometer with Biorad Software Molecular Analyst, version 1.7.
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2 .2 .  M E T H O D S
2.2 .1 . P R E P A R A T IO N  O F  6 -H Y D R O X Y C O U M A R IN
6-hydroxycouinarin (6-HC) was synthesised by Dr. Oliver Egan, BEST Centre, Dublin 
City University, Ireland, using the outlined method supplied by Dr J.R. Fry, University of 
Nottingham, U.K. (Personal Communication). The method was a modification from that reported 
by Murayama et al. (1972) for the synthesis of suberosin and osthol. The reaction scheme is 
outlined in Figure 2.1.
2.5g of 2,5-Dihydroxybenzaldehyde was dissolved in 20mls of ethanol. Following the 
addition of 5.5mls of diethylmalonate and 5 drops of piperidine, the mixture was refluxed for 6 
hours. The mixture was allowed to cool slightly, an equal volume of water was added and the 
solution allowed to stand at 4 °C overnight. The resulting yellow crystals (putative 3- 
carboethoxy-6-HC) were collected by vacuum filtration.
The putative 3-carboethoxy-6-HC was dissolved in 50 mis of hot ethanol and the solution 
maintained at 65 °C (just below boiling), prior to the addition of 30mls of 10%(w/v) sodium 
hydroxide. Heating with stirring was continued for 10 mins, after which the mixture was cooled 
on ice and acidified to pH 3 with concentrated HC1.
The precipitate (approximately 5g of putative 3-carboxy-6-HC) was collected by vacuum 
filtration, and refluxed with 40mls of 30% (w/v) aqueous sodium bisulphite solution, until no 
further C 0 2 evolved. 30mls of concentrated sulphuric acid was added dropwise and refluxing 
continued for 1 hour. After cooling, the mixture was extracted three times with diethylether, the 
pooled organic layers were dried and the solvent evaporated to give crude 6-hydroxycoumarin. 
This was decolourised by refluxing with activated charcoal for 1 hour. This solution was filtered 
hot and, on cooling, crystals of 6-hydroxycoumarin (m.p. 242-245 °C) precipitated. The purity 
and identity were confirmed by I.R. and NMR analysis.
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F igure  2,1: Reaction scheme fo r  the synthesis o f 6-hydroxycoum arin  from  2,5-
dihydroxybenzaldehyde.
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2.2.2. PROTEIN TECHNIQUES
2 .2 .2 .1 . B C A  P ro te in  A ssa y
The BCA assay was used to detect protein quantitatively and was obtained commercially 
as a kit from Pierce, Rockford IL. In this assay, Cu21 reacts with protein under alkaline 
conditions to give Cu+, which reacts with BCA to give a coloured product. Two separate reagents 
are supplied as part of the kit: Reagent A, an alkaline bicarbonate buffer, and Reagent B, a 4% 
(w/v) copper sulphate solution. The working solution was prepared fresh each time by combining 
50 parts of Reagent A to 1 part Reagent B. Protein standards in the range 0-lmg/ml were 
prepared in 0.1M PBS, pH 7.4.
For the assay 1 Oul of sample or standard was placed in the well of a 96-well plate. 200|xl 
of the BCA working solution was added and the plate was gently swirled to ensure mixing of the 
solutions. The plate was then incubated at 37°C for 30 mins, before the absorbance of each well 
at 560nm was determined on a Titertek Twinplus plate-reader. All standards and samples were 
determined in triplicate. The absorbances of the standard solutions were used to construct a 
standard curve from which the protein concentration of the samples could be determined.
2 .2 .2 .2 . P ro te in  E lec tro p h o res is
2.2.2.2.1. Polyacrylam ide Gel Electrophoresis (PAGE)
Polyacrylamide gel electrophoresis (PAGE) was carried out using the discontinuous 
system, in the presence o f sodium dodecyl sulphate (SDS), as described by Laemmli (1970). 8% 
(w/v) resolving and 4% (w/v) stacking gels were normally used and prepared from the following 
stock solutions as outlined in Table 2.1.
Stock Solutions
(A) 30% (w/v) acrylamide containing 0.8% (w/v) bis-acrylamide.
(B) 1.5M Tris-HCl, pH 8.8, containing 0.4% (w/v) SDS.
(C) 0.5M Tris-HCl, pH 6.8, containing 0.4% (w/v) SDS.
(D) 10% (w/v) ammonium persulphate.
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S o lu tio n R eso lv in g  G e l S ta c k in g  G e l
Acrylamide (A) 5.33 mis 1.2 mis
Distilled Water 9.6 mis 5.46 mis
Separating Gel Buffer (B) 5 mis -------
Stacking Gel Buffer (C)   5 mis
Ammonium Persulphate (D) 100^1 75(xl
TEMED 10|ol 10|xl
Table 2.1 This table outlines the quantities o f  stock solutions requ ired fo r an 8%  
resolving and 4%  stacking polyacrylam ide gel.
Samples were dissolved in solubilisation buffer (0.06M Tris-HCl, pH 6.8, 2% (w/v) 
SDS, 25% (v/v) glycerol, 0.014M 2-mercaptoethanol, 0.1%(w/v) bromophenol blue) and boiled 
for 8 mins before loading onto the gel. The gel was electrophoresed in electrode buffer, pH 8.3, 
containing Tris (0.025M), glycine (0.192M) and 0.1% (w/v) SDS, at 15mA (stacking) and 25mA 
(resolving) using an ATTO vertical mini electrophoresis system until the blue dye reached the 
bottom of the gel.
2.2.2.2.2. S tain ing with Coom assie B rillian t B lue
Gels were stained for 1 hour in 0.2% (w/v) Coomassie Brilliant Blue in methanol:acetic 
acid:distilled water (3:1:6), and destained overnight in the same solvent system.
2 .2 .2 .3 . W estern  B lo ttin g
Following electrophoresis, as outlined above (Section 2.2.2.2.), the gel was soaked for 30 
mins in cold (4°C) transfer buffer (0.25M Tris-HCl, pH 8.3, 0.192M glycine, 20% (v/v)
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methanol). A sheet of nitrocellulose and six sheets of Whatman filter paper cut to the same size as 
the gel, were also soaked in transfer buffer. The proteins were transferred from the gel to the 
nitrocellulose using a Bio-Rad Wet Transfer system for 16 hours at 30V.
After transfer, the blot (nitrocellulose) was washed twice in Tris-Buffered Saline (lOmM 
Tris-HCl, pH 8.0, 150mM NaCl), prior to incubation in Blocking Buffer (2% (w/v) BSA, 0.5% 
(v/v) Tween-20, in TBS) for 2 hours at room temperature. Following blocking, the blot was 
washed once with TBS and incubated with primary antibody (at the appropriate dilution in TBS 
containing 1% (w/v) BSA, 0.1% (v/v) Tween-20) for 2Vi hours at room temperature. The blot 
was then washed extensively in TBS, prior to incubation with anti-mouse IgG, alkaline 
phosphatase conjugate (Promega), [Diluted 1/5000 in TBS containing 1% (w/v) BSA, 0.1%(v/v) 
Tween-20] for 2/4 hours at room temperature. The nitrocellulose membrane was washed five 
times in TBS and once in alkaline phosphatase buffer (lOOmM Tris-HCl, pH 9.5, lOOmM NaCl, 
5mM MgCl2), before incubation in substrate solution (175jxg/ml BCIP, 500pg/ml NBT in 
alkaline phosphatase buffer). Colour development was allowed to proceed at room temperature 
without shaking, until the desired bands were apparent, at which time the reaction was stopped by 
washing the membrane in PBS containing 20mM EDTA.
2.2 .3 . C E L L  C U L T U R E  T E C H N IQ U E S
2.2 .3 .1 . C e ll L in e s  a n d  M e d ia  P rep a ra tio n .
The cell lines used in the experimental work and their appropriate culture media are 
outlined in Table 2.2. In all cases, the culture medium was supplemented with FCS (at either 5 or 
10% (v/v) as outlined in Table 2.2.), L-glutamine (2mM), HEPES (ImM) and gentamycin 
(5(j,g/ml). Sodium pyruvate (ImM) and non-essential amino acids (1% (v/v)) were also used to 
supplement the MCF-7 and PC-3 media, respectively. The 28SC culture medium was 
additionally supplemented with 0.03mM thymidine, O.lmM hypoxanthine and 0.05mM 2- 
mercaptoethanol.
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C ell L in e  A T C C N o . D escr ip tio n C u ltu re  M ed iu m
A431 CRL 1555 Human Epidermoid Carcinoma DMEM.Sio
MCF-7 HTB 22 Human Caucasian Breast Carcinoma DMEM.Ss
PC-3 CRL 1435 Human Caucasian Prostate Adenocarcinoma Hams F12. S
T-24 HTB 4 Human Caucasian Bladder Carcinoma DMEM.Sio
A549 CCL 185 Human Caucasian Lung Carcinoma DMEM.Sio
SW480 CCL 228 Human Caucasian Colon Adenocarcinoma DMEM.Sio
SW620 CCL 227 Human Caucasian Colon Adenocarcinoma: 
Lung Metastasis
DMEM.Sio
H L-60 CCL 240 Human Caucasian Promyelocytic Leukemia R P M I 1640. S
N IH 3 T 3 CRL 1658 NIH Swiss Mouse Embryo DMEM.Ss
28SC CRL 9855 Human Peripheral Blood Monocyte lMEMSio
Table 2.2: L is t o f Cell L ines and th e ir cu lture media used th roughout this w o rk .
2 .2 .3 .2 . R eco very  o f  F ro zen  Cells.
Cells were recovered from liquid nitrogen by thawing rapidly at 37°C and transferring to 
a sterile universal tube containing lOmls of DMEM.Sio [DMEM containing 10% (v/v) Foetal 
Calf Serum (FCS)]. The cells were centrifuged at 2000 rpm for 10 mins, resuspended in fresh 
medium, transferred to culture flasks, and incubated at 37°C in a humid 5% C 02 atmosphere. 
Prior to incubation a 100(xl sample was removed and tested for viability using Trypan Blue (see 
section 2.2.3.5). Only cultures with >90% viability on recovery from long tenn storage were 
further cultured and used in experiments.
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2.2.3.3. Culture o f cells in suspension
HL-60 cells and 28SC cells were maintained in DMEM.Sio and IMEM.Sio (see section 
2.2.3.1), respectively, seeded at cell densities of 2 X I05 cells/ml, using 15mls of medium per 
75cm2 culture flasks. Cells were incubated in a humid, 5% C 02 environment at 37°C, ensuring 
that at all times their densities did not exceed 1 X 106 cells/ml. They were harvested by flushing 
from the bottom surface with medium from the culture flask using a sterile pasteur pipette. These 
cells were either used for experiments (see sections 2.2.4. and 2.2.7.), or used for subculturing as 
follows: the cells were centrifuged in a sterile universal tube at 2000 rpm for 10 mins and 
resuspended in medium at the density outlined above.
2.2 .3 .4 . C u ltu re  o f  a d h eren t ce lls
The eight other cell lines used in the experiments were adherent cell lines, and were 
maintained in the appropriate growth medium (see section 2.2.3.1.) at 37°C in a humid, 5% CO2 
environment. All cells were strongly adherent and required trypsinisation for harvesting prior to 
subculturing or experimental usage.
For trypsinisation the medium was decanted and 3 mis of trypsinising solution (Gibco 
0.025% (w/v) trypsin with 0.02% (w/v) EDTA in 0.1M PBS, pH 7.4) was used to rinse the flask, 
thus removing residual FCS which contains a trypsin-inhibitory activity. After this volume was 
decanted a further 5mls of the trypsinising solution was added to the flask and the flask was 
incubated at 37°C until all the cells had detached from the flask surface. 5mls of DMEM.S10 was 
added to this cell suspension, which was then transferred to a sterile universal tube and 
centrifuged at 2000 rpm for 10 mins. The cells were resuspended in culture medium and seeded at 
2 X 105 - 1 X 106 cells/ml, using 15mls of medium per 75cmz culture flask.
2 .2 .3 .5 . C e ll co u n ts  a n d  v ia b ility  te s tin g
Trypan Blue was used routinely to determine cell numbers and viabilities. 20jxl of 
Trypan Blue stain (Sigma, 0.25% (w/v)) was mixed with 100(il of cell suspension and allowed to 
incubate for 3 mins. A sample of this mixture was loaded onto the counting chamber of an 
improved Neubauer Haemocytometer slide, and cell numbers and viabilities were determined.
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Viable cells excluded the dye and remained white, while dead cells stained blue. In all cases the 
minimum number of cells counted was 200.
2 .2 .3 .6 . L o n e-term , s to ra g e  o f  ce lls
Cells required for long-term storage were frozen in liquid nitrogen. Harvested cells were 
pelleted and resuspended in freezing medium (90% FCS, 10% DMSO, (v/v)) to a concentration 
of 1 X 106 cells/ml. 1ml aliquots were then transferred to sterile cryotubes, and lowered slowly 
(over a 3 hour period) into the gas phase, before being eventually immersed in liquid nitrogen.
2 .2 .4 . T O X IC IT Y  T E S T IN G
2.2 .4 .1 . D ru g  P rep a ra tio n s
Drug solutions (coumarins) were prepared fresh for each experiment. Stock solutions of 
all drugs were made in DMSO, from which all required drug dilutions were made into culture 
medium, in such a way that the final concentration of solvent exposed to cells was always less 
than 0.1% (v/v). In all experiments, control cells were exposed to 0.1% (v/v) DMSO in culture 
medium.
2 .2 .4 .2 . In  V itro  P ro life ra tio n  A ssa ys
Cells were seeded into 25cm2 flasks at the appropriate density (see Table 2.3) and 
allowed to adhere for 6 hours, prior to addition of the drug of interest (coumarin, 6- 
hydroxycoumarin, 7-hydroxycoumarin and esculetin) at the desired concentration, hicubation of 
cells with drugs was continued for 96 hours, after which the cell number and viability was 
determined using Trypan Blue as outlined in section 2.2.3.5. All experiments were carried out in 
duplicate on at least three separate occasions. The increase in cell number for drug-treated cells 
was expressed as a percentage of the increase for untreated control cells, and growth curves were 
constructed from this data.
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C ell L in es S e e d in g  D e n s ity
MCF-7, PC-3, A549, T-24, 1 X 105 cells/flask
SW480, SW620,NIH3T3
A431, HL-60 2 X105 cells/flask
Table 2.3: Seeding Densities for In  Vitro Proliferation Assays.
2 .2 .4 .3 . C y to to x ic ity  D e tec tio n : L a c ta te  D e h y d ro g e n a se  (L D H ) A ssa y
This assay is used to examine cell toxicity by quantifying plasma membrane damage. 
When the plasma membrane of any cell is damaged due to exposure to a toxic insult, LDH, a 
ubiquitous cytoplasmic enzyme, is rapidly released into the cells environment. The LDH levels in 
cell culture supernatants can be measured by the 2-step enzyme reaction outlined in Figure 2.2. A 
commercially available kit (Boehringer Mannheim) was used to carry out this assay.
Cells were seeded at 5 X 104 cells/well in sterile 96 well plates, allowed to adhere and 
exposed to drug concentrations (range 0-500(xg/ml) for 24 hours at 37°C. Each drug 
concentration was tested in 7 separate wells in a randomised manner, with each experiment 
repeated on at least three separate occasions.
Immediately prior to testing supernatants, the LDH reaction mix was prepared from the 
kit components as follows: 250ul of catalyst solution (Diaphorase/NAD+ mixture) was mixed 
with 11.25mls dye solution (iodotetrazolium chloride (INT) and sodium lactate). Test 
supernatants were prepared by centrifugation of the cells in their 96 well plates at 250g for 10 
mins. From each well, lOOfxl of supernatant was transferred to a second 96 well plate, 100(0.1 of 
LDH reaction mix was added, and the plates were incubated for 30 minutes at room temperature. 
Absorbances at 492nm were determined on a Titertek Twinplus plate-reader, with a reference 
wavelength of 620nm. Hie absorbances obtained were compared to that of cells exposed to a 1% 
(v/v) Triton X-100 solution (maximal LDH release).
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Figure 2.2: Princip le  o f the L D H  Assay.
2 .2 .4 .4 . M T T A s s a y
This non-radioactive colourimetric assay system is a modification of that first described 
by Mosmann et al. (1983), and involves the use of a tétrazolium salt, MTT (3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). In metabolically active cells, this yellow 
MTT salt is cleaved to form purple formazan crystals, and as such can be used to assess the 
cellular metabolism and viability.
Cells were seeded at 5 X 104 cells/well into sterile 96 well plates, and allowed to adhere 
prior to the addition of I00fj.l of the appropriate drug solution (concentration range: 0-500|ig/ml). 
Incubation with drug was continued for 24 or 96 hours. Following this time period, 10(xl of MTT 
[3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tétrazolium bromide] labelling reagent (5mg/ml in 
0.1M PBS) was added to each well, and the plates were incubated at 37°C for 4 hours to allow 
for formazan crystal formation. 100(j.l of solubilisation buffer (10% SDS in 0.01M HC1) was 
added to dissolve the crystals overnight. The following morning the absorbance at 560nm was 
read on a Titertek Twinplus plate-reader. Drug-treated cells were compared to untreated control
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cells. Each drug concentration was tested in 7 separate wells in a randomised manner and each 
experiment was repeated on at least three separate occasions.
2 .2 .4 .5 . C v to sen so r  M icro v h y s io m e te r  S tu d ie s  on  T ox icity
2.2.4.5.1. Pre-experim ental Preparations.
On the day prior to the experiment A431 cells were seeded into transwell cell capsules at 
a density of 2.5 X 105 cells/capsule in DMEM. Sio and allowed to adhere overnight.
On the day of the experiment, running media was prepared from stock liquid 10X 
DMEM, as a IX  DMEM solution with a low buffering capacity i.e. without HEPES or sodium 
bicarbonate. Sodium chloride was added at 0.044M to compensate for the osmolarity as a result 
of the absence of sodium bicarbonate. Other supplements included L-glutamine (2mM), 
gentamycin (5|xg/ml) and FCS (0.5% (v/v)). After all these additions, the pH was adjusted to 
7.35 with 1M NaOH, and the media was filter-sterilised (0.22|im) using a Millipore apparatus. 
This media was heated to 37 °C prior to use.
2.2.4.5.2. Toxicity Studies
On the day of the experiment the cells were assembled onto the Cytosensor 
Microphysiometer, and running medium (37°C) was passed over them at a 50% flow-rate (~ 
lOOpl/min). The cells were allowed to stabilise on the instrument for 3-4 hours. A pump cycle of 
4 minutes duration was used with the acidification rate being measured in the final 30 secs of this 
4 minute cycle. Once a steady base-line acidification rate was obtained the cells were exposed to 
drugs (6-hydroxycoumarin, 7-hydroxycoumarin, esculetin) in the concentration range 0-100ng/ml 
(final concentrations in running medium) for 4, 12 or 24 hours. The acidification rate was 
measured and recorded every 4 mins during this exposure period.
2.2.4.5.3. R eversibility S tudies
To assess the reversibility of the toxic insult, the cells were re-exposed to drug-free 
running medium on cessation of the drug exposure period. The acidification rate was again 
monitored and recorded every 4 mins. The recovery of the cells was followed for 4, 12 or 24 
hours.
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2.2.5. METASTASES STUDIES
2 .2 .5 .1 . C o llec tio n  o f  C o n d itio n e d  M edia ,
A431 cells were seeded at a density of 1 X 106 cells/flask in 25cm2 flasks and maintained 
in DMEM.Sio for 6 hours, after which this medium was decanted and the cells rinsed with sterile 
0.1M PBS, pH 7.4. 5mls of fresh serum-free medium was then added to each flask, with or 
without the appropriate drug concentration, and the cells were returned to the incubator for 24 
hours. After this time period, the medium (“conditioned medium”) was collected from each flask. 
This conditioned medium was clarified by centrifugation at 3000rpm for 10 mins, and stored at -  
80°C until further analysis was performed. Prior to storage, aliquots were removed from each 
sample for protein determination using the BCA Assay (section 2.2.2.1.),
2 .2 .5 .2 . S u b s tra te  G e l A n a lysis .
Conditioned medium from cells exposed to different concentrations of drug (section
2.2.5.1.) was analysed for the presence of proteases by substrate gel analysis. This involves 
incorporating a protein substrate (gelatin) within the polymerised matrix of an acrylamide gel, 
and running the samples under non-reducing conditions, in such a way that any protease activity 
present can be renatured following electrophoresis, and allowed to degrade the gelatin in the gel.
The gel was prepared as a 10% (w/v) acrylamide gel containing lmg/ml gelatin, as 
outlined in Table 2.4. The solutions used were the same as those described in section 2.2.2.2.I. 
Samples were mixed with solubilisation buffer (0.06M Tris-HCl, pH 6.8, 2.5% (w/v) SDS, 1% 
(w/v) sucrose, 0.02% (w/v) bromophenol blue), ensuring that equal quantities of protein were 
loaded onto lanes of the gelatin-containing gel. The gel was electrophoresed in electrode buffer, 
pH 8.3, containing Tris (0.025M), glycine (0.192M) and 0.1% (w/v) SDS, at 15mA (stacking 
gel) and 20mA (resolving gel), using an ATTO vertical mini electrophoresis system until the blue 
dye reached the bottom of the gel.
Following el^gfrophoresis the gel was soaked in 2.5% (v/v) Triton X-100, with gentle 
shaking, for 30 minutes (with one change of solution) at room temperature, in order to renature 
the proteins by removal of SDS. The gel was then rinsed in substrate buffer (50mM Tris-HCl, 
pH 8.0, 5mM CaCl?) and incubated overnight in the same solution at 37°C. Following this 
incubation the gel was stained with Coomassie Blue (0.5% (w/v) in isopropanol:water:acetic acid,
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3:6:1, v/v/v) for 30 mins with shaking. Destaining in distilled water was continued until clear 
bands (representing protease bands) were visible.
So lu tio n R esolving  G el S ta ck in g  d e l
Acrylamide (A) 6.67 mis 1.5 mis
Distilled Water 3.33 mis 6.0 mis
Separating Gel Buffer (B) 5 mis -------
3mg/inl Gelatin Stock 5 mis
Stacking Gel Buffer (C) -------- 2.5 mis
Ammonium Persulphate (D) lOOpl lOOpl
TEMED 15 pi 15|xl
Table 2.4: Q uantities o f  stock solutions (Section 2.2 .2 .2 .I.) requ ired fo r  Gelatin gels.
These gelatin gels were used fo r  the analysis o f proteases in  conditioned 
medium collected from  A431 cells (Sections 2.2.5.1)
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2 .2 .6 . C E L L  S IG N A L L IN G  S T U D IE S
2 .2 .6 .1  P u rifica tio n  o f  A c tiv e  E p id erm a l G row th  F a c to r  R ecep to r  T yrosin e K in a se  
(E G F -R T K )
A431 cells overexpress the Epidermal Growth Factor Receptor (EGF-R) and its 
associated tyrosine kinase activity, and were therefore used as the source of the enzyme in the 
purification process. Lectin column chromatography can easily purify the receptor to adequate 
levels for tyrosine kinase studies, while maintaining the tyrosine kinase in an unactivated, but 
activatable, form.
A431 cells were grown to confluency in a 75cm2 flask. The culture medium was decanted 
and the cells were washed twice with 0.1M PBS, pH 7.4. The cells were harvested by incubation 
with 0.1M PBS containing ImM EDTA at 37°C for lhour. The detached cells were pelleted at 
600g for lOmins. 2 X 107 cells were resuspended in 1 ml of cold solubilisation buffer (50mM 
HEPES, pH 7.6, 1% (v/v) Triton X-100, 150mM NaCl, 5mM EGTA, ImM PMSF, 25mM 
benzamidine, 50|ig/ml aprotinin and 5jxg/ml leupeptin), for 20mins at 4°C. The lysed cells were 
ultra-centrifuged at 100,000g for 30 mins and the supernatant loaded onto a WGA (Wheat germ 
agglutinin)-Agarose column (500^1 of resin). The column was shaken gently for 2hrs at 4°C, 
after which unabsorbed material was removed and the resin washed sequentially twice with HTN 
buffer (50mM HEPES, pH 7.6, 0.1% (v/v) Triton X-100, 150mM NaCl), twice with HTN buffer 
containing 1M NaCl, and twice with HTNG buffer (HTN with 10% (v/v) glycerol). The bound 
EGF-R was eluted with HTNG containing 0.5M N-acetyl-D-glucosamine. The concentration and 
purity of the purified EGF-R were determined using the BCA Assay (Section 2.2 2.1) and 
Western Blotting (Section 2.2.2.3) respectively. The purified EGF-RTK was used for studies on 
tyrosine kinase inhibition as outlined in Section 2.2.6.2.
2 .2 .6 .2 . E G F -R T K  In h ib itio n  S tu d ie s
A commercially available non-radioactive tyrosine kinase kit (Pierce) was used to assess 
the tyrosine kinase activity of the purified EGF-RTK (Section 2.2.6.3.) and its inhibition by a 
variety of known and putative inhibitors. The basis of the method utilised in the kit is outlined in 
Figure 2.3. Briefly a biotinylated TK peptide (Biotin-EGPWLEEEEEAYGWMDF-Amide), is 
added to a Neutravidin-coated well, where it binds. A tyrosine kinase sample is added, resulting
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in the phosphorylation of the tyrosine residue present in the bound peptide. An anti- 
phosphotyrosine antibody (PY20), conjugated with Horseradish Peroxidase (HRP), is added for 
specific detection of the phosphotyrosine residues, via the HRP-TMB colourimetric reaction. 
Kinase activity can be quantitated by comparison with a phosphopeptide curve, and the tyrosine 
kinase inhibitory activity of compounds can also be ascertained, by comparison of samples 
incubated with the putative inhibitor, with control kinase samples.
Experimentally, this was achieved as follows: 50jxl of Biotinylated peptide was added per 
well of the microtitre plate and allowed to incubate at 37°C for 30 mins. During this incubation 
time, EGF-RTK (60p.g of protein) was incubated with EGF (lOQng) for 30mins at room 
temperature to allow activation of the receptor tyrosine kinase activity. Following the 30 minute 
peptide binding period, the wells of the microtitre plates were emptied and washed three times 
with Tris Buffered Saline (25mM Tris-HCl, pH 7.2, 150mM NaCl). To each experimental well, 
10fj.l reaction buffer (lOOmM HEPES, pH 7.4, 500fiM sodium orthovanadate, ImM DTT), lOp.1 
of distilled water, 20|il ATP solution (5mM ATP, 50mM MgCl2in TBS) and 10|al of activated 
EGF-RTK was added, and the microtiter plate was incubated at 37°C for 20 mins. Appropriate 
controls, and phosphopeptide standards were run concurrently. Following this incubation step, all 
wells were emptied and washed three times with TBS. 75¡al of anti-phosphotyrosine (l/500fxl in 
1% BSA) was added to each well and the plate incubated at 37°C for 1 hour. Following extensive 
washing with TBS, 100pJ of TMB (3,3',5,5'-tetramethylbenzidine) substrate was added to all 
wells. Colour development was allowed to continue for 15 mins, after which time the reaction 
was stopped with I00|il of IN  H2S 04. The absorbances of the wells were determined at 450nm.
To test the tyrosine kinase inhibitory activity of various compounds, the above procedure 
was adopted with the inclusion of lOjil of the test compound instead of distilled water at the 
reaction mix step. At the conclusion of the experiment, absorbances from wells containing 
putative inhibitors were compared to those from control wells.
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Figure 2.3: D iagram  outlin ing the basic protocol involved in the tyrosine kinase assay used
in  Section 2.2.6.2. The accompanying text details the above outlined steps.
2 .2 .6 .3 . E L IS A  fo r  D e te c tin g  T yro sin e  K in a se  A c tiv ity  in  W h ole C ells
This ELISA was developed as a modification of a method published by Trinks et al. 
(1994). Sterile 96 well plates were seeded with A431 cells at a density of 5 X 104 cells/well and 
allowed to adhere for 6 hours in DMEM.Sio, afterwhich the cells were subjected to a 16hr period 
of serum-depletion. Following this serum-free period, each well of cells was stimulated with 
lOOng/ml EGF for 15 minutes at 37°C. The media was immediately removed and the wells were 
washed with ice-cold PBS containing 100|iM sodium orthovanadate, after which the cells were 
fixed with methanol for 10 minutes at -20°C.
200(il of Blocking solution (10% (v/v) FCS, 0.2% (v/v) Tween-20, lOO^ xM sodium 
orthovanadate in Tris Buffered Saline, TBS [lOmM Tris-HCl, pH 8.0, 150mM NaCl]) was
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added per well and the plates were incubated at 37°C for 154 hours. After incubation, the blocking 
solution was removed and the plate was washed once with TBS containing 0.1% (v/v) Tween-20. 
100^1 of primary antibody (Anti-phosphotyrosine, dilution of 1/750 in TBS containing 10% (v/v) 
FCS, 0.1% (v/v) Tween-20) was added per well. The plates were incubated for 1 hour at 37°C.
Following incubation the plates were washed five times with TBS containing 0.1% (v/v) 
Tween-20, and twice with TBS. Anti-mouse IgG-alkaline phosphatase conjugate (Promega) was 
diluted 1/2000 in TBS containing 10% (v/v) FCS, 0.1% (v/v) Tween-20. 100(xl of this solution 
was added per well and incubation was achieved at 37°C for 1 hour. Following incubation the 
plates were washed five tunes with TBS containing 0.1% (v/v) Tween-20 and twice with TBS.
1 OOjul of pNPP was added per well and colour development achieved for 45 minutes before the 
absorbance at 405nm was measured.
To determine the effect of the coumarin compounds on tyrosine phosphorylation, the 
ELISA was performed as outlined above, with cells being pre-exposed to drug solutions (in the 
concentration range 0-100^g/ml), for 1, 6 or 12 hours (as appropriate) prior to EGF stimulation. 
Controls were used which were positive tyrosine kinase inhibitors (Genistein, 1 hour exposure, 
and Tyrphostin A25, 6 hour exposure). In all experiments, increases in absorbances (405nm) in 
stimulated cells compared to unstimulated cells were determined. Absorbance increases for drug- 
treated cells were normalised versus untreated control cells. Inhibition of tyrosine kinase activity 
was demonstrated if the absorbance increase for the drug-treated cells was diminished compared 
to the absorbance increase for control cells.
2 .2 .6 .4 . C v to sen so r S tu d ie s  fo r  D e te c tin s  T yrosin e K in a se  A c tiv ity
2.2.6.4.1. Pre-experim ental Preparations.
On the day prior to the experiment, A431 cells were seeded into transwell cell capsules at 
a density of 2.5 X 105 cells/capsule in DMEM.S)0 and allowed to adhere for 6 hrs. Serum-fiee 
medium was then used to replace the culture medium and the cells were serum-starved for 16 
hours. Running media was prepared from stock liquid 10X DMEM, as a IX  DMEM solution 
with a low buffering capacity i.e. without HEPES or sodium bicarbonate. Sodium chloride was 
added at 0.044M to compensate for the osmolarity as a result of the absence of sodium 
bicarbonate. Other supplements included L-glutamine (2mM), gentamycin (5fig/ml) and BSA 
(lmg/ml). After all these additions the pH was adjusted to 7.35 with 1M NaOH, and the media
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was filter-sterilised (0.22(,im) using a Millipore apparatus. The media was heated to 37 °C prior 
to use.
2.2.6.4.2 Optimisation o f  E G F  stim ulation
On the day of the experiment the cells were assembled into the Cytosensor 
Microphysiometer and running medium (37°C) was passed over them at a 60% flow-rate (~ 
120pl/min). The cells were allowed to stabilise on the instrument for 3-4 hours. A pump cycle of 
2 minute duration was used, with the acidification rate being measured in the final 30 secs of this 
2 minute cycle. Once a steady base-line acidification rate was obtained, the cells were exposed to 
various concentrations of EGF in the range (O-lOOng/ml). By carrying out these experiments in 
quadruplicate, a dose-response curve for the EGF-EGF-R response in the A431 cell line was 
constructed. From this it was determined that the maximal response was obtained at lOOng/ml of 
EGF and this was used in all subsequent experiments (section 2.2.6.4.3.)
2.2.6.4.3. E G F -Receptor Tyrosine K inase Inhibition Studies.
The passing of EGF (lOOng/ml) over A431 cells on the Cytosensor Microphysiometer 
was shown from experiments in Section 2.2.6.4.2. to cause a substantial (~ 170%) immediate 
increase in the acidification rate of the cells. This increase was mainly due to the activation of the 
receptor-associated tyrosine kinase (on EGF binding to the receptor), and could be blocked by 
pre-exposure of the cells to tyrosine kinase inhibitors such as genistein and tyrphostin.
In order to determine if the coumarin compounds could inhibit the activation of the EGF- 
RTK the cells were pre-exposed to 7-hydroxycoumarin (O-lOOug/ml) or esculetin (0-20ug/ml) for 
either 1 or 6 hours prior to the EGF stimulation (lOOng/ml). In all experiments genistein and 
tyrphostin were used as positive controls.
2 .2 .6 .5 . W estern  B lo ttin g  fo r  D e te c tin g  T yro sin e-P h o sp h o rylu te il P ro te in s
A431 cells were seeded into 10cm petri-dishes at a concentration of 1 X 106 cells/plate 
and allowed to adhere to the surface by culturing in DMEM.Sio media for 6 hours. The media 
was then replaced with DMEM.S0.5 and the cells were serum-starved for 16 hours. The serum- 
starved cells were then exposed to EGF (lOOng/ml) for 15 minutes at 37°C. These stimulated 
cells were washed twice with ice-cold PBS containing sodium orthovanadate (100|xM), prior to
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lysis with lOOfj.1 of lysis buffer (50mM Tris-HCl, pH 8.0, 150mM NaCI, 1% (v/v) Triton X-100, 
lmg/ml BSA, ImM PMSF, lOOpM sodium orthovanadate). Protein concentrations in each 
sample were determined using the BCA Assay (Section 2.2.2.1.). Equal concentrations were run 
on an 8% SDS-PAGE as outlined in section 2.2.2.2.1. This gel was then immunoblotted and 
probed with an anti-phosphotyrosine antibody (1:1000 dilution) as outlined in section 2.2.2.3.
To determine the effect of the coumarin compounds on tyrosine phosphorylation as a 
result of EGF stimulation, treatment with drugs (concentration range O-lOOpg/ml) was carried 
out during the 16 hour serum-starvation period for the appropriate pre-exposure time period (1, 6 
or 12 hours). Cells exposed to drugs were immunoblotted and levels of tyrosine phosphorylated 
proteins compared to controls. Positive tyrosine kinase inhibitors (Genistein, 1 hour exposure, 
and Tyrphostin A25, 6 hour exposure) were also included.
2 .2 .6 .6 . C v to sen so r S tu d ie s  o f  P ro te in  K in a se  C  A ctiv ity
2.2.6.6.1. Pre-experim ental Preparations
Running media and cell seeding preparations for these experiments were exactly as 
outlined in Section 2.2.6.4.I.
2.2.6.6.2. A ctivation o f  Protein K inase C  (PKC) Activity
On the day of the experiment the cells were assembled onto the Cytosensor 
Microphysiometer, and running medium (37°C) was passed over them at a 60% flow-rate (~ 
120(xl/min). The cells were allowed to stabilise on the instrument for 3-4 hours. A pump cycle of 
2 minute duration was used, with the acidification rate being measured in the final 30 secs of this 
2 minute cycle. A 20 minute exposure of cells to PMA (optimised at 0.05ng/ml) was used to 
assess the activation of Protein Kinase C activity within the cells. Pre-exposure of cells to H-7 
(25f.ig/ml), a specific PKC inhibitor, blocked the observed activation.
In order to determine if the coumarin compounds could affect the activation of Protein 
Kinase C, the cells were pre-exposed to 7-hydroxycoumarin (O-lOOug/ml) or esculetin (0- 
lOOug/ml) for either 1 or 6 hours prior to the PMA stimulation.
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2.2 .7 . IM M U N E  C E L L  E X P E R IM E N T S
2 .2 .7 .1 . E n d o to x in  P reven tio n
Although media, media supplements and commercial solutions were purchased 
endotoxin-free, they were tested for endotoxin contamination using a commercial E-Toxate® kit 
(Sigma diagnostics). Any homemade solutions also underwent scrutiny with this Limulus 
Ameobocyte Lysate (LAL)-based kit.
Briefly, 100|iil of sample to be tested was incubated with 100ja.l of the E-Toxate* (LAL) 
working solution, in a baked glass tube, for lhr at 37°C. Positive and negative control samples 
were also included. After this incubation period, the test sample was examined for evidence of 
gelation, by 1800 inversion of the tube. A positive test was the formation of a hard gel, permitting 
complete inversion of the tube without disturbance o f the gel.
* E-Toxate is prepared from a lysate of the circulating ameobocytes of the horseshoe crab, 
Limulus polyphemus. When exposed to minute quantities of endotoxin, the lysate increases in 
opacity and viscosity, and gels, if the concentration of endotoxin is sufficiently high.
2 .2 .7 .2 . P rep a ra tio n  o f  Q p so n ified  Z ym osan .
Zymosan is a cell wall preparation of Saccharomyces cerevisiae which alone can act as a 
phagocytic stimulant. However, coating of this preparation with immunglobulins and complement 
(a process known as opsonisation) yields a much more potent stimulator of phagocytic cells.
Opsonified Zymosan (OZ) was prepared according to the method of Allen (1986) as 
follows: A 1ml suspension of zymosan at a concentration of 2.5mg/ml in 0.85% NaCl (w/v) was 
prepared, and heated in a boiling water bath for 20 mins. This suspension was cooled to 22°C, 
centrifuged at 500g for 10 mins and the supernatant discarded. The resultant pellet was 
opsonified by resuspension in 2 mis of normal rabbit serum, with 20 mins of rotation on a blood- 
tube rotator. Following this incubation step, the solution was centrifuged at 500g for 10 mins, 
and the pellet subjected to a second incubation with 2mls serum, as before. The opsonified 
zymosan was again pelleted, and washed three times with normal saline to remove any residual 
protease activity. The final pellet was resuspended in 1ml saline, aliquoted and stored at -80 °C 
until required.
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2.2.7.3. Characterisation o f  Monocytic Cells
2.2.7.3.1. Cytocentrifugation
Glass slides were alcohol-washed and labelled prior to assembly into the cytospin 
apparatus. A cell suspension of the appropriate cells at a density of IX  106 cells/ml was prepared 
following counting (section 2.2.3.5). A lOOfd aliquot of this suspension was transferred to the 
plastic inserts. The cells were centrifuged onto the slides at 1000 rpm for 5 mins using the 
Heraeus Labofuge Ae cytocentrifuge. The resulting cytospins were fixed and stained as described 
in sections 2.2.7.3.2. and 2 .2 .1 3 3
2.2.7.3.2. Eosin/M ethylene B lu e  S taining
Slides were prepared as outlined in section 2.2.7.3.I. prior to fixing and staining with 
Eosin/Methylene Blue (from a Rapi-diff II, triple stain set from Diagnostic Developments) to 
assess cell morphology. Subsequently, the cells were fixed with methanol for 20 seconds, stained 
with Eosin for 15-20 seconds and counterstained with Methylene Blue for 15-20 seconds. Excess 
stain was removed with distilled water and following air-drying, the cells were viewed and 
photographed under 40X magnification.
2.2.7.3.3. a-N aphthyl A ceta te Esterase A ctivity
Esterase activity is routinely used to identify and characterise mononuclear phagocytes, 
and is generally demonstrated by the use of either a-naphthyl acetate or butyrate as a substrate. 
The naphthol liberated by the esterase is coupled with a diazonium salt to give an insoluble 
coloured azo dye. The naphthyl acetate esterase activity was determined in HL60 and 28SC cells 
using a specific kit purchased from Sigma Diagnostics.
Briefly, the stain was prepared fresh each time as follows: 1ml of Sodium Nitrite (0.1M) 
and 1ml of Fast Blue BB Base Solution (15mg/ml in 0.4M HC1) were mixed and allowed to stand 
for at least 2 mins before adding to 40mls of pre-warmed (37°C) distilled water. 5mls of Trizmal 
(Trizma-Maleate, 1M, pH 7.6) and 1ml of a-naphthyl acetate (12.5mg/ml in methanol) were 
subsequently added, and this stain transferred to a staining chamber.
Cells, prepared on slides as outlined in section 2.2.7.3.1., were fixed in a Citrate (18mM 
citric acid, 9mM sodium citrate, 12mM sodium chloride, pH 3.6): Acetone: Formaldehyde (37%
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(v/v)) solution (25:65:8) for 30 seconds, rinsed for 60 seconds in distilled water, and incubated in 
the staining solution for 30 mins at 37°C. Following this incubation the cells were rinsed with 
distilled water for 3 mins, and counterstained with Hematoxylin for 2 mins. Excess stain was 
rinsed off with tap water and the cells allowed to air-dry, prior to viewing and photographing 
under 40X magnification.
2.2.7.3.4. N itroblue Tétrazolium Reduction f o r  detection o f  monocytic respiratory burst
1 X 106 cells in 1 ml of culture medium were incubated with 0.2% nitroblue tétrazolium 
and 100ng/ml PMA for 30 mins at 37°C. 100|al of cell suspension was centrifuged onto slides as 
outlined in section 2.2.7.3.1. and the number of cells containing blue/black intracellular deposits 
was determined, counting at least 200 cells in total.
2 .2 .7 .4 . A c tiv a tio n  o f  M o n o c y tic  C ells: C y to sen so r  S tu d ie s
2.2.7.4.1. Pre-experim entalpreparations
Running medium was prepared as outlined previously in Section 2.2.4.5.1. As both 
HL60 and 28SC are non-adherent cell lines, their assembly into the transwell capsules prior to 
mounting on the Cytosensor Microphysiometer is different to that described in Sections 2.2.4.5.1. 
and 2.2.6.4.1., and involved entrapment of the cells using an agarose matrix.
To achieve this a suspension of cells at a density of 4 X 106 cells/ 300^1 was prepared in 
running medium. To this was added lOOpl of the supplied Agarose cell entrapment medium, 
which had been previously melted in a beaker of boiling water for 5 mins. I0f.il of this 
cell/agarose mixture was then carefully pipetted into the centre of each transwell capsule cup, and 
the agarose was allowed to solidify for 10 mins before the capsules were assembled onto the 
instrument in the conventional way. This procedure yielded a final concentration of 1 X I05 cells 
in each capsule cup.
2.2.7.4.2. A ctivation  o f  M onocytic Cells
The cells were assembled onto the Cytosensor Microphysiometer, and running medium 
(37°C) was passed over them at a 60% fiowrate (~ 120|j,l/min). The cells were allowed to 
stabilise on the instrument for 3-4 hours. A pump cycle of 2 minute duration was used with the 
acidification rate being measured in the final 30 secs of this cycle. Once a steady baseline
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acidification rate was obtained, the cells were exposed to a 20 min pulse of PMA (500ng/ml) to 
activate PKC within the cells. The effect of exposure to various modulators (LPS and IFN-y) was 
also examined.
2.2.7.5. D eterm ina tion  o f  R eactive  O xygen Spec ies by L u m in escen ce
Phagocytic cells, when activated, are capable of reducing molecular oxygen to 
superoxide, via a process called the “respiratory burst”. Conversion of superoxide to hydrogen 
peroxide can occur, and both these processes produce oxygen species with electronically excited 
states, which results in the emission of luminescence from the cells. Measurement of this light 
emission, can therefore be useful in examining the effect of various agents on the inflammatory 
response of immune cells.
The luminescence method used to monitor production of reactive oxygen species from 
monocytic cells was modified from that of Labro et al. (1989). HL60 or 28SC cells were 
pelleted, washed with HBSS (Hanks Balanced Salt Solution) supplemented with 0.1% (w/v) 
gelatin, and resuspended at a concentration of 1 X 106 cells/ml in the HBSS/gelatin solution. 
200(0,1 of this cell suspension was incubated at 37°C, with gentle mixing, with 25 fd of luminol 
(0.25mM). At time zero, the cells were stimulated with the appropriate stimulant (500ng/ml PMA 
or 250|Og/ml OZ) and following a 10 min “lag period” where light emission was not recorded, 
luminescence measurements were obtained for the ensuing 60 min. Under the Repeat Scan mode, 
light emission was recorded for 30 secs every 3 mins for this 1 hr period. Results were expressed 
as integral light units emitted over this 1 hr period.
In experiments determining the effect of coumarins on the generation of reactive oxygen 
species in monocytic cells, cells were pre-exposed to the appropriate drug concentration (0- 
lOOfxg/ml) for either 1 or 24 hours pre-stimulation.
2.2.7.6. D eterm ina tion  o f  R eactive  N itro se n  In term ed ia tes
2.2.7.6.1. Collection o f  Nitrite-Containing Samples
HL60 or 28SC cells were seeded at a density of 1 X 105 cells/well in a 96-well plate, 
prior to exposure to combinations of a variety of modulating/stimulating agents (PMA, LPS, 
IFN-y) over a 24 hour incubation period at 37 °C. Following this incubation, test supernatants
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were prepared by centrifugation of the cells in their 96 well plates at 250g for 10 mins. From 
each well, 100|j.l of supernatant was collected for analysis of nitrite content as outlined in Section
2 .2.7.6.2.
2.2.7.6.2. Determination o f  Nitrite Using Greiss Reagents
Fresh Greiss reagent was prepared for each experiment from stock solutions of N-(l- 
naphthyl)ethylenediamine dihydrochloride (1 mg/ml in distilled water) and sulphanilic acid 
(10mg/ml in 5%  (w/v) phosphoric acid). Equal volumes of these two components were mixed to 
produce the Greiss reagent. Experimental samples, collected as outlined in Section 2.2.7.6.2., and 
standards of sodium nitrite (0-10Q|iM) were analysed using this Greiss reagent. In each 
microplate well the following components were mixed: 13.5(il of Greiss Reagent, I OOfj.1 of Nitrite 
containing sample (sample or standard), and 86.5p.l of distilled water. The microplate was 
incubated for 30 mins at room temperature and the absorbances of each well at 54Qnm were 
determined on a Titertek Twinplus plate-reader. All standards and samples were determined in 
triplicate. The absorbances of the standard solutions were used to construct a standard curve 
from which the nitrite concentration of the samples was determined.
2.2.7.7. D e term ina tion  o f  P rotease A c tiv ity
2.2.7.7. l.Collection o f  Conditioned M edium
HL60 cells and 28SC cells were seeded at a density of 1 X 106 cells/well in 2mls serum- 
free medium in a 12-well plate. The appropriate stimulant (PMA [500ng/ml], OZ [250(ig/ml]) 
was added and the cells incubated at 37°C for 24hours. Wells with appropriate drug 
concentrations (coumarin, 7-hydroxycoumarin, or esculetin [0-1 OOug/ml]) were also included. 
After this time period, the medium (“conditioned medium”) was collected from each flask. This 
conditioned medium was clarified by centrifugation at 3000rpm for 10 mins, and stored at -80UC 
until further analysis by substrate gel analysis as outlined in Section 2.2.7.7.2.
2.2.7.7.2. Substrate Gel Analysis
Substrate gel analysis of the conditioned medium collected from stimulated HL60/28SC 
cells (Section 2.2.7.7.1.) was analysed exactly as outlined in Section 2.2.5.2.
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Chapter 3
Introduction to the 
Cytosensor Microphysiometer
6 2
This chapter introduces the reader to the Cytosensor Microphysiometer, an instrument used 
extensively throughout this work, which measures extracellular acidification rates. A brief overview 
of cellular metabolism and methods for measuring metabolism are given, followed by an outline of 
the cytosensor components and capabilities. A brief summary of the application of this instrument 
in our work is also included.
3.1 . IN T R O D U C T IO N  TO  C E L L U L A R  M E T A B O L IS M
Metabolism is defined as the overall biochemical process through which living systems acquire 
free energy from their environment, and utilise this free energy to maintain their normal 
functioning. Central to this overall process is the ubiquitous cellular energy transmitter, adenosine 
triphosphate (ATP), the measurement of which is often used to assess the physiological state of the 
cell (Lehninger, 1982).
As part of their metabolic cycle, cells intake nutrients and harness the inherent energy of these 
(Ada ATP), for use in cellular processes such as growth, motion, biosynthesis of complex molecules, 
active transport etc. The primary carbon sources used are sugars, amino acids and fatty acids, with 
glucose and glutamine of most importance in in vitro cell culture. The important ATP-yielding 
reactions of the cell utilising these two carbon sources are outlined in T able 3.1. From this it is seen 
that glucose can be converted to lactic acid via glycolysis, or to C 02 via respiration (glycolysis 
followed by the citric acid cycle and oxidative phosphorylation). As shown in this table and 
described in more detail by Owicki & Parce (1992), respiration is more proficient energetically than 
glycolysis, and also produces much less acid per ATP generated (compare 1 H /ATP and 0.167 
FT/ATP, for glycolysis and respiration, respectively). However, although respiration is the 
predominant ATP source of cells in vivo, cells cultured in vitro utilise glycolysis as their major 
ATP-generating reaction. Glutamine metabolism has also been shown to contribute a proportion of 
ATP to mammalian cells in culture [estimated at 30-100% depending on cell type and culture 
medium composition] (Owicki & Parce, 1992).
An intracellular build-up of the protons produced during metabolism is detrimental to the cell, 
therefore they are excreted via numerous mechanisms e.g. proton channels, Na+/H+antiport, 
monocarboxylate carriers. This proton excretion occurs at a rate of » 1 X 10s H 1 /sec/cell (known as 
the extracellular acidification rate), and under unchanging environmental conditions remains 
constant (Owicki & Parce, 1992). Any event (stimulatory or inhibitory) which causes an alteration
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in the metabolic rate of a cell will be efficiently mirrored by a change in the extracellular 
acidification rate of the cell. Therefore, measurement of this entity can yield useful information on 
the metabolic state and well-being of a cell at any particular instant.
Carbon Source Pathway Reaction A T P  Yield
Glucose Glycolysis glucose -> 2  lactate' + 2 IT 2
Glucose Respiration glucose + 6 O2 —> 6HCO3' + 6 H 36
Glucose HMP shunt + 
glycolysis + 
oxidative 
phosphorylation3
3 glucose + 11/2 0 2 —>
5 pyruvate' + 3HC03" + 5H20  + 8FT
27
G lu tam ine Respiration glutamine + 9/2 O2 + 3H20  —» 
5HC03‘ + 2N H / + 3tT
27
Table 3.1: S um m ary o f the  m a jo r A T P -y ie ld in g  reactions w ith in  cu ltu re d  cells.
aH M P  shunt is n o t its e lf a p rim a ry  source o f A T P , bu t i t  produces N A D P H  w hich 
can couple to  o x id a tive  phospho ry la tion  to  y ie ld  A T P .
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3.2. M E A S U R IN G  C E L L U L A R  M E T A B O L IS M
Cellular metabolism has been studied by a variety of both invasive and non-invasive methods. 
Most of these simply involve the measurement of either the rate of uptake of reactants, such as 
glucose or oxygen, or the rate of production of heat or acidic products. The main methods used for 
these determinations are outlined in Table 3.2. The measurements obtained have been primarily 
used to examine the effects of various toxicants (drugs, industrial chemicals and environmental 
pollutants) on the physiological state of cells. During this work we have used a recent addition to 
these tools, the Cytosensor Microphysiometer (section 3.3), to examine the effects of coumarins on 
various cellular events.
M e a su r e m e n t o f T e c h n iq u e  u se d R e fe re n c e s
Glucose Enzymatic (G-6-P-D) 
Microbial Biosensor
Olson (1994) 
Svitel et al. (1998)
Oxygen Oxygen Electrode Li et al. (1988) 
Schnellmann (1994) 
Ara et al. (1994)
Heat Microcalorimetry Gebreselassie & Schon (1993) 
Schon & Wadso (1988)
Acidic Products 
(Lactate, C02)
Enzymatic (LDH)
Cytosensor Microphysiometer
Olson (1994) 
McConnell et al. (1992)
Adenylate
Compounds
HPLC
Enzymatic
Park et al. (1994) 
Lundin (1984)
Table 3.2: L is t o f techniques used to  study ce llu la r m etabolism  in  recent years.
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3.3 . T H E  C Y T O S E N S O R  M IC R O P H Y S IO M E T E R
The Cytosensor Microphysiometer is an instrument which determines the effects of various 
agents on the metabolism of cells. It achieves this by detecting the acidity of the culture medium 
bathing a small sample of cells (Figure 3.1), using a pH-sensitive sensing chip (LAPS sensor, 
section 3.3.2). The measurement of this extracellular acidification rate (ECAR) is used as a measure 
of the catabolic rate (McConnell el al., 1992).
R eceptor A c tiva tio n
o
Glucose In ta ke
Intake
L A P SEN SO R (Detects Acidity)
Figure 3.1: Diagrammatic representation of cellular metabolism and its relationship to cellular 
processes such as receptor activation. Glucose and oxygen are utilised in the production of 
the cellular energy transmitter ATP, with the concurrent production of acidic waste 
products (lactic acid and carbon dioxide). ATP is consumed by a variety of cellular 
processes, e.g. growth, movement or receptor activation (as depicted in this diagram). In 
the Cytosensor Microphysiometer, changes in metabolic rate due to ATP turnover as a 
result of such processes, can be detected by measuring changes in the extracellular levels of 
acidic waste products, using the pH-sensitive LAPS sensor.
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3 .3 .1 . C v to s e n s o r  C o m p o n e n ts
In the Cytosensor Microphysiometer, cells are assembled into a disposable capsule, in such a 
way that they are sandwiched between two porous polycarbonate membranes. This assembly is then 
placed in a micro-flow chamber in aqueous diffusive contact with the pH-sensitive LAPS chip, 
which serves as the bottom wall of the flow chamber (see Figure 3.2). As the location at which a ll 
pH readings are taken, this sensor chamber is the heart of the instrument, and with a volume of only 
3pL allows for the acquisition of very precise and sensitive readings.
Plunger contact ;
.Capsule insert
Cytosensor Cell Capsule and Sensor Chamber
Fluid inlet Fluid outlet
4
, Spacer 
Capsule cu
Sensor chamber body
—  Sensor chip--------
Living cells
F igu re  3 .2 : D iag ram m atic  representa tion  o f the C ytosensor ce ll capsule and sensor
cham ber. T h is d iag ram  was reproduced w ith  k in d  perm ission fro m  M o lecu la r 
Devices C o rp o ra tio n , M en lo  P a rk , C a lifo rn ia , U.S.A.
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As shown in Figures 3.3(a) and (b) [Photograph and Schematic diagram of the Cytosensor 
Microphysiometer components, respectively], a constant flow of fresh low-buffered running media 
is pumped through the system, and introduced into this sensor chamber, providing the encased cells 
with fresh nutrients and removing any waste products from their immediate environment. Other 
components of the system (Figure 3.3) function as follows:
Debubbler removes bubbles and reduces the amount of dissolved gases in 
the fluid.
Valves valve switches introduce different effector agents into the sensor 
chamber via the second fluid channel
• Reference Electrode stabilises the pH readings from the sensor chamber
Computer controls pumps and valves during the experiment 
controls data display, acquisition, and analysis.
3.3 .2 . T h e L A P S  sen so r
The Cytosensor Microphysiometer uses a light-addressable-potentiometric sensor (LAPS) to 
measure the rate of extracellular acidification of the cells. This LAPS sensor consists of a doped 
silicon chip, with a thin insulating layer of silicon oxide and silicon nitride on its surface, (Figure 
3.4). If a potential is applied across this insulating layer (through an external circuit connecting the 
aqueous layer and the uninsulated side of the silicon), an electric field is created in the insulating 
layer and at the silicon-insulator surface. If the silicon is simultaneously pulsed with light from a 
light-emitting diode (LED), electron-hole pairs will be formed due to light absorption. These 
electron-hole pairs move in opposite directions in the electric field, producing an alternating 
photocurrent detectable in the external circuit (Figure 3.4).
The applied potential (v|/) at which the photocurrent begins to flow is defined by the sum of a 
variety of constant potentials (i.e. contacts) and the surface potential of aqueous-insulator interface. 
This surface potential varies due to titration of the surface groups on the insulating layer [in turn 
dependent on the pH of the solution bathing this layer] (Figure 3.4). Therefore, changes in the 
magnitude of the applied potential required to produce a photocurrent are pH-sensitive. This is the
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basis o f  the measuring capab ility  o f the LAPS system. A  properly prepared S i-n itride  surface has a 
su ffic ie n tly  h igh density o f  titra tab le  groups to  make the pH  response o f the surface potentia l 
N em stian [i.e. 61m V/pH  u n it at 37°C] (M cC onnell e t al. 1992).
Computer
Fluid Supply Tubes
Figure 3 Ja: Photograph depicting the major components of the Cytosensor 
Microphysiometer system. The photograph should be compared with the 
schematic diagram (Figure 3.3b)
Schematic Diagram of the Cytosensor System
(Duai-Stream Configuration)
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Figure 3.3b: Schematic diagram  o f the m ajor components o f the Cytosensor M icrophysiom eter
system. This diagram  was reproduced w ith  k ind  perm ission from  M olecular 
Devices C orporation, M enlo Park, C a lifo rn ia , U .S .A .
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F ig u re  3 .4 .: H ow  the LA P S  w orks. The le ft-h a n d  side o f the  d iagram  illu s tra te s  w hat
occurs w ith  a h igh  pH  so lu tion  b a th ing  the  sensor: A  strong  negative charge is 
created a t the ch ip  surface, w h ich  results in  the  repu ls ion  o f ligh t-genera ted 
electrons fro m  the  surface, and a ttra c tio n  o f the  holes to  th is  negative charge. 
A  p h o to cu rre n t is generated as a resu lt. W hen a low  pH  so lu tion  is in  contact 
w ith  the  surface (as depicted on the  rig h t-h a n d  side o f the  d iag ram ), there  is 
on ly a w eak surface charge, w ith  subsequent lit t le  re p u ls io n /a ttra c tio n  o f 
e lectrons/holes, the re fo re  the  p h o to cu rre n t is neg lig ib le .
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3 .3 .3 . M e a s u r in g  A c id i f ic a t io n  R a te s
The pH of the sensor chamber remains constant once media is allowed to flow through it, as no 
build-up of acidic waste products can occur. The pH remains steady at approximately the pH of the 
running medium (pH 7.3-7,4). If the pump is stopped, acidic metabolites (lactic and carbonic acids) 
begin to accumulate in the sensor chamber with a subsequent pH drop, a drop which can be detected 
by the LAPS sensor chip. When the pump is turned on again the flow sweeps out the acidic 
metabolites, returning the pH of the chamber to its original value, where it remains stabilised until 
the pump is stopped again. This pump on-off cycle generates data traces such as that shown in 
Figure 3 .5. The pump off periods are quite short (10-40s) which prevents the build-up of harmful 
levels of metabolic products.
The data obtained during the pump-off interval (also known as the get rate period) are fitted to a 
straight line, the slope [-|iV/sec| of which is plotted as the acidification rate (Figure 3.5). If the 
metabolic rate of the cells changes in response to an effector agent (either stimulatory or inhibitory), 
the acidification rate data will reflect this change (Figure 3.5).
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F igu re  3.5: Raw (A ) and R ate (B ) data derived fro m  an experim ent in  w h ich  A431 cells
w ere exposed to  25ng/m l E G F  fo r 12 m ins (T im e o f E G F  exposure = 1:40:00). 
As can be seen fro m  the  raw  data, a noticeab le increase in  the  a c id ifica tio n  
ra te  d u rin g  the  p u m p -o ff cycle (h igh ligh te d  in  b lue) denotes activa tion  o f the 
E G F -recep to r in  these cells. Th is change in  the  cells m etabo lic ra te  is re flected 
in  the  R ate data  (B ).
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3.4. A P P L IC A T IO N S  O F  T H E  C Y T O S E N S O R  M IC R O P H Y S IO M E T E R
A major attribute of the Cytosensor Microphysiometer is its flexibility: it accurately measures a 
general cellular event (extracellular acidification), and as such is applicable to a variety of 
biological disciplines (Table 3.3).
D is c ip l in e A p p l ic a t io n R e fe r e n c e s
Pharm acology Receptor characterisation 
Signal transduction
Baxter et al. (1994), Pitchford et al. (1997) 
Baxter et al. (1992), Pitchford et al. (1995)
Toxico logy Ocular irritancy
Neurotoxicity
Hepatotoxicity
Bruner et al. (1991) 
Wada et al. (1992) 
Cao et al. (1998)
C ell B io logy Transient transfections 
NaVH' antiport studies
Chio et al. (1994), Skwish et al. (1994) 
Neve et al. (1992), Wada et al. (1993)
Im m uno logy T-cell activation 
B-cell activation 
Macrophage/monocyte studies
Wada et al. (1994)
Renschler et al. (1995)
Romano et al. (1996), DeVries etal. (1998)
O ncology Chemotherapeutic efficacy 
Apoptosis
Wada etal. (1992) 
Kuo et al. (1994)
M ic ro b io lo g y Antibiotic susceptibility assays 
Anti-viral studies 
Ion channel studies
Libby et al. (1998)
Wada et al. (1992) 
Hahnenberger et al. (1996)
Table  3.3: L is t o f the  va rious research app lica tions to -da te  o f the Cytosensor
M icrophys iom e te r in  b io log ica l studies.
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As an assay system that reliably measures cell surface receptor activation, with subsequent 
intracellular signalling events, the cytosensor has been principally applied to pharmacological 
investigations, being particularly advantageous over traditional methods for determining 
agonist/antagonist profiles o f receptors (Baxter et a l, 1994; Jaen etal., 1995; Mierau et al., 1995). 
However, it has also featured in toxicological evaluations of compounds and has been shown to be 
suitable as an in vitro alternative in ocular irritancy testing (Bruner et al., 1991).
Although general in its method of detection, the cytosensor can be used as a specific probe of 
signal transduction events in cells, through the appropriate use of neutralising antibodies, antisense 
oligonucleotides, specific enzyme inhibitors, channel blockers etc. (Baxter et al., 1992; Wada et al.,
1992). It has many advantages over traditional methods for examining signal transduction, as 
outlined in Table 3.4.
A d va n ta g es  o f  th e  C y to sen so r  M ic ro p h ys io m e te r
N on-Invasive  - Internal controls; Can examine recovery from toxic insult.
“ R ea l-tim e”  M easurem ent -  No need to do multiple assays for time course 
points
Fast Results -  Quicker than traditional assays (Ca21 mobilisation, 1P3 assays)
H igh  R e p ro d u c ib ility
F le x ib ility
No R a d io a c tiv ity
Reduced A n im a l Usage
T able  3.4 : Advantages o f the C ytosensor M icrophys iom e te r fo r research app lica tions.
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3.5. U SE  O F  T H E  C Y T O S E N S O R  M IC R O P H Y S IO M E T E R  I N  T H IS  W ORK.
The Cytosensor M icrophysiom eter was used extensively throughout th is w ork to  examine the 
effects o f coumarins on cultured cells. As outlined in  Chapter 4, th is instrum ent was in itia lly  used to  
examine the effects o f coum arin compounds on the basal m etabolic rate o f cultured cells. As this 
was part o f an overall assessment o f the to x ic ity  o f these compounds to  tum our cells, parameters 
such as dose and tim e-dependency, as w e ll as re ve rs ib ility  were examined. This system was found 
to  be superior to  the M T T  assay (a well-established in vitro to x ic ity  assay) w ith  respect to  to x ic ity  
prediction. As a prelude to  th is  w ork, the Cytosensor M icrophysiom eter was evaluated fo r its 
usefulness as a tox ico log ica l to o l by va lida ting  previous to x ic ity  w ork carried out by  d iffe ren t 
investigators (Parce et al., 1989; Bruner et a l , 1991) in  th is  fie ld . This w ork is reported in  Appendix
1.
In  Chapter 5, the cytosensor was used to  examine the e ffect o f coumarins on signal transduction 
in  human tum our cells. Tw o signalling events in  pa rticu la r were investigated: activation o f 
Epiderm al G row th Factor (EGF)-Receptor, and activation o f Protein Kinase C (PKC).
In  Chapter 6, the cytosensor was used to  assess the activation o f tw o  m onocytic ce ll lines (H L - 
60 and 28SC) in  response to  various imm une ce ll m odulators and stim ulators.
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Chapter 4
The effects o f coumarins on the 
growth and metastasis o f human tumour cells
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4.1. IN T R O D U C T IO N  TO  C H E M O S E N S IT IV IT Y  T E S T IN G
As outlined in Section 1.8.1, current cancer therapies, even combination therapies, offer 
limited success for cancer patients, with many common solid tumours completely refractory to 
treatment. Therefore, the harsh reality for scientists and clinicians alike, is that new, more effective 
anti-tumour agents, and better treatment strategies are required, to supplement the current treatment 
modalities. As a result, a vast program of screening of compounds (both natural and synthetic) has 
been instigated by government and private institutions worldwide. Central to these programs, is the 
development and improvement o f biological tests for the accurate prediction of anti-tumour 
properties in screened agents, also known as the field of chemosensitivity testing (Twentyman, 
1985; Weisenthal & Lippman, 1985; Cramer & Woltering, 1991; Bellamy, 1992).
4.1 .1 . C u rren t C h em o sen sitiv ity  T ests
The introduction of chemosensitivity testing has transpired for the following three reasons:
1. The preliminary screening of novel anti-tumour agents.
2. Improvement o f drug responses in patients using existing drugs. This can be achieved 
through the testing of new drug combinations and dose schedules, as well as from 
information gained about their mechanisms of action. Experiments into drug resistance in 
tumour cells also yield improvements in chemotherapeutic potential of existing drugs.
3. Adaptation of chemotherapy regimens to individual patients by testing for drug 
resistance/sensitivity in both relapsed patients or patients with a primary tumour.
For general screening procedures, as presented for the coumarin compounds in this thesis, 
cultured cell lines are widely utilised as the cellular source (Alley el al., 1988; Kratzke & Kramer,
1996). However, the ultimate aim in the development and improvement of chemosensitivity tests is 
for their application in the clinical arena in the hope of eliminating the exposure of patients to harsh, 
non-beneficial chemotherapeutic regimens. Therefore, a substantial portion of the literature in this 
area involves the use o f biopsied patient samples (Sargent & Taylor, 1989; Wilson et al., 1990; 
Sevin el al., 1994) and deals with the issue of correlating in vitro and in vivo observations 
(Bertelsen et al., 1984; Cramer & Woltering, 1985; Yung, 1989)
In examining the sensitivity of tumour cells (both biopsy and cultured cell samples) to 
compounds, one can examine the effect of the compound on one of a number of cellular
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mechanisms e.g. ce llu la r p ro life ra tion , ce llu la r metabolism , ce ll v ia b ility  or ce ll m orphology (Table 
4.1). For m any years now controversy has existed w ith  regard to  the use o f clonogenic versus non- 
clonogenic chem osensitivity testing systems, w ith  clonogenic assays being regarded by some as the 
“ gold standard”  against w hich a ll chem osensitivity tests should be scored. B rie fly  the clonogenic 
assays (used ch ie fly  w ith  biopsied samples) are s im ila r to  an tib io tic  sens itiv ity  testing in bacteria -  
fo llo w in g  exposure to  a test compound, a single suspension o f cells is plated out and fo llo w in g  a 
long (weeks) incubation, the num ber o f colonies form ed is counted (Ham burger &  Salmon, 1977). 
The p ro life ra tive  cells (colony form ing cells) are deemed to  represent the tum our stem cells, the 
portion  o f the tum our believed to  “ regrow ”  fo llo w in g  therapy. I t  is thus thought that measuring the 
stem ce ll population after dm g exposure is the true measure o f the therapeutic effect o f a given 
drug. However, m any investigators disagree as to  the relevance o f th is assay to  chemotherapeutic 
research -  some believe tha t destruction o f other tum our cells (tum our debulking) is as im portant as 
stem ce ll destruction, as these cells m ay be responsible no t fo r grow th, but fo r invasion/metastasis, 
immunosuppression and cancer-related cachexia. In  addition, various papers have questioned die 
v a lid ity  o f the argument that clonogenic assays actually detect tum our stem cells (Twentyman, 
1985; W eisenthal &  Lippm an, 1985; Yung, 1989). W eisenthal and Lippm ann (1985), in  particu lar, 
have addressed the theoretical problem s o f these assays, believing that alternative non-clonogenic 
methods detecting ce ll k ill o r ce ll damage in  to ta l tum our ce ll populations (Table 4.1) are as va lid  
and more techn ica lly feasible fo r the prediction o f chem osensitivity.
From  Table 4.1 it  can be seen tiia tth e  available chem osensitivity assays, w ith  the exception 
o f xenograft im plantation, a ll examine the effect o f compounds in  an in vitro  set-up. Use o f the 
xenograft m odel overcomes some o f the lim ita tions o f in vitro  testing, not least through the 
preservation o f the h isto log ica l features o f the orig ina l tum our. In  addition, drugs that require in 
vivo  m etabolic activation can be tested using xenografts, provided the mouse is an appropriate 
m etaboliser o f the test compound. However, there are disadvantages coupled to  the use o f the 
xenograft model, in  pa rticu la r its  resource and tim e constraints. A  fu ll lis t o f the advantages and 
disadvantages o f the various chem osensitivity methods available is provided in  Table 4.2.
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A ssa y  M e a su re s  M e th o d  R efe ren ce B r ie fD e sc r ip tio n  o f  A ssa y
C ELLU LA R
PR O LIFE R A T IO N
(In Vitro)
(i) ST E M  C EL L C lonogenic Hamburger & Salmon, 
(1977)
Measures colony formation capability o f  
cells (no. o f  stem cells)
(ii) TO TA L CELL Total Cell Counts Lickiss etal. (1974) Measures total number o f  cells
R adionucleotide
Incorporation
K e r n e /al. (1985) Measures rate o f  radioactive precursor 
incorporation into DNA/RNA
K enacid Blue Clothier (1995) Measures total cell protein
C E L LU LA R
PR O L IFE R A T IO N
(In Vivo) X enograft Tveit (1983) Measures the change in size o f  human 
tumour cells transplanted into immune- 
defïcient or immune-deprived m ice
C E L LU LA R
M E T A B O L ISM
M TT A ssay Carmichael et al. (1987) Measures rate o f  reduction o f  tétrazolium  
salt by mitochondrial dehydrogenases in 
metabolically active cells
A T P  A ssay Kangas et al. (1984) Measures intracellular ATP levels in cells 
(levels decrease as cells die)
PTO
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CELL V I ABILITY
STA IN IN G D ye Exclusion W eisenthal & Kern 
A ssay (1991)
Measures ability o f  viable cells to 
exclude stains.
F luorescent Meitner (1988)
C ytoprint A ssay
Measures ability o f  viable cells to 
transport, hydrolyse and retain 
fluorescein.
M E M B RA N E
D A M A G E
LD H  A ssay Welder & Acosta (1994) Measures release o f intracellular enzyme
(LDH) as a result o f  membrane damage
2-Deoxy-D -
Glucose
W alum & Forsby (1995) Measures release o f tritiated 2-deoxy-
D-glucose from cells
C ELL
M O R PH O L O G Y
Trump & Berrezesky Measures changes to morphological
(1994) features o f  cell
Table 4.1: Table o u tlin in g  the  c u rre n t chem osensitiv ity tests ava ilab le . These can be used
fo r the  screening o f novel chem otherapeutic agents, fo r testing  d rug  
com binations, and fo r  d e te rm in ing  m echanism s o f action  o f cu rre n t and new 
drugs. The in fo rm a tio n  gained can be used to  im p ro ve  the  responses o f cancer 
patien ts to  an existing , th e ra p y  o r a novel one, by conducting p red ic tive  
sensitiv ity /res is tance  testing  fo r in d iv id u a ls .
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Table 4.2: Advantages and disadvantages of various chemosensitivity tests.
A s s a y  A d v a n t a g e s  D i s a d v a n t a g e s
CELLULAR
PROLIFERATION
Total Cell Counts • Simple • Labour-intensive
• Rapid: Results < 1 week • Density-dependent responses
9 Versatile i.e. Easily examine • Relevance (to in vivo situation)
time- & dosc-dcpcndencies,
drug combinations
Radionucleotide • Rapid: Results < 1 week • Labour intensive
Incorporation © Versatile • Radionucleotides may be toxic to
• Can be automated cells => cell kill over-estimation
• Uncertain influence of drug on
transport or pool of nucleosides
Kcnacid Blue « Simple & rapid 9 Does not distinguish between
« Semi-automated live and dead cells
• Versatile
Clonogenic Assays • Detects most biologically m Only subpopulation evaluated -
significant population is this truly representative?
• Fibroblast growth prevented • Low cloning efficiencies
« Long assay times (15 days)
• Colony counting laborious
• Difficult to obtain single cell
suspensions without damage
Xenografts • Tumour architecture and • Latent period of 10-40 days
environment maintained before tumour appearance
a Testing of drugs requiring in 9 Sterile handling and housing
vivo metabolic activation required
• Useful for optimising S Maintaining athymic mice
scheduling expensive PTO
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Assay A d v a n ta g e s D is a d v a n ta g e s
C E L LU LA R  
M E T  ABOT JS M
M T T  A ssay • Rapid & Versatile • Cannot distinguish cytostatic vs
• Semi-automated cytotoxic effects
• Must be optimised for each cell
line
• Test drug may interfere with
formazan production or affect
mitochondrial activity (over- or
under-estimation)
A T P A ssay • Rapid & Versatile • Reversible ATP changes can
• Very sensitive assay o f  cell occur without loss o f  viability
death
CELL V IA BIL ITY
Staining • Simple & Rapid • Intra-observer variability
• Cell growth not required • In monolayers, dead cells detach
and may be washed away =>
underestimation
M em brane D am age • Simple & Rapid • Test compound may interfere
(LDH ) * Semi-automated with LDH
• Enzyme leakage does not always
equate to irreversible injury
C EL L M O R PH O L O G Y
C ell m orphology • Very well-studied => excellent • Difficult to standardise
predictions o f  cell death • Observed changes may not
mirror lethal cell damage
Table 4.2 (Continued)
83
There has been an increase in the use of continuous human tumour cell lines in the 
screening of new compounds for their anti-tumour properties (Hill, 1983; Alley et al., 1988; 
Kratzke & Kramer, 1996). The various advantages of using these as opposed to biopsied samples 
for screening new agents are outlined in Table 4.3. This table also includes the limitations of using 
cultured cells, and some remedies that can be applied to overcome these pitfalls.
The chemosensitivity screening for novel anti-cancer compounds described above has 
introduced an exciting new dimension to the drug discovery field. There is little doubt this 
predictive screening, particularly through the use of a battery of tests, will supersede the clinical 
“trial and error” approach o f traditional chemotherapeutic regimes, with the cancer patient 
ultimately reaping the benefits.
A d va n ta g es L im ita tio n s  & R em ed ies
Rapid screening capabilities - Artificial Environment with selection pressures
Identification of lead compounds causes loss of certain physiological properties and 
tumour characteristics =>
Compensate by using a wide spectrum of cell lines in 
the screening test.
Can study both time-and dose-dependencies Altered drug metabolism and pharmacokinetics in
vitro vs in vivo =>
Identify metabolite and use in assay, or include 
metabolising enzyme in in vitro test
Good supply of cellular material -  large Impossible to replicate immunological or
number of assays can be performed inflammatory conditions in vitro.
Table 4.3: Advantages and L im ita tio n s  o f using cu ltu re d  hum an tu m o u r cells in
chem osensitiv ity testing  p ro toco ls.
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4.2. O T H E R  A N T I- T U M O U R  S T R A  T E G IE S
A new avenue currently being examined by cancer scientists is the development of anti­
metastatic compounds, as opposed to anti-proliferative compounds, as tumour treatment agents 
(Denis & Verweij, 1997; Yu et al., 1997).
4.2.1. O verv iew  o f  M eta s ta ses
The ability of primary tumour cells to invade surrounding tissues and establish secondary 
sites of growth in areas distant from the original tumour, characterises them as a malignant, rather 
than benign, growth. Metastasis, the spread of a malignant tumour, is the principal cause of death in 
cancer patients, and has often taken place by the time a patient presents clinically. The formation of 
metastatic lesions entails a number of coupled, sequential steps that must be fully completed by 
tumour cells in order for a secondary tumour to develop (Fidler, 1990). Central to this metastatic 
process is the degradation of the extracellular matrix (ECM), which is accomplished through 
enzymatic attack of the ECM components (Duffy, 1998).
4.2.2. T h e E x tra c e llu la r  M a tr ix  (E C M )
The ECM is a complex network of specialised glycoproteins and proteoglycans, that 
functions as a physical support for cells, isolating tissues and promoting attachment of cells 
(Haralson & Hassell, 1995). The ECM consists of the basement membrane [composed of types IV 
and V collagens, laminin, entactin and a number o f proteoglycans], and the interstitial connective 
tissue [the principal component of which is collagen, with fibronectin, elastin and heparan sulphate 
proteoglycans, also present]. During tumour invasion and progression, disruption of the basement 
membrane is achieved via proteolysis, of collagen in particular, following the release of a number 
of enzymes (Duffy, 1998). Four main enzyme classes are implicated: serine proteinases (e.g. 
urokinase plasminogen activator or uPA), cysteine proteinases (e.g. cathepsin B), aspartyl 
proteinases (e.g. cathepsin D) and matrix metalloproteinases (e.g. MMP-2). The matrix 
metalloproteinases (MMPs) are believed to be most active in the advancement of this degradative 
process.
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4.2 .3 . T he M a tr ix  M eta llo p ro te in a se  (M M P ) F a m ily
To date th is  fa m ily  o f enzymes consists o f approxim ately tw enty members, but th is lis t is 
con tinua lly  grow ing, as new members are cloned and sequenced. A ll members have the fo llow ing  
characteristics: they are endopeptidases that degrade at least one component o f the extracellu lar 
m atrix ; they have a characteristic pattern o f conserved domains, as ascertained through sequencing 
studies; th e ir active site contains a zinc ion, and they require a second m etal cofactor, such as 
calcium , fo r ac tiv ity , they are also inh ib ited  by chelating agents; they are secreted in a latent, 
proenzyme fo rm  and require activation in  order to  in itia te  proteolysis; and they are inh ib ited  by 
specific tissue inh ib ito rs o f metalloproteinases [T IM P s] (M organ, 1998).
These enzymes are invo lved in  both norm al ce llu la r processes e.g. tissue rem odelling and 
repair, and destructive pathological processes e.g. tum our invasion and metastasis, rheumatoid 
arth ritis . As m entioned above the a c tiv ity  o f these enzymes is h ig h ly  controlled through secretion o f 
latent pro-enzym e form s; the genetic expression is also intensely regulated, w ith  transcription o f 
genes pos itive ly  regulated by  a varie ty o f b io lo g ica lly  active agents -  hormones, grow th factors, 
cytokines, oncogenes and tum our prom oters (M atrisian, 1990).
In  the past th is enzyme fa m ily  has been sub-classified according to  th e ir substrate 
spec ific ity  as fo llow s: (a) Type I  collagenases, w h ich degrade fib r illa r  collagenases; (b) Type IV  
collagenases, w hich degrade basement membrane collagens, and (c) S trom olysins, w hich have a 
broad substrate spec ific ity , degrading E C M  proteoglycans and glycoproteins (M atrisian, 1990). 
Expression o f the tw o  members o f the Type IV  collagenases (M M P-2 and M M P -9), is widespread 
and com m only elevated in  human tum ours (Chambers &  M atrisian, 1997). In  particu lar, enhanced 
in vivo  expression o f M M P-2 and M M P -9 has been shown fo r cancers o f the prostate (Steams &  
Wang, 1993), breast (Monteagudo et a l ,  1990), renal (G oh ji et al., 1994), skin (K arelina et al.,
1993) and colon. (Levy e t al., 1991). Regardless o f tum our type both these gelatinases have been 
localised to  the invasive fron t o f the tum our ce ll mass (Chambers &  M a tris ia n , 1997).
Due to  th e ir immense im portance in cancer progression and th e ir correlation w ith  cancer 
m o rta lity  levels, in h ib itio n  o f these enzymes in vivo , w ith  either natural or synthetic inh ib ito rs, is 
now  a large focus o f cancer research programs. I t  is hoped that suitable anti-m etastatic agents, 
w hich function through in h ib itio n  o f M M P  expression o r ac tiv ity , w ill jo in  current anti-p ro life ra tive  
agents, in  future treatm ent strategies (Denis &  V erw e ij, 1997; Yu et a l ,  1997).
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4.3. C O U M A R IN S  I N  C A N C E R  T H E R A P Y
As described earlier in Section 1.8, interest in couinarins as putative anti-cancer agents 
arose from reports that these compounds achieved objective responses in some patients with 
advanced malignancies. In particular the effectiveness of coumarin in vivo, in malignant melanoma, 
renal cell and prostate cancer patients, has been described (Thornes, 1997; Ebbinghaus et a l,  1997; 
Mohler et a l, 1997). As a result of these observations various investigators have focussed their 
attention on the in vitro study of coumarin, and in particular its chief human metabolite, 7- 
hydroxycoumarin, in an attempt to determine the validity of the in vivo reports, and elucidate the 
mechanism of anti-tumour action of coumarin compounds.
4.3.1. In  V itro  T es tin g  o f  C o u m a rin s
4.3.1.1. Coumarin and 7-H ydroxycoumarin
Chemosensitivity testing of coumarin and its chief human metabolite, 7-hydroxycoumarin, 
has been achieved by several investigators utilising in vitro cell proliferation-based methods. Total 
cell counts (Moran et a l, 1993; Marshall et a l, 1994), radionucleotide incorporation (Siegers & 
Bostelmann, 1993; Marshall et al., 1994) and MTT growth assays (Myers et al, 1994) have all been 
utilised. In all studies, a time- and dose-dependent inhibition of cell growth has been observed on 
exposure to both coumarin compounds. 7-hydroxycoumarin appears to exert a more potent 
inhibitory activity, which would support the widespread belief that coumarin is a pro-drug for this 
active agent. To date a variety of cell-lines have been tested and a pattern of cell-type sensitivity has 
begun to emerge, with renal, prostate, breast, glioblastoma and leukemic cell lines most susceptible 
to the cytostatic effects (Ebbinghaus et a l, 1997). Marshall et al. (1994) have conducted 
reversibility studies and found the growth-inhibitory effect of 7-hydroxycoumarin to be reversible.
Combination of coumarin and 7-hydroxycoumarin with other anti-tumour agents has shown 
synergistic effects in vitro. Zippe and co-workers (1990) showed that coumarin and 7- 
hydroxycoumarin in conjunction with tumour necrosis factor (TNF), caused an increased growth 
suppression in prostatic carcinoma cell lines. This scenario was not found for other 
interferon/coumarin combinations (Zippe et al., 1990). In addition Myers et al. (1994) reported 
increased growth inhibition in prostatic cell lines for combined coumarin/suramin (a 
chemotherapeutic agent in clinical trials) dosages, compared to coumarin only exposure, illustrating 
the potential for coumarin usage in combination chemotherapy regimes.
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A  num ber o f natural and synthetic coum arin derivatives have also been examined in vitro 
fo r th e ir grow th in h ib ito ry  ac tiv ity . Rosskopf and colleagues (1992) studied the anti-tum our effects 
o f coum arin and some o f its  derivatives on the in vitro  p ro life ra tion  o f mastocytoma (P-815) and 
leukaem ic (P-388) cells. A ll compounds (7-hydroxycoum arin, 4-hydroxycoum arin, o-, m -, and p- 
coum aric acid) were found to  be cyto toxic a t concentrations greater than lOOpg/ml. Egan et al. 
(1997) determ ined the in vitro  a c tiv ity  o f the synthesised derivative, 8-nitro-7-hydroxycoum arin. 
This compound displayed cyto toxic properties in  tw o  human ce ll lines tested (H L-60 and K562), 
inducing ce ll death by apoptosis. This compound exerted a cytostatic e ffect on the three other ce ll 
lines tested, exerted through a perturbation in th e ir ce ll cycle (Egan e t al., 1997). K olodzie j and co­
workers (1997) evaluated the cy to to x ic ity  o f 22 sim ple coumarins to  tw o human ce ll lines 
(colorectal and sm all ce ll lung carcinoma) using the M T T  assay. W hile  most compounds exhibited 
lo w  tox ic ities  to  these cells lines over 96hrs, they found the dihydroxy-com pounds (6,7- and 6,8- 
dihydroxycom pounds) to  act as very potent an ti-p ro life ra tive  agents.
4.3.2. In  V ivo  T estin g  o f  C o u m a rin s
The chem osensitivity testing o f coum arin and its  derivatives has also taken place in  animal 
(in vivo) models. In  various tum our models in  test animals (Omarbasha e t al., 1989; M aucher et al., 
1993; von Angerer e t al., 1994), coum arin was shown to  strong ly in h ib it m alignant grow th. Tseng 
(1993) also demonstrated the e fficacy o f coumarin in  reducing tum our form ation in transgenic mice, 
at non-toxic levels (200uM ).
Raev et al. (1990) used xenograft models to  assess the anti-tum our a c tiv ity  o f five  
coum arin-pyrid ine derivatives. Im plantation o f leukaem ic and lung carcinoma cells, was fo llow ed 
by intra-peritoneal treatm ent w ith  the test compounds. O nly one caused inh ib ition  o f tum our 
growth.
4.3.3. F u r th e r  W ork w ith  C o u m a rin  D eriva tiv es
As part o f the w o rk  described in th is  chapter, we chose to  examine tw o  coumarin 
compounds, previously unexam ined by coum arin investigators fo r th e ir anti-cancer properties. I t
4.3 .1 .2  O th er  C o u m a rin  D eriva tives
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has become apparent, from  the literature, that the previous b e lie f that 7-hydroxycoum arin was the 
on ly m etabolite o f importance in vivo is flawed. As outlined in  Section 1.4.2.2, the existence o f 
other hydroxy-m etabolites, has been described fo r humans. In  particu lar, 3-hydroxy-, 4-hydroxy-, 6- 
hydroxy- and 6,7-dihydroxy-coum arin (also known as esculetin) production has been observed in 
humans (van Sumere et a l,  1959; Fentem &  Fry, 1992; Steensma et a l,  1994). I t  is plausible that 
one o f these, rather than, or in  conjunction w ith  7-hydroxycoum arin, m ay be responsible fo r the 
anti-cancer properties o f coum arin in vivo.
3-hydroxycoum arin has been well-characterised as a compound, thanks to  the large number 
o f anim al studies accomplished during the controversy regarding the to x ic ity  o f coum arin to 
humans (Section 1.5). Being the structural backbone o f the w id e ly  used anti-coagulant, w arfarin, 
the properties o f 4-hydroxycoum arin have also been well-researched, and w arfarin  has found use in 
the treatm ent o f a varie ty o f cancer ce ll types (Cooke et a l,  1997). However, neither 6- 
hydroxycoum arin nor esculetin have been investigated w id e ly  -  we therefore chose to  examine 
these tw o compounds, in  deta il in  our studies.
V ery little  w ork has been reported on the b io log ica l properties o f 6-hydroxycoum arin -  one 
research group included th is  compound in  th e ir exam ination o f retinal function recovery fo llo w in g  
ischem ia, and the effect o f various coumarins on th is event. Recovery o f re tina l cells in  the presence 
o f 6-hydroxycoum arin was not as effective as in the presence o f esculetin (L iu  et al., 1997). To 
date, no other assessment o f the b io log ica l o r anti-tum our a c tiv ity  o f th is  compound has been 
reported.
The b io log ica l properties o f esculetin have been investigated more thoroughly. Esculetin is 
a known free-radical scavenger (Paya et a l,  1992; Chang et a l,  1996), a property shared w ith  
various coumarins inc lud ing  7-hydroxycoum arin. Some o f its scavenging a b ility  derives from  its 
in h ib itio n  o f the superoxide-generating xanthine-oxidase enzyme (Chang &  Chiang, 1995). 
Esculetin has also been reported as a potent in h ib ito r o f lipoxygenases (Sekiya et al., 1982; K im ura 
et al., 1985; H ou lt et al., 1994) This may be o f some im portance from  a grow th in h ib ito ry  
v iew poin t, as leukotrienes (form ed by  the action o f lipoxygenases on arachidonic acid) have been 
shown to  be invo lved in ce ll transform ation, tum our grow th and metastases form ation (Honn &  
M am ett, 1984; Reich &  M artin , 1996). A dm inistration o f lipoxygenase inh ib ito rs has been shown 
to  decrease p ro life ra tion  o f various cancer ce ll lines in vitro (Rose &  C onnolly, 1990, 1991; 
Hofm anova et al., 1996), and some studies have examined esculetin in  th is  capacity (Hofm anova et 
al., 1996; N oguchi et al., 1997). Esculetin could suppress grow th in  both the presence or absence o f
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lino le ic  acid (N oguchi et al., 1997). The 6,7-d ihydroxy-function  on a coum arin ring was found by 
K o lodzie j and colleagues to  exert a very potent an ti-p ro life ra tive  effect, in  th e ir broad assessment o f 
grow th in h ib itio n  o f coum arin compounds. Esculetin has also been shown to  in h ib it the grow th o f 
vascular smooth muscle cells (Huang et a l ,  1993), but th is e ffect was believed to  be mediated by 
inh ib ition  o f ce llu la r tyrosine kinases.
4.4. C H A P T E R  O U T L IN E
This chapter outlines chem osensitivity studies in to  the effects o f fou r coumarin compounds 
(coum arin, 6-hydroxycoum arin, 7-hydroxycoum arin and esculetin) on cultured human tum our ce ll- 
lines. Coum arin, 7-hydroxycoum arin and esculetin were com m ercially-available products, w h ile  6- 
hydroxycoum arin was synthesised and characterised in  DCU, by Dr. O liver Egan (The 
characterisation o f the synthesised compound is outlined in  A ppendix 2).
The effect o f these fo u r compounds on grow th inh ib ition  in  n ine ce ll lines is outlined. The 
effects o f these compounds on ce llu la r m etabolism  and protease secretion from  one ce ll line  in  
particu lar, is then described in  detail.
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4 .5 . R E S U L T S  A N D  D I S C U S S I O N
4.5.1. In  V itro P ro life ra tio n  A ssa y s
Previous investigators have used ce ll proliferation-based assays in  th e ir chem osensitivity 
assessment o f coum arin compounds (M oran et al., 1993; Siegers &  Bostelmann, 1993; M arshall et 
a l ,  1994; M yers e t a l, 1994). For com parative purposes, we chose in itia lly  to  examine the four 
coumarin compounds, nam ely coum arin, 6-hydroxycoum arin, 7-hydroxycoum arin and esculetin, 
under s im ila r assay procedures, fo r a range o f ce ll lines (Table 2.2). N ine ce ll lines were exposed to  
each o f the fo u r compounds fo r 96 hours as outlined in  Section 2.2.4.2. In  general, cells were 
exposed to  drug concentrations in  the range 0-20 0 |.ig/m] 6-hydroxycoum arin, 0-2 0 ug/m l esculetin, 
w h ile  ranges o f 0-150pg/m l, were u tilised  fo r coum arin and 7-hydroxycoum arin exposure. 
However, variations on th is dosing schedule d id  occur depending on observed ce ll line  sensitivity. 
F o llow ing  exposure, ce ll counts were perform ed, and the increase in ce ll num ber fo r drug-treated 
cells was expressed as a percentage o f the increase fo r solvent-treated contro l cells, and grow th 
curves were constructed from  th is  data.
Figure 4.1. shows typ ica l grow th curves fo r cells exposed to  the fou r coumarin compounds, 
fo r tw o  o f the nine ce ll lines tested -  A431, an epiderm al carcinom a ce ll line  o f vu lva l o rig in , and 
M C F-7, a breast carcinoma ce ll line. In  the case o f the A431 ce ll line , p re lim ina ry studies showed 
th is ce ll line  to  be quite sensitive to  the coum arin compounds and thus exposure to  the four 
compounds is illustra ted in  the range 0-20fig /m l drug (F igure 4.1, top). As shown, a ll four 
compounds caused a s ign ifican t cytostatic e ffect over the 96 hour exposure period, w ith  7- 
hydroxycoum arin illu s tra ting  the m ost potent effect, fo llow ed by esculetin, coum arin and 6- 
hydroxycoum arin, in  decreasing order o f potency. The grow th curve shown fo r the M CF-7 ce ll line 
(Figure 4.1, bottom ) is more typ ica l o f the curve type obtained fo r most o f the other eight ce ll lines 
tested fo r tw o reasons. F irs tly , a concentration range up to  200^g/m l was used fo r a ll compounds 
except esculetin, where the range 0-20p.g/m l was u tilised  to  observe cytostatic effects. Secondly, the 
sensitiv ity  trends observed showed the ce ll line  re la tive ly  insensitive to  the effects o f coumarin, 
extrem ely sensitive to  the effects o f esculetin, w ith  an interm ediate cytostatic effect observed fo r the 
tw o  hydroxycoum arin compounds. G row th curves fo r the other seven ce ll lines tested are included 
in  an appendix (Appendix 2).
The graphs constructed fo r each ce ll line/drug com bination were u tilised  to  obtain IC 50 
values (IC 50 value defined as the concentration o f drug tha t causes a 50% inh ib ition  o f grow th in
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drug-treated cells as compared to  untreated contro l cells). These values are shown in  Table 4.4, and 
together w ith  the grow th curves illustra te  some im portant facets o f the cytostatic effects o f the four 
coumarin compounds. F irs tly , the parental coum arin compound d id  not adversely affect the 
p ro life ra tion  o f the m a jo rity  o f the ce ll lines tested. A lthough a concentration-dependent decrease in 
p ro life ra tion  was observed on exposure to  coum arin, it  was m in im al, and seven o f the ce ll lines 
tested had IC 5o values greater than 140fag/ml. O f the tw o  rem aining ce ll lines, as mentioned before, 
the A431 ce ll line  appeared extrem ely sensitive to  a ll the coum arin compounds, and the N IH 3T3 
ce ll line  is not a tum our ce ll line , bu t a norm al mouse ce ll line , included in  the assays as a 
representative fib rob lastic, rather than epiderm al-type cell. The insensitiv ity  o f most o f the ce ll lines 
tested to  grow th in h ib itio n  by coum arin, seems to  confirm  the genera lly he ld  b e lie f that coumarin is 
no t responsible fo r the observed in vivo  effects, but is a pro-drug fo r other active metabolites.
Secondly, w ith  regard to  6-hydroxycoum arin, addition o f a hydroxyl group at the 6 '- 
position  on the parent structure d id augment the grow th in h ib ito ry  properties o f th is  compound. O f 
seven ce ll lines, five  showed increased grow th inh ib ition  on exposure to  6-hydroxycoum arin 
compared to  tha t observed fo r coum arin. A ll grow th curves showed the concentration-dependent 
e ffect o f th is  grow th inh ib ition . A t tim es, a certain concentration “ threshold”  had to  be reached 
before in h ib itio n  o f grow th was observed, e.g. fo r SW480 cells no effect on ce ll p ro life ra tion  was 
observed u n til ~  50(.ig/m l. This “ threshold”  e ffect was du ly  reflected in  the IC 50 value o f SW480, 
w hich was large at ~149ug/m l. O f the other six ce ll lines, three, nam ely A431, M C F-7 and PC-3 (a 
prostate carcinoma ce ll line ), were more sensitive to  grow th in h ib itio n  by 6-hydroxycoum arin, as 
reflected in  the ir IC 50 values.
A dd ition  o f a hydroxyl group at the 7 '-position o f the coum arin ring  also introduced 
increased grow th in h ib ito ry  properties to  the core coumarin structure. This 7-hydroxycoum arin 
compound has been w ide ly  studied as i t  is the ch ie f human m etabolite, and, thus, o f immense 
interest to  investigators try in g  to  understand the in vivo anti-tum our properties o f coumarin. As 
shown here, th is increased grow th suppression appeared re la tive ly  ce ll-type specific w ith  prostate 
(PC3), leukem ic (H L60), bladder (T -24) and breast (M C F-7) ce ll lines showing increased 
sensitiv ity, but colon and lung lines insensitive to  th is effect. Again the cytostatic effects were dose- 
dependent. These results reflected w e ll the trends outlined by previous investigators (Ebbinghaus et 
al., 1997; Seliger, 1997)
The m ost evident trend from  the p ro life ra tion  curves and table o f IC 50 values, is the 
extraordinary sensitiv ity  o f a ll ce ll lines tested, to  grow th in h ib itio n  by esculetin (6,7-
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dihydroxycoumarin). With the exception of the A431 cell line, this compound is 10-100 times more 
inhibitory to cell proliferation than the parent coumarin compound. This reflects well the previous 
observation by Kolodziej and colleagues (1997), that a dihydroxy-function in either an ortho- or 
meta-format, was an extremely potent chemical structure for toxicity in two human tumour cell 
lines, as ascertained by the MTT assay. As this potency was not evident in either of the single- 
hydroxycoumarin compounds, the added potency must be due to the existence of a double hydroxy- 
function on the coumarin ring,
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Effect of Coumarins on A431 Cell Growth
Qi.Q
E _
i s_  -H
a! § O o 
c «- — O
8  3? (0 at
Concentration o f Drug (ug/ml)
Effect o f Coumarins on MCF-7 Cell Growth
Concentration of Drug (ug/ml)
F ig u re  4 .1 : In  Vitro C e ll P ro life ra tio n  Assays fo llo w in g  exposure o f cells (A431, top  and
M C F -7 , bo ttom ) to  4 coum arin  com pounds fo r 96 hours. A ll experim ents were 
conducted in  dup lica te  on th ree  separate occasions. The increase in  cell 
num ber fo r d rug -tre a te d  cells was expressed as a percentage o f the untreated 
co n tro l cells and p lo tte d  versus the app ro p ria te  d ru g  concentra tion .
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C ell L in e IC 50 C o u m a rin  
(u g /m l)
ICso 6 -H C  
(u g /m l)
ICso 7-H C  
(u g /m l)
IC 50 E scu le tin  
(u g /m l)
A 4 3 1 40.43 ± 0.99 56.94 ±4.17 10.31± 3.03 13.87 ±1.17
M C F -7 >150 57.03 ±2.12 101.33 ± 9.36 4.67 ±0.21
P C -3 > 150 64.44 ±2.63 78.75 ±1.23 8.83 ±1.56
T -2 4 140.75 ± 12.02 117.96 ±2.51 99.50 ±6.32 3.20 ±0.10
A 5 4 9 > 150 91.19 ±2.29 > 150 2.96 ±0.32
H L -6 0 > 150 100.30 ±7.83 69.35 ±4.35 1.59 ±0.09
S W 4 8 0 > 150 148.82 ± 18.34 > 150 4.52 ±0.44
S W 6 2 0 > 150 N.D >150 5.64 ±0.35
N IH 3 T 3 89.21 ±2.11 N.D. 69.36 ±5.10 0.73+0.05
Table 4 .4 : ICso Values determ ined fo r th e  exposure o f va rious ce ll lines to  coum arins.
The IC5 0 value is defined as the concen tra tion  th a t causes a 50%  in h ib itio n  o f 
g ro w th  in  d rug -trea ted  cells, as com pared to  un trea ted  co n tro l cells. F o r each 
ce ll lin e /d ru g  com b ina tion , the  IC50 value was determ ined fro m  in te rp o la tio n  
o f the  re levan t g row th  curve . Each experim ent was ca rrie d  ou t in  dup lica te  on 
th ree  separate occasions (n=3), and the  mean IC 50 value (±  standard devia tion ) 
fo r  these experim ents determ ined and tabu la ted  above.
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4 .5 .2 . F u r th e r  C h e m o s e n s i t iv i tv  T e s t in g  in  A 4 3 1  C e lls
As outlined in  Section 4.1. ce ll p ro life ra tio n  assays are o n ly  one o f a number o f 
chem osensitivity tests w hich can be used to  examine the response o f cells to  chem ical agents. 
Therefore, as part o f our study in to  the effects o f coumarins on cultured cells, we decided not to 
lim it th is investigation so le ly to  the an ti-p ro life ra tive  effects o f these agents, as many investigators 
in  the past have done, but to  also examine the e ffect o f these compounds on other ce llu lar 
mechanisms. W e decided to  lim it th is  investigation to  one ce ll line , A431, w hich as outlined in 
Section 4.5.1, was extrem ely sensitive to  a ll fo u r coumarins tested.
4.5.2.1. Lactate D ehydrogenase (LDH) A ssay
The LD H  assay is used to  examine the effect o f agents on ce ll membrane in te g rity  and is 
often regarded as a measure o f cy to to x ic ity  (W elder &  Acosta, 1994). When the plasma membrane 
o f any ce ll is damaged as a result o f to x ic  insu lt, lactate dehydrogenase (LD H ), a ubiquitous 
cytoplasm ic enzyme is rap id ly  released in to  the extracellu lar environm ent, and can be assayed as 
outlined in  Section 2.2.4.3.
A lthough th is  assay is a rapid and sim ple quantifica tion o f ce llu la r damage, one 
disadvantage o f the assay, as detailed in  Table 4.2. is the poss ib ility  tha t the test compound may 
in h ib it the L D H  enzyme a c tiv ity , causing underestim ation o f membrane damage. A dd itiona lly , the 
test compound m ay also react w ith  other assay components, e.g. te trazolium  salts, causing 
interference, w h ich again m ay lead to  inaccurate results. Therefore it  is essential when assessing 
membrane damage w ith  the LD H  Assay, that these tw o  possible interferences are excluded. 
Inh ib ition  o f L D H  a c tiv ity  is tested by  incubating a standard LD H  solution w ith  various drug 
concentrations, and determ ining the a c tiv ity  o f the enzyme in  the presence o f these drug 
concentrations. The second interference can be discounted by incubating the drug in  culture media 
w ith  the L D H  Assay reagents and detecting whether presence o f the drug gives rise to  an increased 
absorbance at 492nm (assay absorbance w avelength) compared to  drug-free culture medium.
This interference testing was achieved fo r a ll fou r coum arin compounds under investigation 
(coum arin, 6-H C , 7-HC and esculetin) as shown in  Figure 4.2. This diagram illustrates that none o f 
the fo u r compounds are inh ib ito rs  o f the enzyme a c tiv ity  (top), or react w ith  the assay components 
y ie ld ing  in te rfe ring  species (bottom ).
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Effect o f Coumarins on LDH Activity
120
C oum arin  6-HC 7-H C Esculetin
Drug
Interference of Coumarins with LD H  Assay Reagents
1 40
Coumarin 6-HC 7-HC Esculetin
Drug
F ig u re  4.2: C o n tro l tests co n firm in g  th a t coum arin  com pounds (0.25-250pg/m l) do not
in te rfe re  w ith  L D H  Assay reagents. R esults (A 4i»2nm) fo r d ru g  solutions are 
expressed as a percentage o f th e  co n tro l absorbance (A 0) a t 492nm . The 
coum arins w hen incubated w ith  an L D H  standard  (O .lU /m l) d id  no t in h ib it 
th is  L D H  a c tiv ity  (top ). Ao fo r L D H  standard  (O .lU /m l) =  0.594 ±  0.023. The 
coum arins w hen incubated  w ith  cu ltu re  m edium  alone d id  no t in te rfe re  
s ig n ific a n tly  w ith  o th e r L D H  assay reagents (bo ttom ). Ao fo r  co n tro l m edium  
=  0.181 ±  0.003
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H aving excluded interferences, A431 cells were incubated w ith  the fou r coumarins (range 
0.25-250|xg/m l) fo r 24 hours and the culture supernatants assessed fo r enzyme release using the 
L D H  Assay, as outlined in  Section 2.2.4.3. A  1% (v /v) T riton  X -100 solution in  culture medium 
was used as a positive contro l representing 100% membrane damage. The absorbances at 492nm fo r 
cells exposed to  T riton  X -100 were norm alised at 100%, and absorbances o f cells exposed to  the 
various drug concentrations expressed as a percentage o f th is  positive contro l (F igure 4.3). As can 
be seen, 24 hour exposure o f A431 cells to  coumarins caused no sign ifican t membrane damage 
when compared to  untreated cells.
24hr Exposure to Coumarins: LDH Assay
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Figure 4.3: LDH Assay of culture supernatants of A431 cells exposed to coumarins (0-
250pg/ml for 24 hours. Results (A492„m) for coumarin-treated cells are 
expressed as a percentage of A492Dm of positive control (Triton X-100) cells (Abs 
=1.417 ± 0.028). Each drug was tested in seven separate wells/plate, and the 
experiment was carried out on three separate occasions.
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4.5.2.2. A ssa y s  fo r  C e llu la r  M eta b o lism
W e next proceeded to  assess the e ffect o f the coum arin compounds on ce llu la r metabolism. 
Tw o methods were used in  th is  investigation: the M T T  Assay and the Cytosensor 
M icrophysiom eter. As w ill be outlined the la tte r method was found fo r a number o f reasons to  be 
superior fo r th is type o f assessment.
4.5.2.2.I. M T T  A ssay
The M T T  Assay is a well-established co lourim etric assay w hich can be used to  detect the 
effects o f agents on ce llu la r metabolism. The assay is based on the cleavage o f the ye llow  
tétrazolium  salt, M T T  (3 -[4 ,5-d im ethylth iazo l-2-yl]-2 ,5-d iphenylte trazo lium  brom ide), to  purple 
formazan crystals by m itochondria l dehydrogenases. Therefore cells must not on ly  be alive, but also 
m etabolica lly active fo r th is  reaction to  occur (Mosmann, 1983). The assay can be used in  either a 
long- (96hr) or short-term  (24hr) drug-exposure form at, to  assess the effects o f a drug on ce llu la r 
grow th or metabolism , respectively. Previously, the M IT  assay has been used in  the long-term  
form at to  assess the an ti-p ro life ra tive  effects o f coumarins (M yers et al., 1994; K olodzie j et a l ,
1997).
The assay was carried out as outlined in  Section 2.2.4.4. P rio r to  determ ining the effects o f 
the coum arin compounds on ce llu la r m etabolism  in  A 431 cells, optim isation o f ce ll seeding density 
(F igure 4.4) and interference testing (F igure 4.5) were necessary. O ptim um  seeding density o f A 431 
cells was found to  be 5 X  105 cells/m l, and th is  was used in  a ll subsequent assays. Incubating the 
M T T  reagents w ith  drug concentrations in  the absence o f cells (Figure 4.5) tested interference 
effects o f the coum arins. As shown neither coum arin o r 7-hydroxycoum arin interfered w ith  the 
tétrazolium  salt, w h ile  6-hydroxycoum arin interfered very s lig h tly  w ith  the M T T  salt at lOO^g/m l 
(A A 560nm = 0.063 ±  0.003). However, esculetin reacts m ild ly  w ith  the tétrazolium  salt in  the 
concentration range 10-100^g/m l, but intensely at concentrations >100^g/m l (A A 5fiorm =  0.431 ±  
0.010 -  1.847 ±  0.044). Therefore, a ll subsequent M T T  assays were conducted w ith  drug 
concentrations <  100|J.g/ml, and in  the case o f 6-hydroxycoum arin and esculetin, absorbance values 
were corrected fo r the interference effects.
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F ig u re  4.4:
Optimisation of Seeding Density for MTT Assay
Cell Number/ml
O p tim isa tio n  o f Seeding D ensity o f A431 cells fo r  M T T  Assay. 5 X  10s cells/m l 
was chosen as the  op tim um  density as i t  gave a h igh  A56onm value (1.137 ± 
0.033), a t a p re -p la teau  p o in t on th e  curve.
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Interference of Coumarins with the MTT Assay
Concentration of Drug (ug/ml)
Figure 4.5: Examination of the interference of coumarin compounds with MTT
tetrazolium salt in the absence of cells. Neither coumarin nor 7- 
hydroxycoumarin interfere, 6-hydroxycoumarin reacts very slightly at 
100ng/ml, but esculetin reacts intensely with the MTT salt especially at 
concentrations > 50^g/ml.
M T T  assays were conducted on A431 cells fo r a ll fou r coumarin compounds in  the 
concentration range 0-100fig /m l, w ith  24hr drug exposure. Figures 4.6 and 4.7 show the results fo r 
these experiments. From  F igure 4.6 it  can be seen tha t neither coum arin nor 6-hydroxycoum arin 
exerted any detrim ental e ffect on the m etabolic a c tiv ity  o f m itochondria l dehydrogenases in  cells 
exposed to  these drugs fo r 24hrs. Exposure o f cells to  7-hydroxycoum arin fo r 24hrs caused a slight 
decrease in  m etabolic a c tiv ity  a t concentrations greater than 10pg/m l - % decrease o f 5-10%  to 
lOOfxg/ml (90.37 ±  2.8% ). Esculetin exerted a more serious e ffect on the m etabolic conversion o f 
the M T T  salt compared to  con tro l cells, w ith  decreases in  a c tiv ity  observed at greater than 1 fag/ml. 
A n in h ib itio n  o f m etabolism  o f 28.38 ±  2.96 was observed at the highest tested concentration 
(100ng/m l).
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F igu re  4 .6 : M T T  Assay fo llo w in g  24h r exposure to  coum arin  (top ) and 6-
hyd ro xyco u m a rin  (bo ttom ) in  the  concen tra tion  range O -lOOfig/m l. A ll d rug  
concentra tions w ere tested in  seven separate w e lls /p la te  on three separate 
occasions. A ll absorbances (560nm ) o f test w ells w ere expressed as a 
percentage o f c o n tro l w e ll absorbances (A 0). A 0 fo r coum arin  =  1.072 ±  0.020; 
A 0 fo r 6 -h yd roxycou m a rin  =  1.185 ±  0.043
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24hr Exposure to 7-Hydroxycoumarin: MTT Assay
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24hr Exposure to Esculetin: MTT Assay
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F ig u re  4.7: M T T  Assay fo llo w in g  24hr exposure to  7 -hyd roxycou m a rin  (top ) and esculetin
(bo ttom ) in  th e  concen tra tion  range O -lO O jig/m l. A ll d ru g  concentrations were 
tested in  seven separate w e lls /p la te  on th ree  separate occasions. A ll 
absorbances (560nm ) o f test w ells w ere expressed as a percentage o f co n tro l 
w e ll absorbances (A 0). A 0 fo r  7 -hydroxycoum arin  =  0.977 ±  0.018; A 0 fo r 
esculetin =  1.012 ±  0.044.
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4 .5.2.2.2. C yto sen so r M icro p h ysio m e te r
A  second method was used to  evaluate the effect o f coumarins on ce llu la r metabolism. As 
described in  detail in  Chapter 3, th is  biosensing instrum ent determines the extracellu lar acid ifica tion  
rate o f cells, w hich is close ly coupled to  th e ir basal m etabolic rate. M onito ring  o f ce llu la r 
m etabolism  is achieved using a pH -sensitive sensor, in  “ real-tim e” , w hich offers d istinct advantages 
over the end-point nature o f the M T T  assay, when exam ining the effect o f chem ical agents on 
ce llu la r m etabolism.
The effect o f 24hr exposure o f A431 cells to  three coum arin compounds (6- 
hydroxycoum arin, 7-hydroxycoum arin and esculetin) was achieved using th is technique (Figures 
4.8-4.10). In  these experiments the basal m etabolic rate o f the cells was determ ined p rio r to  drug- 
exposure, and th is  value was norm alised as 100%. This was achieved fo r each o f the fou r separate 
sensor chambers in  the Cytosensor. F o llow ing  drug exposure a ll subsequent m etabolic rates were 
expressed as a percentage o f the basal rate o f the pa rticu la r sensor chamber, ensuring each chamber 
w ith  its encased cells acted as its  own in ternal contro l.
F igure 4.8 illustrates the dose-dependent depression o f m etabolism  in  A431 cells, on
exposure o f d ie  cells to  6-hydroxycoum arin over 24hrs. Concentrations required to  achieve th is
were h igh when compared to  levels o f 7-hydroxycoum arin and esculetin (Figures 4.9 and 4.10, 
respectively). In itia lly , during the firs t 4 hours o f exposure, concentrations o f 50 and 100(ig/m l 
caused a slight increase in the m etabolic rate o f the cells, (~  109% and 105%, respectively). This 
was fo llow ed by  a slow  suppression o f m etabolism  over the 24hrs m onitored. The m etabolic rate o f 
the cells also declined steadily a fter 2hrs exposure to  200ng/m l 6-hydroxycoum arin, and attained a 
m etabolic rate ~  65% o f the basal rate a fter 24hrs.
Exposure o f A431 cells to  7-hydroxycoum arin caused a much more imm ediate and
damaging effect on the basal ce llu la r m etabolism  (Figure 4.9). A  continuous, gradual increase in  
m etabolic in h ib itio n  was observed fo r a ll concentrations in  the range 2-100^ig/m l. Again a dose- 
dependent effect was apparent. A t h igher concentrations (10-100|^g/m l), strong depression o f the 
m etabolic rate was evident in  the firs t 2hrs o f exposure.
Figure 4.10 illustrates the exposure o f A431 cells to  a range o f esculetin concentrations and 
the consequent depression o f basal ce llu la r m etabolism  as a result. I t  is obvious from  th is figure  that 
esculetin concentrations greater than 20|ag/ml severely damaged the m etabolic function ing o f cells
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over a 24hr exposure period -  at these concentrations, the m etabolism  o f cells 24hrs post-exposure 
was on ly ~  15-20% o f d ie  basal m etabolic rate. A t 50 and 100|ig/m l the p rinc ipa l damage to  the 
cells m etabolism  occurred w ith in  the firs t ten hours o f exposure. A t low er concentrations, damage 
was dose- and time-dependent.
One deta il that was im possible to  ignore from  the data collected, was the fact that although 
the trends were sim ila r, the Cytosensor M icrophysiom eter was more sensitive to  the effects o f the 
coumarins on ce llu la r m etabolism  than the M T T  assay. For example, the M T T  assay detected a 
decrease in  ce llu la r metabolism  o f — 28%  when A431 cells were exposed to  100jag/ml esculetin fo r 
24hrs (Figure 4.7, bottom ). According to  the cytosensor results, the ce llu la r m etabolism in  cells 
exposed to  100|jg /m l esculetin decreased b y  ~  79% over th is tim e period (Figure 4.10). In fact it 
w ou ld  appear from  com paring the M T T  and Cytosensor results fo r 7-hydroxycoum arin and 
esculetin (F igure 4.11), that the Cytosensor M icrophysiom eter is a much more sensitive predictor o f 
m etabolic inh ib ition . The reason fo r th is is unclear but may be coupled to  the fact that the M T T  
assay relies on the a c tiv ity  o f ju s t one group o f m itochondria l enzymes to  predict adverse effects on 
m etabolism , and in  doing so may underestimate m etabolic effects. The M T T  assay has been shown 
to  underestimate the grow th in h ib ito ry  effects o f interferons (IFN s) in  the past (Jabbar et al., 1989). 
This was p a rtia lly  attributed to  a difference in  the m itochondria l a c tiv ity  o f control and treated cells, 
w ith  IFN -treatm ent causing increased ac tiv ity . Formazan production can also be induced by drugs 
tha t cause perturbations o f the ce ll cycle (Supino, 1995). Cells have also been observed to  
metabolise the te trazolium  dye when le th a lly  damaged and have lost the a b ility  to  exclude v ita l dyes 
(Maehara et al., 1987).
Apart from  the increased sensitiv ity  o f prediction, the Cytosensor has several other 
advantages over the M T T  assay fo r the detection o f m etabolic suppression. As mentioned before, 
the real-tim e aspect o f detection w ith  the cytosensor yie lds large amounts o f in form ation on the 
nature o f the m etabolic suppression (e.g. tim e o f detrim ental effects, etc.), per experiment. To attain 
th is  in fo rm ation  w ith  an end-point system such as the M T T  Assay w ould require m ultip le , kine tic 
end-point assays. In addition, the exposure set-up o f the Cytosensor (flow -through, perfusive) 
m im ics the in vivo  drug delivery/exposure more than the static exposure set-up o f the M T T  Assay. 
F ina lly , as described in  Section 4.5.2.2.3. the Cytosensor M icrophysiom eter allow s fo r reve rs ib ility  
studies to  be carried out on drug-treated cells to  assess th e ir recovery, an experim ent d iffic u lt, i f  not 
im possible to  achieve w ith  cells fo llo w in g  the M T T  Assay.
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24hr Exposure to 6-Hydroxycoumarin: Cytosensor Studies
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F ig u re  4.8: E xposure o f A431 cells to  va rious concentra tions o f 6 -hydroxycoum arin  fo r
24hrs. The above p lo t shows mean o f th ree  experim ents conducted on the 
C ytosensor M icro p h ys io m e te r, to  determ ine the effects o f the  d rug  on ce llu la r 
m etabolism  (Section 2.2.4.5). The ce llu la r a c id ific a tio n  ra te  fo r  each sensor 
cham ber was determ ined p r io r  to  d rug  exposure, using a 4 m in  pum p cycle, 
w ith  the  a c id ific a tio n  ra te  m easured in  the fin a l 30secs. o f th is  cycle. This ra te 
was norm alised at 100%  and a ll subsequent a c id ifica tio n  rates d u rin g  d rug - 
exposure expressed as a percentage o f th is  norm alised va lue. These values o f 
m etabo lic ra te  (m ean o f th re e  experim ents) were p lo tte d  vs tim e  in  the  above 
g raph . T yp ica l basal a c id ific a tio n  rates (-^vo lts/sec) fo r  the  fo u r ou tlined  
cham bers fro m  one experim en t w ere -116.78 (C o n tro l), -120.05 (50 fig /m l), - 
125.8 (100|Xg/m l) and -125.65 (200^g /m l).
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24hr Exposure to 7-Hydroxycoumarìn: Cytosensor Studies
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F ig u re  4.9: Exposure o f A431 cells to  va rious concentra tions o f 7 -hyd roxycoum arin  fo r
24hrs. The above p lo t shows the  mean o f fo u r experim ents conducted on the 
C ytosensor M icro p h ys io m e te r, to  determ ine the  effects o f the  d rug  on ce llu la r 
m etabolism  (Section 2.2.4.5). In  in d iv id u a l experim ents, the ce llu la r 
a c id ifica tio n  ra te  fo r  each sensor cham ber was determ ined p r io r  to  d rug  
exposure, using a 4 m in  pum p cycle, w ith  the  a c id ifica tio n  ra te  measured in  
the  fin a l 30secs. o f th is  cycle. T h is ra te  was norm alised at 100%  and a ll 
subsequent a c id ific a tio n  rates d u rin g  drug-exposure expressed as a percentage 
o f th is  norm a lised  va lue. These values o f m etabo lic ra te  (m ean o f fo u r 
experim ents) w ere p lo tte d  vs tim e  in  the above g raph. T yp ica l basal 
a c id ifica tio n  rates (-^vo lts /sec) fo r  the  seven ou tlined  cham bers in  one o f the 
experim ents w ere -139.09 (C o n tro l), -117.15 (2pig/m l), -151.22 (5 fig /m l), -158.97 
(lO fig /m l), -116.42 (2 0 jig /m l), -113.79 (50 fig /m l), and -166.18 (100 |ig /m l).
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24hr Exposure to Esculetin: Cytosensor Studies
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F ig u re  4.10: Exposure o f A431 cells to  va rious concentra tions o f esculetin fo r 24hrs. The
above p lo t shows the  mean o f fo u r experim ents conducted on the  Cytosensor 
M icrophys iom e te r, to  determ ine the  effects o f the  d ru g  on c e llu la r m etabolism  
(Section 2.2.4.S). In  in d iv id u a l experim ents, the ce llu la r a c id ifica tio n  ra te  fo r 
each sensor cham ber was de term ined p r io r  to  d rug  exposure, using a 4 m in 
pum p cycle, w ith  the a c id ific a tio n  ra te  m easured in  the fin a l 30secs. o f th is  
cycle. Th is ra te  was norm alised  at 100%  and a il subsequent a c id ifica tio n  rates 
d u rin g  drug-exposure  expressed as a percentage o f th is  norm alised value. 
These values o f m etabo lic ra te  (m ean o f fo u r experim ents) w ere p lo tted  vs tim e 
in  the  above graph. T yp ica l basal a c id ifica tio n  rates (-fivo lts/sec) fo r the  seven 
o u tlin e d  cham bers in  one o f th e  experim ents w ere -124.58 (C o n tro l), -134.25 
(2 fig /m l), -107.59 (5ng /m l), -127.85 (lO ^g /m l), -145.15 (20tig /m l), -122.52 
(50 (ig /m l), and -115.84 (lOOfxg/m l).
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Comparison of 24hr MTT and Cytosensor Values
following exposure to 7-Hydroxycoumarin
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Comparison of24hr MTT and Cytosensor Values 
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F ig u re  4.11: C om parison  o f values obta ined fro m  M T T  Assays and C ytosensor Studies on
m etabo lism  suppression in  cells by  7 -hyd roxycoum arin  (to p ), and esculetin 
(bo ttom ) fo llo w in g  24hr exposures. The C ytosensor studies appear m ore 
sensitive in  the  p re d ic tio n  o f m etabolism  p e rtu rb a tio n s .
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4.5 .2 .2 .3 . R eversib ility  S tu d ie s  w ith  th e  C yto sen so r M icro p h ys io m e te r
Previous reve rs ib ility  studies on the effects o f coum arin compounds on cultured cells have 
u tilised  proliferative-based assessments to  determ ine i f  cells could recover from  exposure to  these 
compounds (M arshall e t al., 1994; Egan e t a l ,  1997). In  m ost instances, th is type o f experiment 
entailed a period o f drug exposure, fo llow ed by a drug-free recovery grow th period fo r a sub­
population o f the o rig ina l exposed cells. This introduces an element o f selection in to  the 
reve rs ib ility  study -  outgrow th o f a sub-population o f drug-resistant cells could account fo r the 
appearance o f a “ reversible”  effect.
W e were, therefore, interested in  assessing the recovery o f cells exposed to  coumarins using 
an alternative method, preferably in terna lly-con tro lled , to  avoid the above problem s o f sub­
population selection. The Cytosensor M icrophysiom eter is an ideal instrum ent fo r such an 
experim ent - each sensor chamber, w ith  its encased cells, acts as its own internal control. D uring 
exposure o f cells to  a compound, the m etabolic rate o f the cells is compared to  the m etabolic rate o f 
the same sample o f cells p rio r to  exposure; during a recovery period the same complete sample o f 
exposed cells, not a sub-population, are allow ed to  recover, and again the ir m etabolic rate during 
recovery is compared to  the o rig ina l m etabolic rate. This allow s fo r a complete and va lid  
assessment o f the re ve rs ib ility  o f the effects o f a compound on the cells metabolism.
As outlined in  Section 2.2.4.5. re ve rs ib ility  studies were completed fo r 6-hydroxycoum arin, 
7-hydroxycoum arin and esculetin. Various exposure/recovery periods were assessed, the results o f 
w hich are shown in  Figures 4.12-4.19. The recovery o f A431 cells from  exposure to 6- 
hydroxycoum arin was assessed fo llo w in g  both 12hr (F igure 4.12) and 24hr (F igure 4.13) periods. 
The effects o f 6-hydroxycoum arin on ce llu la r m etabolism  were described previously (Section 
4.5.2.2.2) as re la tive ly  s ligh t fo r the high concentrations used (especially when compared to  both 7- 
hydroxycoum arin and esculetin). However, when the exposed cells were allowed to  recover from  
the drug-exposure, o n ly  a b rie f, transient increase in  the m etabolic rate was observed at the 
in itia tio n  o f the recovery period. A lthough the m etabolic rate o f the cells d id not continue to 
decrease, as during the exposure period, neither d id  i t  recover to  its pre-exposure levels. Instead, it  
remained at a level s im ila r to  tha t observed im m ediately pre-recovery e.g. in  F igure 4.13, we see 
that fo r cells exposed to  200fig /m l 6-hydroxycoum arin, the m etabolic rate im m ediately pre- 
recovery (i.e. a t 24hrs) was 65.5% , and excepting a s ligh t increase in  m etabolism  in the firs t five  
hours o f recovery, the m etabolic rate remained steady at ~  61-67%  over the rem aining nineteen 
hours o f recovery. Therefore it  w ould appear tha t the damage to  ce llu la r metabolism  in flic te d  by 6-
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hydroxycoum arin exposure was irreversible. This trend was apparent in  both the 12hr and 24hr 
reve rs ib ility  studies (Figures 4.12 and 4.13, respectively).
R evers ib ility  studies were also completed fo r A431 cells exposed to  7-hydroxycoum arin fo r 
various tim e periods as outlined in  Section 2.2.4.5, w ith  the results shown in  Figures 4.14-4.16. In  
Figure 4.14, we see the effect o f a 4hr exposure and 4hr recovery period, in  the concentration range 
20-100|ig/m l. As expected exposure caused a dose-dependent decrease in  the m etabolic rate o f the 
cells, but on rem oval o f drug exposure, complete recovery o f the cells to  pre-exposure m etabolic 
rates was achieved. In  fact, the m etabolic rate o f the cells was higher on recovery than the pre­
exposure rate. Figure 4.15 illustra tes the data obtained fo r a I2 h r exposure and 12hr recovery period 
fo r 7-hydroxycoum arin-exposed A431 cells. 12hrs o f drug exposure again caused a dose-dependent 
suppression o f metabolism , but th is tim e fu ll recovery o f the cells was not achieved at any o f the 
concentrations involved. Cells exposed to  concentrations o f 7-hydroxycoum arin in  the range 5- 
20(ig/m l d id  attain recovery o f the m etabolism  to  -80 -90%  o f th e ir o rig ina l values. W ith  50|xg/ml 
and 100|4g/ml these recovery values were -  68% and —57%  respectively. 24hr exposure yielded 
rem arkably s im ila r results -  despite the increased suppression o f ce llu la r metabolism  due to  the 
increased exposure tim es, recovery o f ce llu la r m etabolism  was alm ost identica l w ith  recovery 
values o f -87% , -78% , -6 9 %  and -5 4 %  fo r cells exposed to  10, 20, 50 and 100fig/m l 7- 
hydroxycoum arin, respectively (F igure 4.16).
Data obtained from  re ve rs ib ility  studies accomplished w ith  esculetin and A431 cells are 
shown in  Figures 4.17-4.19. 4hr exposure to  esculetin concentrations in  the range 20-100|ag/ml 
caused a suppression o f ce llu la r m etabolism  w hich was dose-dependent and reversible, as shown in 
F igure 4.17. U n like  7-hydroxycoum arin, th is  reve rs ib ility  o f m etabolic suppression was s till 
achievable fo llo w in g  12hr exposures to  the drugs (Figure 4.18), an unexpected result considering 
the extreme suppression o f m etabolism  involved (at concentrations o f 20-100|jg/m l the ce llu la r 
m etabolic rate had dropped to  -  20-30%  o f its orig ina l value). However, fo llo w in g  24hrs o f 
esculetin exposure, th is a b ility  to  fu lly  recover from  such severe m etabolic suppression was lost by 
the cells, and on ly  cells exposed to  low  (2-5(jg /m l) esculetin concentrations were able to  approach 
fu ll recovery, w ith  recovery re flecting  exposure conditions at higher concentrations (Figure 4.19).
In  many o f these re ve rs ib ility  studies, it  was observed tha t fo llo w in g  drug w ithdraw al (0- 
5hrs post-w ithdraw al), the increase in  m etabolic rate was to  levels above those o f the contro l. This 
was observed fo r example in the 4hr reve rs ib ility  studies o f 7-hydroxycoum arin and esculetin 
(Figures 4.14 and 4.17). Longer tem poral studies also displayed th is feature e.g. 50 /ig /m l 6-
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hydroxycoum arin (Figure 4.12), or 5(.ig/m l esculetin (F igure 4.18); in  many cases cells achieved 
low er, more stable m etabolic rates, as recovery periods continued. W h ile  we cannot explain this 
“ overshoot” , we can say it  is not due to  pH  differences between the drug-free and drug-containing 
running media, as a ll media was adjusted to  pH  7.35-7.40. An increase in  the m etabolic rate o f cells 
also occurred on in itia l exposure to  the drug [c .f. Figures 4.12 and 4.18 (2 &  5jig /m l esculetin)]. 
This phenomenon is not apparent fo r h igher concentrations in  the p lotted graphs, but increases did 
occur in  the firs t O-lOmins fo r a ll drugs tested (results not shown). This increase may represent 
activation o f an ATP-coupled transporter prote in  e.g. the P-glycoprotein, w hich results in  the e fflu x  
o f drug from  the in trace llu la r environm ent. Prolonged exposure to  h igh drug concentrations 
overcomes th is e fflu x  mechanism
These studies regard the re ve rs ib ility  o f the effects o f coumarins on ce llu la r metabolism, 
and fin d  tha t the suppression o f ce llu la r metabolism  in  cells exposed to  coumarins is no t fu lly  
reversible fo llo w in g  prolonged (12-24hr) exposure. The extent o f recovery appears to  be dose- 
dependent. One fa ilin g  o f the experim ent is that we do no t know  i f  a ll cells recovered equally i.e. 
fo r the sample o f cells exposed to  100(ig /m l esculetin fo r 24hrs, d id  45% o f the cells recover fu lly  
to  th e ir pre-exposure m etabolic rate, o r did 100% o f the cells achieve a recovery o f 45% o f the ir 
m etabolism , o r is some other interm ediate scenario responsible fo r the observed 45% recovery?
The results obtained disagree w ith  previous re ve rs ib ility  assays carried out on coumann 
compounds. Previous studies w ith  7-hydroxycoum arin determ ined th e ir cytostatic effect on cell 
p ro life ra tion  to  be com pletely reversible. I t  is believed that ~  40%  o f a cells m etabolism  is directed 
towards grow th (O w ick i &  Parce, 1992) -  one m ight expect then tha t an incom plete m etabolic 
recovery from  coum arin exposure m ight re flect its e lf in  a proliferative-based reve rs ib ility  study, 
such as tha t conducted by M arshall e t al. (1994). However, M arshall and co-workers in  th e ir study 
o f re ve rs ib ility  u tilised  an extended (9-day) recovery period, w hich may hide m etabolic differences 
o f cells su ffic ie n tly  in  term s o f ce ll num ber increase.
F in a lly  the results obtained in  these cytosensor studies (exposures and recoveries) w ould 
seem to  indicate a d iss im ila r mechanism o f action o f each o f the three studied coumarins (6- 
hydroxycoum arin, 7-hydroxycoum arin and esculetin) a t a sub-cellular level. This is an area tha t was 
exam ined in  fu rther deta il in  Chapters 5 and 6 o f th is thesis.
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12hr Reversibility Studies with 6-Hydroxycoumarin
Time (hours)
F ig u re  4.12: Exposure o f A431 cells to  va rious concentra tions o f 6 -hydroxycoum arin  fo r
12hrs, fo llow ed  by a fu rth e r 12hrs pe riod  o f recovery in  d rug -free  m edium . 
The above p lo t shows the mean o f th ree  experim ents conducted on the 
C ytosensor M icro p h ys io m e te r, to  determ ine the re v e rs ib ility  o f the  effects o f 
the d ru g  on ce llu la r m etabolism  (Section 2.2.4.5). In  in d iv id u a l experim ents, 
the ce llu la r a c id ific a tio n  ra te  fo r each sensor cham ber was determ ined p r io r  to  
d rug  exposure, using a 4 m in pum p cycle, w ith  the  a c id ifica tio n  ra te  m easured 
in  the  fin a l 30secs. o f th is  cycle. T h is ra te  was norm alised at 100%  and a ll 
subsequent a c id ific a tio n  rates d u rin g  exposure and recovery periods were 
expressed as a percentage o f th is  no rm alised  value. These values o f m etabolic 
ra te  (m ean o f th ree  experim ents) w ere p lo tte d  vs tim e  in  the  above graph. 
T yp ica l basal a c id ific a tio n  rates fo r cells in  the  experim ents were -1 0 0  to  -200  
pvolts/sec.
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24hr Reversibility Studies with 6-Hydroxycoumarin
Time (hours)
F igu re  4.13: Exposure o f A431 cells to  va rious concentra tions o f 6 -hyd roxycoum arin  fo r
24hrs, fo llow ed  by  a fu rth e r 24hrs pe riod  o f recovery in  d rug -free  m edium . 
The above p lo t shows the mean o f th ree  experim ents conducted on the 
C ytosensor M ic ro p h ys io m e te r, to  determ ine the  re v e rs ib ility  o f the  effects o f 
the  d ru g  on c e llu la r m etabolism  (Section 2.2.4.5). In  in d iv id u a l experim ents, 
the  c e llu la r a c id ific a tio n  ra te  fo r each sensor cham ber was determ ined p r io r  to 
d rug  exposure, using a 4 m in  pum p cycle, w ith  the  a c id ifica tio n  ra te  m easured 
in  th e  fin a l 30secs. o f th is  cycle. T h is ra te  was norm alised at 100%  and a ll 
subsequent a c id ific a tio n  rates d u rin g  exposure and recovery periods w ere 
expressed as a percentage o f th is  norm alised  value. These values o f m etabolic 
ra te  (m ean o f th ree  experim ents) w ere p lo tte d  vs tim e  in  the  above graph. 
T yp ica l basal a c id ific a tio n  rates fo r cells in  the  experim ents w ere -1 0 0  to  -200  
jjvo lts/sec.
114
4hr Reversibility Studies with 7-Hydroxycoumarin
c0) o 
IS o
0£ T3
M 3
S i(0 c4-* fc.
0) o 
S  Z
140
120
100
80
60
40
20
-Oug/ml 7-Hydroxycoumarin 
-20ug/m l 7-Hydroxycoumarin 
-50ug /m l 7-Hydroxycoumarin 
-  100ug/ml 7-Hydroxycoumarin
-2 10
Time (hours)
F ig u re  4.14: Exposure o f A431 cells to  various concentra tions o f 7 -hydroxycoum arin  fo r
4hrs, fo llow ed  by  a fu rth e r 4hrs pe riod  o f recovery in  d rug -free  m edium . The 
above p lo t shows th e  mean o f th ree  experim ents conducted on the Cytosensor 
M icrophys iom e te r, to  dete rm ine  the  re v e rs ib ility  o f the effects o f the  d rug  on 
ce llu la r m etabolism  (Section 2.2.4.5). In  in d iv id u a l experim ents, the ce llu la r 
a c id ifica tio n  ra te  fo r each sensor cham ber was determ ined p r io r to  d rug  
exposure, using a 4 m in  pum p cycle, w ith  the  a c id ifica tio n  ra te  m easured in  
the fin a l 30secs. o f th is  cycle. This ra te  was norm alised at 100%  and a ll 
subsequent a c id ific a tio n  rates d u rin g  exposure and recovery periods w ere 
expressed as a percentage o f th is  norm alised value. These values o f m etabolic 
ra te  (m ean o f th re e  experim ents) w ere p lo tte d  vs tim e  in  the  above graph. 
T yp ica l basal a c id ific a tio n  rates fo r cells in  the  experim ents were -1 0 0  to  -2 0 0  
pvolts/sec.
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F ig u re  4.15: Exposure o f A431 cells to  va rious concentra tions o f 7 -hyd roxycoum arin  fo r
12hrs, fo llow ed  by a fu rth e r 12hrs pe rio d  o f recovery in  d rug -free  m edium . 
The above p lo t shows the  mean o f th ree  experim ents conducted on the 
C ytosensor M ic ro p h ys io m e te r, to  determ ine the  re v e rs ib ility  o f the  effects o f 
the  d rug  on c e llu la r m etabolism  (Section 2.2.4.5). In  in d iv id u a l experim ents, 
the c e llu la r a c id ifica tio n  ra te  fo r  each sensor cham ber was determ ined p r io r  to  
d ru g  exposure, using a 4 m in  pum p cycle, w ith  the  a c id ifica tio n  ra te  m easured 
in  the  fin a l 30secs. o f th is  cycle. Th is ra te  was norm alised at 100%  and a ll 
subsequent a c id ifica tio n  ra tes d u rin g  exposure and recovery periods were 
expressed as a percentage o f th is  norm alised va lue. These values o f m etabolic 
ra te  (m ean o f th re e  experim ents) w ere p lo tte d  vs tim e  in  the  above graph. 
T yp ica l basal a c id ifica tio n  rates fo r cells in  the  experim ents were -1 0 0  to  -200  
jivo lts/sec.
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F ig u re  4.16: E xposure o f A431 cells to  va rious concentrations o f 7 -hydroxycoum arin  fo r
24hrs, fo llow ed  by a fu rth e r 24hrs pe rio d  o f recovery in  d rug -free  m edium . 
The above p lo t shows the  mean o f th ree  experim ents conducted on the 
C ytosensor M icrophys iom e te r, to  determ ine the re v e rs ib ility  o f the  effects o f 
the  d ru g  on c e llu la r m etabolism  (Section 2.2.4.5). In  in d iv id u a l experim ents, 
the  c e llu la r a c id ific a tio n  ra te  fo r each sensor cham ber was determ ined p r io r to  
d ru g  exposure, using a 4 m in  pum p cycle, w ith  the a c id ific a tio n  ra te  m easured 
in  th e  fin a l 30secs. o f th is  cycle. T h is ra te  was norm alised  a t 100%  and a ll 
subsequent a c id ifica tio n  rates d u rin g  exposure and recovery periods w ere 
expressed as a percentage o f th is  norm alised value. These values o f m etabolic 
ra te  (m ean o f th ree  experim ents) w ere p lo tte d  vs tim e  in  the  above graph. 
T yp ica l basal a c id ific a tio n  rates fo r cells in  the  experim ents w ere -1 0 0  to  -2 0 0  
(ivolts/sec.
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4hr Reversibility Studies with Esculetin
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F igu re  4.17: Exposure o f A431 cells to  various concentra tions o f esculetin  fo r 4hrs, fo llow ed
by a fu rth e r 4hrs pe rio d  o f recovery in  d rug -free  m edium . The above p lo t 
shows the mean o f th ree  experim ents conducted on the Cytosensor 
M icro p h ys io m e te r, to  determ ine th e  re v e rs ib ility  o f the effects o f the  d rug  on 
c e llu la r m etabolism  (S ection 2.2.4.5). In  in d iv id u a l experim ents, the ce llu la r 
a c id ifica tio n  ra te  fo r  each sensor cham ber was determ ined p r io r  to  d rug  
exposure, using a 4 m in  pum p cycle, w ith  the a c id ifica tio n  ra te  m easured in  
the  fin a l 30secs. o f th is  cycle. T h is ra te  was norm a lised  at 100%  and a ll 
subsequent a c id ific a tio n  rates d u rin g  exposure and recovery periods were 
expressed as a percentage o f th is  norm alised value. These values o f m etabolic 
ra te  (m ean o f th ree  experim ents) w ere p lo tte d  vs tim e in  the  above graph. 
T yp ica l basal a c id ifica tio n  rates fo r cells in  the  experim ents w ere -1 0 0  to -200  
p.volts/sec.
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F igure  4.18: Exposure o f A431 cells to  va rious concentra tions o f esculetin fo r 12hrs,
fo llow ed  by a fu rth e r 12hrs pe riod  o f recovery in  d rug -fre e  m edium . The 
above p lo t shows the  mean o f th ree  experim ents conducted on the C ytosensor 
M icrophys iom e te r, to  dete rm ine  the  re v e rs ib ility  o f the  effects o f the  d rug  on 
c e llu la r m etabolism  (S ection 2.2.4.5). In  in d iv id u a l experim ents, the  ce llu la r 
a c id ifica tio n  ra te  fo r each sensor cham ber was determ ined p r io r to d rug  
exposure, using a 4 m in  pum p cycle, w ith  the  a c id ifica tio n  ra te  measured in  
the fin a l 30secs. o f th is  cycle. T h is ra te  was norm a lised  at 100%  and a ll 
subsequent a c id ifica tio n  ra tes d u rin g  exposure and recovery periods w ere 
expressed as a percentage o f th is  norm alised  value. These values o f m etabolic 
ra te  (m ean o f th ree  experim ents) w ere p lo tted  vs tim e in  the  above graph. 
T yp ica l basal a c id ific a tio n  rates fo r cells in  the  experim ents w ere -1 0 0  to  -200  
(ivolts/sec.
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F igu re  4.19: Exposure o f A431 cells to  va rious concentra tions o f esculetin fo r 24hrs,
fo llow ed  by a fu rth e r 24hrs pe riod  o f recovery in  d rug -free  m edium . The 
above p lo t shows the  mean o f th ree  experim ents conducted on the Cytosensor 
M icrophys iom e te r, to  determ ine the  re v e rs ib ility  o f the effects o f the  d rug  on 
ce llu la r m etabolism  (Section 2.2.4.5). In  in d iv id u a l experim ents, the ce llu la r 
a c id ifica tio n  ra te  fo r each sensor cham ber was determ ined p r io r  to  d rug  
exposure, using a 4 m in  pum p cycle, w ith  the a c id ifica tio n  ra te  m easured in  
the  fin a l 30secs. o f th is  cycle. T h is ra te  was norm alised at 100%  and a ll 
subsequent a c id ifica tio n  ra tes d u rin g  exposure and recovery periods were 
expressed as a percentage o f th is  norm alised value. These values o f m etabolic 
ra te  (m ean o f th ree  experim ents) w ere p lo tte d  vs tim e in  the  above graph. 
T y p ica l basal a c id ifica tio n  rates fo r  cells in  the experim ents w ere -1 0 0  to  -2 0 0  
Hvolts/sec.
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4 .5 .3 . E f f e c t  o f  C o u m a r in s  o n  P r o te a s e  P r o d u c t io n  b y  H u m a n  T u m o u r  C e lls
As outlined in  Section 4.2, the expression o f m a trix  metalloproteinases by tum our cells has 
correlated w e ll w ith  th e ir a b ility  to  invade and metastasise in vivo  (Chambers &  M atrisian, 1997). 
The expression o f M M P-2 and M M P -9 is enhanced in vivo  in  cancers o f the skin, prostate, kidney, 
breast and colon during progression from  the benign to  m alignant state (Monteagudo et a l ,  1990; 
Levy et a l ,  1991; K arelina et a l ,  1993; Stearns &  W ang, 1993; G oh ji et a l ,  1994). Coumarin 
compounds have been shown to  be active in vivo  against some o f these m alignancies. Hence, we 
chose to  examine the effect o f coum arin compounds on the a c tiv ity  and production o f m atrix 
metalloproteinases.
According to  the method described in  Section 2.2.5, A431 cells were found to  constitu tive ly 
secrete a protease o f m olecular w eight ~  70kDa (Figure 4.20). The presence o f th is  band was 
inh ib ited  by Im M  E D TA , ind icating a metalloproteinase a c tiv ity , w hich we assigned as M M P-2, a 
m atrix  m etalloproteinase o f m olecular w eight 72kDa, w hich has been previously showed to  be 
expressed by  A431 cells (X ie  e ta l.,  1994a)
Figure 4.20; Constitutive expression of MMP-2 (72kDa) by A431 cells, as analysed by 
substrate gel (gelatin) analysis of their conditioned medium.
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In  exam ining the e ffect o f coumarins on A 431 M M P-2, we in itia lly  determ ined the effect o f 
these compounds on the a c tiv ity  o f th is  enzyme, using gelatin gel analysis. This was achieved by 
addition o f drug to  the substrate bu ffe r post-electrophoresis. A  decrease in  the intensity o f bands 
fo llo w in g  drug exposure indicated that the coum arin was an M M P-2 in h ib ito r at that particu lar 
concentration. F igure 4.21 is an example o f one such experim ent and illustrates the in h ib ito ry  effect 
o f 150fxg/ml 6-hydroxycoum arin on the a c tiv ity  o f the M M P-2 protease. Results o f the in h ib ito ry  
a c tiv ity  o f a ll fo u r drugs are summarised in  Table 4.5. B rie fly , coum arin on ly  affected the cata lytic 
a c tiv ity  o f M M P-2 at concentrations greater than 100^g/m l, and then on ly  m ild ly . 6- 
hydroxycoum arin was s lig h tly  more inh ib ito ry , causing increasing enzyme in h ib itio n  from  
100|ig/m l upwards. 7-hydroxycoum arin displayed increasing inh ib ition  o f enzyme from  50(xg/ml, 
w h ile  esculetin was either strongly, or to ta lly  in h ib ito ry  at the concentrations tested.
Figure 4.21: Substrate gel analysis of conditioned medium from A431 cells, to determine
the effect of 150fig/ml of 6-hydroxycoumarin on the activity of the MMP-2 
protease. Equal amounts of medium were electrophoresed in 6 lanes across the 
gel. The gel was then halved and one half placed in drug-free substrate buffer 
(left hand side), while the second half was incubated in substrate buffer 
containing 150(ig/ml 6-hydroxycoumarin (right hand side). Incubation was 
carried out for 16hrs, after which detection of protease bands was achieved by 
Coomassie Blue staining and destaining of the gels. The band intensities were 
then compared to ascertain if the drug was inhibitory to the MMP-2 activity.
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D rug Control 50fig/m l 100fig/m l 150fig/m l
C oum arin  -I l I I- 1 1 1 1 H l l +++
6-hyd roxycoum arin  I 1 I I 1 1 1 l +++ ++
7-hydroxycoum arin  ++++ +++ ++ +
E scu le tin  ++++ + - -
Table 4 .5: In h ib itio n  o f M M P -2  ca ta ly tic  a c tiv ity  by coum arin  com pounds as assessed
using substra te  gel analysis. Band in tensities are described by (+ ) sym bols, 
w ith  (++++) set as co n tro l band in te n s ity . (-) ind icates no band present Le. to ta l 
in h ib itio n  o f protease a c tiv ity .
W e next proceeded to  examine the effect o f coumarins on the production /secretion o f 
M M P -2 from  A431 cells. This was achieved b y  incubation o f cells w ith  the various drugs fo r 24 
hrs, fo llow ed by  co llection  and analysis o f the conditioned m edium  by gelatin gel analysis. 
D ensitom etric analysis was achieved to  quan tify  th is  effect, and the results o f these experiments are 
shown in  Figures 4.22 and 4.23. As is illustrated, coum arin did not affect the expression o f M M P-2 
except a t concentrations o f 100|Xg/ml, and the expression was on ly  m ild ly  affected at this 
concentration. The other three hydroxy-com pounds displayed a dose-dependent suppression o f 
M M P -2 expression by the cells, w ith  the m ost severe effects observed w ith  esculetin. These 
suppressive effects m ay be due to  the coumarins targeting either transcription, translation or 
secretion o f the M M P-2 enzyme. I t  is doubtfu l tha t these effects are due to  the inh ib ition  o f enzyme 
a c tiv ity  detailed in  Table 4.5, as a ll gels were washed in tensive ly p rio r to  incubation in  drug-free 
substrate buffer. Therefore, unless the drugs had irreve rs ib ly  bound to  or inactivated the enzyme 
during drug-exposure, the suppression o f M M P-2 outlined in  Figures 4.22 and 4.23 should represent 
on ly  negative effects on M M P  production or secretion.
The in h ib itio n  o f enzyme a c tiv ity  is not a new characteristic fo r coum arin compounds 
Coumarins have been shown to  in h ib it the activ ities o f a number o f enzymes in  the past e.g.
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xanthine oxidase, lipoxygenase, D N A  gyrase, glyoxylase (Brandt et al., 1986; M axw ell 1993; 
Chang &  Chiang, 1995; H ou lt el a l ,  1994). The precise mechanism o f in h ib itio n  is undocumented 
W ith  regard to  the d irect in h ib itio n  o f metalloproteinase a c tiv ity  described above, it  is possible that 
the coumarins m ay exert th e ir in h ib ito ry  effects through one o f a num ber o f effects. F irs tly , the 
relationship between Type IV  collagenase expression and lipoxygenases has been previously 
documented (Reich and M artin , 1996; L iu  el a l ,  1996). The dose-dependent suppression o f M M P-2 
and M M P-9 expression by  esculetin in  human breast cells has been described (Reich &  M artin, 
1996), w ith  the decrease in  enzyme expression related to  gene expression. The results o f th is  study 
were reflected by those o f L iu  et al. (1996), where again, esculetin decreased the production o f type 
IV  collagenases in lino le ic-acid  stim ulated human breast tum our cells. These results reflect w e ll the 
outcome o f our experiments w ith  A431 cells (F igure 4.23 C &  D). Coumarin and 7- 
hydroxycoum arin have once being reported as inh ib ito rs o f prostaglandin biosynthesis (Lee et al., 
1981), but no fu rther w ork in  th is  area has been achieved, and lipoxygenase in h ib itio n  is no t a 
documented property o f these compounds. Hence, i t  is u n like ly  th is can explain fu lly  the ir 
in h ib itio n  o f collagenase activity/expression.
A  second p o ss ib ility  is tha t chelation o f metal ions m ay contribute to  th is  suppressive 
effect: 7-hydroxycoum arin has been previously reported as a useful ind icator fo r Ca2+ and Cu2+in 
titrim e tric  determ inations, th is  ro le  being accomplished as a result o f chelation o f these ions 
(H u itn ik  &  D iehl, 1974). The m etal-chelatory properties o f esculetin have also been described 
(Cooke et al., 1997). I t  is possible tha t some o f the in h ib itio n  o f m etalloproteinase a c tiv ity  and/or 
expression may be achieved v ia  these effects, as chelation o f the m etal ions (Ca2+ and M g2") 
essential to  the correct function ing  o f the metalloproteinases, is detrim ental to  th e ir activ ity. 
R ecently it  has been postulated tha t the therapeutic (and adverse) effects o f asp irin -like  drugs, are 
m odulated through the chelation o f various physio log ica lly  im portant m eta llic cations in  the body 
(W ang, 1998)
F ina lly , it  is in trigu ing  to  note the w ork o f Lu  and colleagues (1996) on the effect o f 7- 
hydroxycoum arin on tum our locom otion. They described experiments whereby 7-hydroxycoum arin 
suppressed the m o tility  o f tum our cells in  3-D  collagen m atrices over a 6 day period. They 
correlated th is  anti-locom otory e ffect w ith  decreases in  the in trace llu la r levels o f the p21ras protein. 
The ras oncogene is a potent inducer o f type IV  collagenases (M atrisian, 1990). Thus, it  is possible 
tha t the net e ffect o f ras protein suppression by 7-hydroxycoum arin, was a decrease in  the 
constitu tive expression o f collagenases, resulting in  the prevention o f tum our ce ll movement 
through the collagen matrices
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Regardless o f the mechanism by which the coumarins suppress the activity and expression 
o f Type IV  collagenases, the implications o f these findings are important when one considers the 
role o f m atrix metalloproteinases in vivo in invasion and metastases (Section 4.2). The effect o f 
coumarins on invasiveness can be determined in vitro using in vitro invasion assays w ith Matrigel, 
and such experiments should be completed to ascertain i f  the above suppression o f 
metalloproteinase activity and production has real effects on tumour cell invasiveness. This may aid 
in an overall explanation o f the observed anti-cancer effects o f coumarin, in vivo, in patients with 
advanced malignancies.
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Figure 4.22: Effect o f 24hr exposure to coumarins on the constitutive expression o f M M P-2
from A431 cells. (A ) shows the results o f densitometric analysis from three 
different experiments (mean ±  s.d.) for A431 cells exposed to coumarin in the range 
0-100(jg/m l. A  representative coumarin gel is depicted in (B). (C ) shows the 
densitometric analysis from three different experiments (mean ±  s.d.) for A431 
cells exposed to 6-hydroxycoumarin in the range 0-100|a.g/ml. A  representative 6- 
hydroxycoumarin gel is depicted in (D ).
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Densitornelric Analysis of Proteose Levelsfollowing 24hr Exposure to Coumarins
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Figure 4.23: Effect o f 24hr exposure to coumarins on the constitutive expression o f M M P-2
from A431 cells. (A ) shows the results o f densitometric analysis from three 
different experiments (mean ±  s.d.) for A431 cells exposed to 7-hydroxycoumarin 
in the range 0-100^g/m l. A  representative 7-hydroxycoumarin gel is depicted in 
(B). (C ) shows the densitometric analysis from three different experiments (mean + 
s.d.) for A431 cells exposed to esculetin in the range 0-100^g/ml. A  representative 
esculetin gel is depicted in (D ).
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4.6. CHAPTER SUMMARY
In  this chapter we examined the effect o f coumarin and its hydroxy-derivatives, 6- 
hydroxycoumarin, 7-hydroxycoumarin and esculetin, on the growth, metabohsm and metastatic 
potential o f human tumour cells.
Proliferation assays yielded some interesting information on growth-inhibition by 
coumarins:
1. The potency o f growth inhibition by esculetin (6,7-dihydroxycoum arin)» 7-hydroxycoumarin 
> 6-hydroxycoumarin »  coumarin.
2. Certain cell types e.g. prostate, breast, bladder and leukemic cells, were particularly sensitive to 
growth suppression by the mono-hydroxycoumarins, while esculetin exhibited a more general 
growth inhibition.
3. A431 cell line was extremely sensitive to all compounds.
None o f these four compounds caused significant membrane damage to A 431 cells as assessed 
by the LD H  Assay. The effects o f the four coumarins on cellular metabolism was examined using 
both the M T T  Assay and the Cytosensor Microphysiometer, although the Cytosensor method 
proved more useful for the following reasons:
1. “Real-time” measurement vs “end-point” M T T  assay
2. Flow-through system mimics in vivo exposure more accurately, than static M T T  conditions
3. Reversibility studies possible
4. Increased sensitivity o f the Cytosensor method compared to M T T  assay
5. Esculetin interfered with the M T T  assay
The tested coumarin compounds all displayed a dose- and time-dependent effect on cellular 
metabolism, with esculetin displaying the most potent effects. The suppression o f cellular 
metabolism in cells exposed to coumarins was not fu lly  reversible following prolonged (12-24hr) 
exposure, w ith the extent o f recovery dose-dependent.
Finally, the effect o f coumarins on the metastatic potential o f tumour cells was examined in 
terms o f their effect on protease expression in tumour cells. A ll coumarin compounds were found to 
reduce the activity and expression o f matrix metalloproteinases from tumour cells, although the 
exact mechanism by which they achieve this is unclear.
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Chapter 5
Effect o f coumarins on signalling pathways within cells
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eventual effect o f nuclear transcription. It  has been determined that phosphorylation reactions are 
the central mechanism for the progression o f these growth signals from membrane to nucleus. 
Protein kinases and phosphatases are enzymes that respectively, add or remove phosphate residues, 
on either serine/threonine or tyrosine residues o f proteins, utilising ATP as a phosphate source. 
These enzymes are crucial to signal propagation in signalling pathways - in many cases, the 
phosphorylation reaction has been shown to have a profound activating effect on the enzyme 
activity o f the targeted substrate.
The reversible phosphorylation o f proteins on tyrosine residues is a particularly important 
event in the regulation o f many eukaryotic processes. Activation o f tyrosine kinases is responsible 
not only for control o f growth signalling pathways, but is also important in cellular differentiation, 
cell cycle control, cell attachment, gene transcription and synaptic transmission (Hunter, 1998). 
However, in this work, it is the importance o f tyrosine phosphorylation in growth control, and its 
deregulation in cancer that is addressed.
Three distinct classes o f receptors exist which use tyrosine phosphorylation to propagate 
proliferative signals (Hunter, 1998). The details o f these are summarised in Table 5 .1 and Figure
5.1. As outlined, members o f the Receptor Tyrosine Kinase (R TK ) fam ily o f receptors have an 
intrinsic intracellular tyrosine kinase domain, which is activated on ligand binding. Downstream 
phosphorylation o f proteins on tyrosine residues transduces the extracellular signal to the nucleus. 
The binary RTKs do not possess an intracellular tyrosine kinase domain, and can only signal by 
association w ith a cytoplasmic tyrosine kinase molecule. This event launches a cascade of 
phosphorylation reactions, resulting in propagation o f the external signal to the nucleus. Finally, the 
G-protein-coupled receptors (GCRs), do not themselves use tyrosine phosphorylation to transduce 
the transmembrane signal. However, through GTP coupling, the GCRs cause activation o f a number 
o f signalling intermediates with the eventual downstream activation o f cytoplasmic kinases. O f 
these three receptor types, the most important in proliferative signalling pathways is the fam ily o f 
Receptor Tyrosine Kinases (R TK ), which are discussed in more detail in Section 5.2.2. Where 
necessary, the other two receptor classes w ill be mentioned.
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Receptor Class Ligands Activation Results
1. Receptor
Tyrosine Kinases 
(RTK)
PolvDCDtide Growth Factors e.s. 
Epidermal Growth Factor 
(EGF), Platelet Derived Growth 
Factor (PDGF)
Ligand binding results in activation of 
intracellular tyrosine kinasc-domain, 
resulting in phosphorylation o f  specific 
tyrosine residues on intracellular targets.
2. Binary Receptor 
Tyrosine Kinases 
(BRTK)
Cvtokines
e.g. IFN -a, -ß, -y, IL-2, IL4.
Ligand binding results in the recruitment 
and activation o f a cytoplasmic tyrosine 
kinase e.g. JAK activation, which  
propagates the signal.
3. Seven-
transmembrane/ 
G protein- 
coupled receptors 
(GCR)
M itoeenic PeDtides
e.g. Bombesin, Angiotensin
Ligand binding results in activation o f  
heterotrimeric G-proteins, with  
downstream activation o f  tyrosine 
kinases for m itogenic signalling
Tabic 5.1: Table summarising the properties of the three classes of membrane receptors which
utilise tyrosine phosphorylation as a means of propagating the external signal [c.f. 
Figure 5.1]. (Information derived from Hardie (1991) and Hunter (1998))
Figure 5.1: Diagram of the three classes of membrane receptor which utilise tyrosine
phosphorylation to propagate the external signal. The RTKs directly phosphorylate 
substrates. The BRTKs associate with a cytoplasmic kinase to induce downstream 
phosphorylation, and the GCRs launch signals which eventually cause downstream 
tyrosine phosphorylation [c.f. Table 5.1 and main text for details].
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5.2.2. Receptor Tyrosine Kinases (RTKs) and their Substrates
The Receptor Tyrosine Kinase (R TK ) fam ily o f receptors consist o f a group o f cell-surface 
proteins, all members o f which possess a large glycosylated extracellular ligand-binding domain, a 
single transmembrane domain, and an intracellular cytoplasmic domain that contains a tyrosine- 
kinase catalytic region (Yarden &  Ullrich, 1988). Sixteen subclasses o f RTKs have been described, 
based on sequence sim ilarity and structural characteristics, (Hunter, 1998), and the characteristics o f 
the five principal subclasses are represented in Figure 5.2.
; i l  M
F A M IL Y E G F -R P D G F -R 1NS-R N G F -R PGF-R
M K M B E R S : E G F -R , P D G F -R ct , Insu lin-R , TrkA F G F -R  1-4
E rbB 2 P Ü G F -R ß I G F - l -R T rkB
C ata ly t ic  D o m a in C  Im m u no g lo bu lin  like region
C y ste in e -r ich  reg ion Q L euc in e-r ich  region
Figure 5.2: Schematic representation of the five principal Receptor Tyrosine Kinase sub­
classes (Ullrich & Schlessinger, 1990; Feldkamp et aL, 1997; Hunter, 1998)
Many growth factors mediate their actions by binding to their cognate receptors e.g. the 
binding o f epidermal growth factor (EG F) to the epidermal growth factor receptor (EGF-R), as was 
the focus o f this work. This causes activation o f the intrinsic tyrosine kinase activity, which leads to 
the intracellular transmission and amplification o f the extracellular signal. The signal due to 
extracellular ligand binding must be relayed across the extracellular membrane, and this is achieved 
by receptor oligomerisation, usually dimérisation (U llrich &  Schlessinger, 1990; Weiss &  
Schlessinger, 1998). Through dimérisation, an intracellular conformational change occurs, which 
allows the kinase domain o f one receptor molecule to phosphorylate tyrosine residues on the 
intracellular domain o f the second receptor molecule, and vice versa, a process termed
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autophosphorylation (Figure 5.3). Using tryptic phosphopeptide mapping and mutational analyses, 
the exact autophosphorylation sites for the major receptor molecules have been described 
(Downward et al., 1984; Rosen, 1987; Malarkey e ta l,  1995).
Receptor autophosphorylation enables the activated kinase to phosphorylate cytoplasmic 
molecules on tyrosine residues, thus initiating the cascade o f signals downstream towards the 
nucleus (Figure 5.3). A  number o f R TK  substrates have been identified to date. These include 
Phospholipase C-y [PLC-y] (Meisenhelder et al., 1989; Nishibe el al., 1990), p85 
Phosphatidylinositol-3' Kinase [PI3K] (Coughlin et al., 1989), SHP2 [Src-Homology Phosphatase] 
(Lechleider et al., 1993), Growth factor Receptor Binding Protein-2 [Grb2] (Arvidsson et al., 
1994), 120-GAP [GTPase-Activating Protein] (Kazlauskas et al., 1990), and members o f the non­
receptor Src fam ily o f tyrosine kinases (M ori et al., 1993). Each o f these substrates recognise 
specific autophosphorylated residues and bind only to these, as shown for autophosphorylated 
PDGF-R in Figure 5.4.
Crucial to the protein-protein interactions which take place between the activated R TK  and 
the cytoplasmic target proteins are the existence o f regions known as SH2 (Src homology) domains. 
These are regions o f -60 -100  amino acids within the target protein, which specifically recognise 
phosphorylated tyrosine (pTyr) residues, and, thus, in activated receptors couple strongly with 
autophosphorylation regions (Pawson, 1995). The amino acid sequence in which a particular pTyr 
lies determines which SH2 region, and thus, which target protein, binds with high affinity to that 
particular site, e.g. the SH2 domain o f Src tyrosine kinases recognise the sequence pTyr- 
hydrophilic-hydrophilic-Ile/Pro, while the PLC-y molecule prefers at least five hydrophobic 
residues following the pTyr (Malarkey et al., 1995; Pawson, 1995). Thus, the SH2 domains 
function to recruit target substrates in a highly specific manner to the vicinity o f the receptor 
tyrosine kinase domain (as represented in Figures 5.3 and 5.4).
Proteins with SH2 domains commonly possess another distinct sequence o f -5 0  amino 
acids, the SH3 domain, which is also critical in the protein-protein associations at the core o f signal 
transduction. SH3 domains recognise one or more proline residues in a short (— lOaa) peptide 
stretch o f effector proteins, and like the SH2 domains are responsible for the accurate docking of 
the appropriate downstream target (Pawson, 1995). W ith regard to proliferative signal transduction, 
the SH3 domains couple with the Ras signalling pathway, the importance o f which is outlined in 
Section 5.2.3. It  has been ascertained that certain molecules, for example Grb-2 molecule, contain 
only SH2 and SH3 domains, with no other functional domains. It is believed that these molecules
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function only as adaptor molecules to couple the activated receptor to other signalling intermediates 
(M alarkey e ta l,  1995).
LIGAND  
e -g -  EGF
DIMERISATION & 
AUTOPHOSPHORYLATION
L IGAND BINDING  
 ►
1*
■i—  P
A d a p to r
M o le c u le 8 H 3 E f f e c t o r
Protein
SIGNAL TRANSDUCTION  
TOW ARDS NUCLEUS
Figure 5.3: Diagram illustrating the events which occur following ligand (&g. EGF) -
receptor interaction. The EGF-Receptor dimerises with a neighbouring 
receptor, allowing autophosphorylation of receptor tyrosine residues. 
Molecules containing SH2-domains (either adaptor e.g. Grb2, or effector 
proteins e.g. PLC-y) can bind to tyrosine phosphorylated (P-Tyr) residues, 
leading to transduction of the binding signal towards the nucleus.
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Figure 5.4: Schematic diagram illustrating the phosphotyrosine residues critical in the
coupling of the PDGF-R to downstream signalling proteins.
5.2.3. TheRas Protein and its Coupled Transducers
For over a decade, the Ras protein has been assumed to act as a key regulator o f cell growth 
and other functions. The first experiments demonstrating the importance o f Ras proteins in the 
proliferation o f normal cells, used antibodies to achieve inactivation o f endogenous Ras (Mulcahy 
et al., 1985). A  major goal o f research into the regulation o f eukaryotic proliferation has been the 
identification o f the critical activators and cellular targets o f the Ras protein. Due to the 
evolutionary conservation o f the signalling pathway involving Ras, much lead information on 
mammalian signalling has been gained from studies in lower eukaryotes, such as Saccharomyces 
cerevisiae, Drosophilia melanogaster and Caenorhabditis elegans (Egan &  Weinberg, 1993).
Ras is a 21kDa guanine nucleotide-binding protein whose biological activity is determined 
by the bound nucleotide. Activated protein contains bound GTP, while the inactive state binds 
GDP. During normal signalling, activated Ras-GTP couples transiently with an effector molecule. 
However, the Ras protein intrinsically possesses a GTPase activity to dephosphorylate bound GTP, 
thus lim iting the lifetim e o f the activated Ras-GTP species. In transformed cells, however, the Ras 
protein usually has diminished GTPase activity, (as a result o f mutations in the amino acids
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important for guanine nucleotide co-ordination), causing extended signalling periods, and the 
hyperproliferating cancerous cell (Downward, 1998).
Activation o f Ras proteins is a key step in the signal transduction process, and is triggered 
by the RTKs discussed in Section 5.2.2. Central to the activation o f Ras is a fam ily o f guanine 
nucleotide release factors (GRFs) (Feig, 1993). The GRF fam ily are molecules responsible for the 
release o f bound GDP from the Ras protein, thereby enabling its activation as mentioned above. 
Deactivation o f Ras occurs by hydrolysis o f GTP to GDP, a reaction dramatically hastened by 
GTPase activating proteins (GAPs). Therefore, the relative activities o f GRFs and GAPs acting on 
Ras at any instant determine its activation state (Figure 5.5).
The first GRF for Ras, CDC25, was identified following genetic studies in S. cerevisiae. 
Three GRF mammalian homologues have since been cloned —2 mouse, mSosl and mSos2, and one 
human, hSos. These GRF molecules function directly upstream o f Ras but are coupled to the RTKs 
via the previously-mentioned adaptor molecule Grb2 (see Figure 5.6). This is achieved through 
Grb2 SH3 domain binding o f a proline-rich sequence in the Sos/CDC25 molecule (Feig, 1993).
Figure 5.5: Schematic representation of the activation/deactivation cycle of Ras. Inactive Ras
binds GDP, while active Ras contains bound GTP. Two molecule types, the 
Guanine-nucleotide Releasing Factors (GRFs, e.g. Sos) and the GTPase Activating 
Proteins (GAPs, e.g. 120-GAP) control the activation state of Ras, with their 
relative activities at any instant, deciding its state of activation. The GRFs cause 
the release of bound GDP from Ras, enabling its activation. The deactivation of 
Ras occurs by the hydrolysis of GTP to GDP, catalysed by GAPs.
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In addition to the elucidation o f upstream activators o f the Ras protein, a considerable 
amount o f research has focused on the search for downstream Ras targets (Malarkey et al., 1995; 
Vojtek &  Der, 1998). The first effectors identified were the GTPase activating proteins (GAPs), 
recognised to maintain normal p21 Ras in a biologically inactive GDP-bound state in Xenopus 
oocytes (Trahey &  McCormick, 1987). GAPs are, therefore, negative regulators o f Ras, and may be 
involved in a negative feedback mechanism. To date four mammalian GAPs have been identified: 
GAP-120, neurofibromin, G A P l”  and GAP11P4BP (M alarkey et al., 1995). As mentioned in Section
5.2.2, GAP-120 is also a direct substrate o f autophosphorylated RTKs.
The GAP proteins do not account for all signals emanating from Ras. A  more clearly 
understood and crucial proliferative pathway emerging from Ras involves the activation o f an 
evolutionarily conserved cascade o f serine/threonine kinases, as outlined in Figure 5.6 (Malarkey et 
al., 1995; Vojtek &  Der, 1998). Direct interactions o f the Ras protein with the amino terminal o f the 
serine/threonine kinase, Raf-1, have been reported in both in vitro and yeast expression systems 
(Low y &  Willumsen, 1993; Van Aelst et al., 1993). Raf-1, a 70-75kDa protein, has a two-domain 
structure, with a kinase domain occupying the carboxy-terminal half o f the molecule, and a 
regulatory domain occupying the remainder. The Raf-1 protein preferentially binds GTP-Ras in 
comparison to GDP-Ras (Votjek &  Der, 1998). The Ras-Raf binding reaction does not itself 
stimulate the inherent kinase activity o f the Raf-1 protein, rather it only localises the Raf-1 protein 
to the plasma membrane where some unknown activation o f R af takes place (Leevers et al., 1994).
Activated Raf-1 in turn phosphorylates a second kinase, M E K  kinase. This enzyme controls 
a third fam ily o f enzymes, the Mitogen-Activated Protein Kinases (M A P kinases), again through 
phosphorylation on both tyrosine and threonine residues. The M AP kinases (ERK1 &  ERK2) are 
proline-directed serine/threonine kinases, which have been implicated in the control o f cell cycle 
progression and meiosis. Activated ERK translocates to the nucleus where it phosphorylates a 
number o f factors (e.g. Rsk-2, Elk-1)  required for the transcription o f immediate early gene products 
e.g. c-fos. Thus activation o f Raf-1 results in nuclear transcription (Roussel, 1998).
Other signalling intermediates can interact with Raf-1 e.g. Protein Kinase C (section 5.2.4) 
is also known to directly activate Raf-1 by direct phosphorylation (Kolch et al., 1993). In addition, 
it appears G-protein-coupled receptors (Section 5.2.1) are capable o f causing activation o f the M AP  
Kinase signalling pathway (M alarkey et al., 1995). Although the mechanism behind this recent 
observation is unclear, it is believed that activation o f cytoplasmic kinases, including Protein Kinase 
C (as a result o f diacylglycerol generation) couples G-protein-receptors to this pathway. Therefore,
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even signals from different receptor types appear to converge and co-operate on this central 
proliferative pathway. Likewise, as shown in Figure 5.6, signal pathways that appear to diverge on 
initiation by RTK autophosphorylation, can converge later through co-operation along the MAP 
Kinase cascade e.g. Raf activation via Grb2/Sos/Ras as opposed to Raf activation via PLC- 
y/DAG/PKC.
As mentioned above, the Ras/MAP Kinase pathway regulates the transcription of c-fos, and 
also c-jun, which together dimerise to become the AP-1 nuclear transcription factor. Another 
important immediate early gene is c-myc. This transcription factor also becomes activated following 
the binding of growth factor to its cognate RTK through phosphorylation of the Src family of 
cytoplasmic tyrosine kinases (Hunter, 1998).
Figure 5.6: Components of the RTK -> MAP Kinase pathway. Ligand binding to its cognate
receptor at the membrane surface results in signal cascades towards the nucleus 
via the Ras/MAP kinase pathway, with eventual nuclear phosphorylation of 
transcription factors (precise details in text). Divergent signals at the receptor e.g. 
activation of PLC-y, vs Grb2 binding, can re-converge along the MAP kinase 
pathway as shown, for PLC-y-mediated activation of Protein Kinase C.
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5.2.4. Protein Kinase C in Signalling Pathways
Protein Kinase C (PKC) is a large fam ily o f serine/threonine kinases involved in multiple 
signalling pathways. Three major sub-classes have been isolated (Table 5.2), and the members are 
continuously growing. The different iso-enzymes presumably activate diverse functions in the cell -  
secretion, ion conductance modulation, smooth muscle contraction and cell proliferation to name a 
few. As shown in Table 5.2, various PKC isozymes are activated by the second messengers 
diacylglycerol (D A G ) and calcium. These are products o f the phosphoinositide hydrolysis pathway, 
initiated through the stimulation o f PLC-y by many receptor types (Figure 5.7). The critical 
substrates o f PKC have not been conclusively identified but include various transcription factors, 
Raf-1 and M EK  (Kolch et al., 1993; Malarkey et al., 1995; Mochly-Rosen &  Kauvar, 1998). 
Therefore, Protein Kinase C would appear to interact with proliferative pathways within the cell.
PKC Family Members Properties
Classical a , Pi, P2, Y 1. Bind phospholipid, diacylglycerol (DAG) and Phorbol
Myristate Acetate (PMA)
2. Ca2+-dependent
N ovel 5, s, ti, 0 1. Bind phospholipid, D A G  and PM A
2. Ca2+-independent
A typical C A 1. Bind phospholipid; do not bind DAG  and PM A
2. Ca2+-independent
Table 5.2: Table summarising the properties and iso-enzymes of the various PKC
families. Compiled from data in Weinstein et al. (1997) and Mellor &  Parker 
(1998).
However, PKC appears to play a paradoxical role in the cellular signalling network, as it is 
believed to act as a negative regulator, over various steps o f the cell proliferation signalling process. 
PKC appears to be important in decreasing the elevated Ca2+ levels induced by inositol 
triphosphates. It  may achieve this by inactivating the lipid triphosphates with inositol-triphosphate- 
phosphatase (Connolly et a l,  1986). Alternatively, it may activate the Ca2+ transport ATPase and 
the Na+/  Ca2+ exchange protein, effecting the removal o f intracellular Ca2+ (Nishizuka, 1986). In 
addition, PKC acts as a negative regulator o f growth factor receptors. PKC has repeatedly been 
shown to phosphorylate the EG F-R  in vivo and in vitro on threonine residues (Cochet et al., 1984;
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Downward et ah, 1985). This action causes a rapid decrease in EGF binding, with consequent 
receptor downregulation.
G C R  O R  R T K
Figure 5.7: Schematic representation of the PLC-y -mediated Phosphoinositide hydrolysis
pathway, the products of which include diacylglycerol, which can lead to 
Protein Kinase C activation. Either G-protein-coupled receptors or Receptor 
tyrosine kinases can cause activation of PLC-y, with eventual PKC 
stimulation.
5.2.5. Oncosenes and Signalling Pathways
The growth signalling pathways described in Sections 5.2.1- 5.2.4 are clearly complex, and 
their regulation as yet is not completely determined. W hile the signalling pathway from the plasma 
membrane to the nucleus is elucidated (the Ras/MAP kinase pathway), it is evident that other 
signalling intermediates infringe/con verge on this pathway at each step in the cascade. Divergent 
pathways are also initiated from this central signalling scheme (Figure 5.8). It is apparent, therefore, 
that deregulation or malfunctioning at any step along this pathway has severe consequences for 
growth control within the cell. Oncoproteins, which are altered versions o f normal growth proteins,
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have been identified at all stages along the growth control pathway (Table 5.3 and Figure 5.8). In  
many instances the oncoprotein possesses much enhanced enzyme activity e.g. neu oncogenic 
mutant receptor has enhanced tyrosine kinase activity.
However, despite the identification o f many oncoproteins with the capability to deregulate 
normal growth signalling pathways, only a few are commonly associated with human cancer e.g. 
ras has been associated with 30-40%  o f cancers. Instead, the most common cellular fault in human 
cancers involves autocrine activation, in association with growth factor receptor over-expression. 
Many tumours and cell lines co-express growth factors and receptors, including EG F/TG F-a, 
PDG F-A/B  and FGF (Table 5.4), leading to persistent, enhanced signalling, observed as cancer.
Category Oncogene (Cellular Homologue) Associated Cancer
Growth Factors Sis (PDGF) 
lnt-2 (FGF)
Simian sarcoma
Transmembrane growth 
factor receptors
ErbB (EGF-R) Breast, ovary, prostate, renal cell, 
glioblastomas
Membranc-associated Src Colorectal, renal.
tyrosine kinases Abl Leukemia
Membrane-associated 
guanine nucleotide 
binding protein
Ras Colorectal, lung, prostate, 
pancreatic, thyroid, skin
Nuclear factors Myc Neuroblastoma, Burkilts lymphoma
Table 5.3: Selected oncogenes, their cellular homologues and cancers in which they are
implicated. This table was compiled from data from a number of sources 
(Boutin, 1994; Carter & Kung, 1994; Levitzki, 1994; Lodish et al., 1995; 
Kolibaba & Druker, 1997)
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Growth Factor Receptor Involved____________________Associated Cancer
EGF-R Autocrine Loop / Glioblastomas, Prostate, Renal Cell, Breast, Bladder,
Over-expression of EGF-R & TGF-a Lung, Neck,
PDGF-R Autocrine Loop/ Glioblastomas, Breast
Over-expression of PDGF-R & PDGF
Over-expression of Her2/«ew Breast, Ovary, Non-small cell lung.
Table 5.4: Selected growth factor autocrine loops and cancers in which they are implicated.
This table was compiled from data from a number of sources (Derynck, 1988; 
Carter & Kung, 1994; Levitzki, 1994; Lodish et al., 1995; Feldkamp et al., 1997; 
Voldberg et a l , 1997)
Figure 5.8: Summary of growth factor-mediated signalling pathways within cells, illustrating
the divergence and convergence of various signalling intermediates along the main 
MAP Kinase route, as detailed in the text. Oncoproteins at any stage along this 
pathway can seriously deregulate normal growth control processes, and the 
intermediates which are commonly associated with human cancers are highlighted 
with black stars.
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5.3. SIGNAL TRANSDUCTION THERAPY
As described in sections 5.1 and 5.2, cancer can arise as a result o f the aberrant relay o f 
growth signals within the cell. The persistent downstream signalling arises from either over­
expression of, or mutations in, the normal signalling proteins. Signal transduction therapy involves 
utilising novel agents specifically designed to block signalling pathways or their components, 
thereby averting the uncontrolled growth o f cancerous cells. Any component o f the signalling 
pathways described in Section 5.2 can be targeted. Efforts in this approach have concentrated in two 
principal areas to-date: 1. Tyrosine kinase inhibition
2. Ras pathway inhibition,
5.3.1. Tyrosine Kinase Inhibition
Protein tyrosine kinases are excellent targets for the development o f anti-cancer drugs, on 
the basis o f the critical role they play in the creation o f signals responsible for cell proliferation and 
malignancy. The transforming ability o f protein tyrosine kinases is removed when recombinant 
D N A  techniques are used to immobilise the kinase activity (Yarden &  Ullrich, 1988). It would be 
expected i f  a drug could exhibit the same kinase inhibition, it would also have beneficial anti- 
proliferating effects. A  variety o f chemical structures, many based on natural products, have been 
determined which inhibit protein tyrosine kinases.
The first known protein tyrosine kinase inhibitor was quercetin, a member o f the 
bioflavonoid group, which was shown to inhibit the tyrosine phosphorylation activity o f p60-Src 
both in vivo and in vitro. However, this inhibitory activity was found to be non-specific, due to the 
fact that it was competitive with respect to ATP (Brunton &  Workman, 1994). The isoflavone 
genistein proved a more efficient inhibitor o f the EG F-R TK  activity -  it was potent to tyrosine 
kinases at concentrations that had no effect on serine/threonine kinases (Brunton &  Workman, 
1994).
Erbstatin, a natural isolate from actinomycete broth, was the first described tyrosine 
analogue, which had tyrosine kinase inhibitory activity. It  blocks the peptide-site o f the EGF-R, 
thus competing with the substrates for phosphorylation, in EGF-R-containing membrane fractions 
(Brunton &  Workman, 1994). The structure o f erbstatin was used as the lead for the specific and 
systematic design o f a fam ily o f chemical tyrosine kinase inhibitors, the tyrphostins (Gazit et al., 
1989). H ighly selective inhibitors o f the EG F-RTK, PDG F-RTK and Abl-T K  have been reported
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(Gazit et a l, 1991; Anafi et al., 1992). Other chemical families e.g. 4-hydroxycinnamide, 
dianilophthalimide and 2-phenylaminopyrimidine, have also been assessed (Shiraishi et al., 1989; 
Trinks et a l, 1994; Buchdunger et a l, 1995). An expanding list o f highly specific and potent in 
vitro inhibitors o f all the major tyrosine kinases currently exists, and these are likely to enter clinical 
trials in the near future.
5.3.2. Inhibitors o f the Ras Pathway
As a normal transducer o f upstream mitogenic signals, the Ras protein plays an important 
role in proliferative signalling, and inhibition o f Ras function is therefore an excellent target for 
drug discovery. Drug discovery programs have concentrated on two main areas for the inhibition of 
Ras function: 1. inhibition o f Ras activation by Sos exchangers
2. inhibition o f Ras post-translational modification.
Small molecules which interfere with the Grb2/Sos interactions and/or Sos/Ras interactions 
are attractive drug targets. Since Grb2 interacts with SH2 domains on phosphorylated RTKs 
through a small conserved sequence, in theory it should be relatively easy to screen for compounds 
which block Grb2 binding (Grbstatins). Active research in this area is documented (Levitzki, 1994).
Therapeutic intervention o f Ras has concentrated on the area o f Ras famesylation (Gibbs et 
al., 1994). It is well-established that membrane association is essential for Ras functioning. 
Localisation o f Ras to the plasma membrane is mediated by the famesyl (15-C  isoprenyl) group. 
The post-translational addition o f this famesyl group is catalysed by a number o f enzymes, the most 
important o f which is Famesyl-Protein-Transferase (FPTase). This enzyme is also the most 
important therapeutic target for the Ras molecule. Drug discovery programs have yielded successful 
in vitro FPTase inhibitors, although laboratory studies are still ongoing (Heimbrook &  O liff, 1998).
5.3.3. Other Strategies
Various other strategies for the disruption o f aberrant growth signalling pathways include 
growth factor agonists, antibodies and anti-sense strategies. Mclnnes and Sykes (1997) review the 
current status o f research in the area o f peptidomimetic growth factor agonists, and highlight the 
various difficulties facing this approach to abolishing autocrine activation. To date, suramin is the
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sole chemical agonist o f growth factors, and has been used clinically in the treatment o f renal and 
prostate cancers (Levitzki &  Gazit, 1995).
Antibodies generated to block the ligand-receptor binding step, is an alternative strategy for 
preventing the initiation o f growth signals. Murine monoclonal antibodies (Mabs) to the EGF-R  
were shown to inhibit proliferation o f both cultured and xenograft cells. In clinical trials, successful 
targeting o f primary lung and metastatic cells was achieved with these Mabs. A  human-mouse 
chimeric version is currently in clinical trials. As the nature o f growth inhibition with antibodies is 
cytostatic, combination therapies with cytotoxic chemotherapeutic agents are currently undergoing 
clinical trial assessment, w ith promising results (Fan &  Mendelsohn, 1997).
Anti-sense oligonucleotides are a further intervention possibility being examined, although 
to date studies are in the early laboratory phases (Voldberg et a l, 1997).
5.4. COUMARINS IN SIGNALLING PROCESSES
Interest in the study o f coumarin compounds has originated in the clinical observation o f its 
efficacy in cancer patients, especially renal cell carcinoma, prostate cancer and melanoma. The 
widely-held belief, is that coumarin is the pro-drug for the active agent, 7-hydroxycoumarin, and 
laboratory work has concentrated on proving this belief. Much presented work has shown that both 
coumarin and 7-hydroxycoumarin inhibit the in vitro growth o f a range o f cell lines in a dose-and 
time-dependent manner, with some cell lines more sensitive than others to these effects (Chapter 4, 
as w ell as Moran et al., 1993; Siegers &  Bostelmann, 1993; Marshall et al., 1994). In all cases 7- 
hydroxycoumarin was more potent than its parent compound.
To date, however, very little understanding o f the growth inhibitory action has been 
achieved, with both direct and immunomodulatory mechanisms often cited to explain in vivo 
observations. In order to exploit the effects o f any drug optimally, it is essential to locate it precise 
cellular or molecular target. To date this has not been achieved with the coumarins. However, it is 
apparent from the previous discussion on signalling pathways in normal and cancerous cells 
(Section 5.2), that any compound with an anti-tumour effect may infringe on these pathways, or 
their components, in mediating their action.
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One hypothesis regarding the precise mode o f action o f coumarins, suggests that these 
compounds modulate their action by down-regulating autocrine loops in growing cells. Indirect 
evidence lies in the fact that both coumarin and 7-hydroxycoumarin inhibit the growth o f 
glioblastoma cell lines (Seliger, 1993). These cell lines are heavily dependent on both PDGF and 
EGF autocrine loops (Feldkamp et al., 1997). Direct evidence for the involvement o f coumarins in 
down-regulating autocrine loops, stems from the report that 7-hydroxycoumarin selectively and 
reversibly downregulates m RNA expression o f PDGF in glioblastomas. m RNA levels o f PDGF-R, 
EGF, EG F-R and T G F -a are unaffected by 7-hydroxycoumarin treatment, and growth factor 
binding is also unchanged (Seliger, 1997). These results do not indicate whether the negative 
regulation o f the PDGF loop is a cause or consequence o f treatment with 7-hydroxycoumarin. 
Given the prevalence o f autocrine loops in many cancers (Section 5.2.5), including prostate and 
renal cell cancers, which are responsive to coumarin in vivo, further work into the study o f autocrine 
loops and their associated signalling pathways would be very beneficial.
The central role o f the Ras protein in growth signalling pathways was also highlighted in 
Section 5.2.3. Various studies into the direct effects o f coumarins have observed changes in ras 
activity and expression as a result o f treatment with coumarins. Zanker (1997) reported that 7- 
hydroxycoumarin dramatically inhibited the growth o f the RBA mammary and T-24 bladder 
carcinoma cell lines, which are both heavily dependent on the constitutively-activated Ha-ras 
oncogene for growth. 7-hydroxycoumarin could alter the level o f Ha-ra? expression (at the mRNA  
level) in the RBA cell line (Zanker, 1993). Seliger and Pettersson (1994) also observed reversible 
growth inhibition by 7-hydroxycoumarin in fibroblasts transformed with ras. Northern blot analysis 
revealed a decrease in the specific ras-m RNA levels. Kahn and colleagues (1994) showed that 
coumarin could decrease ras expression in cells transformed with the ras oncogene, which resulted 
in decreased numbers o f cells entering the S-phase o f the cell cycle. Therefore, coumarin 
compounds also appear to interact extensively with the Ras protein in transformed cells.
The effect o f 7-hydroxycoumarin on the c-myc oncogene, an important transcription factor, 
has also been addressed. Zanker (1993) examined the growth inhibition and m RNA expression o f c- 
myc in the D U K X  cell line, which overexpresses the c-myc oncogene, i f  transiently exposed to 
40°C. Concentrations o f 100 and 200(ig/m l caused a dose-dependent and reversible growth 
inhibition o f this cell line. The m RNA expression was only marginally affected by 7- 
hydroxycoumarin treatment (Zanker, 1993). In /wyc-transformed fibroblasts, both growth and myc- 
gene expression were strongly inhibited by 7-hydroxycoumarin treatment (Seliger &  Pettersson,
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1994). Treatment o f H L-60 leukemic cells with coumarin also caused down-regulation o f c-myc 
expression (Shima et al. , 1989).
Finally, the effect o f coumarins on Protein Kinase C pathways has been previously 
described in human monocytes, with regard to cytokine production (Stuhlmeier et a l, 1991; 
Zlabinger et al., 1993). Coumarin, 7-hydroxycoumarin and 4-hydroxycoumarin all potentiate the 
release o f IL -1 , IL -6  and T N F -a  from monocytes stimulated with LPS (Stuhlmeier el a l, 1991). 
Zlabinger and co-workers (1993) ascertained that the LPS-induced cytokine release involved both 
the Protein Kinase C and lipoxygenase signalling pathways, and determined that the coumarins also 
interacted with these pathways in displaying their augmenting effect.
It  is evident from the above discussion, that the coumarin compounds exert a number of 
effects on important components o f normal signalling pathways. Since these components are 
commonly deregulated in cancer, the coumarins may be exerting their anti-tumour effect by renewal 
o f regulated signalling. The review o f growth signalling pathways in Section 5.2, highlighted the 
importance o f tyrosine phosphorylation reactions in the accurate regulation o f growth control. To 
further the investigation o f the effect o f coumarin compounds on signalling components and 
pathways, we decided to investigate the effect o f coumarins on tyrosine phosphorylation within 
cells.
Tyrosine phosphorylation, and in particular inhibition o f tyrosine kinases, interested us for a 
number o f reasons. Firstly, esculetin (6,7-dihydroxycoumarin) has been reported to inhibit the 
growth o f smooth muscle cells, exerting this effect through inhibition o f protein tyrosine kinases 
(Huang et al., 1993). It also inhibited tyrosine kinase activity in T-lymphoid leukemia cells (Huang 
et al., 1994). The origin o f this activity may be derived from the structural sim ilarity o f the “phenol- 
moiety” o f esculetin and tyrosine (Figure 5.9). In addition, many bioflavonoids, e.g. genistein and 
quercetin, are well-documented tyrosine kinase inhibitors (Boutin, 1994). Other known tyrosine 
kinase inhibitors (Figure 5.9) also share phenolic groups which may act as competing substrates for 
the tyrosine kinase activity. Lazaro et al. (1995) have reported on the inhibition characteristics of 
phenolic compounds on spleen protein tyrosine kinases. Diphenolic and triphenolic compounds 
were shown to display exceptional inhibitory capabilities, while monophenolic compounds were 
much poorer inhibitors o f tyrosine kinases.
In this work, we were interested in testing the hypothesis that 7-hydroxycoumarin (a 
monophenolic compound) may cause slight inhibition o f cellular tyrosine kinases. Such an event
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would cause a dampening o f persistent deregulated signalling, which may account for the observed 
effects o f coumaiins on signalling components. The fact that coumarin has shown effects in vivo 
with renal cell and prostate cancer, two cancer types w ith deregulated EG F/EG F-R autocrine loops, 
prompted us to examine this ligand-receptor system in detail. The very potent growth inhibition o f 
the A431 cell line, which over-expresses the EGF-Receptor, by coumarin compounds observed in 
Chapter 4, also directed us to investigate the EG F/EG F-RTK.
Figure 5.9: Chemical Structures of tyrosine, 2 tyrosine kinase inhibitors (tyrphostin and
genistein) and coumarin compounds.
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5.5. CHAPTER OUTLINE
The effect o f two coumarin compounds, 7-hydroxycoumarin and esculetin, on tyrosine 
phosphorylation in cancer cells was examined, to determine if  these compounds exhibit tyrosine 
kinase inhibitory properties. The EGF-Receptor tyrosine kinase, chosen as an easily-inducible TK  
activity, was examined in detail, using the A431 cell line as a source. The activity o f this RTK was 
in itially assessed following purification in an in vitro format. However, it was decided to examine 
this activity in intact cells, and the effect o f the coumarins on tyrosine phosphorylation was 
examined by ELISA, Cytosensor studies and Western Blotting. The effect o f the coumarins on 
Protein Kinase C pathways was also examined.
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5.6.1. Activation of the EGF~Recevtor inA431 Cells;
5.6. RESULTS AND DISCUSSION
As described in Section 5.5, this study involved examining the effect o f coumarins on 
tyrosine phosphorylation events in cancer cells. The A431 cell line, known to over-express the 
EGF-Receptor was chosen in conjunction w ith EGF, as a model signalling pathway, w ith inducible 
tyrosine kinase activity. Prelim inary studies were conducted to ensure that the A431 cells responded 
to EGF, using the Cytosensor Microphysiometer. As described in Chapter 3, this instrument has 
been used extensively in the examination o f cellular responses to neurotransmitters, cytokines and 
growth factors. The stimulation o f normal keratinocytes w ith EGF on the Cytosensor 
Microphysiometer has been reported (Parce et al., 1989). Fok and colleagues (1994) also used this 
instrument for the detection o f EG F-R  ligand in the conditioned media o f ovarian carcinoma cells. 
The metabolic response o f mammary cells over-expressing the HER-2 Receptor, an EGF-R  
homologue, has also been reported (Chan et al., 1995).
The response o f A431 cells to stimulation w ith EGF was therefore assessed on the 
Cytosensor Microphysiometer, according to the method outlined in Section 2.2.6.4. As outlined in 
Table 5.5, various experimental conditions were optimised. Using these optimised parameters, the 
response o f A431 cells on exposure to a range o f EGF concentrations was examined. As expected a 
dose-dependent increase in the acidification rate o f the cells was observed in the range O-lOQng/ml 
EGF (Figure 5.10). Through integration o f the area under the curve o f these response curves (Figure 
5.10) a dose-response curve for the A431 cells and EGF was constructed (Figure 5.11). From this it 
can be seen that the maximal response was obtained at concentrations in the range 50-100ng/ml o f 
EGF. This value corresponds w ell w ith studies using other parameters e.g. inositide formation 
(maximal response at 50-100ng/m l), to determine maximal responses to EGF in the A431 cell line 
(T illy  et al. , 1988). From this result, we concluded that our ligand-receptor model was useful for 
further studies, and an appropriate ligand concentration for these studies was ascertained.
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Variable Examined Optimised Conditions
Cell Seeding Density 2.5 X 105 cells/capsule
Pump Cycle 2 mins cycle @ 60% speed (~ 120 1^/min)
Serum-starvation Period 16hrs
EGF Exposure Period 12mins
Table 5.5: Optimisation of experimental conditions for the exposure of A431 cells to EGF on the
Cytosensor Microphysiometer, as outlined in Section 2.2.6.4.
Response o f A431 Cells to  Epidermal Growth Factor (EGF)
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Figure 5.10: Exposure of A431 cells to various concentrations of Epidermal Growth Factor (EGF).
The above plot shows the experiment conducted on the Cytosensor Microphysiometer 
to determine the feasibility of using the EGF/A431 system as an appropriate ligand- 
receptor model. In individual experiments, the cellular acidification rate for each 
sensor chamber was determined prior to EGF exposure, using a 2 min cycle, with the 
acidification rate measured in the final 30 secs, of this cycle. This rate was normalised 
at 100% and all subsequent acidification rates during and following EGF exposure 
were expressed as a percentage of this normalised value. These values of metabolic 
rate (mean of four experiments) were plotted vs time in the above graph. Typical basal 
acidification rates for the cells in all experiments were -100 to -200pvolts/sec.
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Figure 5.11:
Dose-Response Curve fo r A431 cells with EGF
Concentration of EGF (ng/ml)
Dose-Response curve for the interaction of EGF with the EGF-Receptor on 
A431 cells. This curve was constructed from the data presented in Figure 5.10 
as follows: Briefly, integration of the area under each of the curves (AUC) in 
Figure 5.10 was achieved using the Kaleidagraph (version 3.0 -  Abelbeck 
software) program. From this analysis, data for the AUC for zero effect, EGF 
concentration of maximal effect (i.e. 100ng/ml) and all intermediate 
concentrations (0.01-50ng/ml) was available. By subtracting the zero value 
from each concentration value, and expressing the result as a % of the 
maximal value a mean excess acidification value for each concentration value 
was obtained. The above dose response curve was obtained by plotting the 
mean excess acidification rate vs the concentration of interest.
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5.6.2. Studies on the Inhibition o f the EGF-R Tyrosine Kinase Activity
The critical role o f the EGF-Receptor at the head o f signalling pathways has been discussed 
in Section 5.2. The prevalence o f both EGF-R autocrine loops and deregulating mutations in many 
cancer types was also reviewed (Section 5.2.5). Due to the importance o f such anomalies in prostate 
and renal cell cancers, two cancer types responsive to coumarin treatment, we were interested in 
assessing the effect o f 7-hydroxycoumarin on the tyrosine kinase activity o f the EGF-Receptor, and 
this was achieved as outlined in Sections 5.6.2.1 and 5.6.2.2.
5.6.2.1. Purification o f the EGF-Receptor
In the past, purification o f the EGF-Receptor has been accomplished by various methods, 
including use o f EGF A ffi-G el affin ity (Cohen et ah, 1980), and immunoaffmity columns with anti- 
EGF-Receptor (Weber el al, 1984). Both methods require competitive elution with EGF. However, 
in experiments examining kinase activity, it is preferred that the intrinsic receptor tyrosine kinase 
activity is not activated (through ligand binding) prior to its use. This requires the purification of 
active, but unactivated kinase, and was achieved in this work using lectin chromatography (using a 
wheat-germ agglutinin (WGA)-agarose column), as outlined in Section 2.2.6.1. This does not yield 
100% pure receptor, but fractions substantially enriched for the receptor and its associated tyrosine 
kinase activity.
The purification process was followed using dot blots and western blots for detection o f the 
receptor, and a typical western blot illustrating the purified EGF-Receptor (M r =  170kDa) is 
outlined in Figure 5.12. The bands on the left hand side o f the gel (Lanes 1 &  2) indicated the 
presence o f EG F-R  in the lysed cellular (A431) fraction, both pre- and post-ultracentrifugation -  
overloading o f these samples was evident from the wide bands. Various washes o f the column were 
performed to remove non-bound proteins - no EGF-receptor was lost during this procedure (Lanes 
3-6). EG F-R  was only present in samples obtained following specific elution o f the receptor from 
the column (Lane 7). Some degradation o f the receptor (lower bands) was apparent. The yield o f 
total protein from the purification shown in Figure 5.12 was ~  0.15mgs, as determined using the 
BCA Assay (Section 2.2.2.1). The fraction obtained was used to assess the effect o f 7- 
hydroxycoumarin on the EGF-Receptor tyrosine kinase, as outlined in Section 5 .6.2.2.
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Figure 5.12:
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Assessment o f EGF-receptor purification by Western Blot analysis w ith anti-EGF- 
Receptor antibodies. Purification was carried out as described in Section 2.2.6.1 
and immunoblotting accomplished as in Section 2.2.2.3. Samples from each of the 
purification steps were run on an 8% SDS gel and immunoblotted, prior to probing 
with anti-EGF-Receptor. Samples were run as follows, with an X  denoting a well 
where no sample was loaded: Lane 1: Solubilised cells, pre-ultracentrifugation; 
Lane 2: Post-ultracentrifugation supernatant; Lane 3: Unabsorbed WGA-Agarose 
column sample; Lanes 4-6: Column Washes; Lane 7: Eluted fraction from W G A- 
Agarose.
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5.6.2.2. Tyrosine Kinase Assays using Purified EGF-RTK.
The phosphorylating ability o f many cellular tyrosine kinases have been assessed in the past 
using radioactive 32P-ATP (Akiyama et a l, 1987; Gazit et a l, 1989). In  recent years, there has been 
a movement away from the use o f radioactivity in experiments, which has lead to an increase in the 
number o f non-radioactive E LIS A  based methods for the detection o f kinase activity (Lazaro et al., 
1991; Farley et a l, 1992). In these, specific anti-phosphotyrosine antibodies are used to detect the 
extent o f tyrosine phosphorylation following the exposure o f a specific peptide to the kinase o f 
interest. Recently, this assay format has become available commercially.
The tyrosine kinase activity o f the EGF-R-containing fraction isolated in Section 5.6.2.1 
was examined using one such commercial kit, as outlined in Section 2.2.6.2. Briefly, this entailed 
activating the EGF-Receptor Tyrosine Kinase activity, through EGF binding. The efficiency o f the 
R TK  in phosphorylating a tyrosine-containing peptide substrate, in the absence or presence o f 
known and putative inhibitors, was then ascertained using the ELISA-based system. Tyrphostin 
A25, a specific inhibitor o f the EG F-RTK was used as a positive control for tyrosine kinase 
inhibition, while 7-hydroxycoumarin was the putative inhibitor under assessment.
The results o f this study are shown in Figure 5.13. It  is evident that the exposure o f the 
EG F-R  to tyrphostin caused a dose-dependent decrease in the receptor-associated tyrosine kinase 
activity. The decrease o f ~  37%  at a concentration o f lOOpg/ml was much lower than expected as 
Tyrphostin A25 has previously been stated as an extremely potent inhibitor o f the EG F-RTK  
activity, with IC50 values o f 3|ig/m l for receptor autophosphorylation, and 0.6pg/ml using poly- 
G A T as an external substrate (Gazit et a l, 1989). Figure 5.13 also illustrated a slight decrease in the 
tyrosine kinase activity o f the EG F-R  on exposure to 7-hydroxycoumarin. This decrease appeared to 
be dose-dependent, but was small -  at concentrations o f lOOpg/ml an inhibition o f -  15% was 
observed. There are a number o f possibilities for this: firstly, and most obviously, the 7- 
hydroxycoumarin molecule may not be an efficient tyrosine kinase inhibitor, or i f  it is, the EGF- 
R TK  may not be its preferred/optimal target. The second reason addresses the possibility that the 
test system used (i.e. kit) may not be optimal. It  has previously been shown by Songyang and 
colleagues (1995), using degenerate peptide libraries, that the tyrosine kinases have optimal peptide 
substrates i. e. unique sequences o f peptides, that they preferentially phosphorylate. For example it 
has been shown that the c-Src tyrosine kinase prefers the sequence EEEIYG EFD , while the EGF- 
R T K  w ill preferentially phosphorylate tyrosine in the following sequence EEEEYFELV. The 
number o f currently available commercial tyrosine kinase kits and peptide substrates are limited,
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giving rise to the possibility o f sub-optimal conditions for any enzyme/substrate combination. The 
peptide sequence used in this k it was EGPW LEEE EE A Y  G W M D F, and this may account for the 
reduced “sub-optimal” effect o f Tyrphostin. In addition, we were concerned about the stability o f 
the EG F-R  and it associated tyrosine kinase activity. Figure 5.12 had illustrated the presence o f 
some degraded receptor in the purified fraction, and we were concerned that the purified fraction 
was not optimally active.
As a result o f these observations it was decided to examine the effect o f coumarins on 
tyrosine phosphorylation in intact cells, where the events observed mirror more effectively the 
natural situation. This approach is also more labour- and cost-efficient than the task o f screening a 
number o f pure kinases in the hope that 7-hydroxycoumarin inhibits one o f them. Instead 
examination o f the effect o f this compound on total tyrosine phosphorylation, can quickly prove or 
disprove this research avenue as a viable one.
Effect of 7-H^Jroxyeoumarin on EGF-R Tyrosine Kinase Activity
120 -----------------------------------------------------------------------------------------------------------
Control 20}jg/ml 50|ig/mt 75pg/ml 100|ig/ml 10pg/ml 100|ig/ml
7-HC 7-HC 7-HC 7-HC TYR TYR
Figure 5.13: In  Vitro Tyrosine Kinase Assay to examine the effect of 7-hydroxycoumarin on
the kinase activity of the EGF-RTK. The effect of 20-100pg/ml 7- 
hydroxycoumarin on the tyrosine kinase ability of EGF-stimulated EGF-RTK 
was assessed using an ELISA-based system (Section 2.2.6.3). Absorbance 
values for the test samples were normalised vs control wells (Abs 450nm= 
1.106 i  0.109). All experiments were carried out in duplicate on four separate 
occasions. Tyrphostin was included as a positive tyrosine kinase inhibitor.
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5.6.3. ELTSA-Detection o f Tyrosine Phosphorylation in Whole Cells
As outlined in Section 5.6.2.2, it was decided to examine the effect o f coumarin 
compounds, namely 7-hydroxycoumarin and esculetin, on total tyrosine phosphorylation in intact 
cells. In itially, an ELISA-based system was used to achieve this. The E L IS A  used (Section 2.2.6.3) 
was adapted from the method o f Trinks et a l (1994), where it had been used to screen for efficient 
tyrosine kinase inhibitors from a group o f systematically-designed candidates. The rationale behind 
the assay is the following: When serum-starved A431 cells are exposed to EGF, their signalling 
pathways become activated, and the overall levels o f phosphorylated tyrosines (P-Tyr) within the 
cells increase. The phosphorylated tyrosines can be detected in an ELISA-system using anti- 
phosphotyrosine antibodies. I f  cells are exposed to tyrosine kinase inhibitors, and then stimulated 
with EGF, the increase in P-Tyr should be diminished in inhibitor-treated cells compared to control- 
cells.
In itial experiments were necessary to optimise a number o f parameters, and the optimised 
E LIS A  parameters are shown in Table 5.6. The effect o f 7-hydroxycoumarin and esculetin on 
growth factor-stimulated tyrosine phosphorylation was then determined, following pre-exposure 
periods o f 1, 6 and 12 hrs. Positive controls used in the experiments were genistein (a general 
tyrosine kinase inhibitor) and Tyrphostin A25 (a specific EG F-R TK  inhibitor). In all experiments, 
increases in P-Tyr levels in drug-treated cells were compared to P-Tyr increases in control cells, 
with diminished increases illustrating tyrosine kinase inhibition. The results o f these experiments 
are shown in Tables 5.7-5.9. Table 5.7 shows the results o f the control compounds, genistein and 
tyrphostin. As shown, genistein caused a strong, dose-dependent inhibition o f tyrosine 
phosphorylation in EGF-stimulated A431 cells, after lh r pre-exposure, with ~  70% inhibition at the 
highest concentration tested (lOOpg/ml). Increasing the drug pre-exposure time to 6hrs did cause a 
slight augmentation o f this effect [—80% inhibition at 100pg/ml]. Pre-exposure o f A431 cells to 
Tyrphostin A25 for lh r caused increased tyrosine phosphorylation, as opposed to inhibition, at all 
concentrations tested. However, following 6hrs o f drug pre-exposure a very potent inhibition o f 
tyrosine kinase activity was evident, w ith > 50% inhibition at concentrations in the range 10- 
100pg/ml. This delayed effect has previously been observed and is believed to result from the 
requirement for tyrphostin to accumulate in the cell before it potency is effected (Lyall et al., 1989).
Table 5.8 shows the results obtained, following the stimulation o f tyrosine phosphorylation 
in A431 cells pre-exposed to 7-hydroxycoumarin for various time periods, lh r pre-exposure to 7- 
hydroxycoumarin lead to a slight decrease (~  10% decrease at 100pg/ml) in the levels o f cellular
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tyrosine phosphorylation. 6hrs pre-exposure again saw little decrease in the levels o f tyrosine 
phosphorylation except at the highest tested concentration (100pg/m l) where a decrease o f -21%  
was observed. However, following a 12hr exposure o f cells to 7-hydroxycoumarin, a dose- 
dependent decrease in the cellular tyrosine phosphorylation was observed in the concentration range 
10-100pg/ml. This decrease was not extremely potent -  again the highest concentration tested 
caused a decrease in tyrosine phosphorylation o f —22.5%.
Table 5.9 presents the results obtained, following the stimulation o f tyrosine 
phosphorylation in A431 cells pre-exposed to esculetin for various time periods, lh r pre-exposure 
o f A431 cells to esculetin followed by stimulation with EGF did not affect cellular tyrosine 
phosphorylation levels except at concentrations o f 100pg/ml, where a decrease o f -1 2 %  was 
observed. However, increasing the drug pre-exposure time to 6hrs, caused an dose-dependent 
decrease in the P-Tyr levels observed in the cells, with a maximum inhibition o f -39% , at the 
highest concentration tested (100pg/m l). Incubation o f cells with drug for longer time periods (i.e. 
12hrs) maintained this level o f inhibition.
These results indicate that the two coumarin compounds under investigation do inhibit 
growth factor-stimulated tyrosine phosphorylation by 30-40% , in a dose- and time-dependent 
manner. This inhibition was not as effective for 7-hydroxycoumarin as for esculetin, requiring 
longer time periods to exert this effect. Neither compound prevented phosphorylation with the 
efficiency o f the positive controls, genistein (maximal effect o f -7 0 %  inhibition at lOOpg/ml, 
following lh r exposure) or tyrphostin (maximal effect o f -8 0 %  inhibition at 100pg/ml, following 
6hr pre-exposure). This ELISA-based system yielded no information as to which kinases/substrates 
are affected by different compounds, therefore we examined this effect using two distinct methods: 
the Cytosensor Microphysiometer (Section 5.6.4) and Western Blotting (5.6.5).
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Variable Examined Optimal Conditions
Cell Seeding Density 5 X K)4 cells/well
EGF Concentration lOOng/ml, 15mins.
ELISA Blocking Conditions I Vt hrs @ 37°C
10% FCS, 0.2% Tween-20 
in Tris-Buffered Saline.
Primary Ab (Anti-Phosphotyrosine) Exposure 1/750 Dilution
llir @ 37°C
Secondary Ab (AP-labelled Anti-Mouse IgG) Exposure 1/1500 Dilution
Ihr @ 37°C
Table 5.6: Optimised parameters for the ELISA-based assessment of tyrosine
phosphorylation in EGF-stimulated A431 cells.
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Alteration In Tyrosine Phosphorylation (% o f  Control)
Concentration of Ih r  pre-exposure 6hr pre-exposure Ih r pre-exposure 6hr pre-exposure
Drug (fig/ml) to Genistein to Genistein to Tyrphostin 25 to Tyrphostin 25
0 100.00 ±  1.98 100.00 ± 3 .2 7 100.00 ± 5 .1 2 100.00 ±5 .28
2 69.55 ±1 .8 8 73.62 ± 1 .6 6 103.50 ± 4 .3 3 102.10 ± 2 .47
10 50.66 ± 1 .0 9 47.82 ±  1.84 118.20 ± 4 .8 9 51.57 ±1 .88
20 41.67 ± 0 .8 9 45.70 ±  1.69 122.5 6 ±  3,33 37.60 ±  2.24
50 36.12 ± 1 .5 7 35.13 ±1 .71 118.96 ± 2 .8 7 27.57 ±2 .69
100 30.57 ±2 .4 3 20.74 ±2 .63 109.19 ± 2 .8 6 21.58 ±3 .85
Table 5.7: ELISA Results obtained for the inhibition of tyrosine phosphorylation in EGF-
stimulated A431 cells, by genistein and tyrphostin. All experiments were 
replicated six times, and carried out on three separate occasions (Section 2.2.6.3), 
and absorbances for drug-treated cells was normalised vs absorbances of 
untreated control cells. Control absorbances were as follows: 1.279 ± 0.060 (Gen 
Ihr); 1.467 ± 0.053 (Gen 6hrs); 1.055 ± 0.062 (Tyr Ihr) and 1.171 ± 0.027 (Tyr 
6hrs).
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Alteration In Tyrosine Phosphorylation (% o f  Control)
Concentration of 
7-Hydroxy coumarin 
(fig/ml)
lh r  pre-exposure 6hr pre-exposure 12hr pre-exposure
0 100.00 ± 2 .8 2 100.00 ± 6 .2 7 100.00 ±5 .79
2 107.38 ± 2 .6 2 95.65 ±1 .4 5 N .D .
10 90.96 ± 5 .3 4 101.34 ±3 .8 2 86.44 ±  7.66
20 93.00 ±2 .53 96.21 ±4 .2 7 85.53 ±4 .80
50 96.31 ±5 .15 92.49 ±5.51 79.86 ±4 .33
100 89.60 ± 3 .5 0 78.74 ±8.41 77.53 ±6 .68
Table 5.8: ELISA Results obtained for the time-dependent inhibition of tyrosine
phosphorylation in EGF-stimulated A431 cells, by 7-hydroxycoumarin. All 
experiments were replicated six times, and carried out on three separate 
occasions (Section 2.2.6.3), and absorbances for drug-treated cells was 
normalised vs absorbances of untreated control cells. Control absorbances 
were as follows: 1.030 ± 0.031 (lhr); 1.344 ± 0.039 (6hrs); and 0.988 ± 0.057 
(12hrs).
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Alteration In Tyrosine Phosphorylation (%> o f  Control)
Concentration o f 
Esculetin (pg/ml) lh r  pre-exposure 6hr pre-exposure 12hr pre-exposure
0 100.00 ±3 .51 100.00 ± 4 .4 2 100.00 ± 4 .00
2 100.10 ± 2 .7 4 102.10 ± 2 .4 7 N .D
10 99.30 ±3 .6 0 92.87 ±3.61 79.85 ±0 .78
20 98.97 ± 5 .1 4 83.67 ±3 .4 9 75.04 ±2.01
50 94.34 ±4 .8 0 71.39 ±  3.18 68.96 ±1 .26
100 88.17 ± 8 .7 4 61.41 ±2 .6 0 63.25 ±5 .34
Table 5.8: ELISA Results obtained for the time-dependent inhibition of tyrosine
phosphorylation in EGF-stimulated A431 cells, by esculetin. All experiments 
were replicated six times, and carried out on three separate occasions (Section 
2.2.6.3), and absorbances for drug-treated cells was normalised vs absorbances 
of untreated control cells. Control absorbances were as follows: 1.167 ± 0.041 
(lhr); 1.178 ± 0.060 (6hrs); and 0.996 ±  0.040 (12hrs).
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5.6.4. Cytosensor Microphysiometer Studies into Tyrosine Kinase Inhibition
The Cytosensor Microphysiometer has been used in the past to dissect various cellular 
signalling pathways e.g. Nerve Growth Factor (N G F) pathway in PC-12 cells (Pitchford et a l,
1995), GM -CSF pathway in TF-1 cells (Wada et a l, 1993), etc. Use o f chemical enzyme inhibitors, 
antibodies and oligonucleotide probes can all aid in the determination o f the components o f a 
specific pathway, and inhibitors o f tyrosine kinase activity have been previously used (Wada et a l, 
1993; Pitchford et al., 1995). Therefore, we chose to use microphysiometry to examine the effect o f 
7-hydroxycoumarin and esculetin on EGF-stimulated pathways in A431 cells.
Although we had previously determined (Section 5,6.2) that 7-hydroxycoumarin appeared 
to slightly inhibit the R TK  activity o f the EGF-Receptor in vitro, we were unsure that the test 
system used to obtain these results was optimal. In addition to the question o f sub-optimal 
peptide/enzyme recognition, there was the question o f the R TK  stability -  the existence o f degraded 
receptor had been shown by Western blotting (Figure 5.12). The Cytosensor Microphysiometer 
offered an attractive alternative for examining the inhibition o f the EG F-R TK  in A 431 cells for two 
reasons:
1. The study was carried out in intact cells, thereby eliminating worries o f receptor stability and 
suboptimal substrates (endogenous substrates are present at natural concentrations).
2. Downstream signalling events could be observed concurrently, thereby yielding more 
information per experiment.
The EGF-stimulation o f EG F-R TK  in A431 cells had been previously optimised on the 
cytosensor system as outlined in Section 5.6.1. Maximal stimulation o f the cells was with lOOng/ml 
EGF (Figure 5.10) and this concentration was used in all subsequent experiments. As shown in 
Figure 5.14 exposure o f A431 cells to lOOng/ml EGF for 12 mins caused a rapid increase in the 
acidification rate o f the cells, to a peak o f -8 0 %  above baseline values. This peak in acidification 
rate was transient, but did not return immediately to baseline levels. Instead, the cells maintained a 
sustained higher acidification rate o f —30% above baseline for hours, following the growth factor 
stimulation, representing the downstream signalling and eventual nuclear transcription and 
translation, initiated by EGF addition. The cellular metabolism eventually returned to baseline 
levels -  8hrs post-EGF treatment (results not shown). The initial rise in acidification rate is 
principally due to the activation o f the EGF-Receptor-associated tyrosine kinase activity, as it can 
be blocked by pre-exposure o f cells to the tyrosine kinase inhibitors genistein or tyrphostin, for lh r 
or 6hrs, respectively (Figure 5.14).
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Figure 5.14 portrays the activation o f EG F-R TK  in cells pre-exposed to 7-hydroxycoumann 
for 1 or 6hrs. The activation o f EG F-R TK  was unaffected by pre-exposure to 20pg/ml 7- 
hydroxycoumarin for either 1 or 6hrs. However, a modest inhibition o f the R TK  activation (-60%  
increase in metabolic rate vs -  80% in control cells) was observed in cells pre-exposed to 100pg/ml 
7-hydroxycoumarin. Experiments with cells pre-exposed to 7-hydroxycoumarin for 12hrs were not 
carried out, as the basal metabolic rates o f these cells were at levels below the rates recommended 
for use on the instrument (i.e. <-60pvolts/sec).
As shown in Figure 5.15, pre-exposure o f A 431 cells to 20pg/ml esculetin did not block the 
activation o f the EG F-RTK. However, as shown, the shape o f the metabolic rate curve o f the 
esculetin-treated cells differed from that o f the control cells - it did not maintain the sustained 
increase o f -  30%  o f the control cells, instead the metabolic rate returned to baseline levels within 
2hrs. This may indicate a block in the signalling pathway downstream o f the EGF-RTK. 6hrs pre­
exposure o f the cells to 20(^g/ml esculetin prior to EGF-stimulation, caused a slight decrease 
(-12% ) in the peak o f activation o f the EG F-R TK  (Figure 5 .15). Again, the esculetin-treated cells 
return to their baseline acidification rates within lhr, suggesting a downstream block o f EGF- 
stimulated signalling pathway.
The observed results are in good accordance with the E L IS A -TK  results o f Section 5.6.3, if  
one considers that the ELISA  examined the tyrosine phosphorylation events in the first 15mins 
following EGF-stimulation. Decreases in T K  activity observed for 7-hydroxycoumarin after 6hrs 
pre-exposure o f 100[ig/ml and esculetin following 6hrs exposure to 20pg/ml, reflect w ell the 
decreases in P-Tyr levels observed in Section 5.6.3. Unfortunately, 12hr experiments could not be 
carried out. The EG F-R TK  appears modestly inhibited by both compounds, and esculetin also 
appears to exhibit a blockade on downstream events. To further clarify these observations, Western 
Blotting was carried out as reported in Section 5.6.5.
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Effect cf 7-Hydroxycoumarin on EGF-Receptor Tyrosine Kinase
Activity in A431 Cells
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Figure 5.14: Exposure of A431 cells to various concentrations of 7-hydroxycoumarin, prior
to stimulation with 100ng/ml EGF. The above plot shows the experiment 
conducted on the Cytosensor Microphysiometer to determine the effect of 7- 
hydroxycoumarin on the activation of the EGF-RTK in A431 cells. Genistein 
and Tyrphostin were included as positive tyrosine kinase inhibitors controls. 
In individual experiments, the cellular acidification rate for each sensor 
chamber was determined prior to EGF exposure, using a 2 min cycle, with the 
acidification rate measured in the final 30 secs, of this cycle. This rate was 
normalised at 100% and all subsequent acidification rates during and 
following EGF exposure were expressed as a percentage of this normalised 
value. These values of metabolic rate (mean of three experiments) were plotted 
vs time in the above graph. Typical basal acidification rates for the cells in all 
experiments were -100 to -200pvolts/sec.
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Effect of Esculetin on EGF-Receptor Tyrosine Kinase Activity
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Figure 5.14: Exposure of A431 cells to various esculetin for different time periods, prior to
stimulation with lOOng/ml EGF. The above plot shows the experiment 
conducted on the Cytosensor Microphysiometer to determine the effect of 
esculetin exposure on the activation of the EGF-RTK in A431 cells. Genistein 
and Tyrphostin were included as positive tyrosine kinase inhibitors controls. 
In individual experiments, the cellular acidification rate for each sensor 
chamber was determined prior to EGF exposure, using a 2 min cycle, with the 
acidification rate measured in the final 30 secs, of this cycle. This rate was 
normalised at 100% and all subsequent acidification rates during and 
following EGF exposure were expressed as a percentage of this normalised 
value. These values of metabolic rate (mean of three experiments) were plotted 
vs time in the above graph. Typical basal acidification rates for the cells in all 
experiments were -100 to -200jivolts/sec.
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5.6.5. Western Blotting Studies o f Tyrosine Phosphorylation
Zippel et al. (1986), first described a non-radioactive immunoblotting technique using anti- 
phosphotyrosine antibodies to detect proteins phosphorylated on tyrosine residues in PDGF- 
stimulated cells. This technique is often used to dissect cellular growth signalling pathways (Draker 
et al., 1989; Meisenhelder et a l, 1989) and, to a lesser extent, to examine the effect o f known or 
putative tyrosine kinase inhibitors on tyrosine phosphorylation events in cells.
Western blotting experiments were carried out as outlined in Section 2.2.6.5, and the results 
are shown in Figures 5.16 -  5.20. In normal cells, approximately 0.05%  o f proteins are 
phosphorylated on tyrosine residues (Hunter, 1998) and Figure 5.16 illustrates the optimised set-up 
for immunoblotting these P-Tyr residues. In quiescent cells, few proteins are phosphorylated on 
tyrosine residues (Druker et al., 1989), as shown in Figure 5.16 (Lanes 2-6). However, as shown, 
EGF-treatment o f A431 cells, caused a number o f cellular proteins, including the EGF-receptor, to 
become phosphorylated on tyrosine residues (arrows). The predominant band (lanes 7-11) across 
the top o f the gel was that o f the EGF-receptor (~170kDa), which becomes autophosphorylated on 
tyrosine residues on binding its ligand. Fainter bands o f P -Tyr proteins were observed at —110- 
120kDa, ~85-90kDa and ~60-70kDa, which may correspond to the GAP-120, p85 P I-3K , and c- 
Src/SH-PTP proteins, respectively. A  faint band at ~35kDa was also apparent -  a similar molecular 
weight band has been observed in PDGF-treated fibroblasts (Zippel et a l, 1986), although its 
identity is as yet unknown. A ll drug-treated samples were pre-exposed to drugs for lh r prior to 
EGF-stimulation. As shown only genistein (25pg/m l) affected tyrosine phosphoiylation activity, 
with P-Tyr levels o f both the EGF-Receptor and lower molecular weight proteins affected.
Figure 5.17 illustrates the effect o f 6hr pre-exposure o f 7-hydroxycoumarin on EGF- 
stimulated tyrosine phosphorylation. A slight decrease in the density o f the EGF-R band was 
apparent for lOO^g/ml sample, but none o f the other exposures affected the cellular 
phosphorylation. This result reflects well the ELISA  and Cytosensor results o f Sections 5.6.3 and
5.6.4, respectively. Figure 5.18 shows the effect o f 12hr 7-hydroxycoumarin treatment on the 
tyrosine phosphorylation o f cellular proteins. This treatment caused a dose-dependent reduction in 
the levels o f protein tyrosine phosphorylation in EGF-stimulated A431 cells. A  decrease in the 
density o f the EGF-Receptor band indicated that receptor autophosphorylation was diminished. 
Corresponding decreases in the phosphorylation o f lower molecular weight proteins were observed, 
and were probably due to decreased EG F-RTK activity. Therefore, it would appear from these
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results that treatment o f cells for 12hrs with 7-hydroxycoumarin caused inhibition o f tyrosine kinase 
activity in A431 cells.
The effect o f esculetin on tyrosine phosphorylation in EGF-stimulated A431 cells was also 
examined and the results are outlined in Figures 5.19 and 5.20. 6hr esculetin exposure (Figure 5.19) 
did not decrease tyrosine phosphorylation levels significantly. A slight decrease in the 
phosphorylation o f both the EG F-R  and lower molecular weight proteins was apparent, at 
100fig/ml. However, this effect was significantly enhanced for cells exposed to esculetin for 12hrs 
(Figure 5.20). In this figure we see that 12hr exposure to esculetin caused a dose-dependent 
decrease in tyrosine phosphorylation for all concentrations tested. Almost complete abolition o f 
tyrosine kinase activity was evident at concentrations o f 50-100pg/m I esculetin.
Hence, these immunoblotting results indicate that both 7-hydroxycoumarin and esculetin 
are capable o f inhibiting tyrosine phosphorylation in EGF-stimulated A431 cells. This inhibition is 
both dose- and time-dependent, and esculetin is more potent than 7-hydroxycoumarin in the 
manifestation o f these effects. Inhibition o f the EGF-Receptor associated tyrosine kinase activity is 
evident, with decreased autophosphorylation and phosphorylation o f downstream targets.
The results from sections 5.6.4, 5.6.5 and 5.6.6, clearly indicate that both 7- 
hydroxycoumarin and esculetin cause a dose- and time-dependent decrease in tyrosine 
phosphorylation in growth factor-stimulated cells. Although direct inhibition o f tyrosine kinases is 
the most evident explanation, other events may be important in the manifested result. For example, 
decreased growth factor binding to receptor would account for decreased R TK  activation, with 
consequent reduction o f tyrosine phosphorylation. Seliger (1997) has previously discounted this as 
an effect o f the coumarin compounds. Another possibility is the activation o f a negative regulatory 
mechanism to decrease tyrosine phosphorylation, examples being activation o f cellular 
phosphatases, which would dephosphorylate tyrosine residues (Hunter, 1998), or the negative 
regulation o f the EGF-Receptor by Protein Kinase C (Cochet et a l, 1984; Downward et a l, 1985). 
Given the previous reports o f the involvement o f coumarins in PKC signalling, activation o f PKC 
was examined in more detail (Section 5.6.7).
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Effect of 1hr exposure of Coumarins and TK Inhibitors
on Tyrosine Phosphorylation in EGF-stimulated cells
+ 100ng/ml EGF
Figure 5.16: Effect o f drug pre-exposure (lh r) on tyrosine phosphorylation in A431 cells. The
above photograph is one o f three experiments carried out to determine, by Western 
blotting, the levels o f tyrosine phosphoiylated proteins in EGF-stimulated A431 
cells following exposure to various known and putative tyrosine kinase inhibitors 
for lh r (Section 2.2.6.5). Cell extracts (equal protein concentrations) were run on 
8% SDS gels, immunoblotted and probed with anti-phosphotyrosine antibody. As 
shown, samples on the right hand side o f the gel were stimulated with 100ng/ml 
EGF for 15 mins prior to extraction, while those on the left hand side were left 
unstimulated The following samples were run: Lanes 1 &  12: Molecular weight 
markers; Lanes 2 &  7: 20pg/ml 7-hydroxycoumarin; Lanes 3 &  8: 20pg/ml 
esculetin; Lanes 4 &  9: 20|ig/m l tyrphostin; Lanes 5 &  10: 25pg/ml genistein; 
Lanes 6 &  11: No drug treatment.
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Figure 5.17:
Effect of 6hr Exposure of 7-Hydroxycoumarin
on Tyrosine Phosphorylation in EGF-stimulated cells
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Effect o f 7-hydroxycoumarin pre-exposure (6hrs) on tyrosine phosphorylation in 
A431 cells. The above photograph is one o f three experiments carried out to 
determine, by Western blotting, the levels o f tyrosine phosphorylated proteins in 
EGF-stimulated A431 cells following exposure to various concentrations of 7- 
hydroxycoumarin (Section 2.2.6.5). Following EGF-stimulation (100ng/m l), cell 
extracts (equal protein concentrations) were run on SDS gels, immunoblotted and 
probed with anti-phosphotyrosine antibody. The following samples were run: Lane 
1: unstimulated control; Lane 2: 25pg/ml genistein; Lane 3: 20pg/ml tyrphostin; 
Lanes 4 & 10, Molecular weight markers; Lane 5: No drug (positive 
phosphorylation); Lane 6: 10pg/ml 7-hydroxycoumarin; Lane 7: 20pg/ml 7- 
hydroxycoumarin; Lane 8: 50pg/ml 7-hydroxycoumarin; Lane 9: 100pg/ml 7- 
hydroxycoumarin. As illustrated samples in all lanes except Lanes 1, 4 and 10 had 
been stimulated w ith 100ng/ml EGF for 15 mins, prior to preparation.
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Effect of 12hr Exposure of 7-Hydroxycoumarin
on Tyrosine Phosphorylation in EGF-stimulated cells
+ 100ng/ml EGF
Effect o f 7-hydroxycoumarin pre-exposure (12hrs) on tyrosine phosphorylation in 
A431 cells. The above photograph is one o f three experiments carried out to 
determine, by Western blotting, the levels o f tyrosine phosphorylated proteins in 
EGF-stimulated A431 cells following exposure to various concentrations o f 7- 
hydroxycoumarin (Section 2.2.6.5). Following EGF-stimulation (100ng/m l), cell 
extracts (equal protein concentrations) were run on SDS gels, immunoblotted and 
probed with anti-phosphotyrosine antibody. The following samples were run: Lanes 
1 &  10: Molecular weight markers; Lane 2: unstimulated control; Lane 3: 25fig/ml 
genistein; Lane 4: 20pg/ml tyrphostin; Lane 5: No drug (positive phosphorylation); 
Lane 6: lOpg/ml 7-hydroxycoumarin; Lane 7: 20pg/m l 7-hydroxycoumarin; Lane 
8: 50pg/ml 7-hydroxycoumarin; Lane 9: lOO^ig/ml 7-hydroxycoumarin. As 
illustrated, samples in all lanes except Lanes 1, 2 and 10, had been stimulated with 
100ng/ml EGF for 15 mins, prior to preparation.
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Effect o f 6hr Exposure of Esculetin on
Tyrosine Phosphorylation in EGF-stimulated cells
Esculetin Exposure
Figure 5.19: Effect o f esculetin pre-exposure (6hrs) on tyrosine phosphorylation in A431 cells.
The above photograph is one o f three experiments carried out to determine, by 
Western blotting, the levels o f tyrosine phosphorylated proteins in EGF-stimulated 
A431 cells following exposure to various concentrations o f esculetin (Section
2.2.6.5). Following EGF-stimulation (10Gng/ml), cell extracts (equal protein 
concentrations) were run on SDS gels, immunoblotted and probed with anti- 
phosphotyrosine antibody. The following samples were run: Lanes 1 &  10: 
Molecular weight markers; Lane 2: unstimulated control; Lane 3: 50pg/ml 
genistein; Lane 4: 20pg/ml tyrphostin; Lane 5: N o drug (positive phosphorylation); 
Lane 6: 10pg/ml esculetin; Lane 7: 20pg/m l 7-esculetin; Lane 8: 50pg/ml 
esculetin; Lane 9: 100pg/ml esculetin. As illustrated, samples in all lanes except 
Lanes 1, 2 and 10, had been stimulated w ith 100ng/ml EGF for 15 mins, prior to 
preparation.
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Figure 5.19:
Effect o f 12hr Exposure of Esculetin on
Tyrosine Phosphorylation in EGF-stimulated cells
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Effect o f esculetin pre-exposure (12hrs) on tyrosine phosphorylation in A431 cells. 
The above photograph is one o f three experiments carried out to determine, by 
Western blotting, the levels o f tyrosine phosphorylated proteins in EGF-stimulated 
A431 cells following exposure to various concentrations o f esculetin (Section
2.2.6.5). Following EGF-stimulation (lOOng/ml), cell extracts (equal protein 
concentrations) were run on SDS gels, immunoblotted and probed with anti- 
phosphotyrosine antibody. The following samples were run: Lanes 1 &  11: 
Molecular weight markers; Lane 2: unloaded lane; Lane 3: unstimulated control; 
Lane 4: 25pg/m l genistein; Lane 5: 20pg/m l tyrphostin; Lane 6: No drug (positive 
phosphorylation); Lane 7: lOpg/m l esculetin; Lane 8: 20pg/m l 7-esculetin; Lane 9: 
50pg/ml esculetin; Lane 10: lOOpg/ml esculetin. As illustrated, samples in all lanes 
except Lanes 1, 2 , 3 and 11, had been stimulated w ith 100ng/ml EGF for 15 mins, 
prior to preparation.
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5.6.6. Effect o f Coumarins on Protein Kinase CActivity.
Protein Kinase C (PKC) is an important intermediate in cellular signalling, which infringes 
on many o f the important growth-regulating pathways in cells. It maintains a paradoxical role, both 
activating and negatively regulating, many critical signalling substrates (Section 5.2.4). PKC has 
been shown to reduce the EGF-R-associated tyrosine kinase activity, via phosphorylation, an event 
which causes both immediate decreased tyrosine phosphorylation on ligand binding, and long-term 
downregulation o f receptor (Cochet et al., 1984; Downward et a l,  1985). 7-hydroxycoumarin has 
previously been shown to augment the function o f PKC in other cellular events [LPS-induced 
cytokine production (Zlabinger et al., 1993)]. Therefore, we were interested in ascertaining whether 
7-hydroxycoumarin and esculetin affected PKC signalling in A431 cells.
This was achieved with studies o f A431 responses to the PKC activator PM A, in the 
absence or presence o f coumarin compounds, using the Cytosensor Microphysiometer. The 
exposure o f A431 cells to PM A on this instrument was optimised, and the optimised experimental 
parameters are shown in Table 5.10. Figure 5.21 illustrates the optimised stimulation o f PKC 
activity in A431 cells, with exposure to 0.05ng/ml PM A  for 20mins causing an -  12-15% increase 
in the metabolic rate o f the cells, a response which was sustained over the monitoring period o f 
60mins. The activation o f PKC could be very efficiently blocked by pre-exposure o f A431 cells to 
25pg/ml H -7 (a known PKC inhibitor) for lh r prior to PM A  activation (Figure 5.21)
Experiments were then performed in which A431 cells were pre-exposed to either 7- 
hydroxycoumarin or esculetin, for either 1 or 6hrs, prior to PKC activation with 0.05ng/ml PM A, 
and these results are shown in Figures 5.21-5.24. As shown in Figure 5.21, A431 cells pre-exposed 
to 7-hydroxycoumarin (20-100pg/m l) for lh r prior to PM A stimulation, clearly exhibited a much 
increased response to PM A  stimulation. At all concentrations tested, the metabolic rate increase in 
7-hydroxycoumarin-treated cells was ~  35-39%  lh r post-PMA, compared to -1 5 %  for untreated 
cells. Increasing the drug pre-exposure time to 6hrs, maintained this augmentation o f PKC activity 
over control cells (Figure 5.22), although the increase was not as pronounced as the drug- 
concentrations increased (compare -4 0 %  increase in metabolic rate for 20pg/ml 7- 
hydroxycoumarin, and ~  26%  increase in metabolic rate for lOOpg/ml).
Pre-exposure to esculetin for lh r prior to P M A  stimulation, yielded similar results to those 
obtained with 7-hydroxycoumarin, with increases due to PKC activation much higher in drug- 
treated cells, compared to untreated cells (Figure 5.23). As shown, the augmented activation o f PKC
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in esculetin-treated cells was dose-dependent -  metabolic rates on cell stimulation with PM A  
increased to levels o f —115% (Ofag/ml), —122% (20(jg/m l) and —134-136% (50 and 100fig/ml), lh r 
post-stimulation (Figure 5.23). Increasing the pre-exposure time o f esculetin to 6hrs maintained this 
dose-dependent augmentation o f metabolism in response to PKC activation (Figure 5.24). As shown 
in this figure, cells exposed to concentrations o f 50 and lOOpg/ml for 6hrs prior to stimulation with 
PMA, immediately became activated at levels twice that o f control cells, and maintained this level 
o f activation for the 60mins monitoring period.
Therefore, in these experiments it was demonstrated that pre-exposure o f A 431 cells to a 
range o f concentrations o f either 7-hydroxycoumarin and esculetin, caused augmentation in the 
activation o f Protein Kinase C by PM A. This effect occurred at all concentrations and exposure 
times tested, although to varying degrees (metabolic increases in range -1 .5 -3  times control 
increases). These two coumarin compounds, therefore, do display synergism with this enzyme, as 
has been previously proposed by Zlabinger and colleagues (Stuhlmeier el a l,  1991; Zlabinger el a l, 
1993). Given the extensive networking role o f PKC in growth signalling pathways, it is probable 
that this effect impacts on signalling pathways in cells. PKC has been previously shown to 
negatively downregulate the activity o f the EG F-RTK  through phosphorylation (Cochet et a l, 
1984). It is possible that this role may be augmented by the presence o f coumarins, an event which 
may explain the decreased tyrosine phosphorylation o f both the EG F-RTK and its downstream 
substrates in EGF-stimulated A431 cells, observed in sections 5.6.3-5.6.5.
Variable Exam ined Optimised Conditions
Cell Seeding Density 2.5 X  105 cells/capsule
Pump Cycle 2 mins cycle @ 60% speed (~  120pl/min)
Serum-starvation Period 16hrs
PMA Concentration 0.05ng/ml
PMA Exposure Period 20mins
Table 5.10: Optimisation of experimental conditions for the exposure of A431 cells to
PMA on the Cytosensor Microphysiometer, as outlined in Section2.2.6.6.
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Effect of Ihr 7-Hydroxycoumarin Pre-exposure 
on Protein Kinase C Activity in A431 Cells
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Figure 5.21: E ffect of 7-hydroxycoum arin on Protein Kinase C A ctivity in A431 cells. The
above plot shows the experim ent conducted on the Cytosensor 
M icrophysiom eter to determ ine the effect o f lh r  7-hydroxycoum arin exposure 
on the activation o f the Protein Kinase C , w ith 0.05ng/m l P M A , in A431 cells. 
H -7  was used as a positive PK C  inh ib itor. In  individual experiments, the 
cellular acidification rate for each sensor chamber was determined prior to 
E G F exposure, using a 2 m in cycle, w ith the acidification rate measured in the 
fin a l 30 secs, of this cycle. This rate was normalised at 100%  and all 
subsequent acidification rates during and following P M A  exposure were 
expressed as a percentage of this normalised value. These values of metabolic 
rate (mean of three experiments) were plotted vs time in the above graph. 
Typical basal acidification rates for the cells in a ll experiments were -1 0 0  to 
-2 0 0  pvolts/sec.
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Figure 5.22: Effect of 7-hydroxycoumarin on Protein Kinase C Activity in A431 cells. The
above plot shows the experiment conducted on the Cytosensor 
Microphysiometer to determine the effect of 6hr 7-hydroxycoumarin exposure 
on the activation of the Protein Kinase C, with 0.05ng/ml PMA, in A431 cells. 
H-7 was used as a positive PKC inhibitor. In individual experiments, the 
cellular acidification rate for each sensor chamber was determined prior to 
EGF exposure, using a 2 min cycle, with the acidification rate measured in the 
final 30 secs, of this cycle. This rate was normalised at 100% and all 
subsequent acidification rates during and following PMA exposure were 
expressed as a percentage of this normalised value. These values of metabolic 
rate (mean of three experiments) were plotted vs time in the above graph. 
Typical basal acidification rates for the cells in all experiments were -100 to 
-200 pvolts/sec.
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Figure 5.23: Effect o f esculetin on Protein Kinase C A ctiv ity  in A431 cells. The above plot
shows the experim ent conducted on the Cytosensor M icrophysiom eter to 
determ ine the effect o f lh r  esculetin exposure on the activation of the Protein  
Kinase C , w ith 0.05ng/m l P M A , in A431 cells. H -7  was used as a positive PK C  
inh ib itor. In  individual experim ents, the cellular acidification rate for each 
sensor chamber was determ ined p rio r to E G F exposure, using a 2 min cycle, 
w ith the acidification rate measured in the final 30 secs, of this cycle. This rate 
was norm alised at 100%  and all subsequent acidification rates during and 
following P M A  exposure were expressed as a percentage o f this normalised 
value. These values of metabolic rate (mean o f three experiments) were plotted 
vs tim e in the above graph. Typical basal acidification rates for the cells in all 
experiments were -1 0 0  to -200pvolts/sec.
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Effect of 6hr Esculetin Pre-exposure on Protein Kinase C Activity
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Figure 5.24: Effect of esculetin on Protein Kinase C Activity in A431 cells. The above plot
shows the experiment conducted on the Cytosensor Microphysiometer to 
determine the effect of 6hr esculetin exposure on the activation of the Protein 
Kinase C, with 0.05ng/ml PMA, in A431 cells. H-7 was used as a positive PKC 
inhibitor. In individual experiments, the cellular acidification rate for each 
sensor chamber was determined prior to EGF exposure, using a 2 min cycle, 
with the acidification rate measured in the final 30 secs, of this cycle. This rate 
was normalised at 100% and all subsequent acidification rates during and 
following PMA exposure were expressed as a percentage of this normalised 
value. These values of metabolic rate (mean of three experiments) were plotted 
vs time in the above graph. Typical basal acidification rates for the cells in all 
experiments were -100 to -200pvolts/sec.
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5.7. CHAPTER SUMMARY
In this chapter, the effect o f two coumarin compounds, 7-hydroxycoumarin and esculetin on 
growth signalling pathways in tumour cells was examined. The A431 cell line was used in all 
experiments for examining two distinct signalling molecules -  the EGF-Receptor and its associated 
tyrosine kinase activity, and the Protein Kinase C molecule.
The binding o f EGF to its cognate receptor causes activation o f the receptor tyrosine kinase 
activity, with consequent signalling via tyrosine phosphorylation events (Section 5.2). Growth 
factor-mediated tyrosine phosphorylation was examined in A431 cells using a variety o f methods, 
namely, in vitro tyrosine kinase assay, ELISA, Cytosensor Microphysiometer and Western blotting. 
The work focussed particularly on the assays examining phosphorylation in intact cells, as these 
assays mirror more effectively the natural situation, as well as being more labour- and cost-effective 
when screening for tyrosine kinase inhibitors.
The above methods were used to examine the effect o f coumarins on tyrosine phosphorylation, 
as a result o f growth factor stimulation. ELISA  and Western Blotting results revealed that 7- 
hydroxycoumarin and esculetin were both capable o f inhibiting tyrosine phosphorylation in A431 
cells following EGF binding. This inhibition was dose- and time-dependent, and esculetin was 
shown to be more effective than 7-hydroxycoumarin at this task. Neither compound was as potent 
as commercial T K  inhibitors, genistein or tyrphostin.
Western blot analysis illustrated that autophosphorylation o f the EGF-receptor and 
phosphorylation o f its downstream targets was reduced in cells treated with coumarins. It is unclear 
whether direct inhibition o f receptor tyrosine kinase activity is responsible for this effect -  results 
from the direct in vitro assay did suggest that 7-hydroxycoumarin can inhibit the EG F-RTK activity 
directly. However, alternative explanations can be offered to account for the observed inhibition of 
tyrosine phosphorylation. In  particular, activation o f negative regulators o f the EGF-RTK by 
coumarins would explain the observed results. Protein Kinase C is a well-documented regulator of 
EG F-R TK  activity and we examined the effect o f coumarins on its activity, using the Cytosensor 
Microphysiometer. Pre-exposure o f A431 cells to a range o f concentrations o f 7-hydroxycoumarin 
and esculetin caused augmentation o f the activation o f PKC by PM A. A  synergism between PKC 
and coumarins has been previously reported in immune cells (Zlabinger et al., 1993) and our results 
support such an effect. As PKC is a negative regulator o f EG F-RTK, the coumarins may function 
by indirect inhibition o f the EG F-R TK  through the PKC molecule, rather than direct inhibition o f
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EG F-RTK, leading to the observed decrease in tyrosine phosphorylation following EGF 
stimulation.
Regardless o f whether they directly or indirectly inhibit the EG F-RTK, the decrease in 
tyrosine phosphorylation effected by coumarin compounds may offer an explanation for the precise 
mode o f their anti-tumour action. Anomalies in tyrosine phosphorylation are extremely prevalent in 
tumour cells, and are responsible for persistent growth signalling in these cells. 
Interruption/disruption o f this persistent signalling suppresses this abnormal proliferation, and 
therefore any compound which decreases tyrosine phosphorylation has anti-proliferative properties.
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Chapter 6
Investigation o f the effects o f coumarins on 
monocyte functions in model monocyte systems
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6.1. INTRODUCTION TO TUMOUR IMMUNITY
Changes in the membrane components o f cancerous cells compared to their normal 
counterparts, known as either tumour-specific or tumour-associated antigens, provoke the immune 
system to respond to the presence o f these “foreign” cells in the body. In mounting an efficient 
immune response against tumour cells, the immune system employs the assistance o f all major 
immune cell types -  T-cells, B-cells (through antibody-production), macrophages and natural killer 
(N K ) cells. The major methods used in tumour rejection are outlined in Table 6.1.
However, the effectiveness o f these mechanisms must be questioned when one considers 
the fact that in many hosts, tumour cells escape this immune surveillance and continue to grow and 
metastasise. The various modes by which tumour cell evasion o f the immune system occur, include 
antigenic modulation and/or production o f immunosuppressive products (e.g. prostaglandins) by 
tumour cells. In addition, the size or location o f the tumour mass may preclude its destruction by the 
immune system. Certain immune cells including suppressor T-lymphocytes (T s cells), and even 
tumour-associated macrophages (TA M s) may also lead to tumour enhancement rather than 
regression. Therefore, despite the presence o f a natural system for foreign cell elimination, the 
immune system must often be manipulated to effectively mount an anti-tumour response. This is the 
underlying basis o f cancer immunotherapy, which can use both passive (e.g. immunotoxin 
administration), or active (e.g. cytokine therapy) immune responses to provide a potential fourth 
treatment modality - to join surgery, chemotherapy and radiotherapy - in the management o f cancer. 
The principal means o f manipulation o f our innate defences to effect an anti-tumour response are 
outlined in Table 6.2 (Benjamini et a l,  1996; Elgert, 1996; Scott &  W elt, 1997; Andreesen et al., 
1998; Chen &  W u, 1998; Salgaller &  Lodge, 1998). Although still in their infancy, the human 
clinical trials o f many o f these options have proved quite promising.
184
Mechanisms o f  Immune Response to Tumours
Humoral:
1. Antibody (Ab) &  complement-mediated lysis o f tumour cells
2. Opsonisation and destruction o f tumour cells by phagocytosis (Ab- and complement- 
mediated)
3. Antibody-mediated loss o f tumour cell adhesion 
Cellular:
1. Destruction by activated macrophages
2. Destruction by Natural K iller (N K ) cells
3. Destruction by cytotoxic T-lymphocytes (C T L ’s)
4. Antibody-dependent cell-mediated cytotoxicity (ADCC)
Table 6.1: Important immune mechanisms in the destruction of tumour cells.
Im m uno the rapyA ppr o a c h e s  ___
1. Cytokine Therapy [IFNs, IL -2 ] administration
2. Tumour Vaccines
3. Immunotoxins
4. Adoptive Immunotherapy (e.g. LA K  cells)
Table 6.2: Immunotherapy approaches to the treatment of cancer
As outlined in Table 6.1, various immune cell types are essential to the innate anti-tumour 
defence mechanism w ithin humans. However, in terms o f significance, many investigators believe 
the cells o f the macrophage/monocyte lineage to be o f most importance in the whole area o f tumour 
immunity. The advantages o f these cells over other immune cells in providing an anti-tumour effect 
have been cited recently (Bonta &  Ben-Efraim, 1993; Zlabinger, 1997) and are included as Table
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6.3. As a result, stimulation o f monocyte/macrophage anti-tumour mechanisms is an attractive 
option as an immunotherapeutic approach to cancer management.
Advantages o f  Macrophages/Monocytes in Tumour Immunology
1. Anti-tumour activity spectrum o f these cells is wide &  not species-specific
2. Activated macrophages react against “immunogenic”, “weakly immunogenic” &  “non- 
immunogenic” tumours in an indiscriminate maimer
3. Macrophages recognise only foreign cells, never normal cells (self/non-self discrimination).
4. Malignancy progression is often accompanied by a decline in immune cell competence -  
macrophages are the last immune cell type to be affected during immune suppression.
5. Macrophage and monocyte cells can be easily isolated from cancer patients, activated in 
vitro, and re-injected into patients as an immunotherapy option.
6. No reports o f induced tumour cell resistance to macrophages have been published to date.
Table 6.3: Advantages of Monocyte/Macrophages cells over other immune cells in
evoking an anti-tumour response (adopted from Bonta & Ben-Efraim, 1993; 
Zlabinger, 1997).
6.2 INTRODUCTION TO THE MONONUCLEAR PHAGOCYTE SYSTEM (MPS)
6.2.1. Cells o f  the M P S  Lineage
The Mononuclear Phagocyte System (M PS) is the general term used to describe the cells o f 
the macrophage/monocyte lineage within the immune system. This includes the precursor bone 
marrow monoblasts and promonocytes, as w ell as their progeny, the peripheral blood monocytes 
and tissue macrophages. Macrophages are found widely located within the body in lymphoid organs 
(spleen, lymph nodes and thymus), lungs (as alveolar macrophages), liver (Kupffer cells), gastro­
intestinal tract, central nervous system (microglia), bone (osteoclasts), skin (histiocytes) and 
synovial fluids (type A  cells). The MPS system has been extensively reviewed (Adams &  Hamilton, 
1992; Auger &  Ross, 1992; Lewis, 1995), the salient points o f which are included here.
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Macrophages originate in the bone marrow from precursor stem cells (colony forming unit, 
granulocyte-macrophage, C FU -G M ), which are believed to be the common progenitor cell for both 
macrophages and granulocytes. The C FU -G M  stem cells give rise to monoblasts, which 
progressively differentiate into pro-monocytes and monocytes. The monocytes rapidly enter the 
circulation and migrate into the tissues within a four day period to yield the appropriate tissue 
macrophages. The various stages o f this cell differentiation are distinguishable at both a 
morphological and histochemical level e.g. transition from monocyte to macrophage is 
accompanied by an increase in the number and activity o f mitochondria, a decrease in peroxidase 
activity, and changes in the expression o f various surface receptors.
Cells o f the MPS engage in a broad range o f physiological and pathological processes, as 
summarised in Table 6.4, with active destruction o f foreign cells the primary function. 
Macrophages, on stimulation with an appropriate agent, are activated to become microbicidal and 
tuinouricidal machines. As part o f this function they are involved in the secretion o f a wide range of 
biologically important products, including cytokines, enzymes, oxygen radicals, coagulation factors 
(for a complete list consult Table 1.7, Auger &  Ross, 1992), as w ell as in antigen processing and 
presentation. In addition, macrophages are central components o f the inflammatory response, and 
are inherently involved in the production o f cytokines and angiogenic factors necessary for correct 
wound healing. Their phagocytic capabilities also allow them to participate in normal homeostatic 
and metabolic functions such as removal o f effete red blood cells, and iron and lipid metabolism, 
respectively. Finally, macrophages play an important developmental role, particularly in the 
selection and destruction o f cells with potential reactivity to self-antigens.
Functions o f  MPS Cells
1. Destruction o f micro-organisms
2. Tumour cell control
3. Inflammation and Wound Healing
4. Secretion
5. Homeostasis
Table 6.4: Normal functions of cells of the Mononuclear Phagocyte System.
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6.2.2. Activation o f  MPS Cells
As mentioned above, monocytes/macrophages must be activated to elicit an anti-microbial 
or anti-tumour killing effect, and the requirements for this event have been reviewed extensively 
(Adams &  Hamilton, 1992; Lewis, 1995). The acquisition o f cytocidal capacity usually involves a 
multi-step cascade o f events, whereby a cell goes through a “priming” step, before it can become 
fu lly activated to cytocidal competence. Activation o f mammalian macrophages in vivo can occur 
via two major routes. In the first, direct interaction with micro-organisms, or microbial cell wall 
constituents, such as muramyl dipeptide (M D P ), or microbial products, such as lipopolysaccharide 
(LPS), activate macrophages. LPS has been used as the model macrophage activating signal over 
many years, with its activity attributed to the lipid A  portion o f the molecule. Macrophage binding 
o f LPS initiates intracellular phosphoinositide (P I) breakdown, stimulates Protein Kinase C (PKC) 
activity, and results in the expression o f a large number o f cytokines, including T N F -a , IL -1 , IL -6, 
M -CSF, G M -CSF and IF N a /p . The second macrophage activation pathway involves the use of 
lymphokines such as interferon-y (IFN -y) or macrophage-activating factor (M A F). IFN -y is a 55kDa 
glycoprotein produced by T-lymphocytes and N K  cells. It  possesses anti-viral and 
immunomodulatory functions, and activates monocytes/macrophages following interaction with its 
cell surface receptor. IFN -y activation o f MPS cells induces the production o f many secreted 
molecules, including IL -1 , CSF-1, IL-2-Receptor, and reactive oxygen species (ROS). The secretion 
o f prostaglandin and the activation o f integrin genes (LFA-1 adhesion molecule) also occur. IFN-y 
also increases the expression o f M H C  Class I  and I I  molecules, which is important for antigen 
presentation and M H C  Class I-restricted T-cell cytotoxicity. Various synthetic molecules e.g. 
phorbol esters and ionophores, have been shown to activate macrophages in vitro. They achieve this 
effect by activating the signalling pathways utilised by the in vivo macrophage activators, thus 
mimicking their effect, e.g. phorbol myristate acetate (PM A ) causes stimulation and translocation o f 
PKC, and can thus partly mimic macrophage activation by LPS.
Suppression o f macrophage activity can also be accomplished by biological molecules, with 
prostaglandins (especially PGE2) the most significant negative regulators o f immune activation. 
Glucocorticoids and transforming growth factor-p (TG F-P) also exert suppressive effects on 
immune cells, including MPS cells.
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6.2.3. M PS Cells in Tumour Immunity
6.2.3.1. Overview
MPS cells have become the focus o f much investigation in tumour immunity studies due to 
observations o f their ability to elicit cytostatic and cytotoxic effects on tumour cells in vitro 
(Grabstein el al., 1986; Hasday et al, 1990). In addition, the recruitment o f MPS cells into tumours 
is also a well-known event (Mantovani et al., 1992). The anti-tumour effects o f 
monocytic/macrophage cells, like their anti-microbial effects, are mediated through the secretion o f 
a broad range o f products in the tumour mass environment. The more important anti-tumour 
mechanisms are as follows:
1. Production o f cytostatic and cytolytic cytokines
2. Production o f reactive oxygen species (ROS)
3. Production o f reactive nitrogen intermediates (R N I)
4. Production o f enzymes
The execution o f these tumouricidal mechanisms is achieved by cell activation through sequential 
“priming” and “triggering” stimuli as detailed in section 6.2.2, A  brief outline o f the most important 
facets o f each o f these mechanisms is outlined in the subsequent sections (section 6.2.3.2 -  6.2.3.5).
6.2.3.2. Cytokines as anti-tumour asents
Briefly, cytokines can be defined as multifunctional peptide molecules ranging in size from 
6-60kDa, which act as intercellular signals, usually in an autocrine or paracrine manner. They 
include monokines, produced by monocytes, lymphokines produced by T - &  B-lymphocytes, 
interferons, haematopoietic CSFs and connective tissue growth factors. These molecules play a 
crucial role in the regulation o f many important physiological processes, including immunity, 
haematopoiesis, tumourigenesis, homeostasis, cellular growth and differentiation and tissue repair 
(Detrick &  Hooks, 1997), The importance o f these molecules in tumour immunity lies firstly in 
their capacity for general immune system-activation (e.g. IL -1  production leads to stimulation o f T - 
cells and APC cells; IF N -a  release potentiates N K  cell activity etc.), and secondly, in the existence 
o f individual cytokines with distinct anti-tumour capabilities (e.g. T N F -a  has direct cytocidal 
properties). Two cytokines o f importance in monocyte anti-tumour mechanisms (T N F -a  and IL -1) 
are described below.
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Tumour necrosis factor (T N F -a) is a cytokine (17.3 kDa) secreted prim arily by cells o f the 
M PS system, which has been shown to have a broad range o f immunomodulatory and physiological 
effects (Dietrich &  Hooks, 1997). T N F -a  production is regulated by a collection o f substances: 
P M A , LPS, IL -1 , IL -2 , IFN -y and T N F -a  (all positive mediators), and TG F-p, prostaglandins, 
glucocorticoids and IL -4  (a ll negative regulators). It  is an important effector molecule, playing a 
huge part in the activation o f neutrophils, eosinophils, macrophages and N K  cells. It  has been 
shown to have direct anti-tumour effects both in vivo (Carswell et a l, 1975) and in vitro (Sugarman 
et al., 1985, Feinman el al., 1987). This activity can be synergistically increased w ith IFN-y and IL - 
1 (Feinman et al., 1987; Fidler &  Ichinose, 1989).
Interleukin-1 (IL -1 ), as w ell as increasing the tumouricidal effects o f TNF, acts 
independently in an anti-tumour fashion (Nakane et a l, 1990). In addition, it can cause increased 
binding o f N K  cells to tumour target cells. However, it is the myriad biological actions o f this 
cytokine which it are o f most importance -  IL -1 is capable o f inducing IL -2 , IL -6 , IL -8 , IFNs, TNF, 
CSFs and TGF-P, each with resultant independent or synergistic anti-tumour/inflammatory effects, 
that highlight the significance o f this molecule in the overall anti-tumour response (Dietrich &  
Hooks, 1997).
6.2.3.3. Production o f Reactive Oxygen Species (ROS)
When appropriately activated, cells o f MPS origin, like other phagocytes, undergo changes 
in their metabolism: their rates o f oxygen uptake increase, and within seconds, activation o f a 
special metabolic pathway takes place (this overall process has been reviewed by Babior, 1984). 
The ultimate fate o f oxygen is its reduction to water, however, it is converted en route to a series of 
intermediate oxygen compounds, namely superoxide (0 2‘), hydrogen peroxide (H 20 2) and hydroxyl 
radicals (O H ), as follows:
O2 -----^ O2 ^ H2O2 ^ OH ^ H2 O
Oxygen Superoxide Hydrogen H ydroxyl W ater 
Radical Peroxide Radical
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This “respiratory burst” is achieved through activation o f NADPH-oxidase, a membrane-bound 
enzyme complex, which is responsible for the production o f superoxide from molecular oxygen. 
Superoxide dismutates w ith itself to form hydrogen peroxide. Hydrogen peroxide can cause D N A  
strand breaks in tumour cells, at concentrations produced physiologically (Chong et al., 1989). The 
conversion o f hydrogen peroxide to oxidised halogens (e.g. hypochlorous acid [HOC1]), through the 
action o f myeloperoxidase, is thought to cause extreme oxygen-mediated damage by these 
compounds (Babior, 1984; Rodgers, 1995). Production o f the toxic hydroxyl radical and hydroxyl 
anion from hydrogen peroxide, via an iron-dependent reaction, is also an important harmful ROS 
generator. Therefore, it is evident that measurement o f ROS species can be an important indicator 
o f the cytocidal capabilities o f monocyte/macrophage cells, and augmentation o f ROS release by 
agents is an attractive anti-tumour strategy.
6.2.3.4. Production o f Reactive Nitrogen Intermediates
Production o f reactive nitrogen intermediates (RN1) by mammalian cells is quite a recent 
(1980s) discovery. R N I are formed through the conversion o f L-arginine by nitric oxide synthase 
(NOS), with the nitric oxide radical (N O *) the principal product. NO» can react in vivo to form 
many nitrogen-based products, w ith nitrite and nitrate principal among them. The NOS pathway is 
known to be o f particular importance in inflammation (Dietert et al., 1995), and also notable in 
tumour immunity, with NO« reported to have a direct tumouricidal effect (Hibbs et al, 1988). NO» 
has been produced in vitro by activated mammalian macrophages, on stimulation with a range o f 
cellular/biological stimulators (Keller et al., 1990; Dietert et al., 1995), although to date few in vivo 
studies have been completed.
6.2.3.5. Production o f Enzymes
A variety o f enzymes are secreted as MPS products, and include lysozyme, lysosomal acid 
hydrolases, neutral proteases and lipases (Auger &  Ross, 1992). A  number o f these enzymes are 
important from a destructive/phagocytic viewpoint (e.g. lysosomal enzymes), while others function 
in wound-healing through remodelling o f the extracellular matrix (e.g. neutral proteases such as 
collagenases). The release o f enzymes from MPS cells has been regularly cited as a possible 
mechanism o f anti-tumour attack, but evidence for this event is relatively weak. However, as 
mentioned previously, some immune cells appear to display a paradoxical role in tumour immunity
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-  this is evident w ith regard to tumour-associated macrophages, where many o f their products 
appear to benefit the growth and metastasis o f the tumour mass, rather than inhibiting these 
processes (Mantovani et al., 1992).
The expression o f m atrix metalloproteinase (M M P ) enzymes has been reported for various 
immune cells including neutrophils, monocytes and macrophages (Garbisa et al., 1986; Opdenakker 
et al., 1991; X ie et al., 1994b), with stage-specific expression patterns evident in cells o f the MPS 
lineage (Shapiro et a l, 1991). The normal expression o f these enzymes in MPS cells probably 
relates to their requirement to traverse basement membranes, in response to 
inflammatory/chemotactic signals. However, as outlined in chapter 4, the expression o f M M P  
enzymes by tumour cells is correlated with their invasive potential. Therefore, M M P  production by 
MPS cells, especially tumour-associated macrophages, can, in theory, benefit tumour cell 
metastasis. In practice, the coexistence o f PBMCs was found to increase the invasion o f bladder 
cells in vitro, and this effect coincided with the secretion o f M M P -9 by the PBMC (Kageyama et 
a l, 1997). Thus, examination o f M M P  release from MPS cells, and its inhibition may be an 
attractive anti-tumour option.
6.3. CPU MARINS AND THE IMMUNE SYSTEM
Coumarin has been pharmacologically classified as a biological response modifier. The 
immunomodulatory effects o f coumarins have been briefly introduced in sections 1.7.3.1 and
1.7.3.2, with regard to their clinical role in oedema and chronic infection treatment. As outlined in 
section 1.8.5.2, coumarin has a stimulatory effect on many cells in the immune system. Much o f the 
early work (1970s) on coumarin was carried out to explain the observed anti-oedema effect o f 
coumarin. The benzopyrones, including coumarin, were shown to exert their effect by increasing 
the number and activity o f macrophages in oedematous tissue (Piller and Casley-Smith, 1975; Piller 
1977a, 1977b, 1977c, 1978). Koh and W illoughby (1979) found similar number and activity 
increases in mouse macrophages, in studies comparing coumarin and levamisole as macrophage 
activators. However, Filice and Remington (1981) reported that neither coumarin, nor warfarin, 
could elicit a microbicidal or tumouricidal activity from mouse macrophages challenged with 
Toxoplasma gondii, or tumour cells, respectively. More recently, Marshall and co-workers (1991b), 
using monoclonal antibodies and FACS analysis, reported an increase in the expression o f D R  and 
DQ antigens on normal donor peripheral blood mononuclear cells (PBM C), following in vitro 
exposure to coumarin. Enhanced expression o f these antigens is consistent with an activated state.
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The increase in D R  antigen expression was also in evidence in vivo, when monocytes taken from  
patients with renal cell carcinoma, undergoing treatment with coumarin and cimetidine, were 
examined for surface antigen expression (Marshall et al., 1987a).
The effect o f coumarins on the activity o f other immune cells has also been examined. It  
has been shown that coumarin increases the ratio o f TH: T s cells in vitro, and activates natural killer 
(N K ) cells in vivo (Thomes &  Lynch, 1983; Thornes, 1997). Marshall and co-workers showed that 
coumarin did not alter the N K  cell activity in vitro (Marshall et al., 1989b). Marshall et al. (1987c) 
found no quantitative changes in peripheral blood lymphocytes or natural k iller cells, in patients 
with advanced malignancies undergoing coumarin treatment. Coumarin did produce a modest 
increase in the mitogenic response o f lymphocytes to phytohaemagglutinin (PHA) but not to 
concanavalin A (Con A) or pokeweed mitogen (PW M ) both in vivo and in vitro, (Berkada et al., 
1983; Marshall et a l, 1989b). Coumarin was also shown to augment the in vitro production o f 
lymphokine activated killer (LA K ) activity in peripheral blood monocytes (Triozzi et a l, 1990).
As outlined in section 6.2.2, the most relevant secreted MPS products for tumour 
immunology are cytokines, reactive oxygen species and reactive nitrogen species. A  number of 
studies have been performed in order to determine the effect o f coumarins on the secretory products 
o f monocytes. Stulmeier et a l (1991) showed that coumarin, 7-hydroxycoumarin and 4- 
hydroxycoumarin all potentiated the LPS-stimulated release o f IL -ip  from monocytes. The effect o f 
coumarins on LPS-induced IL -6  and T N F -a  production from donor monocytes was also assessed. 
W hile a synergistic effect was also observed for the production o f these cytokines, it was not as 
prevalent as for IL -1 [the coumarin/LPS synergism was evidenced for IL -1 secretion in 95% o f 
donors, but only in 53% and 32%  o f donors, for IL -6  and T N F-a, respectively]. In all cases o f 
cytokine production, 7-hydroxycoumarin was the most effective synergiser, and in no instance were 
any o f the coumarins capable o f inducing significant cytokine production by themselves. 
Stuhlmeiers colleagues continued work in this area, probing the signalling pathways involved in the 
LPS/coumarin synergism (Zlabinger et a l, 1993). They found that the LPS-induction o f IL-1  
production from monocytes was coupled to both PKC and lipoxygenase pathways. The augmenting 
effect o f 7-hydroxycoumarin on LPS-induced secretion o f IL -1  also involved these two signalling 
pathways.
The generation o f reactive oxygen species (ROS) by PMA-stimulated MPS cells was shown 
by Marshall and co-workers (1989b) to be influenced by coumarin species. Coumarin inhibited the 
generation o f superoxide and hydrogen peroxide in a dose-dependent manner in freshly isolated
193
human monocytes. This effect was not observed for macrophages (monocytes cultured for 72hrs) 
stimulated with PM A. Triozzi and colleagues (1990) found coumarin inhibited the IL-2-induced 
generation o f ROS by 58% in human peripheral blood monocytes. However, neither o f these studies 
addressed the issue o f the free-radical scavenging abilities o f the coumarin compounds (Paya eta/., 
1992).
To date, no studies have been achieved on the effect o f coumarins on the production of 
reactive nitrogen intermediates (R N I) by MPS cells.
Finally due to their extensive networking w ith cytokine pathways, arachidonic acid 
metabolites are also important in tumour immunity (Bonta &  Ben-Efraim, 1993). Prostaglandins, in 
particular, are known to exert a strong immunosuppressive effect in humans. In contrast, 
leukotrienes generate increases in the release o f T N F -a  from macrophages. Coumarin, 7- 
hydroxycoumarin and 4-hydroxycoumarin were shown to inhibit the conversion o f arachidonic acid 
to prostaglandins, with equipotency to the inhibition attained by acetylsalicylic acid (Lee et al., 
1981). Triozzi and colleagues (1990) found that coumarin completely inhibited the IL-2-induced 
production o f prostaglandin E2 by human peripheral blood mononuclear cells. Zlabinger et al. 
(1993) made a brief observation that coumarin synergistically enhanced the LPS-induced 
production o f leukotriene B4 in human monocytes.
Many o f the experiments achieved to date in studying the effect o f coumarins on immune 
cells have been achieved with peripheral blood monocytes from either normal donors or patients. 
The use o f human mononuclear cells in any study introduces many problems for the experimenter. 
Firstly, there is the problem o f sourcing: unless a laboratory has regular access to blood bank or 
hospital blood samples, a consistent, fresh (<6hrs old) supply o f mononuclear cell samples, in 
sufficient numbers for experiments, can be difficult to achieve. Once availability is overcome, the 
next problem to be addressed is the issue o f cell uniformity: many inter-experimental differences in 
cell response arise due to donor heterogeneity. There is also the issue o f cell subsets (as a result o f 
distinct differentiation stages) even in cells from a single donor. Purification o f the mononuclear 
fraction from blood samples or buffy coats, introduces further problems -  apart from loss o f large 
numbers o f cells, there is the worry that activation o f monocytes by, for example, endotoxin 
contamination, can occur. In  addition, 100% purification is rarely achieved, thus, low levels o f 
contamination with other blood cells must be taken into account in experimental designs.
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These problems have been largely overcome by two methods:
1. Use o f animal (usually mouse) sources o f macrophages. This can allow access to large numbers 
o f cells for exploratory work, however, problems with cell uniformity can still exist.
2. Use o f immortalised cell lines. These overcome availability and heterogeneity problems, and 
studies can be performed on human cells. However, many "monocytic/macrophage" cell lines 
are leukemic in origin - therefore, there is the issue o f deciding i f  they are appropriate models o f 
"normal" monocytes. In addition, there is the possibility that the process o f immortalisation may 
cause loss o f some normal functions.
6.4. CHAPTER OUTLINE
In this chapter two human cell lines were examined to determine their suitability for use as 
"models" o f human monocytes. The H L-60 cell line, derived from a single patient with acute 
promyelocytic leukemia has been widely used in immune cell studies. It can be induced to 
differentiate in vitro from its promonocytic state to a number o f different cell types -  granulocytes, 
monocytes, macrophages and eosinophils -  by exposure to a range o f chemical and biological 
agents (Collins, 1987). In addition to this cell line we also chose to study the 28SC cell line: these 
cells, recently deposited w ith the American Type Culture Collection (A TC C ), are monocytic in 
nature, having been established from human peripheral blood mononuclear cells (Collins &  Largen, 
1995). W e were particularly interested in these, as they were not leukemic in origin.
Both cell lines were exposed to a variety o f immune cell stimulators and modulators, and 
the secretion o f various anti-tumour products, namely reactive oxygen species, reactive nitrogen 
intermediates and proteases examined. The effect o f coumarins on the secretion o f these products 
was then investigated.
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6.5.1. Characterisation of HL-60 and 28SC Cells
6.5. RESULTS AND DISCUSSION
6.5.1.1. Staining o f Cytocentrifuged Cells
The H L-60 (pro-monocytic) and 28SC (monocytic) cells were assessed morphologically 
and cytochemically by methylene blue/eosin (M B /E ), and non-specific esterase (NSE) staining, 
respectively. M B /E  staining provides for a morphological assessment o f gross cellular structure. 
NSE is an enzyme found on the external surface o f the plasma membrane o f monocytes and 
macrophages, and is commonly used as a positive cytochemical stain for these cell types. The 
staining o f cytocentrifuged cells was accomplished as outlined in section 2.2.7.3, and the results are 
shown in Figure 6.1. It  can be seen morphologically, that the two cell types are quite similar, 
however the 28SC cells possess a more highly “ruffled” membrane, which is indicative o f a 
phagocytic cell. These cells, as expected, express high levels o f non-specific esterase, a monocyte 
marker, on their plasma membrane as indicated by the intense black staining (Figure 6 .ID ), 
compared to the negative pro-monocytic H L-60 cells (Figure 6.1C).
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Figure 6.1: Cytochemical staining o f H L-60 or 28SC cells. Both cell lines were subjected to
either Methylene blue/eosin (M B /E ) or Non-specific esterase (NSE) staining as 
outlined in section 2.2.13. The results for HL-60 are shown in A  (M B /E  staining) 
and C (NSE staining), and for 28SC in B (M B /E  staining) and D  (NSE staining).
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6.5.1.2. Nitroblue Tetrazolium (NBT)Reduction
This test is commonly used to determine the respiratory burst in monocytic cells. Cells are 
activated with PM A, and their ability to reduce a tetrazolium salt ascertained, as evidence o f the 
magnitude o f the activation. This experiment was carried out as outlined in section 2.2.7.3.4 and the 
results are presented in Table 6.5. As shown neither cell line responded greatly to the applied PM A  
stimulus. However, the H L-60 cell line was ten times more responsive than the 28SC cell line to 
PM A. As this N B T  reduction technique is quite a crude and subjective method, we were interested 
in examining the activation o f these two cell lines with PM A  in more detail, and proceeded to do so 
using the Cytosensor Microphysiometer as outlined in section 6.5.2.
Cell % Cells Reducing NBT
HL-60 8.62 ±1 .31  (0.11 ± 0 .1 8 )
28SC 0.83 ± 0 .60  (0.12 ± 0 .2 1 )
Table 6.5: NBT reduction in HL-60 and 28SC cells. Cells were stimulated with lOOng/ml
PMA as outlined in section 2.2.7.3.4, and following cy to centrifugation, 
~200cells were counted. The number of cells containing blue/black deposits 
(i.e. positive NBT reduction) was expressed as a percentage of the total 
number of cells counted. The experiment was carried out on 5 separate 
occasions and the mean ± s.d. shown in the above table. Values for 
unstimulated controls are displayed in brackets.
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6.5.2. Activation o f  M PS cells on Cytosensor Microvhvsiometer
The Cytosensor Microphysiometer has been used in the past to examine activation in a 
variety o f immune cell types. Nag et al. (1992) examined the specific response o f T-cells to a pre­
formed M HC-Class H-peptide. The activation o f T-cells by interaction w ith anti-CD3 and anti-TCR  
monoclonal antibodies, as well as IL -2  exposure, have also been assessed on the Cytosensor 
Microphysiometer (Wada et a l, 1994). Activation o f B-lymphoma cells, through binding o f anti- 
idiotypic antibody and antigen binding receptor ligands, has also been studied on this instrument 
(Renschler et a l, 1995). The effect o f various inflammatory mediators on the activation o f 
neutrophils (PM Ns) has been investigated using microphysiometry - in this experiment the potency 
o f different immune cell activators was compared. Leukotriene B4 (LTB 4) and FM LP (n-formyl- 
methionine-leucine-phenylalanine) were shown to be extremely potent P M N  activators, while IL -8  
and platelet-activating factor (PAF) illustrated only weak activating capabilities (Gronert et a l, 
1998). The effect o f lipoxins on monocytes and monocytic cell lines has also been examined on the 
Cytosensor Microphysiometer, but these inflammatory mediators were found to have no effects on 
the acidification rates o f these cell types (Romano et al., 1996). Finally, this instrument has also 
been used to examine the effect o f lipoprotein on the metabolic state o f cultured mouse 
macrophages (DeVries e ta l,  1998).
Having observed the poor stimulation o f metabolic activity for both the H L-60 and 28SC 
cell lines using the N B T reduction technique, we proceeded to examine the activation o f the HL-60  
and 28SC cell lines by PM A, using the Cytosensor Microphysiometer. The experiment was 
achieved as outlined in section 2.2.7.4, and the results for the exposure o f H L-60 and 28SC cells to 
a range o f P M A  doses (0-5000ng/m l), are shown in Figures 6.2 and 6.3, respectively.
Figure 6.2 illustrates the stimulation o f H L-60 cells in response to PM A  exposure. As 
shown, a dose-dependent increase in the metabolic activity o f these cells was observed. In  the range 
0.5-5ng/ml PM A , an initial “burst” to -106%  (0.5ng/ml PM A ) and —109% (5ng/ml PM A ) was 
observed, but this was only a transient increase in metabolic activity, and the metabolic activity o f 
both cell populations returned to their baseline levels within 60 mins o f stimulus application. The 
metabolic rate o f cells exposed to 50ng/ml PM A  immediately increased to -109%  o f its “basal” 
level following stimulation, but sustained this increased metabolic rate at -  110-113% over the 60 
min post-exposure period. Exposure o f cells to both 500 and 500Qng/ml PM A , initially caused a 
gradual increase in metabolic activation over the first 15mins post-exposure, however the increase 
was sustained at a level 110-115%  above the basal metabolic rate over the 60 mins following PM A
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stimulation. Overall, activation o f H L-60 cells was optimal in the range 50-500ng/ml PM A  -  the 
metabolic rate o f cells exposed to 500Qng/ml, did begin to return towards baseline levels, 40mins 
post-activation.
Figure 6.3 illustrates the activation o f 28SC cells in response to PM A  exposure. As 
outlined, these cells were not as responsive to stimulation by PM A  as the H L-60 cells -  the 
metabolic rate o f the cells did not increase by greater than -6 %  for any o f the PM A  concentrations 
tested in the range 0-5000ng/ml. Cells exposed to 5ng/ml PM A  did not respond at all to the applied 
stimulus. A t 50ng/ml PM A , the metabolic rate o f the cells increased to —106%, and gradually 
decreased to baseline levels o f the 60mins post-stimulation. Cells exposed to both 500 and 
5000ng/ml did not in itially respond to the stimulus, but a slow, gradual increase in their metabolic 
rate was observed over the 60 mins post-stimulation period.
The low responsiveness o f these cells to the cell activator PM A  is unusual, as it acts by 
activating the ubiquitous Protein Kinase C (PKC), causing its translocation to the cell membrane, 
with subsequent initiation o f cell signalling events. However, the existence o f PKC isozymes has 
been widely established, and these isozymes are classified as one o f three types: classical, novel and 
atypical (see Section 5.2.4), on the basis o f their responsiveness to phorbol esters and their Ca2+- 
dependency (M ellor &  Parker, 1998). Members o f the atypical PKC sub-classification are PM A- 
unresponsive. The presence/absence o f different PKC isoforms has been investigated for various 
monocyte-like cells. Changes in the levels o f PKC isoforms have been reported in H L-60 cells on 
differentiation to granulocytes or monocytes (Makowske et al., 1988; Solomon et al, 1991). A  
similar study o f PKC isoforms in U937 cells also showed a differential expression o f isozymes in 
undifferentiated and differentiated cells (K iley &  Parker, 1995). Overexpression o f PKC-£ (PM A- 
unresponsive) in U937 cells was associated with a more differentiated phenotype in those cells 
(Ways et a l, 1994). A  decrease in the expression o f Ca2+-dependent PKC isoforms in macrophages 
compared to monocytes has also been recently demonstrated (Monick et al., 1998). Therefore, it is 
possible that the more differentiated 28SC cells possess PKC isozymes which are PM A- 
unresponsive, while the PKC isozymes present in H L-60 cells belong to the more classical PM A- 
responsive fam ily. A  fu ll isozyme analysis by immunoblotting would clarify this issue. Another 
simpler alternative, is that PKC expression/activity (irrespective o f isozymes') is decreased in 28SC 
cells; such a loss o f enzyme activity is not unusual during establishment o f immortalised cells in 
culture. Whatever the reason for their non-responsiveness to PM A, this facet o f these cells may 
preclude their use in the subsequent experiments o f this chapter.
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Activation of HL60 Cells on Cytosensor with PMA
Time (mins)
Figure 6.2: Exposure of HL-60 cells to concentrations of PMA in the range 0-5000ng/ml
over 60mins. The above plot shows the mean of three experiments conducted 
on the Cytosensor Microphysiometer to determine the activation of HL-60 
cells in response to PMA (Section 2.2.7.4). In individual experiments, the 
cellular acidification rate was determined prior to PMA exposure, using a 2 
min pump cycle, with the acidification rate measured in the final 30secs. of this 
cycle. This rate was normalised at 100% and all subsequent acidification rates 
during PMA-exposure expressed as a percentage of this normalised value. 
These values of metabolic rate (mean of three experiments) were plotted vs 
time in the above graph. Typical basal acidification rates (-p.volts/sec) for the 
HL-60 cells in the experiments were -80  to -130^. volts/sec.
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Figure 6.3: Exposure of 28SC cells to concentrations of PMA in the range 0-5000ng/ml
over 60mins. The above plot shows the mean of three experiments conducted 
on the Cytosensor Microphysiometer to determine the activation of HL-60 
cells in response to PMA (Section 2.2.7.4). In individual experiments, the 
cellular acidification rate was determined prior to PMA exposure, using a 2 
min pump cycle, with the acidification rate measured in the final 30secs. of this 
cycle. This rate was normalised at 100% and all subsequent acidification rates 
during PMA-exposure expressed as a percentage of this normalised value. 
These values of metabolic rate (mean of three experiments) were plotted vs 
time in the above graph. Typical basal acidification rates (-^.volts/sec) for the 
28SC cells in the experiments were -100 to -160pvolts/sec.
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6.5.3. Generation o f  Reactive Oxygen Species by Monocytic Cells -  Chemiluminescent
Studies
As outlined in Section 6.2.3.3, the measurement o f ROS is an important method for 
ascertaining the cytocidal capacity o f a phagocyte. Measurement o f ROS species can be 
accomplished by a number o f methods. The most common method entails use o f colourimetric 
assays for the assessment o f superoxide and hydrogen peroxide release from stimulated immune 
cells, as detailed by Rodgers (1995). An alternative method is based on the fact that the production 
o f ROS produces molecules in electronically excited states; on relaxation to their ground state, these 
compounds emit photons, known as chemiluminescence (C L). Luminescence measurements are 
non-destructive, and unlike the available colourimetric techniques, allow for continuous monitoring 
o f the phagocyte chemiluminescence emission (Allen, 1986). Due to their sensitivity, they are 
usually carried out immediately following cell activation, whereas colourimetric measurements 
require build-up o f the oxygen species to detectable levels, an event that can require up to 24hrs.
6.5.3.1. Selection o f Optimal Chemiluminescent Probe for Monitoring o f CL Emission
The native CL emitted as a result o f phagocyte stimulation can be amplified (100-10000- 
fold) through the use o f various chemiluminescence probes. A  choice o f chemiluminescent probes 
are available to aid the measurement o f CL emission from  activated cells and two o f these, luminol 
and lucigenin, were tested to determine their suitability for use in the assay system (Figure 6.4). 
From this it can be seen that only luminol was suitable for the use in monitoring the CL emission 
from PMA-stimulated H L-60 cells, and this probe was used in all subsequent assays. It  has been 
previously shown that luminol and lucigenin measure temporally different ROS-generating 
activities (Allen, 1986), and this may account for the lack o f any CL response with lucigenin as a 
probe, in the time interval observed. Allen (1986) also showed the choice o f stimulus to affect the 
observation o f CL emission with different chemiluminescent probes.
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Determination of Optimal Chemiluminescent Probe
for Chemiluminescence Experiments
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Figure 6.4: Determination of the optimal chemiluminescent probe for the monitoring of
CL emission from HL-60 cells exposed to PMA. 2 X  105 HL-60 cells were 
stimulated with 500ng/ml PMA at time = 0. CL emission from the cells was 
monitored for 60mins. following an initial lOmin. lag period where no 
measurements were recorded. CL measurements were made as outlined in 
section 2.2.7.5, with light emission recorded for 30 secs., every three minutes, 
for time = 10-70mins, following PMA stimulation. The light generated, 
expressed as Relative Light Units (RLU), was plotted vs time in the above 
graph. The different probe concentrations tested were 80}iM luminol and 
lOOfiM lucigenin as recommended (Allen, 1986)
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6.S.3.2. Optimisation o f Cell Concentration for CL Generation
Different concentrations o f H L-60 cells were incubated w ith 500ng/ml PM A  as stimulant, 
in order to determine the optimum cell concentration for use in CL-emission experiments. The 
results are illustrated in Figure 6.5, as light-generation curves, and in Table 6.6, as integrated units 
(area under curve). As can be seen from Figure 6.5, light emission from H L-60 cells exposed to 
50Qng/ml PM A, increased as a function o f the number o f cells per assay in the cell concentration 
range 0-5 X  105 cells/assay. A t a concentration o f 5 X  105 cells per assay, the light generation curve 
started to plateau at ~  50 mins, probably as a result o f exhaustion o f the CL probe luminol. 
Concentrations o f cells o f 1 X  106 cells per assay, exhibited an overall decreased light generation, as 
a result o f 1) exhaustion o f luminol, and more importantly 2) re-absorption o f the generated-light by 
the cells. The optimal cell concentration chosen was 2 X  105 cells per assay, as the hght generation 
event had not plateaued after the observed 60min. time period, and this concentration o f cells was 
used in all subsequent experiments. Solvent (0.1%  DM SO ) controls were included in all 
experiments and as shown in Table 6.6, caused no stimulation o f light generation by the cells.
Three different concentrations o f 28SC cells were exposed to 50Qng/ml PM A  but as shown 
in Table 6.7, hght emission was almost non-existent. This result was not wholly surprising when 
one recalls the low increases in metabolic rates observed for this cell line, using the Cytosensor 
Microphysiometer, on P M A  stimulation (section 6.5.2). As explained in that section, this non­
responsiveness to P M A  may be due to the specific PKC isoforms present in these cells, or a 
complete loss o f PKC activity as a result o f cell immortalisation.
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Optimisation ofHL-60 Cell Concentration
in Chemiluminescence Experiments
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Figure 6.5: Optimisation of cell concentration for chemiluminescence experiments on
PMA-stimulated HL-60 cells. Various concentrations of HL-60 cells were 
incubated with 80fiM luminol, and stimulated with 500ng/ml PMA, at time =
0. CL emission from the cells was monitored for 60mins. following an initial 
lOmin. lag period where no measurements were recorded. CL measurements 
were made as outlined in section 2.2.7.5, with light emission recorded for 30 
secs., every three minutes, for time = 10-70mins, following PMA stimulation. 
The light generated, expressed as Relative Light Units (RLU), was plotted vs 
time in the above graph. Concentrations of HL-60 cells in the range 2 X 104 
cells/assay — 1 X 106 cells/assay were tested, and a sample curve is illustrated 
for each cell concentration. The CL emission for each cell concentration was 
tested in quadruplicate, and determined on three separate occasions.
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Cells p er assay 
(HL-60)
+  500ng/m l PM A
(Integral RL U)
+ 0.1% DMSO
(Integral RLU)
Table 6.6:
Table 6.7:
2 X 104 531.60 + 61.54 77.77 + 0.12
5X 104 2059.67 ± 92.74 59.65+2.53
IX  10s 3342.30 ±89.86 36.92 + 4.46
2 X 10s 4319.70+253.50 36.89 + 6.55
5 X 10s 5672.30 ±208.14 18.67 + 0.63
1 X 106 3531.30+271.48 5.86+0.43
Optimisation of cell concentration for chemiluminescencc experiments on PMA- 
stimulated HL-60 cells. Concentrations of HL-60 cells in the range 2 X 104 cclls/assay 
1 X 106 cells/assay were tested. Experimental conditions are outlined in the legend of 
Figure 6.5. This table outlines the integrated (area under light generation curves) 
Relative Light Units for the curves shown in Figure 6.5. All experiments were 
replicated 4 times, and determined on three separate occasions and the table values 
shown are mean ± s.d. for all such experiments. Solvent control samples (0.1% DMSO) 
are also included.
Cells per Assay (28SC) Integral R L U
0 3.41+0.50
IX  10s 12.18 ±0.62
2 X 10s 16.71+0.32
5 X 10s 18.65 + 5.73
Optimisation of cell concentration for chemiluminescencc experiments on PMA- 
stimulated 28SC cells. Concentrations of 28SC cells in the range 1 X 10s cells/assay -  5 
X 10s cells/assay were tested. Experimental conditions arc identical to those used for 
HL-60 cells, outlined in the legend of Figure 6.5. This table details the integrated (area 
under light generation curves) Relative Light Units. All experiments were carried out 
in triplicate, and determined on three separate occasions and the table values shown 
are mean ± s.d. for all such experiments.
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6.5.3.3. Optimisation o f Cell Stimulation in Chemiluminescent Experiments
From the experiments outlined in sections 6.5.2 and 6.5.3.2, PM A appeared to act as an 
appropriate activator o f H L-60 cells, with activation leading to the production o f ROS, as shown by 
CL-emission. Figure 6.2 shows that optimal activation o f H L-60 cells was achieved with 500ng/ml 
PM A. W e wished to confirm that this was the most appropriate PM A concentration for optimal CL- 
emission. Therefore we carried out suitable experiments as illustrated in Figure 6.6. As shown, the 
PM A  concentration increased CL emission from H L-60 cells in a dose-dependent manner, with a 
large emission o f light (>  1000 R LU ) created at PM A  concentrations >  5ng/ml. W e therefore 
arbitrarily chose 500ng/ml PM A  as the concentration to use in all subsequent experiments, as it had 
been the optimal stimulatory concentration for H L-60 cells as observed on the Cytosensor 
Microphysiometer (section 6.5.2). In  the CL experiments, this relatively low stimulant 
concentration caused a large light emission (4313.46 ±  203.67 Integrated RLU).
In section 6.2.1, the concept o f sequential “priming” and “activation” o f MPS cells was 
introduced. Therefore, we examined the effect o f other stimulators or modulators on the CL  
emission o f H L-60 cells, and the results o f these experiments are shown in Table 6.8. Firstly, we 
utilised the common phagocyte stimulator, opsonised zymosan (O Z), [a cell wall preparation of 
Saccharomyces cerevisiae, prepared as outlined in section 2.2.7.2], as a stimulator o f CL emission 
from H L-60 cells. W e found this effectively activated H L-60 cells to generate ROS, and emit 
chemiluminescence, but was not as competent as PM A  at this task (Table 6.8). When H L-60 cells 
were incubated for 24hrs with either lOng/ml LPS or lOOU/ml IFN -y (as a “priming” step), the light 
emission from H L-60 cells on stimulation with 500ng/ml PM A increased significantly (Table 6.8). 
Similar results were obtained for “primed” H L-60 cells activated with 250(j,g/ml OZ (Table 6.8). 
These results reflect well those o f other investigators using CL-based assays to examine the 
modulation and stimulation o f macrophage cell lines (De Baetselier &  Schram, 1986). It should also 
be noted here that incubation o f IFN -y (100-1 OOOU/ml) w ith H L-60 cells for 5 days has been 
previously shown to induce differentiation to monocytes (Harris et al., 1985), therefore the increase 
in CL may be accompanied by early differentiation changes.
In sections 6.5.2 and 6.5.3.2, it was demonstrated that PM A  does not effectively activate 
28SC cells. Therefore, we examined the effect o f other immune cell modulators and stimulators on 
the generation o f ROS (as measured by CL emission). The results o f these experiments are outlined 
in Table 6.9. As shown, “priming” o f 28SC cells by pre-incubation with either LPS or IFN -y, did 
result in an increase in the emission o f light from PMA-stimulated 28SC cells compared to
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“unprimed” cells. However, the light emission was still extremely low, and insignificant, when 
compared to those values obtained for sim ilarly treated H L-60 cells (Table 6.8). 28SC cells were 
shown to be capable o f CL emission when exposed to the phagocytic stimulator, opsonised 
zymosan (Table 6.9). The generation o f ROS (as assessed by CL emission) was significantly 
improved for O Z compared to PM A  (Figure 6.7). Pre-incubation with lQng/ml LPS only slightly 
augmented the OZ-induced light emission (Table 6.9). However, pre-incubation o f 28SC cells with 
lOOU/ml IFN -y, caused a significant (4.7-fold) increase in the CL-emission from these cells when 
stimulated with opsonised zymosan (Table 6.9).
Optimisation of PMA Concentration 
in Chemiluminescence Experiments
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Figure 6.6: O ptim isation of PMA concentration for chemiluminescence experiments on HL-60
cells (2 X 10s cells/assay). HL-60 cells were incubated with 80n_M luminol, and 
stimulated with various concentrations of PMA, at time = 0. CL emission from the 
cells was monitored for 60mins. following an initial lOmin. lag period where no 
measurements were recorded. CL measurements were made as outlined in section
2.2.7.S, with light emission recorded for 30 secs., every three minutes, for time = 10- 
70mins, following PMA stimulation. The light generated, expressed as Integral 
Relative Light Units (RLU), was plotted vs cell concentration in the above graph. 
Concentrations of PMA in the range 0-5000ng/ml PMA were tested. The CL emission 
for each concentration was tested in quadruplicate, and repeated on four separate 
occasions.
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Stimulatory Agent H I-60 Cells HL-60 Cells + HL-60 Cells +
10ng/ml LPS 100U/mlIFN-y
0.1%  DMSO 36.89 ±6 .5 5  47.74 ±4 .60  60.46 ±1.95
500ng/ml PMA 4313.46 ±  203.67 8991.68 ±  79.88 13929,30 ±  560.94
250^g/mlOZ 1490.60 ±54 .61  4443.65 ±  568.09 15530.00 ±231.00
Table 6.8: Effect of various modulators and stimulators on the generation of light from
HL-60 cells. HL-60 cells were incubated for 24hrs in the absence or presence 
of LPS (10ng/ml) or IFN-y (100U/ml), prior to activation with either 500ng/ml 
PMA or 250(j.g/ml OZ. Measurement of chemiluminescence was achieved 
exactly as outlined in the legend of Figure 6.6. All modulator/stimulator 
combinations were tested in triplicate, on at least three separate occasions, and 
the mean ± s.d. provided in the table.
Stimulatory Agent 28SC Cells 28SC Cells + 
10ng/ml LPS
28SC Cells + 
100U/ml IFN-y
0.1% DMSO 0.70 ±1 .54 1.39 ±0.75 6.01 ±1 .02
500ng/ml PMA 16.71 ±0 .3 2 27.16 ±2 .27 72.70 ±1 .68
250|xg/ml OZ 413.90 ±30 .75 455.88 ±35.52 1955.75 ±59 .99
Table 6.9: Effect of various modulators and stimulators on the generation of light from
28SC cells. 28SC cells were incubated for 24hrs in the absence or presence of 
LPS (10ng/ml) or IFN-y (100U/ml), prior to activation with either 500ng/ml 
PMA or 250|xg/ml OZ. Measurement of chemiluminescence was achieved 
exactly as outlined in the legend of Figure 6.7. All modulator/stimulator 
combinations were tested in triplicate, on three separate occasions, and the 
mean ± s.d. provided in the table.
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Effect of Different Stimulators on 
Chemiluminescence Generation in 28SC Cells
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Figure 6.7: 28SC cells (2 X 10s cells/assay) were incubated with 80|xM luminol, and
stimulated with either 500ng/ml PMA, or 250pg/ml OZ, at time = 0. CL 
emission from the cells was monitored continuously for 72mins. following 
stimulation. CL measurements were made as outlined in section 2.2.7.5, with 
light emission recorded for 30 secs., every three minutes, for time = 0-72mins. 
The light generated, expressed as Relative Light Units (RLU), was plotted vs 
time in the above graph. Concentrations of PMA in the range 0-5000ng/ml 
PMA were tested. The CL emission for each concentration was tested in 
triplicate, and determined on three separate occasions.
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6.5.4. Time-dependent Decrease in the Response o f HL-60 cells to PMA
Results from the previous sections, illustrated that o f the two cell-lines tested, the HL-60 
cells were more appropriate for use as a model for assaying ROS generation by chemiluminescence. 
However, as we were carrying out experiments with these cells we perceived that they too could 
prove problematic. W e noticed that over time, the H L-60 cells were losing their ability to emit 
chemiluminescence in response to stimuli such as PM A . As shown in Figure 6.8, during culture, the 
H L-60 cells appeared to lose their capacity for light-generation. Immediately following 
resuscitation from liquid nitrogen, the H L-60 cells were immune to the stimulatory effects o f PM A, 
but by Day 5, the cells could respond to PMA-stimulation with the emission o f large levels o f 
chem iluminescence This response was sustained at high levels until about Day 10-12, after which 
time the luminescence response started to decrease rapidly over time to almost base-line levels by 
D ay 20 (Figure 6.8 &  Table 6.10). The most likely explanation o f this effect is the differentiation of 
the H L-60 cells over time in culture. The H L-60 cells are pro-monocytic in nature, but are known to 
differentiate over time to cells more monocyte/macrophage-like in nature. Such a differentiation 
step is often accompanied by alterations in the levels o f cellular enzymes, including peroxidases. In 
fact, the level o f peroxidases peaks in pro-monocytes, and falls on differentiation o f these cells to 
monocytes and macrophages (Adams &  Hamilton, 1992; Auger &  Ross, 1992), an event which 
might explain the decrease in ROS generation in H L-60 cells over time. In addition, as mentioned 
earlier, differentiation o f cells may result in a change in the levels o f PMA-responsive PKC 
isozymes, resulting in the observed decrease in luminescence.
W e determined whether this decrease in ROS generation, was mirrored by a general 
decrease in cell activation in PMA-stimulated H L-60 cells, using the Cytosensor Microphysiometer, 
as outlined in Section 6.5.2. The results are shown in Figure 6.9. It  can be seen that the loss o f 
chemiluminescence as a result o f extended culture (Figure 6.10), was mirrored by a decreasing 
metabolic activation o f H L-60 cells, in response to PM A  over time, with an eventual complete loss 
o f activation, following 20 days o f culture. As a result o f this observation, all further 
chemiluminescence experiments (Section 6.5.5) used only H L-60 cells, within Days 5-12 o f their 
resuscitation.
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Figure 6.8: Effect of culture time on the CL emission from PMA-stimulated HL-60 cells.
HL-60 cells were resuscitated from liquid nitrogen on Day 1, and cultured as 
outlined in section 2.2.3.3. For experiments, HL-60 cells, cultured for the 
appropriate length of time, were incubated with 80pM luminol, and stimulated 
with 500ng/ml of PMA, at time = 0. CL emission from the cells was monitored 
for 60mins. following an initial lOmin. lag period where no measurements 
were recorded. CL measurements were made as outlined in section 2.2.7.5, 
with light emission recorded for 30 secs., every three minutes, for time = 10- 
70mins, following PMA stimulation. The light generated, expressed as Relative 
Light Units (RLU), was plotted vs time. This experiment was repeated on three 
separate occasions to ensure the observed luminescence decrease was accurate. 
The results of one experiment are shown in the above graph.
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D a y s  fo l l o w i n g  R e s u s c i ta t io n Integral RLU
Table 6.10:
Day 1 92.99 ±  15.67
Day 5 4566.4 ±314.99
Day 10 3378.00 ±52 .78
Day 15 884.54 ±  18.09
Day 20 228.0419.88
Effect of culture on luminescence generation in PMA-stimulated HL-60 cells. 
Experimental conditions are outlined in the legend of Figure 6.8. This table 
outlines the integrated (area under light generation curves) Relative Light 
Units for the curves shown in Figure 6.8. All experiments were carried out in 
triplicate, on three separate occasions and the table values shown are mean ±  
s.d. for these experiments.
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Decrease in activation of HL60 Cells 
over time observed on Cytosensor
Time (mins)
Figure 6.9: Decreased response of HL-60 cells to PMA-stimulation, as a function of their
time in culture, ascertained using the Cytosensor Microphysiometer. HL-60 
cells were resuscitated from liquid nitrogen on Day 1, and cultured as outlined 
in section 2.2.3.3. For experiments, HL-60 cells, cultured for the appropriate 
length of time, were assembled onto the Cytosensor Microphysiometer, as 
outlined in Section 2.2.7.4, and stimulated with 500ng/ml PMA, over 60mins. 
The above plot shows one of three experiments conducted to determine if 
extended periods of culture affected the activation of HL-60 cells in response 
to PMA (Section 2.2.7.4). In individual experiments, the cellular acidification 
rate was determined prior to PMA exposure, using a 2 min pump cycle, with 
the acidification rate measured in the final 30secs. of this cycle. This rate was 
normalised at 100% and all subsequent acidification rates during PMA- 
exposure expressed as a percentage of this normalised value. These values of 
metabolic rate were plotted vs time in the above graph. Typical basal 
acidification rates (-fxvolts/sec) for the HL-60 cells in the experiments were -80  
to -130p.volts/sec.
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6.5.5. Effect o f  Counuirin Compounds on ROS Generation from Monocytic Cells -
Chemiluminescence Studies
From the results obtained in Sections 6.5.3 and 6.5.4, it was decided that the H L-60 cell line 
(Day 5-12) was the more appropriate model, o f the two cell lines tested, for assessing the effects of 
coumarin compounds on ROS generation. It was decided to assess the effect o f coumarin 
compounds on the generation o f ROS species in two different scenarios -  1) H L-60 cells activated 
with 500ng/ml PM A , and 2) H L-60 cells primed with lOOU/ml IFN -y for 24hrs, and activated with 
500ng/ml PM A. However, prior to carrying out these experiments, it was necessary to complete a 
number o f control experiments, as detailed in the following paragraphs.
As outlined in section 6.3, the coumarin compounds have been shown previously to 
decrease the production o f ROS from fresh donor human blood mononuclear cells (PBM C), but not 
cultured PBMC, on PM A  stimulation. (Marshall et al., 1989b). However, the experimental set-up in 
these studies involved the measurement o f superoxide (0 2‘) and hydrogen peroxide (H 20 2) 
production, with coumarins present in the reaction mixture. As compounds o f the coumarin fam ily 
have been previously shown to act as free-radical scavengers (Paya et al., 1992), it is unclear 
whether the observed reductions in ROS generation are a result o f this scavenging capability, or due 
to other effects. Therefore, for our assay system we in itially evaluated the effect o f coumarins 
(coumarin, 7-hydroxycoumarin and esculetin) on the generation o f ROS from PMA-stimulated H L - 
60 cells, by including or omitting these compounds in the assayed reaction m ix (Figure 6.10). As 
can be seen from Figure 6.10, concentrations o f >50(ig/m l o f coumarin, and > 10f!g/ml 7- 
hydroxycoumarin, caused decreases in the observed emission o f chemiluminescence (generation of 
ROS) from PMA-stimulated H L-60 cells over a lh r period. Therefore, the decreases in ROS 
production observed by Marshall and colleagues (1989b) over a 24hr period, are probably due to 
this “scavenging effect”. W ith regard to esculetin, all tested concentrations o f this drug (0.1- 
50pg/m l), had severe effects on CL-emission, again probably as a result o f free-radical scavenging. 
It  was therefore concluded that all further luminescence readings would be acquired in the absence 
o f coumarins in the assay wells. Therefore, all cells exposed to coumarins were washed twice in 
drug-free salt solution, prior to cell stimulation, to ensure complete removal o f drug traces from the 
extracellular medium.
Another necessary control experiment was that to determine the effect o f the coumarin 
compounds on the natural “basal” level o f chemiluminescence emission in H L60 cells. This was 
achieved to ensure that incubation o f coumarins with HL60 cells did not themselves “activate” the
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cells for increased luminescence emission. As shown in Table 6.11, the low levels o f natural 
luminescence o f H L-60 cells did not change significantly in cells exposed to the different coumarin 
compounds for 24hrs. This insignificance is clearly demonstrated when one compares the levels o f 
“basal” luminescence emitted from these drug-treated cells, with the luminescence emitted when 
cells are stimulated with 500ng/ml PM A. A  1000-5000-fold difference in light emission is 
observed, which confirms the fact that the coumarin compounds do not themselves activate CL- 
emission from H L-60 cells.
Having completed these control experiments, we next investigated the effects of 
coumarin compounds on the generation o f ROS in PMA-stimulated H L-60 cells (500ng/ml PM A), 
which had been incubated in the absence or presence o f IFN -y for 24hrs (Figures 6.11-6.16). 
Incubation with coumarin compounds was achieved for either 1 or 24hrs. Coumarin (1 or 24hr pre­
exposure) did not effect ROS generation in either unprimed or IFN-prim ed H L-60 cells (Figures 
6.11 and 6.12), with CL-emission was between 95-110%  o f control emission. The only exception 
was for cells exposed to lOOpg/ml for 24hrs (CL-emission was suppressed -35-40% ). lh r 7-HC  
pre-exposure did not significantly alter the generation o f ROS in unprimed or IFN-primed HL-60  
cells (Figures 6.13 and 6.14), w ith increases o f -6 -14%  observed. 24hr exposure to 7-HC did cause 
a dose-dependent suppression o f ROS-generation (Figure 6.13). IFN-prim ing reversed this 
suppression at lower 7-HC concentrations (Figure 6.14). Esculetin pre-exposure (1 and 24hrs) 
caused a dose-dependent suppression o f ROS-generation, with the effects more potent on lh r 
exposure (Figures 6.15 and 6.16). IFN-prim ing partially reversed this effect in cells pre-exposed to 
esculetin for lh r, but had little effect on cells exposed to esculetin for 24hrs (Figures 6.15 and 6.16).
From these results, a number o f points can be made. Firstly, the coumarin compounds 
investigated did not appear at any concentration to display significant stimulatory effects to the 
monocytic cells. Previously, various reports have described the general stimulatory effect o f 
coumarins on MPS cells (P iller, 1978; Koh &  Willoughby, 1979, Marshall et al., 1991b). This 
general effect does not appear to translate into a stimulation o f ROS generation in this “model” 
monocyte system. However, Filice and Reminton (1981) disputed the fact that coumarin could elicit 
a microbicidal or tumouricidal response at all in mouse macrophages. Overall, we were surprised at 
the obtained result, as the applied stimulus (PM A ) activates the Protein Kinase C signalling 
pathway, and coumarin has been previously shown to augment LPS-induced cytokine production, 
by networking with die protein kinase C and lipoxygenase pathways (Zlabinger el a l, 1993). In 
addition, our results from Chapter 5 suggested that the coumarins interact synergistically with PKC, 
enhancing its effect. Hence, we expected an increase in ROS generation to be observed.
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Another unusual result was the observation that IFN -y was capable o f partially reverting the 
coumarin-induced suppression o f CL-emission, suggesting that the two compounds may effect 
similar intercellular signalling pathways. IFN -y is known to signal through its receptor, activating 
JAKs and STATs [c.f. Section 5.2.1], an event that involves tyrosine phosphorylation (Leonard &  
O ’Shea, 1998). However, it is believed that the protein kinase C pathway is also involved (Adams 
&  Hamilton, 1992), complicating die question o f the cellular target o f coumarins.
Finally, it must be admitted that the experimental set-up, with washing o f cells to remove 
excess coumarins, would not have removed intracellular coumarin, therefore scavenging o f ROS by 
intracellular coumarin may still have occurred. This might explain the unexpected results detailed 
above, as the scavenging effects o f coumarins may be much stronger than their PKC effects. 
Scavenging might also explain the dose-dependency o f CL-suppression, and the increase in CL- 
suppression on 24hr exposure to drugs. Regardless, o f whether this is the reason for the dose-and 
time-dependent suppression o f PMA-stimulated CL, the fact remains that in vivo ROS scavenging 
would also occur. Thus, the anti-tumour effect o f coumarins is unlikely to be due to augmentation 
o f ROS-generation by immune cells.
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Figure 6.10: Effect of coumarins on CL-emission from PMA-stimulated HL-60 cells. HL-60
cells (2 X 105/assay) were incubated with 80pM luminol in the presence or absence 
of various coumarin concentrations, and stimulated to emit chemiluminescence, 
with 500ng/ml PMA, at time = 0. CL emission from the cells was monitored for 
60mins. following an initial lOmin. lag period where no measurements were 
recorded. CL measurements were made as outlined in section 22.1.5, with light 
emission recorded for 30 secs., every three minutes, for time = 10-70mins, 
following PMA stimulation. The light generated from control HL-60 cells 
(unexposed to drugs), expressed as Integral Relative Light Units (RLU), was 
normalised at 100%, as the control CL-emission. CL-values from all drug treated 
cells were expressed as a percentage of the control CL-emission. These values are 
plotted vs drug concentrations in the above bar charts. This experiment was 
carried out in triplicate and repeated on three separate occasions. The CL- 
emission from control cells was 3024.43 ± 508.03 RLU.
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(fjg/ml)
Drug Concentration Coumarin 7-Hydroxycoumarin Esculetin
Ong/ml Drug (+ PMA) 4319.70 ±253.50
0 36.89 ±6 .55
0.1 N .D . N .D . 21.57 ±0 .52
0.5 N .D . N .D . 5.14 ±2 .57
1 43.01 ±3 .32 12.58 ±0 .87 3.00 ±0 .29
5 37.96 ±0 .9 0 12.97 ±0 .58 6.54 ±  1.44
10 41.04 ±5 .05 20.91 ±3 .52 9.24 ±0 .06
50 42.68 ±  5.76 6.81 ±0 .14 10.50 ±1.21
100 51.28 ±0 .8 7 11.86 ±2 .7 7 N .D .
Table 6.11: Effect of coumarin compounds on the background luminescence of HL-60
cells. In these experiments, HL-60 cells (2 X 105/assay) were incubated ±  
various drug concentrations for 24 hrs. These cells were then washed, 
incubated with 80fiM luminol, and their “basal” level of CL-emission 
determined over 60 mins. CL emission from the cells was monitored for 
60mins. following an initial lOmin. lag period where no measurements were 
recorded. CL measurements were made as outlined in section 2.2.7.5, with 
light emission recorded for 30 secs., every three minutes, for time = 10-70mins. 
The light generated was expressed as Integral Relative Light Units (RLU) in 
the above table. The CL emission for each drug concentration was tested in 
triplicate, and determined on three separate occasions. For comparative 
purposes, the CL-emission of HL-60 cells exposed to 500ng/ml PMA is also 
shown in the table.
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Effect of Coumarin Pre-exposure on the CL-Emission of
PMA-Stimulated HL-60 Cells
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Figure 6.11: Effect of coumarin on the emission of chemiluminescence from HL-60 cells.
Cells were pre-exposed to coumarin (1-100 fig/ml) for either lhr or 24hrs. 
These cells were then used in the following experiment: 2 X 10s cells/assay 
were incubated with 80p.M luminol and stimulated to emit chemiluminescence, 
with 500ng/ml PMA, at time = 0. CL emission from the cells was monitored for 
60mins. following an initial lOmin. lag period where no measurements were 
recorded. CL measurements were made as outlined in section 2.2.7.5, with 
light emission recorded for 30 secs., every three minutes, for time = 10-70mins, 
following PMA stimulation. The light generated from control HL-60 cells 
(unexposed to drugs), expressed as Integral Relative Light Units (RLU), was 
normalised at 100% as the control CL-emission. CL-values from all drug 
treated cells were expressed as a percentage of the control CL-emission. These 
values are plotted vs drug concentrations in the above bar charts. This 
experiment was carried out in triplicate and repeated on three separate 
occasions. The CL-emission from control cells was 4026.93 ± 349.15 RLU (lhr) 
&  5033.63 ± 327.85 (24hr)
221
Effect of Coumarin Pre-exposure on CL-emission from IFN-
primed, PMA-stimulated HL-60 Cells
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Figure 6.12: Effect of coumarin on the emission of chemiluminescence from HL-60 cells.
Cells were “primed” with IFN-y (lOOU/ml) for 24hrs prior to PMA 
stimulation, and were pre-exposed to coumarin (l-100ng/ml) for either lhr or 
24hrs of this time period. These cells were then used in the following 
experiment: 2 X 10s cells/assay were incubated with 80p.M luminol and 
stimulated to emit chemiluminescence, with 500ng/ml PMA, at time -  0. CL 
emission from the cells was monitored for 60mins. following an initial lOmin. 
lag period where no measurements were recorded. CL measurements were 
made as outlined in section 2.2.7.5, with light emission recorded for 30 secs., 
every three minutes, for time = 10-70mins, following PMA stimulation. The 
light generated from control HL-60 cells (“primed” with IFN-y, but unexposed 
to drugs), expressed as Integral Relative Light Units (RLU), was normalised at 
100% as the control CL-emission. CL-values from all drug treated cells were 
expressed as a percentage of the control CL-emission. These values are plotted 
vs drug concentrations in the above bar charts. This experiment was carried 
out in triplicate and repeated on three separate occasions. The CL-emission
from control cells was 13440.5 ±  1378.27 (lhr) & 12702.92 ± 1454.21 (24hr)
RLU.
222
co
«W
c E O m
(0 _j
.52 u
w g
- j  c  
O o 
o
140
120
= 100 - -
80
60
t  40
20
Effect of 7-Hydroxycoumarin Pre-exposure on the
CL-Emission of PMA-stimulated HL-60 Cells
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Figure 6.13: Effect of 7-hydroxycoumarin on the emission of chemiluminescence from HL-
60 cells. Cells were pre-exposed to 7-hydroxycoumarin (l-100p.g/ml) for either 
lhr or 24hrs. These cells were then used in the following experiment: 2 X 10s 
cells/assay were incubated with 80p.M luminol and stimulated to emit 
chemiluminescence, with 500ng/ml PMA, at time = 0. CL emission from the 
cells was monitored for 60mins. following an initial lOmin. lag period where no 
measurements were recorded. CL measurements were made as outlined in 
section 2.2.7.5, with light emission recorded for 30 secs., every three minutes, 
for time = 10-70mins, following PMA stimulation. The light generated from 
control HL-60 cells (unexposed to drugs), expressed as Integral Relative Light 
Units (RLU), was normalised at 100% as the control CL-emission. CL-values 
from all drug treated cells were expressed as a percentage of the control CL- 
emission. These values are plotted vs drug concentrations in the above bar 
charts. This experiment was carried out in triplicate and repeated on two 
separate occasions. The CL-emission from control cells was 3743.81 ± 426.09 
(lhr) &  5179.60 ± 729.14 (24hr) RLU.
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Effect of 7-Hydnoxycoumarin Pre-exposure on the
CL-Emission of IFN-primed, PMA-stimulated HL-60 Cells
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Figure 6.14: Effect of 7-hydroxycoumarin on the emission of chemiluminescence from HL-
60 cells. Cells were “primed” with IFN-y (lOOU/ml) for 24hrs prior to PMA 
stimulation, and were pre-exposed to 7-hydroxycoumarin (l-lOOjig/ml) for 
either lhr or 24hrs of this time period. These cells were then used in the 
following experiment: 2 X 10s cells/assay were incubated with 80fiM luminol 
and stimulated to emit chemiluminescence, with 500ng/ml PMA, at time = 0. 
CL emission from the cells was monitored for 60mins. following an initial 
lOmin. lag period where no measurements were recorded. CL measurements 
were made as outlined in section 2.2.7.5, with light emission recorded for 30 
secs., every three minutes, for time = 10-70mins, following PMA stimulation. 
The light generated from control HL-60 cells (“primed” with IFN-y, but 
unexposed to drugs), expressed as Integral Relative Light Units (RLU), was 
normalised at 100% as the control CL-emission. CL-values from all drug 
treated cells were expressed as a percentage of the control CL-emission. These 
values are plotted vs drug concentrations in the above bar charts. This 
experiment was carried out in triplicate and repeated on three separate 
occasions. The CL-emission from control cells was 10648.25 ±  493.58 (lhr) & 
12095.88 ± 1269.82 (24hr) RLU.
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Effect of Esculetin Pre-exposure on the CL-Emission of PMA
stimulated HL-60 Cells
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Figure 6.15: Effect of esculetin on the emission of chemiluminescence from HL-60 cells.
Cells were pre-exposed to esculetin (0.1-50ng/ml) for either lhr or 24hrs. 
These cells were then used in the following experiment: 2 X 10s cells/assay 
were incubated with 80|j.M luminol and stimulated to emit chemiluminescence, 
with 500ng/ml PMA, at time = 0. CL emission from the cells was monitored for 
60mins. following an initial lOmin. lag period where no measurements were 
recorded. CL measurements were made as outlined in section 2.2.7.5, with 
light emission recorded for 30 secs., every three minutes, for time = 10-70mins, 
following PMA stimulation. The light generated from control HL-60 cells 
(unexposed to drugs), expressed as Integral Relative Light Units (RLU), was 
normalised at 100% as the control CL-emission. CL-values from all drug 
treated cells were expressed as a percentage of the control CL-emission. These 
values are plotted vs drug concentrations in the above bar charts. This 
experiment was carried out in triplicate and repeated on three separate 
occasions. The CL-emission from control cells was 3835.86 ± 435.22 (lhr) & 
3534.21 ± 973.36 (24hr) RLU.
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Figure 6.16: Effect of esculetin on the emission of chemiluminescence from HL-60 cells.
Cells were “primed” with IFN-y (lOOU/ml) for 24hrs prior to PMA 
stimulation, and were pre-exposed to esculetin (0.1-50fxg/ml) for either lhr or 
24hrs of this time period. These cells were then used in the following 
experiment: 2 X 10s cells/assay were incubated with 80p.M luminol and 
stimulated to emit chemiluminescence, with 500ng/ml PMA, at time = 0. CL 
emission from the cells was monitored for 60mins. following an initial lOmin. 
lag period where no measurements were recorded. CL measurements were 
made as outlined in section 2.2.7.5, with light emission recorded for 30 secs., 
every three minutes, for time = 10-70mins, following PMA stimulation. The 
light generated from control HL-60 cells (“primed” with IFN-y, but unexposed 
to drugs), expressed as Integral Relative Light Units (RLU), was normalised at 
100% as the control CL-emission. CL-values from all drug treated cells were 
expressed as a percentage of the control CL-emission. These values are plotted 
vs drug concentrations in the above bar charts. This experiment was carried 
out in triplicate and repeated on three separate occasions. The CL-emission 
from control cells was 9980.9 ± 806.20 (lhr) &  11762.50 ± 1667.50 (24hr) RLU.
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6.5.6. Production o f  Reactive Nitrogen Intermediates (RNI) from Monocytic Cells
As outlined in Section 6.2.3.4, the secretion o f reactive nitrogen intermediates is believed to 
be one o f the mechanisms, through which monocytes/macrophages exert an anti-tumour effect. We 
therefore investigated the production o f R N I from H L-60 and 28SC cells in response to various 
immune cell stimulators/modulators, using the Greiss method to measure nitrite production (Section 
2.2.7.6). The results o f this study are shown in Table 6.12 -  it can be clearly seen that none o f the 
tested treatments resulted in the production o f nitrite from either cell line. No further experiments 
with coumarins were completed.
Cell/Treatment Abs. @  560nm juM Nitrite
HL-60 Medium only 0.002 < ljiM
HL-60 + 500ng/ml PMA 0.002 <
HL-60 +1 Ong/ml LPS + 500ng/ml PMA 0.002 < 1 uM
HL-60 +1001j/ml IFN-y + 500ng/ml PMA 0.001 < lfjM
28SC Medium only 0.001 < 1(jM
28SC + 500ng/ml PMA 0.001 < ImM
28SC + lOng/ml LPS + 500ng/ml PMA 0.001 < lpM
28SC +1 OOU/ml IFN-y + 500ng/ml PMA 0.001 < 1(jM
Table 6.12: Experiments to examine the production of Reactive Nitrogen Intermediates
(RNI) from HL-60 and 28SC cells in response to various immune modulators 
and stimulators. Cells (1 X 10s cells) were exposed to 500ng/ml PMA ± lOng/ml 
LPS or lOOU/ml IFN-y, for 24hrs. The production of RNI by these treatments 
was then assessed by measurement of nitrite, using the Greiss method, as 
outlined in Section 2.2.1.6. A standard curve of nitrite was prepared in the 
range O-lOOpM, and used to convert absorbance values at 560nm, to fJ-IVl 
nitrite. As shown by this table, neither HL-60 nor 28SC cells were stimulated 
to RNI production by any of the treatments tested.
227
Although there are numerous reports on the production o f R N I from animal macrophages 
(Ding el al., 1988; Keller el al., 1990; Dietert et a l, 1995), the generation o f these anti-tumour 
products from human cells is still under investigation. Cancer patients receiving IL -2  treatment have 
been shown to develop a significant increase in serum and urine nitrate levels, and a number o f 
different cell types can produce R N I in response to cytokines and LPS (O ’Donnell &  Liew, 1994). 
However, the relevance o f R N I production in human monocytes/macrophages is still undetermined.
6.5.7. Production o f  Proteases from Monocytic Cells:
As outlined in Section 6.2.3.5, the production o f various proteases by MPS cells provides a 
paradoxical view o f the role o f these cells in tumour immunity. The release o f M M P products by 
MPS cells has been widely reported, and it is now believed they may aid the invasion o f tumour 
cells rather than prevent it (Kageyama et a l, 1997). As we had shown that coumarins could 
decrease both activity and expression o f M M P -2 from A431 tumour cells in Chapter 4, we chose to 
examine the effects o f coumarins on the M M P  enzymes released by monocyte cells.
M M P-9 (92-kDa Type IV  collagenase) is the most predominantly expressed matrix- 
metalloproteinase o f cells o f the monocytic/macrophage lineage (X ie  et a l, 1994b, 1998). M M P-2 
is also produced in smaller amounts (X ie  et al., 1994b). Shapiro et al. (1991) has shown M M P  
expression to be dependent on the degree o f differentiation for monocytic/macrophage cells.
W e examined the MMP-expression o f both H L-60 cells and 28SC cells, in the absence or 
presence o f stimulating factors (500ng/ml PM A, and 250f.ig/ml OZ, respectively), as outlined in 
Section 2.2.7.7. We found both cell lines expressed a number o f M M P  enzymes (Figure 6.17). H L - 
60 cells constitutively expressed three proteases -  M M P-2 (72kDa), M M P-9 (92kDa) and a third 
unidentified protease, with a molecular weight o f > 205 kDa. This profile was similar to that 
reported by other investigators (Saarialho-Kere et al., 1993; X ie et a l,  1994b). Stimulation o f H L - 
60 cells with 500ng/ml PM A  caused a ~4-fold increase in the levels o f M M P -9, and a ~  2-fold 
increase in M M P-2 expression, with expression o f the third enzyme unchanged (Figure 6.17). 
Constitutive expression o f both M M P -2 and M M P-9 were observed for 28SC cells -  however, 
levels o f M M P-9 were extremely low in comparison to H L-60 cells (Figure 6.17). No change in 
levels or profiles o f M M Ps occurred on stimulation o f these cells with 250jj.g/ml OZ.
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Figure 6.17: Protease production from Monocytic Cells. The production o f proteases by H L-60
and 28SC cells was assessed in the absence or presence o f appropriate stimuli 
(500ng/ml P M A  and 250(xg/ml OZ, respectively), as outlined in Section 2.2.7.7. 
Conditioned media was prepared from 1 X  106cells, exposed to appropriate 
stimulus for 24hr, and analysed for protease secretion by gelatin gel analysis.
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From the results in Figure 6.17, it was decided to examine the effects o f coumarins on the 
expression o f proteases from H L-60 cells which were stimulated with 500ng/ml PM A for 24 hrs. 
The effect o f coumarins on the expression o f all three proteases (M M P -2, M M P-9 and 210kda 
protein) was quantitated by densitometric analysis o f substrate gels (Figures 6.18-6.20). As 
illustrated in these results, and as expected from sim ilar experiments in Chapter 4, all coumarin 
compounds caused a dose-dependent suppression o f protease expression in PMA-stimulated H L-60  
cells. As outlined in Chapter 4, this decrease may be due to one o f a number o f possibilities:
1. Effects on lipoxygenase signalling pathways, which are known to be networked with 
collagenase expression (Reich &  Martin, 1996). Arachidonic acid metabolites play a huge role 
in immune responses and coumarins have been shown to affect prostaglandin synthesis (Lee et
al., 1981).
2. Chelation o f metal ions e.g. Ca2+/Cu2+, interferes with M M P  activity, and the coumarins have 
reported chelatory properties (Huitnik &  Diehl, 1974).
Regardless o f the mechanism o f action, the coumarins do decrease the expression o f MM Ps from 
monocytes. Consequently, this may be a significant anti-tumour mechanism o f these compounds, 
especially with regard to tumour-associated macrophages, as these often aid tumour invasion 
through M M P  release, and thus, inhibition o f this process may be a valuable anti-tumour 
mechanism.
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Figure 6.18: Effect o f 24hr exposure to coumarin on the PMA-stimulated expression o f
proteases from H L-60 cells. The top graph depicts the densitometric analysis from 
three different experiments (mean ±  s.d.) for H L-60 cells exposed to coumarin in 
the range 0-100|xg/ml, A  representative gel is also shown (bottom).
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Figure 6.19: Effect o f 24hr exposure to 7-hydroxycoumarin on the PMA-stimulated expression
o f proteases from H L-60 cells. The top graph depicts the densitometric analysis 
from three different experiments (mean ±  s.d.) for H L-60 cells exposed to 7- 
hydroxycoumarin in the range 0-100(xg/ml, A  representative gel is also shown 
(bottom).
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Figure 6.19: Effect o f 24hr exposure to esculetin on the PMA-stimulated expression o f proteases
from H L-60 cells. The top graph depicts the densitometric analysis from three 
different experiments (mean ±  s.d.) for H L-60 cells exposed to esculetin in the 
range 0-50fig/m l. A  representative gel is also shown (bottom).
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6.6 CHAPTER SUM MARY
In this chapter, two monocytic-like cell lines (28SC and H L-60) were assessed to determine 
their suitability as appropriate “models” o f monocytes, and a number o f monocytic “functions” 
were examined. Cytochemical staining confirmed the ATCC designation, with the 28SC cells 
monocytic in nature, while the H L-60 cells were pro-monocytic. However, functional activation of 
the 28SC cell line, both on the Cytosensor Microphysiometer and in terms o f their ability to 
generate ROS, illustrated that this cell-line did not respond to stimulation with PM A. This was an 
unusual result as P M A  acts as a general PKC activator. It  is probable that the inactivity o f the cells 
in response to PM A  was due to either expression o f PMA-unresponsive PKC isoforms or complete 
loss o f PKC activity due to cell immortalisation. The cells did respond to activation with OZ, which 
illustrates that some monocytic functions (microbicidal) are present. As we were interested in 
tumouricidal activities, we excluded the 28SC cells in further experiments.
The second cell line examined was the promonocytic H L-60 cell, which is leukemic in 
origin. It  was efficiently activated by PM A , both on the Cytosensor Microphysiometer, and in ROS 
generation studies, w ith 500ng/ml P M A  the optimal stimulating concentration. However, problems 
were also encountered in the use o f this cell line: it was discovered that reproducible activation of 
cells was only possible between Days 5-12 post-resuscitation. The decline in response o f HL-60 
cells to PM A over time was probably due to changes in isozyme (PKC) and enzyme (peroxidase) 
expression, as a result o f differentiation.
The H L-60 cell line (D ay 5-12 cells) was used to examine the effect o f coumarins on ROS 
generation. None o f the coumarins tested (coumarin, 7-hydroxycoumarin and esculetin) were shown 
to activate ROS generation by themselves. A ll coumarins were shown to scavenge the ROS 
generated in response to PM A, and therefore extensive washing o f cells was required to assess other 
effects o f coumarin exposure on PMA-stimulated ROS generation. In this assessment the coumarin 
compounds did not appear at any concentration to display significant stimulatory effects to the 
monocytic cells, which is in disagreement with previous studies detailing the stimulatory effect o f 
coumarins on MPS cells (Piller, 1978; Koh &  W illoughby, 1979, Marshall et a l, 1991b). We did 
expect to observe increases in ROS-generation in response to PMA-stimulation (on the basis of 
augmentation o f PKC activity) but the opposite was observed for higher concentrations o f 7-HC and 
esculetin; this result may be due to scavenging by coumarins. IFN -y partially reverted the ROS 
suppression at lower drug concentrations through an unidentified mechanism. Overall, it is doubtful 
that the anti-tumour mechanism o f coumarins is mediated through ROS mechanisms
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The effect o f coumarin compounds 011 protease expression in monocytic cells was also 
examined. As expected die coumarins decreased the expression o f monocytic MM Ps and this may 
be important in the anti-tumour effect o f coumarins.
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Chapter 7 
Conclusions
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7.1. SUM M ARY OF WORK ACHIEVED
The purpose o f this research was an examination into the anti-cancer properties o f coumarin 
compounds at a cellular level, in order to comprehend the observed clinical properties o f these 
natural products. In  particular, the direct vs immunomodulatory effects o f these compounds on cells 
was evaluated.
The initial work undertaken, examined the effect o f a number o f coumarin compounds on 
the growth, metabolism and metastatic potential o f human tumour cell lines. Previous work by 
investigators has concentrated on examining the growth inhibitory properties o f coumarin and its 
main human metabolite, 7-hydroxycoumarin (Moran et al., 1987; Marshall el al., 1994). However, 
work on the metabolism o f coumarin by humans, has revealed the existence o f other minor 
metabolites, which may also be important chemotherapeutically. W e therefore examined the effect 
o f 6-hydroxycoumarin and esculetin on various cellular functions, and compared their activity to 
coumarin and 7-hydroxycoumarin. W ith regard to growth inhibition, 6-hydroxycoumarin was 
almost comparable to 7-hydroxycoumarin in its potency, but neither was as effective as esculetin, in 
an anti-proliferative role. Unlike the mono-hydroxycoumarins, esculetin was non-specific in its 
potent, inhibitory effect. Coumarin itself displayed only low levels o f growth inhibition. The 
potency o f esculetin was also evident in studies on metabolism, where again it caused large 
decreases in the cellular metabolism as determined by the M T T  and Cytosensor studies. Both 
mono-hydroxycoumarins also caused decreased cellular metabolism in cells, but 6- 
hydroxycoumarin exerted milder effects than 7-hydroxycoumarin. The detrimental effects o f all 
three coumarins were tim e- and dose-dependent, and prolonged exposure (12-24hrs) caused 
irreversible effects.
The search for novel cancer chemotherapeutic agents has aroused interest in properties 
other than growth inhibition, which may be useful at controlling the spread o f cancer. Thus, a 
preliminary examination o f the effectiveness o f coumarins at preventing metastasis was conducted. 
Various proteases are implicated in the process o f cancer cell invasion and metastasis, with matrix 
metalloproteinases (M M Ps) especially important in this event. The four tested coumarin compounds 
were found to dose-dependently decrease the activity and expression o f M M Ps, with decreasing 
order o f effectiveness as follows: esculetin >  7-hydroxycoumarin »6-hydroxycoum arin > 
coumarin. It  is possible that this effect o f 7-hydroxycouxnarin might aid its in vivo anti-tumour 
effect. It  is unclear how this inhibition works, although the mechanism may be related to
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1. Interaction with the lipoxygenase signalling pathway, which is important in M M P  
expression.
2. Chelation o f metal ions, necessary for M M P activity
3. Suppression o f ras activity which is necessary for M M P  expression.
These effects may be important in explaining the overall mode o f action o f coumarin in tumour 
cells (Section 7.2).
The second study undertaken aimed at determining more precisely the cellular target of 
coumarin action. Previous investigators had reported on the association o f coumarin and 7- 
hydroxycoumarin w ith growth signalling pathways e.g. Seligers work on autocrine loops (Seliger &  
Pettersson, 1994a). Given the importance o f signalling anomalies in cancer cells, we were interested 
in determining i f  the cellular target o f 7-hydroxycoumarin was a signalling pathway component. 
Given that tyrosine phosphorylation is essential to the emanation o f growth signals, and the fact that 
esculetin has been reported to inhibit cellular tyrosine kinases, we decided to concentrate on this 
aspect o f signalling. Both 7-hydroxycoumarin and esculetin were found to inhibit tyrosine 
phosphorylation in EGF-stimulated tumour cells in a time- and dose-dependent manner. It appears 
that this effect may be achieved by reduction o f the tyrosine kinase activity o f the EGF-Receptor. 
Direct in vitro assays suggested a direct inhibition o f the R TK  activity by 7-hydroxycoumarin. 
However, activation o f Protein Kinase C (a negative regulator o f EG F-RTK) was shown to be 
augmented by 7-hydroxycoumarin and esculetin exposure, and may be an indirect means o f 
inhibition o f the EG F-RTK. Regardless o f the mechanism, this information is useful in the proposal 
o f a mode o f action o f 7-hydroxycoumarin (Section 7.2)
The final investigation regarded the effect o f coumarins on monocyte functions in a model 
system. W hile the model “monocyte” system used was not ideal, it did yield some useful 
information regarding the coumarin compounds. These compounds are effective scavengers of 
superoxide radicals, and therefore it is unlikely that they aid in the secretion o f ROS as part o f an 
anti-tumour immune response. RN1 do not appear important either, and it appears likely that the 
existence o f an anti-tumour immunomodulatory effect lies principally in the augmentation of 
cytokine production as determined by Zlabingers research group (Stuhlmeier el. al., 1991; Zlabinger 
et al., 1993). The expression o f proteases by immune cells was also reduced by coumarins, which 
may be o f importance in reducing the invasion o f cancer cells, which can be aided by production of 
proteases by tumour-associated immune cells (Mantovani et al., 1992).
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7.2. MODE OF ACTION OF COVMARIN IN CANCER CELLS
W hile the pleiotropic effects o f the coumarin compounds in the biological arena are w ell- 
established, as yet no cellular target(s) o f coumarins has been identified comprehensively. This 
work aimed at inching closer to identifying such a target. The information obtained from this work 
in conjunction with data reported by other investigators enables a number o f plausible cellular 
targets to be suggested, and each o f these w ill now be briefly discussed (see also Figure 7.1). In all 
instances, the discussion w ill concentrate on 7-hydroxycoumarin.
1. Growth Factor Receptors and Tyrosine Kinases
The work presented in Chapter 5 o f this thesis outlines the fact that the activity o f the EGF- 
Receptor tyrosine kinase is affected adversely by exposure to 7-hydroxycoumarin and esculetin. 
The inhibition o f the R TK  may be direct as determined by direct in vitro assays, or may be through 
an indirect Protein Kinase C effect (Point 2). In  addition to this report, 7-hydroxycoumarin has 
previously been shown to negatively regulate the PDGF-autocrine loop in glioblastoma cells 
(Seliger, 1997). The downregulation o f RTK-induced tyrosine phosphorylation is important for the 
downstream growth factor signalling, and i f  inhibited, causes gross perturbation and 
downregulation o f its signalling targets (particularly at the m RNA level). This might explain 
previous reports o f downregulation o f ras and c-myc, in 7-hydroxycoumarin-treated cells (Shima et 
al., 1989; Zanker, 1993; Seliger &  Pettersson, 1994b; Lu et al., 1996).
2. Protein Kinase C
Cytosensor results from Chapter 5 illustrate that both 7-hydroxycoumarin and esculetin are 
important in augmenting the activity o f Protein Kinase C. In the case o f the cell system examined, 
this may be important in the negative regulation o f the EGF-Receptor and its associated signalling 
networks. Augmentation o f Protein Kinase C by coumarins has been previously reported in immune 
cells (Zlabinger el al., 1993), and was important for caused increased cytokine release from LPS- 
stimulated cells. Protein Kinase C interacts extensively with many signalling intermediates and 
therefore 7-hydroxycoumarin may influence cellular events by interacting with this molecule.
3. Metal Chelation
The metal chelatory actions o f coumarins have been previously documented (Huitnik &  Diehl, 
1974), and although it is unlikely that they can fu lly  explain the anti-tumour effects o f coumarins, it
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is possible that they may augment effects. It has been previously suggested that chelation o f Ca2+ 
and M g2+ may explain the decrease in metalloproteinase activity and expression observed for both 
tumour and immune cells. In addition, the essential functioning o f tyrosine kinases and other 
signalling enzymes within the cells is dependent on the presence o f M g2+ and M n2+ ions. W hile it 
seems doubtful that chelation alone could explain the effects o f coumarins in cells, chelation o f 
cations by aspirin has been recently proposed to explain the therapeutic effects o f aspirin like 
compounds (Wang, 1998).
The above three suggestions (see also Figure 7.1) are possible targets for the 7- 
hydroxycoumarin molecule intracellularly. However, more detailed investigations are required to 
fu lly  ascertain i f  one, all or any o f these, are the important targets in tumour cells.
Extracellular
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Figure 7.1: Proposed Mode of Action of 7-Hydroxycoumarin (7-HC) in Cancer Cells. 7-HC
may function by inhibiting the RTK activity of growth factor receptors. This will 
prevent growth signals reaching other signalling intermediates such as Ras, or 
activation of transcription factors such as Myc. Alternatively, Protein Kinase C 
may be the target. As a negative regulator of EGF-RTK activity, this also affects 
downstream signalling targets. Finally, the target may be metallic cations e.g. 
Ca2+/ Mg2+, which are also necessary signalling components.
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A l.  L IN T R O D  U C TIO N  TO  V A L ID A T IO N  S T U D IE S  U N D E R TA K E N
The Cytosensor Microphysiometer (Chapter 3) is a useful alternative method for toxicity 
testing (Parce et a l, 1989; Bruner et al, 1992; Wada et a l, 1992). Its detection method, reporting 
decreases in basal metabolic rates of cells, certainly appears useful for predicting the toxicity of 
various agents, and its use in screening compounds, perhaps as one of a battery of in vitro 
alternatives to animals for toxicity testing, seems plausible. Very little validation work is recorded 
towards achieving such an application for this instrument. Validation of an alternative toxicity 
testing method involves demonstration of its reliability, and its relevance for the particular purpose. 
In addition, the method must be reproducible across several laboratories (Bruner et a l, 1998).
When we initiated our work with this instrument, previous toxicological assessment of the 
cytosensor had been carried out principally by a combined laboratory effort between Molecular 
Devices Corporation and The Proctor & Gamble Company, with their focus being ocular irritancy 
(Parce at a l, 1989; Bruner et al., 1992). We decided to reproduce their microphysiometry work in 
our laboratory, and assess the applicability of the method to the toxicity testing o f the coumarin 
compounds, the focus o f our interest. We also decided to compare the Cytosensor 
Microphysiometer to the MTT assay (a well-established in vitro toxicity test) as part of the 
validation procedure.
A1.2. PR O C E D U RES  
A l.2 .1 . Cytosensor S tudies
The studies used the exact experimental set-up described by Bruner and co-workers (1992), 
during their investigational toxicity work on the cytosensor into ocular irritancy, with the exception 
of the cells used on the instrument -  they worked with normal human keratinocytes, while we used 
A431 epidermal cells (vulval tumour cells) and NIH3T3 fibroblasts, in our work.
Briefly, the experiment was undertaken as follows: Half-log serial dilutions of the test 
compounds were prepared in the low-buffered running medium (formulated as outlined in Section 
2.2.4.5.1). The cells were assembled on the cytosensor, and their acidification rates allowed to 
stabilise prior to exposure to any test substance. The cells were sequentially exposed to increasing 
concentrations of test substance over successive pump cycles. Each pump cycle (Figure A l.l)
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involved the following: during a flow-off period, the test substance (300^1) was injected through a 
dosing loop into the chamber to begin the cycle (equivalent to time zero). Flow of running medium 
was immediately started at a speed of 100|il/sec for 120 sec, and then halted for 200sec to allow 
exposure to the cells. The flow was restarted at 100pl/sec for 380 sec to wash out the test material. 
Stopping the flow for 200 sec, during which time the acidification rate was determined, completed 
the sequence. The exposure sequence was repeated with increasing concentrations of test material 
until the acidification rate reached zero. The acidification rates were expressed as a percentage of 
the control rate and plotted versus the concentration of test compound (as shown in Figure A1.2B). 
From these plots the MRD50 value i.e. the concentration of test material (g/ml) sufficient to reduce 
the metabolic rate of the cells by 50% of the control rate, was determined. All experiments were 
performed in triplicate.
A l.2 .2 . M T T A ssa y
The basis of this assay has been described previously in Section 2.2.4.4, and it was carried 
out as outlined in Section 2.2.4.4. Cells were exposed to half-log serial dilutions of the test 
compounds. After 24 hours incubation, detection of viable cells was determined according to the 
procedure in Section 2.2.4.4. The average absorbance for wells exposed to test compounds was 
expressed as a percentage of the control wells, and this value was plotted versus concentration of 
test compound (as shown in Figure A1.2A). From these plots the IC50 value i.e. the concentration of 
test material (g/ml) sufficient to reduce the activity of the mitochondrial dehydrogenases by 50% of 
the control rate, was determined.
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Figure Al.l: Typical Pump schedule during a toxicity run.
(a) Prior to exposure to test material the cells are bathed in low-buffered 
medium and during a 200s pump-off period, their basal acidification rate is 
measured.
(b) As a result of a valve switch, the test material is flushed into the sensor 
chamber from 0-120s at a rate of 1 OOpl/min. After 120s the pump is switched 
off for 200s, to allow exposure of the cells to the sample. The pump is then 
turned on again and as a result of a simultaneous valve switch, fresh medium 
(without test material) is introduced to the cells in the chamber (again at a rate 
of lOOpl/min), for 380s. This step ensures complete flush-out of the test 
compound. The pump-flow is again interrupted for 200s to allow measurement 
of the cellular acidification rate following chemical exposure, to complete the 
900s cycle.
(c) Cessation of the acidification rate measurement of (b) marks the 
commencement of a new 900s pump cycle, with the introduction of a higher 
concentration of the test compound into the sensor chamber.
This repetition of cycles with augmenting concentrations of test compound 
continues, until the acidification rate of the cells reaches zero.
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A l .  3  R E S U L T S  A N D  D I S C U S S I O N
A l.3 .1 . Validation o f  previous toxicity w ork
Previous work in this area carried out by the collaborating Molecular Devices Corp./Proctor 
& Gamble Co. laboratories, examined a range of compounds with known in vivo irritancy levels 
(Parce et a l, 1989; Bruner et a l, 1992). For our validation of their work and the instrument, we 
chose seven such compounds, namely (in increasing order of irritancy), dimethyl sulfoxide 
(DMSO), methanol, ethanol, acetone, n-butanol, sodium dodecyl sulphate (SDS) and Triton X-100. 
These seven compounds were subjected to both Cytosensor and MTT analysis, as described in 
Section A1.2. Figure A1.2. shows the results obtained from these studies for the A431 epidermal 
cell line. In both graphs (A & B) the curves for the most irritating test compounds lie to the left of 
those for the least irritating compounds. The results obtained for the NIH3T3 fibroblastic cell line 
(not shown) were almost identical.
These graphs were used to determine IC50 values (that concentration of compound which 
causes a 50% reduction in the activity of mitochondrial dehydrogenases), and MRD50 values (that 
concentration of compound that causes a 50% reduction in the metabolic rate of the cells), for MTT 
assays and Cytosensor studies, respectively, by interpolation, and these values are presented in 
Table A l.l.
As can be seen from this data, the cytosensor analysis yielded comparable results to those 
of the MTT assay for six of the seven compounds analysed, and as such, would appear useful as an 
alternative method for toxicity prediction of compounds. In the case of n-butanol, the MTT assay 
returned an IC50 value ten times lower than that obtained from the cytosensor analysis (7 0 X 10"4 
g/ml vs 7.5 X 10'3 g/ml, respectively). In this case the disparity between the two results may arise 
from the differences in exposure time (24hrs vs 320s) during the assays and may indicate a 
limitation of the cytosensor analysis (see Section A 1.3.2.).
The advantages of the cytosensor analysis technique over the MTT assay include speed 
(compare 4 vs 24hrs), automation and the fact that each experiment, unlike the MTT assay, is 
internally controlled. By this we mean that each chamber acts as its own control -  i.e. the metabolic 
rate o f the cells in any one chamber post-drug exposure, is expressed as a percentage of the pre­
exposure metabolic rate of the same set of cells, rather than by comparison to a separate set of cells. 
This latter scenario occurs with the MTT assay: due to the semi-invasive nature of the technique,
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responses in drug-treated cells are expressed as a percentage o f a separate sample of untreated cells. 
Using this “external” control, a source of error may arise, if, for example, the seeding densities of 
control and drug-treated cells were not identical.
In their exploratory toxicity experiments with the cytosensor, Parce et al. (1989) compared 
the MRD5o values of the tested compounds (using the negative logarithm of their values) with their 
in vivo ocular irritancy. They found a high correlation between the two sets of data, with the least 
irritating materials causing damage to cellular metabolism at relatively high concentrations, while 
more irritating materials altered cellular function at much lower concentrations. A similar 
comparison of our experimental data is outlined in Table A 1.2. As can be seen, a 4-fold log range of 
MRD50 values existed between the most mild (DMSO) and most severe (Triton X-100) compounds.
One important issue (and flaw) in the whole validation process described above was the 
relevance of this test to the compounds of interest to us i.e. the coumarin compounds. The seven 
compounds examined were used in order to reproduce and validate previous cytosensor results, and 
compare them to an established in vitro test (MTT Assay). As an objective this was achieved. 
However, we were concerned that the compounds used were irrelevant to the focus of our work, 
chiefly because of their chemical nature. All seven compounds examined were either solvents or 
detergents, and as such their detrimental action on cells involves disruption of the cellular 
membrane. However, if interested, as we were, in a method for assessing toxicity of non-solvent 
type compounds, the issue of adequate penetration and exposure time of the investigational 
compound to a cell becomes important.
It should be recalled that the procedure validated above involves a short (320s) exposure of 
compound to cells. In the case of a solvent/detergent compound, as its toxic effect is essentially 
externally-mediated, a procedure involving a short exposure time (mins) may be sufficient to detect 
the toxic effect(s). For compounds with an internal target, such a short exposure may not provide 
for elucidation of toxicity (in many cases it may take hours or days for toxicity to manifest itself). 
We therefore assessed the above procedure for its utility in detecting the toxic effects of coumarin 
compounds on cells.
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Figure A1.2: Exposure of A431 cells to seven different toxic irritants as part of the
cytosensor validation experiments. The M T T  assay was used for comparison 
with the cytosensor in these experiments.
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C o m p o u n d MRDso [Cytosensor] 
(g/ml)
ICso[MTT AssayJ 
(g/ml)
D M S O 2.25 X 101 1.50 X 10’1
Methanol 7.50 X 10 '2 4.00 X 10'2
Ethanol 7.50 X 10 '2 1.20 X I  O'2
Acetone 7.00 X 10 '2 1.50 X 10 '1
n-Butanol 7.50 X  10J 7.00 X  10"*
SDS 1.75 X 10"4 1.50 X 10"*
Triton X-100 2.00 X 10'5 1.50 X I0 '5
Table Al.l: Comparison of the M R D 50 values from the Cytosensor analysis to the
IC5ovalues from M T T  assays. The values (g/ml) were similar for six of the 
seven compounds. The dissimilar results obtained for n-butanol are 
highlighted.
C om pound In  Vivo Irritancy -1 ogio(MRDso)
D M S O Mild 0.648
Methanol Mild-Moderate 1.12
Ethanol Mild-Moderate 1.12
Acetone Mild-Moderate 1.15
n-Butanol Moderate 2.12
SDS Moderate-Severe 3.76
Triton X-100 Severe 4.70
Table A1.2: Comparison of in vivo irritancy data with M R D 50 values from the cytosensor
analysis.
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A 1.3.2 A ssessm ent o f  validated technique fo r  general toxicity assessment.
Cells were exposed to coumarin compounds (either coumarin, 7-hydroxycoumarin, 4- 
hydroxycoumarin or esculetin) under identical conditions as those outlined above (detailed in 
Figure A l.l). The results of this experiment (sample one of three) are shown in Figure A1.3A. 
From these results it is clear that the cells were unaffected by exposure to the four coumarin 
compounds in the concentration range 0-200(xg/ml. From previous proliferation studies which we 
had accomplished in Chapter 4 with these compounds (especially with regard to esculetin), we were 
unconvinced that these results accurately reflected the effect of these compounds on cells. We 
therefore decided to modify the pump cycle to lengthen the exposure time of the cells to the various 
compounds. Different formats were tested, all enabling increased cellular penetration by the drugs, 
and all demonstrated that the coumarins, given adequate exposure time, did suppress the basal 
metabolic rate of cells. Figure A1.3B shows results obtained with the following 35 min pump cycle:
0-30 mins -  Exposure to test compound at 20^1/min 
30-34 mins -  Wash-out with running medium at 100|j.l/min 
34-35 mins -  Pump o f f : Acidification Rate measured.
As detected in this diagram, the increased exposure of the cells to the test compound, via the 
modified pump cycle, enabled us to observe the suppressive effect of esculetin in particular, on the 
basal metabolic rate of the cells. Thus the method outlined in Section Al.3.1. is, as we anticipated, 
unsuitable for the detection o f non-solvent-based toxic effects.
As a result of this information, we decided to address the issue of using the cytosensor 
microphysiometer as a toxicity tool in an alternative format. We decided to adopt the approach used 
by various groups with microcalorimetry and oxygen electrodes, whereby they monitored 
continuously the metabolic rate of cells, and also determined in real-time, the effect of compounds 
on the basal cellular metabolism (Ara et al, 1994; Schon & Wadso, 1988). The complete use of 
such a set-up is described procedurally in Section 2.2.4.5., and the experimental results given 
completely in Chapter 4. A sample set of results is shown here in Figure A1.4.
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Figure A1.3A: Examination of the effect of exposure time on the detection of toxic effects in 
non-solvent/non-detergent compounds. A431 cells were exposed to four 
different coumarin compounds using the same exposure cycle as was used in 
Section Al.3.1 for solvent compounds. The pump cycle is outlined in Figure 
Al.l , and briefly involved exposure of cells to coumarins for 320s in total. As 
shown in this diagram this short exposure time did not cause any decrease in 
acidification rate for the exposed cells. Thus, it was decided to expose the cells 
to coumarins for longer time periods to allow time for drug penetration, as 
shown in Figure A1.3B
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Figure A1.3B: Examination of the effect of exposure time on the detection of toxic effects in 
non-solvent/non-detergent compounds. A431 cells were exposed to four 
different coumarin compounds using a longer exposure cycle than that used in 
all previous studies, and in Figure A1.3B. The pump cycle involved exposure 
of cells to coumarins for 30 mins. in total, as oulined in Section Al.3.2. As 
shown in this diagram this longer exposure time did cause a decrease in 
acidification rate for the exposed cells, as a result of increased drug 
penetration.
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Figure A1.4: Continuous exposure of A431 cells to Esculetin over 4 hours. The acidification
rate (every 20 minutes) was normalised versus the basal rate before exposure. 
This value was plotted versus time for each concentration to generate the 
above dose-response curves. The reversibility of the toxic insult was examined 
by allowing the cells to recover in drug-free medium following this exposure 
period.
This real-time toxicity-testing format (Figure A1.4) has many advantages over other in vitro 
formats. Firstly, it is a continuous monitoring system, unlike most in vitro toxicity tests, which are 
end point methods. Therefore, the time-frame over which the toxic effect of a compound occurs can 
be determined easily using the cytosensor format. With end-point tests, this information could only 
be gained by tedious, multiple end-point kinetic determinations. Secondly, as shown in Figure A1.4, 
the reversibility of a toxic insult to cells can be easily examined. The format of traditional 
reversibility tests often involves taking sub-populations of treated cells and examining their 
recovery from toxic insult. This introduces an element o f error, if the sub-population chosen is 
inherently sensitive/resistant to the test material. The advantage of the cytosensor system format is 
that the total population of exposed cells is monitored for recovery, thus eliminating this selection 
error. Thirdly, the Cytosensor system is a flow-through perfusion system, and this format mimics
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the in vivo blood-stream delivery of toxic compounds more closely than the static conditions of 
many traditional in vitro toxicity formats. Finally, the non-invasive nature of the testing format 
means all experiments are internally controlled, and if  required, permits the re-use of the cells in 
other experiments post-test.
A1.4. C O N C LU SIO N
This appendix outlines the work achieved to investigate the usefulness of the Cytosensor 
Microphysiometer as a tool for in vitro toxicity testing. Initially, a previously-developed cytosensor 
toxicity test for compounds (Parce et al. 1989) was compared to an established in vitro toxicity 
assay (the MTT Assay) to validate its effectiveness as an alternative method. The cytosensor was 
found comparable to the MTT assay for the prediction of toxicity for the seven compounds 
examined. However, as this cytosensor assay had been formulated to address in vivo ocular 
irritancy, we were concerned about its relevance and general applicability to toxicity testing of 
compounds with intracellular toxic effects. We found that the method of Parce and colleagues was 
unsuitable for use as a general toxicity assay, on the basis that with its short exposure times it did 
not allow for adequate penetration and targeting of a compound within the cell. Therefore a new 
continuous method was implemented for the determination of toxic effects and this was utilised in 
assessing the detrimental effects of coumarins on cellular metabolism (outlined fully in Chapter 4). 
The various advantages of this method over existing in vitro toxicity tests were also outlined.
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Appendix 2
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A 2 .1 . C H A R A C T E R I S A T I O N  O F  6 - H Y D R 0 X Y C 0 U M A R 1 N
The purity and identity of the compound, 6-hydroxycoumarin, synthesised according to the 
method outlined in Section 2.2.1, by Dr. Oliver Egan, BEST Centre, D.C.U., was assessed using IR 
and NMR spectra. (Figures A2.1-A2.3)
A2.1.1. In frared  (IR) Spectrum  Analysis:
An IR spectrum of 6-hydroxycoumarin is shown in Figure A2.1. The presence of a 
hydroxy-group on a parent coumarin compound was confirmed by the presence of bands at 3188cm' 
1 (-OH), and 1673cm'1 (-C=0). A series of bands at -1300cm'1 are representative of the C-O-C 
stretch on the pyrone ring.
A2.1.2. N M R  Analysis: 'H  & 13C- N M R  Spectrom etry
A proton spectrum of 6-hydroxycoumarin was determined in DMSO, exposed to a 
magnetic field of 400MHz (Figure A2.2). Together with the 13C -NMR spectrum (Figure A2.3), a 
C-H correlation was obtainable, with the aid of the spectral tables of Silverstein et al., (1991). The 
proton spectrum reveals the presence of 6 hydrogen peaks (4 doublets and two single peaks) 
assigned to carbon atoms as follows: 2C-H 5 6.4ppm (doublet), 3C-H 5 7.95ppm (doublet), 5C-H 5 
7ppm (singlet), 6C-OH 5 9.75ppm (singlet), 7C-H 8 7.3 ppm (doublet) and “C-H 5 7ppm (doublet).
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Figure A2.1: Infra-red spectrum for 6-hydroxycoumarin, showing the presence of O H
(3188cm'1) and -C=0 (1673cm1) bands.
Figure A2.2: Proton N M R  spectrum of 6-hydroxycoumarin in deuterated D M S O  showing
the presence of 6 protons at 5= 6.4, 7 (2 H-nuclei), 7.3, 7.95 and 9.75ppm (- 
OH), corresponding to protons on Carbon atoms 2, 5, 8, 7, 3 and 6 (OH), 
respectively.
298
-  -
L —i - -  4
J.
T
I 
. 
*
r 1------------- 1------------- 1------------- 1------------- 1------------- 1-----------1
145 140 135 130 125 120 115 (PPM)
Figure A2.3: C-H correlation chart - peaks in the XH - NMR (y-axis) and 13C-NMR (x-axis)
were correlated, in order to ensure correct assignment of H-atoms to the 
coumarin structure and ensure correct identification of 6-hydroxycoumarin.
A 2.2  I N  VITRO  C ELL P R O L IF E R A T IO N A S S A  YS
The growth curves for seven cell lines (PC3, T-24, A549, HL-60, SW480, SW620 & 
N1H3T3) following exposure to coumarin compounds (coumarin, 6-hydroxycoumarin, 7- 
hydroxycoumarin and esculetin) as outlined in Section 2.2.4.2, are shown in Figures A2.4-A2.7. 
These results are discussed in Chapter 4 in conjunction with those from Figure 4.1 and Table 4.4.
Effect o f Coumarins on PC3 Cell Growth
Concentration of Drug (ug/ml)
Figure A2.4: In  Vitro Cell Proliferation Assays following exposure of PC3 cells to 4
coumarin compounds for 96 hours. All experiments were conducted in 
duplicate on three separate occasions. The increase in cell number for drug- 
treated cells was expressed as a percentage of the untreated control cells and 
plotted versus the appropriate drug concentration.
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Figure A2.5:
Effect of Coamarins on T-24 CeN Growth
Concentration of Drug (ug/ml)
Effect o f Coumarins on AS49 Cell Growth
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In  Vitro Cell Proliferation Assays following exposure of cells (T-24, top and 
A549, bottom) to 4 coumarin compounds for 96 hours. All experiments were 
conducted in duplicate on three separate occasions. The increase in cell 
number for drug-treated cells was expressed as a percentage of the untreated 
control cells and plotted versus the appropriate drug concentration.
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Figure A2.6:
Effect o f Coumarins on HL-60 Cell Growth
Concentration of Drug (ug/ml)
Effect o f Coumarins on SW480 Cell Growth
Concentration of Drug (ug/ml)
In  Vitro Ceil Proliferation Assays following exposure of cells (HL-60, top and 
SW480, bottom) to coumarin compounds for 96 hours. All experiments were 
conducted in duplicate on three separate occasions. The increase in cell 
number for drug-treated cells was expressed as a percentage of the untreated 
control cells and plotted versus the appropriate drug concentration.
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Effect of Coumarins on SW620 Cell Growth
Concentration of Drug (ug/ml)
Effect o f Coum arins on NIH3T3 Cell Growth
Concentration of drug (ug/ml)
Figure A2.7: In  Vitro Cell Proliferation Assays following exposure of cells (SW620, top;
NIH3T3, bottom) to coumarin compounds for 96 hours. All experiments were 
conducted in duplicate on three separate occasions. The increase in cell 
number for drug-treated cells was expressed as a percentage of the untreated 
control cells and plotted versus the appropriate drug concentration.
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